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(57) Abstract: Inhibitors of sepiapterin reductase of formula (I) or (Γ), wherein the substituents are defined as in the claims, and uses
o of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation
are disclosed.o
HETEROARYL DERIVATIVES AS SEPIAPTERIN
REDUCTASE INHIBITORS
BACKGROUND
[0001] Tetrahydrobiopterin (BH4) is an enzyme cofactor for various aromatic amino acid
hydroxylases, including phenylalanine, tyrosine and tryptophan hydroxylases, as well as
being an important cofactor for other enzymes such as the nitric oxide synthases (inducible
NOS (iNOS), endothelial NOS (eNOS), and neuronal NOS (nNOS)), and alkylglycerol
monooxygenase. As such, BH4 is involved in regulating production of various
neurotransmitters (e.g., serotonin and dopamine) and nitric oxide. Deficiencies in BH4 are
associated with deficiencies in neurotransmitters including serotonin and dopamine. Reduced
BH4 production is also associated with reduced pain sensitivity after injury.
[0002] The last step in the de novo pathway for BH4 biosynthesis is conversion of 6-
pyruvoyltetrahydropterin to BH4 by the action of sepiapterin reductase. Sepiapterin
reductase (SPR) is inhibited by the clinically approved drug sulfasalazine and other sulfa
drugs, thereby interfering with the de novo biosynthesis of BH4.
SUMMARY
[0003] Disclosed herein are compounds of formulae I, Γ , II, ΙΓ , III, IIP, IV, IV', V, and
V , and pharmaceutically acceptable salts thereof:
[0004] Also disclosed are compositions (e.g., pharmaceutical compositions) comprising
one or more of the compounds disclosed herein and a pharmaceutically acceptable carrier.
[0005] Further disclosed are methods of using one or more of the compounds disclosed
herein, or a pharmaceutical composition thereof. The methods include methods of inhibiting
sepiapterin reductase (SPR), methods of treating a subject suffering from pain, methods of
treating a subject suffering from inflammation, and/or methods of treating a subject suffering
from an immunological disorder.
[0006] These and other embodiments and features of the present invention will become
apparent from the following detailed description of the preferred embodiments.
DETAILED DESCRIPTION
[0007] Disclosed herein are inhibitors of sepiapterin reductase (SPR) and uses of
sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-
inflammation, and immune cell regulation. In mouse models, administration of an SPR
inhibitor reduced pain hypersensitivity and BH4 levels in target tissues (Latremoliere et al.,
Neuron, 86:1393-1406 (2015)).
[0008] The use of the terms "a," "an," "the," and similar referents in the context of
describing the invention (especially in the context of the claims) are to be construed to cover
both the singular and the plural, unless otherwise indicated. Recitation of ranges of values
herein merely are intended to serve as a shorthand method of referring individually to each
separate value falling within the range, unless otherwise indicated herein, and each separate
value is incorporated into the specification as if it were individually recited herein. The use
of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended
to better illustrate the invention and is not a limitation on the scope of the invention unless
otherwise claimed. No language in the specification should be construed as indicating any
non-claimed element as essential to the practice of the invention.
[0009] As used herein, the term "alkyl" refers to straight chained and branched
hydrocarbon groups, including but not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl,
sec-butyl, t-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, n-hexyl,
2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl,
3,3-dimethylbutyl, and 2-ethybutyl. The term Cm_ means the alkyl group has "m" to "n"
carbon atoms. The term "alkylene" refers to an alkyl group having a substituent. An alkyl
(e.g., methyl), or alkylene (e.g., -CH2-), group can be substituted with one or more, and
typically one to three, of independently selected halo, trifluoromethyl, trifluoromethoxy,
hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups, for example.
[0010] As used herein, the term "halo" refers to fluoro, chloro, bromo, and iodo. The term
"hydroxy" is defined as -OH. The term "alkoxy" is defined as -OR, wherein R is alkyl. The
term "amino" is defined as -NH2, and the term "alkylamino" is defined as -NR2, wherein at
least one R is alkyl and the second R is alkyl or hydrogen. The term "carbamoyl" is defined
as -C(=0)NR 2. The term "carboxy" is defined as -C(=0)OH or a salt thereof. The term
"nitro" is defined as -N0 2. The term "cyano" is defined as -CN. The term "trifluoromethyl"
is defined as -CF3. The term "trifluoromethoxy" is defined as -OCF3.
[0011] As used herein, the term "aryl" refers to a monocyclic or polycyclic aromatic group,
preferably a monocyclic or bicyclic aromatic group. Examples of aryl groups include, but are
not limited to, phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthryl, pyrenyl, biphenyl,
and terphenyl. Aryl also refers to bicyclic and tricyclic carbon rings, where one ring is
aromatic and the others are saturated, partially unsaturated, or aromatic, for example,
dihydronaphthyl, indenyl, indanyl, or tetrahydronaphthyl (tetralinyl). Unless otherwise
indicated, an aryl group can be unsubstituted or substituted with one or more, and in
particular one to four, groups independently selected from, for example, halo, alkyl, alkenyl,
-OCF3, -N0 2, -CN, -NC, -OH, alkoxy, amino, alkylamino, -C0 2H, -C0 2alkyl, -OCOalkyl,
aryl, and heteroaryl.
[0012] As used herein, the term "benzyl" refers to -CH2-phenyl. Unless otherwise
indicated, a benzyl group can be unsubstituted or substituted with one or more, and in
particular one to four, groups independently selected from, for example, halo, alkyl, alkenyl,
-OCF3, -N0 2, -CN, -NC, -OH, alkoxy, amino, alkylamino, -C0 2H, -C0 2alkyl,
-OCOalkyl, aryl, and heteroaryl.
[0013] As used herein, the term "heterocyclic" refers to a heteroaryl or heterocycloalkyl
ring system. As used herein, the term "carbocyclic" refers to an aryl or cycloalkyl ring
system.
[0014] As used herein, the term "heteroaryl" refers to a monocyclic or polycyclic ring
system (for example, bicyclic) containing one or two aromatic rings and containing at least
one nitrogen, oxygen, or sulfur atom in an aromatic ring. Each ring of a heteroaryl group can
contain one or two O atoms, one or two S atoms, and/or one to four N atoms, provided that
the total number of heteroatoms in each ring is four or less and each ring contains at least one
carbon atom. In certain embodiments, the heteroaryl group has from 5 to 20, from 5 to 15, or
from 5 to 10 ring atoms. Examples of monocyclic heteroaryl groups include, but are not
limited to, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl,
pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl,
tetrazolyl, triazinyl, and triazolyl. Examples of bicyclic heteroaryl groups include, but are not
limited to, benzofuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl,
benzothiazolyl, benzothienyl, benzothiophenyl, benzotriazolyl, benzoxazolyl, furopyridyl,
imidazopyridinyl, imidazothiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl,
isobenzothienyl, isoindolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxazolopyridinyl,
phthalazinyl, pteridinyl, purinyl, pyridopyridyl, pyrrolopyridyl, quinolinyl, quinoxalinyl,
quiazolinyl, thiadiazolopyrimidyl, and thienopyridyl. Unless otherwise indicated, a
heteroaryl group can be unsubstituted or substituted with one or more, and in particular one to
four, substituents selected from, for example, halo, alkyl, alkenyl, -OCF 3, -NO2, -CN, -NC,
-OH, alkoxy, amino, alkylamino, -C0 2H, -C0 2alkyl, -OCOalkyl, aryl, and heteroaryl.
[0015] As used herein, the term "cycloalkyl" means a monocyclic or polycyclic (e.g.,
bicyclic), saturated or partially unsaturated, ring system containing three or more (e.g., three
to twelve or three to eight) carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, and cyclooctyl, optionally substituted with one or more, and
typically one to three, of independently selected halo, trifluoromethyl, trifluoromethoxy,
hydroxy, alkoxy, nitro, cyano, alkylamino, or amino groups, for example.
[0016] As used herein, the term "heterocycloalkyl" means a monocyclic or polycyclic (e.g.,
bicyclic), saturated or partially unsaturated, ring system containing 3 or more (e.g., 4 to 12)
total atoms, of which one to five of the atoms are independently selected from nitrogen,
oxygen, and sulfur and the remaining atoms are carbon. Nonlimiting examples of
heterocycloalkyl groups are azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, dihydropyrrolyl,
morpholinyl, thiomorpholinyl, dihydropyridinyl, oxacycloheptyl, dioxacycloheptyl,
thiacycloheptyl, diazacycloheptyl, each optionally substituted with one or more, and typically
one to three, of independently selected halo, C 1-6 alkyl, C1-6 alkoxy, cyano, amino, carbamoyl,
nitro, carboxy, C2-7 alkenyl, C2-7 alkynyl, or the like on an atom of the ring.
[0017] The compounds disclosed herein include all pharmaceutically acceptable
isotopically-labeled compounds wherein one or more atoms of the compounds disclosed
herein are replaced by atoms having the same atomic number, but an atomic mass or mass
number different from the atomic mass or mass number usually found in nature, examples of
which include isotopes of hydrogen, such as 2H and 3H. In some cases, one or more
hydrogen atoms of the compounds disclosed herein are specifically H (deuterium).
Isotopically-labeled compounds as disclosed herein can generally be prepared by
conventional techniques known to those skilled in the art or by processes analogous to those
described in the accompanying examples and schemes using an appropriate isotopically-
labeled reagent in place of the non-labeled reagent previously employed.
[0018] Certain of the compounds as disclosed herein may exist as stereoisomers (i.e.,
isomers that differ only in the spatial arrangement of atoms) including optical isomers and
conformational isomers (or conformers). The compounds disclosed herein include all
stereoisomers, both as pure individual stereoisomer preparations and enriched preparations of
each, and both the racemic mixtures of such stereoisomers as well as the individual
diastereomers and enantiomers that may be separated according to methods that are known to
those skilled in the art. Additionally, the compounds disclosed herein include all tautomeric
forms of the compounds.
[0019] In one aspect, the disclosure provides a compound of formula I or Γ , or a
pharmaceutically acceptable salt thereof:
wherein:
= is an optional double bond;
Z is CR1 or N R 1, or if the double bond is present, then Z is CR1 or N;
2 2 2Y is NR or CR , or if the double bond is present, then Y is N or CR ;
X is N or CR a;
1 2R and R , taken together with the atoms to which they are attached form a 4-, 5-, 6-,
or 7-membered ring; or
1 2R and R are independently selected from the group consisting of H, Ci-salkyl,
C 3_5cycloalkyl, Ci-shaloalkyl, and halo;
R5 and R a are independently selected from the group consisting of H and Ci_5alkyl;
L is heteroaryl-Co-5alkylene-, aryl-Co-salkylene-, -S-Ci-salkylene-aryl, -S-Ci_
5alkylene-heteroaryl, -Ci-salkylene-S-aryl, or -Ci-salkylene-S-heteroaryl;
R and R4, taken together with nitrogen atom to which they are attached form a 3-, 4-,
5-, 6-, or 7-membered monocyclic ring or 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered
spiro, fused, and/or bridged polycyclic (e.g., bicyclic) ring; or
R is selected from the group consisting of H, Ci-salkyl, C 3_iocycloalkyl, Ci_
shaloalkyl, aryl, heteroaryl, and Ci_5alkylene-G,
R4 is selected from the group consisting of Ci_salkyl, C 3_iocycloalkyl, Ci-shaloalkyl,
aryl, heteroaryl, and Ci_5alkylene-G; and
each G is independently selected from the group consisting of CN, aryl, heteroaryl,
cycloalkyl, and heterocycloalkyl.
[0020] In some embodiments, the compound of formula I does not include a compound
having a structure as recited in Table D, below.
[0021] In some embodiments, the disclosure provides a compound having a formula IA or
IA':
wherein:
Y is NR2 or CR2, or if the double bond is present, then Y is CR2; and
R1 and R2, taken together with the atoms to which they are attached form a
4-, 5-, 6-, or 7-membered ring.
[0022] Compounds of formula IA or IA' include, but are not limited to, compounds
having a structure selected from the roup consisting of:
formula IA or IA' also include, but are not limited to, compounds having a structure:
[0023] In some embodiments, R1 and R2, taken together with the atoms to which they are
attached form a heteroaryl ring, an aryl ring, a heterocycloalkyl ring, or a cycloalkyl ring. In
some embodiments, R1 and R2, taken together with the atoms to which they are attached form
a pyrrole ring, a cyclopentene ring, a thiophene ring, a dihydrofuran ring, a cyclohexene ring,
a pyrazole ring, a thiazole ring, a benzene ring, an imidazole ring, or a cyclobutene ring.
[0024] In some embodiments, the disclosure provides a compound having a formula IB or
IB':
wherein R1and R2are independently selected from the group consisting of H, Ci_
5alkyl, C _5cycloalkyl, Ci-shaloalkyl, and halo.
[0025] In some embodiments,
is selected from the group consisting of:

[0026] In some embodiments, L is -S-Ci-salkylene-aryl, -S-Ci-salkylene-heteroaryl, -Ci_
5alkylene-S-aryl, or -Ci_5alkylene-S-heteroaryl. In other embodiments, L is aryl-Ci_5alkylene-
or heteroaryl-Ci_5alkylene-. In still other embodiments, L is heteroaryl or aryl, such as, but
not limited to a 5- or 6-membered heteroaryl ring. Suitable L groups include, but are not
limited to, pyrazolyl, triazolyl, thiazolyl, pyridinyl, imidazolyl, phenyl, thiophenyl, pyrrolyl,
and indolyl.
[0027] In some embodiments, L is
n is 0 or 1;
Q is CH, CR6, or N;
each R6 is selected from the group consisting of Ci_salkyl, C3_5cycloalkyl,
heterocycloalkyl, Ci-shaloalkyl, halo, benzyl, Ci-shaloalkylene-OH, Ci_5alkylene-CN, Ci_
salkoxy, Ci_5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR 11 , -NR C0 2R lla , -S0 2R , -
S0 2NHR , -SOR 11 , -C0 2R , -CONHR 11 , aryl, and heteroaryl; and
R 11 and R lla are each independently selected from the group consisting of H, Ci_
salkyl, Ci-shaloalkyl, -Co-5alkylene-C 3_6cycloalkyl, -Co-salkylene-heterocycloalkyl, -Co-
5alkylene-aryl, and -Co-salkylene-heteroaryl. In some cases,
[0028] In some embodiments L is
n is 0, 1, or 2;
R6 is selected from the group consisting of Ci_salkyl, C3_5cycloalkyl, heterocycloalkyl,
Ci_5haloalkyl, halo, benzyl, Ci-shaloalkylene-OH, Ci_5alkylene-CN, Ci_salkoxy, Ci_
shaloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR 1 1, -NR C0 2R lla , -S0 2R , -S0 2NHR ,
-SOR 1 1, -C0 2R , -CONHR 1 1, aryl, and heteroaryl; and
R 11 and R lla are each independently selected from the group consisting of H, Ci_
salkyl, Ci-shaloalkyl, -Co-5alkylene-C3_ 6cycloalkyl, -Co-salkylene-heterocycloalkyl, -Co-
5alkylene-aryl, and -Co-salkylene-heteroaryl. Suitable L groups include, but are not limited
to,
[0029] In some embodiments, L has a structure selected from N¾
substituted with 0, 1,
or 2 R substituents.
In some cases, L is
[0030] In some cases, one or more hydrogen atoms of the L groups disclosed herein are
and is substituted
with 1 or 2 deutero Ci_salkyl substituents, such as CH2D, CHD2, or CD3. In some cases, L
has a structure selected from
[0031] In some embodiments, R and R4, taken together with the nitrogen atom to which
they are attached form a 3-, 4-, 5-, 6-, or 7-membered ring, including, but not limited to,
piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl,
oxaziridinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl,
isothiazolidinyl, azepanyl, diazepanyl, or diazabicycloheptane.
O
[0032] In some embodiments NR R4 1S
m is 0, 1, 2, or 3;
R7' and 9 are each independently selected from the group consisting of halo, Ci_
salkyl, C3_5cycloalkyl, heterocycloalkyl, Ci-shaloalkyl, Ci-shaloalkylene-OH, Ci-salkylene-
CN, Ci_5alkoxy, Ci_5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR8, -NR C0 2R a, -
S0 2R8, -C0 2R8, -CONHR 8, aryl, and heteroaryl, or
two R groups, together with the carbon atom(s) to which they are attached, form a 3-,
4-, 5-, 6-, 7-, or 8-membered cycloalkyl, a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocycloalkyl,
aryl, or a 5- or 6-membered heteroaryl ring; and
R8° and R8a are each independently selected from the group consisting of H, Ci-salkyl,
Ci_5haloalkyl, -Co-5alkylene-C 3_6cycloalkyl, -Co-salkylene-heterocycloalkyl, -Co-salkylene-
aryl, and -Co-salkylene-heteroaryl; or
one R7 group and R9, together with the atoms to which they are attached, form a 5- or
6-membered heterocycloalkyl or heteroaryl ring.
0033] In some embodiments,
R7' and 9 are each independently selected from the group consisting of halo, Ci_
salkyl, C3_5cycloalkyl, heterocycloalkyl, Ci-shaloalkyl, Ci_shaloalkylene-OH, Q-salkylene-
CN, Ci-salkoxy, Ci-shaloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR8, -NR C0 2R a, -
S0 2R8, -C0 2R8, -CONHR 8, aryl, and heteroaryl; and
R8° and R8a are each independently selected from the group consisting of H, Ci_5alkyl,
Ci-shaloalkyl, -Co-5alkylene-C 3_6cycloalkyl, -Co-salkylene-heterocycloalkyl, -Co-salkylene-
aryl, and -Co-salkylene-heteroaryl.
[0034] In some embodiments, R7 or R9 is selected from the group consisting of C3_
5cycloalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, aryl, and heteroaryl. In some
embodiments, R is oxazolyl or pyridinyl, each of which is optionally substituted with CN or
[0035] In some embodiments, R9 is C3_5cycloalkyl. In some embodiments, R9 is
cyclopropyl or cyclobutyl, each of which is optionally substituted with 1, 2, 3, or 4 F atoms.
In some embodiments, wherein R9 is selected from the group consisting of ¾ ,
[0036] In some embodiments,
[0037] some embodiments,
; and the two R groups are present on adjacent carbon atoms, and in some
cases, the two R groups form a 4-, 5-, 6-, or 7-membered heterocyclic group or carbocyclic
o
group with the carbon atoms to which they are attached. In some embodiments, ¾· N R 3 R 4
on the same carbon atom, and in some cases, the two R groups form a 3-, 4-, 5-, 6-, or 7-
membered heterocycloalkyl group or cycloalkyl group with the carbon atom to which they
are attached.
[0038] In some embodiments, at least one R7 or R9 is F, CF3, CH3, CH2CH3, -CH2CF3,
cyclopropyl, 1-cyano-cyclopropyl, CN, -C(CH3)2CN, -CH(CN)CH 2CH3, 3,3-
difluoropyrrolidine, -OH, -OCH3, -OCH2CH3, -OCH2CF3, -C(OH)(CF3)2, -C(OH)CH3CF3, -
C0 2C(CH3)3, -CONHC(CH3)3, -N(CH3)C0 2C(CH3)3, phenoxy, phenylsulfonyl, 3,4-
difluorobenzenesulfonyl, phenyl, fluorophenyl, difluorophenyl, cyanophenyl, indolyl,
difluoropyrrolidinyl, or benzothiazolyl, or two R groups, together with the carbon atoms to
which they are attached, form a fused benzene ring. In some embodiments, at least one R is
3-indolyl, 6-fluoro-3-indolyl, N-methyl-3-indolyl, 4-indolyl, 2-benzothiazolyl, or 5-fluoro-2-
benzothiazolyl.
[0039] In some embodiments, R9 is -Co-salkylene-aryl. In some embodiments, R9 is 2,4-
difluorophenyl, 5-fluorophenyl, phenyl, or 2-chlorophenyl.
[0040] In some embodiments, R and R4, taken together with the nitrogen atom to which
they are attached form a 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered spiro, fused, or
bridged polycyclic (e.g., bicyclic ring). Suitable 6- to 14-membered spiro, fused, or bridged
bicyclic rings include, but are not limited to, 10-azabicyclodecane, 9-azabicyclononane, 8-
azabicyclooctane (e.g., 8-azabicyclo[3.2.1]octane), azabicycloheptane (e.g., 7-
azabicycloheptane), 3-azabicyclohexane (e.g., 3-azabicyclo[3.1.0]hexane),
diazabicyclononane (e.g., l,4-diazabicyclo[4.3.0]nonane), diazabicyclooctane,
diazabicycloheptane, diazaspirononane, azaspirononane, diazaspirooctane, azaspirooctane,
spiro [isobenzofuran-piperidine, diazaspiroheptane, azaspiroheptane,
octahydrocyclopenta[£]pyrrole, or octahydrocyclopenta[c]pyrrole. In some embodiments, the
6- to 14-membered spiro, fused, or bridged polycyclic (e.g, bicyclic) ring is substituted with
one or two substituents independently selected from the group consisting of halo, Ci-salkyl,
Ci_5haloalkyl, Ci_5alkoxy, aryloxy, heteroaryloxy, CN, OH, -S0 2R 10 , -C0 2R10 , -CONHR 10 ,
C 3_5cycloalkyl, oxo, aryl, and heteroaryl; and R 10 is selected from the group consisting of H,
Ci-salkyl, -Co-salkylene-aryl, and -Co-salkylene-heteroaryl. In some embodiments, at least
one substituent of the 6- to 14-membered spiro, fused, or bridged polycyclic (e.g., bicyclic)
ring is cyclopropyl, F, -C0 2C(CH3 )3, -CH2CF3, CF3, fluorophenyl, cyanophenyl, OH, or
phenyl.
[0041] In some embodiments, R is selected from the group consisting H, CH3, -CH2CH3, -
CH2CH2CH3, -CH(CH3)2, -CH2CF3, -CH2CH2CN, -CH2CH(OH)CF3, and benzyl; and R4 is
selected from the roup consisting of H3, -CH2CH3, -CH2CH2 H3, -CH2CH2CF3, -
O
[0042] In some embodiments, NR R4
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[0044] Exemplary compounds of formula I include, but are not limited to, the compounds
listed in Table A.
TABLE A

[0045] Exemplary compounds of formula I also include, but are not limited to, the
compounds listed in Table B.
TABLE B

[0046] Provided herein are compounds as disclosed in Table C:
TABLE C
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[0047] In one aspect, the disclosure provides a compound of formula II or ΙΓ , or a
pharmaceutically acceptable salt thereof:
wherein L is heteroaryl or aryl; and
R is selected from the group consisting of H, Ci-salkyl, C3_iocycloalkyl, Ci_
shaloalkyl, aryl, heteroaryl, and Ci-salkylene-G;
R4 is selected from the group consisting of Ci_salkyl, C3_iocycloalkyl, Ci-shaloalkyl,
aryl, heteroaryl, and Ci_5alkylene-G; or
R and R4, taken together with the nitrogen atom to which they are attached form a 3-,
4-, 5-, 6-, or 7-membered monocyclic ring or a 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-
membered spiro, fused, or bridged bicyclic ring, and
each G is independently selected from the group consisting of CN, aryl, heteroaryl,
cycloalkyl, and heterocycloalkyl.
[0048] In one aspect, the disclosure provides a compound of formula III or IIP, or a
pharmaceutically acceptable salt thereof:
wherein:
is an optional double bond;
Z is CR1 or NR1, or if the double bond is present, then Z is CR1 or N;
2 2 2Y is CR or NR , or if the double bond is present, then Y is CR or N;
X is CH or N;
1 2R and R are independently selected from the group consisting of H, Ci-salkyl,
C3_5cycloalkyl, Ci-shaloalkyl, and halo; or
1 2R and R , taken together with the atoms to which they are attached form a 5- to 6-
membered ring;
R5 is selected from the group consisting of H and Ci-salkyl;
L is heteroaryl-Co-5alkylene-, aryl-Co-salkylene-, -S-Ci-salkylene-aryl, -S-Ci_
5alkylene-heteroaryl, -Ci_5alkylene-S-aryl, or -Ci_salkylene-S-heteroaryl;
A is selected from the group consisting of
[0049] In some embodiments, the compound of formula III or ΙΙΓ does not include a
compound having a structure:
[0050] In one aspect, the disclosure provides a compound of formula IV or IV, or a
pharmaceutically acceptable salt thereof:
wherein:
is an optional double bond;
Y is NR , or if the double bond is present, then Y is CR ;
R1 and R2, taken together with the atoms to which they are attached form a 5-
membered ring;
n is 0 or 1;
each R6 is selected from the group consisting of Ci-5alkyl, C3-5cycloalkyl,
Ci_5haloalkyl, halo, and benzyl;
Q is CH, CR6, or N;
R3 and R4, taken together with nitrogen atom to which they are attached form a 3-, 4-,
5-, 6-, or 7-membered monocyclic ring or 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered
spiro, fused, or bridged bicyclic ring.
51] In some
m is 0, 1, 2, or 3;
7 9R ' and R are each independently selected from the group consisting of halo, Ci_
5alkyl, C3_5cycloalkyl, heterocycloalkyl, Ci-shaloalkyl, Ci-shaloalkylene-OH, Ci_5alkylene-
CN, Ci_5alkoxy, Ci_5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR8, -NR C0 2R a, -
S0 2R8, -C0 2R8, -CONHR8, aryl, and heteroaryl, or
two R groups, together with the carbon atom(s) to which they are attached, form a 3-,
4-, 5-, 6-, 7-, or 8-membered cycloalkyl, a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocycloalkyl,
aryl, or a 5- or 6-membered heteroaryl ring; and
8 8aR° and R are each independently selected from the group consisting of H, Ci_5alkyl,
Ci-shaloalkyl, -Co-5alkylene-C3_6cycloalkyl, -Co-salkylene-heterocycloalkyl, -Co-salkylene-
aryl, and -Co-salkylene-heteroaryl; or
7 9one R group and R , together with the atoms to which they are attached, form a 5- or
6-membered heterocycloalkyl or heteroaryl ring.
[0052] In some embodiments,
and is optionally substituted with one to four
substituents selected from the group consisting of F, CI, and Ci_3alkyl.
[0053] In some embodiments,
[0054] In some embodiments, two R groups are present on adjacent carbon atoms, and in
some cases, the two R groups and the carbons to which they are attached form a 3-, 4-, 5-, 6-
, or 7-membered heterocycloalkyl group or cycloalkyl group. In some embodiments, two R
groups are present on the same carbon atom, and in some cases, the two R groups and the
carbon to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl or
cycloalkyl group. In some embodiments, the 6- to 14-membered spiro, fused, or bridged
polycyclic (e.g., bicyclic) ring is substituted with one or two substituents independently
selected from the group consisting of halo, Ci_5alkyl, Ci-shaloalkyl, Q-salkoxy, aryloxy,
heteroaryloxy, CN, OH, -S0 2R10 , -C0 2R10 , -CONHR 10 , C3-5cycloalkyl, aryl, and heteroaryl;
and R10 is selected from the group consisting of H, Ci-salkyl, -Co-salkylene-aryl, and -Co-
5alkylene-heteroaryl. In some embodiments, the 3-, 4-, 5-, 6-, or 7-membered
heterocycloalkyl or cycloalkyl group is substituted with one or two substituents selected from
the group consisting of fluoro, hydroxy, cyano, methyl, ethyl, trifluoromethyl, trifluoroethyl,
cyanopropyl, methoxy, trifluoromethoxy, trifluoroethoxy, hexafluorohydroxypropyl,
cyclopropyl, 1-cyano-cyclopropyl, 1-trifluoromethylcyclopropyl, 3,3-difluoropyrrolidine,
C(0)-t-butoxy, phenyl, fluorophenyl, difluorophenyl, cyanophenyl, indolyl,
difluoropyrrolindinyl, benzothiazolyl, and N(methyl)C(0)t-butoxy.
[0055] Suitable 6- to 14-membered spiro, fused, or bridged bicyclic rings include, but are
not limited to, 10-azabicyclodecane, 9-azabicyclononane, 8-azabicyclooctane (e.g., 8-
azabicyclo[3.2.1]octane), azabicycloheptane (e.g., 7-azabicycloheptane), 3-azabicyclohexane
(e.g., 3-azabicyclo[3.1.0]hexane), diazabicyclononane (e.g., l,4-diazabicyclo[4.3.0]nonane),
diazabicyclooctane, diazabicycloheptane, diazaspirononane, azaspirononane,
diazaspirooctane, azaspirooctane, spiro [isobenzofuran-piperidine, diazaspiroheptane,
azaspiroheptane, octahydrocyclopenta[£]pyrrole, or octahydrocyclopenta[c]pyrrole. In some
embodiments, the 6- to 14-membered spiro, fused, or bicyclic ring is substituted with one or
two substituents independently selected from the group consisting of halo, Ci-salkyl, Ci_
shaloalkyl, Ci_5alkoxy, aryloxy, heteroaryloxy, CN, OH, -S0 2R 10 , -C0 2R10 , -CONHR 10 , C3_
5cycloalkyl, aryl, and heteroaryl; and R10 is selected from the group consisting of H, Ci_
salkyl, -Co-salkylene-aryl, and -Co-salkylene-heteroaryl.
[0056] In one aspect, the disclosure provides a compound of formula V or V , or a
pharmaceutically acceptable salt thereof:
(V)
wherein:
=^= is an optional double bond;
1 is N, or if the double bond is present, then Y1 is C;
is a 5-membered ring;
n is 0 or 1;
each R6 is selected from the group consisting of Ci-salkyl, C 3_5cycloalkyl,
Ci_5haloalkyl, halo, and benzyl;
Q is CH, CR6, or N;
R and R4, taken together with nitrogen atom to which they are attached form a 3-, 4-
5-, 6-, or 7-membered monocyclic ring or 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered
spiro, fused, and/or bridged polycyclic ring.
[0057] In some embodiments, " is a pyrrole ring, a cyclopentene ring, a thiophene
ring, a dihydrofuran ring, a pyrazole ring, a thiazole ring, or an imidazole ring. In some
some embodiments,
or and is optionally substituted with one to four substituents selected from the
group consisting of F, CI, and Ci_3alkyl. In some embodiments,
or
In so . In some
embodiments, ¾/
embodiments, or
[0059] In some embodiments, R and R4, taken together with nitrogen atom to which they
are attached form a 3-, 4-, 5-, 6-, or 7-membered ring. Suitable 3-, 4-, 5-, 6-, or 7-membered
rings include, but are not limited to, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl,
morpholinyl, thiomorpholinyl, aziridinyl, oxaziridinyl, imidazolidinyl, pyrazolidinyl,
oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, azepanyl, diazepanyl, or
diazabicycloheptane.
m is 0, 1, 2, or 3;
R7' and 9 are each independently selected from the group consisting of halo, Ci_
salkyl, C 3_5cycloalkyl, heterocycloalkyl, Ci-shaloalkyl, Ci-shaloalkylene-OH, Ci-salkylene-
CN, Ci-5alkoxy, Ci_5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR8, -NR C0 2R a, -
S0 2R8, -C0 2R8, -CONHR8, aryl, and heteroaryl, or
two R groups, together with the carbon atom(s) to which they are attached, form a 3-,
4-, 5-, 6-, 7-, or 8-membered cycloalkyl, a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocycloalkyl,
aryl, or a 5- or 6-membered heteroaryl ring; and
R8° and R8a are each independently selected from the group consisting of H, Ci_5alkyl,
-Co-5alkylene-aryl, and -Co-salkylene-heteroaryl; or
one R7 group and R9, together with the atoms to which they are attached, form a 5- or
6-membered heterocyclic or heteroaryl ring.
R7' and 9 are each independently selected from the group consisting of halo, Ci_
5alkyl, C 3_5cycloalkyl, heterocycloalkyl, Ci-shaloalkyl, Ci-shaloalkylene-OH, Ci_5alkylene-
CN, Ci-5alkoxy, Ci_5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR8, -NR C0 2R a, -
S0 2R8, -C0 2R8, -CONHR8, aryl, and heteroaryl; and
R8° and R8a are each independently selected from the group consisting of H, Ci_5alkyl,
-Co-5alkylene-aryl, and -Co-salkylene-heteroaryl.
[0062] In some embodiments, R7 or R9 is selected from the group consisting of C3
5cycloalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, aryl, and heteroaryl. In some
embodiments, R is oxazolyl or pyridinyl, each of which is optionally ith CN or
F. In some embodiments, R7 is selected from the group consisting of
[0063] In some embodiments, R9 is C3_5cycloalkyl. In some embodiments, R9 is
cyclopropyl or cyclobutyl, each of which is optionally substituted ith 1, 2, 3, or 4 F atoms.
In some embodiments, R9 is selected from the group consisting of , and
[0064] In some embodiments, the compound is selected from
acceptable salt thereof.
[0065] Further disclosed are compounds listed in Table D, below, for use in inhibiting
SPR.
TABLE D
Methods of Using SPR Inhibitors
[0066] The uses of the compounds and compositions disclosed herein include use as an
SPR inhibitor, an analgesic, a treatment for acute or chronic pain, an anti-inflammatory,
and/or as an immune cell regulator. The disclosed methods include inhibiting sepiapterin
reductase (SPR) by a method comprising contacting SPR with a compound or composition
disclosed herein in an amount effective to inhibit SPR. In some aspects, the contacting is in
vitro. In other aspects, the contacting is in vivo. In various aspects, contacting comprises
administering the compound or the composition to a subject in need thereof. In various
aspects, the subject is a mammal. In a preferred aspect, the mammalian subject is human.
[0067] It is contemplated that the SPR inhibitor compounds, compositions, and methods
are useful in the treatment of diseases and disorders associated with the BH4 synthesis
pathway, such as, but not limited to, pain, inflammation, and immunological disorders. In
addition, it is contemplated that the SPR inhibitor compounds, compositions, and methods are
useful in the treatment of diseases and disorders associated with increased levels of BH4,
such as, but not limited to, pain, inflammation, and immunological disorders, compared with
normal subjects not known to suffer from pain, inflammation, and/or immunological
disorders. In other aspects, the subject suffers from pain (e.g., acute or chronic pain),
inflammation, and/or an immunological disorder.
[0068] The disclosed methods include methods of treating a subject suffering from pain,
such as acute pain or chronic pain, comprising administering to the subject a therapeutically
effective amount of a compound or composition as disclosed herein. The disclosed methods
also include methods of treating a subject suffering from inflammation, such as chronic
inflammation, comprising administering to the subject a therapeutically effective amount of a
compound or composition as disclosed herein. The disclosed methods further include
methods of treating a subject suffering from an immunological disorder, comprising
administering to the subject a therapeutically effective amount of a compound or composition
as disclosed herein.
[0069] Pain includes, but is not limited to, AIDS/HIV -related pain, ankylosing spondylitis,
arachnoiditis, back pain, breakthrough pain, burning mouth syndrome, bursitis, cancer pain,
carpal tunnel syndrome pain, cauda equina syndrome, central pain syndrome, Charcot-Marie-
Tooth disease, chronic functional abdominal pain, chronic pancreatitis pain, complex regional
pain syndrome, corneal neuropathic pain, degenerative disc disease, Dercum's disease,
dermatomyositis, diabetic peripheral neuropathy, Ehlers-Danlos syndrome, endometriosis,
erythromelalgia, failed back surgery syndrome, fibromyalgia, intercostal neuraligia,
interstitial cystitis, irritable bowel syndrome, juvenile dermatositis, leg pain, loin pain-
haematuria syndrome, meralgia paresthetica, migraine, multiple sclerosis pain,
musculoskeletal pain, myofascial pain, myositis, neuropathic pain, occipital neuralgia,
osteoarthritis pain, Paget's disease, pelvic pain, peripheral neuropathy, phantom limb pain,
pinched nerve, polymyalgia rhuematica, polymyositis, post-herniorraphy pain syndrome,
post-mastectomy pain syndrome, post-stroke pain, post-thorocotomy pain syndrome, post
traumatic neuropathy, postherpetic neuralgia, post-polio syndrome, primary lateral sclerosis,
psoriatic arthritis, pudendal neuralgia, Raynaud's disease, restless leg syndrome, rheumatoid
arthritis, sacroiliac joint dysfunction, sarcoidosis, sciatica, postherpetic neuralgia, sickle cell
pain, Sjogren's syndrome, spasmodic torticollis, sphincter of Oddi dysfunction, spinal cord
injury, spinal stenosis, syringomyelia, Tarlov cysts, thoracic outlet syndrome (TOS),
temporomandibular joint disorder, transverse myelitis, trigeminal neuralgia, ulcerative
Colitis, vascular pain, vulvodynia, and whiplash pain.
[0070] Immunological disorders include, but are not limited to, acid-induced lung injury,
acne (PAPA), acute respiratory distress syndrome, ageing, headache, AIDS, alcoholic
hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis (NASH), allergen induced
asthma, allergic bronchpulmonay aspergillosis, Alzheimer's disease, amyotropic lateral
sclerosis (ALS), angina pectoris, anhidrotic ecodermal dysplasia- ID, ankylosiing spondylitis,
antiphospholipid syndrome, aphthous stomatitis, appendicitis, arthritis, asthma, atopic
dermatitis, autoimmune diseases, bee sting-induced inflammation, behcet's disease, Bell's
palsey, Blau syndrome, bronchiolitis, burns, cancer, cardiac hypertrophy, catabolic disorders,
cataracts, cerebral aneurysm, Cystic Fibrosis, chemical irritant-induced inflammation, chronic
heart failure, chronic lung disease of prematurity, chronic obstructive pulmonary disease,
colitis, complex regional pain syndrome, congenital muscular dystrophies, connective tissue
diseases, Crohn's disease, cryopyrin-associated periodic syndromes, cyrptococcosis, cystic
fibrosis, deficiency of the interleukin-1 -receptor antagonist (DIRA), dermatitis,
dermatomyositis, DIPG (Diffuse Intrinsic Pontine Glioma), endometriosis, endotoxemia,
eosiniphilic esophagitis, familial amyloidotic polyneuropathy, familial cold urticarial,
familial mediterranean fever, fetal growth, FSHD, glaucoma, glomerular disease, glomerular
nephritis, gut diseases, peritoneal endometriosis, head injury, hearing loss, heart disease,
Henoch-Scholein purpura, hepatitis, hereditary periodic fever syndrome, Herpes zoster and
simplex, HTV-1, Huntington's disease, hyaline membrane disease, hypercholesterolemia,
hyperimmunoglobulinemia D with recurrent fever (HIDS), hypoplastic and tother anemias,
incontinentia pigmenti, infectious mononucleosis, inflammatory bowel disease, inflammatory
lung disease, inflammatory neuropathy, inflammatory pain, insect bite-induced inflammation,
irritant-induced inflammation, ischemia/reperfusion, Kawasaki Disease, kidney disease,
kidney injury caused by parasitic infections[ml], leptospiriosis, leukemia, limb girdle
muscular dystrophy 2A, limb girdle muscular dystrophy 2B, lung injury, lupus, lupus
nephritis, lymphoma, meningitis, mesothelioma, Muckle-Wells syndrome (urticaria deafness
amyloidosis), multiple sclerosis, muscle wasting, muscular dystrophy, myasthenia gravis,
mycarditis, mycosis fungoides, myelodysplastic syndrome, myositis, nasal sinusitis,
necrotizing enterocolitis, neonatal onset multisystem inflammatory disease (NOMID),
nephrotic eyndrome, neuritis, neuropathological diseases, non-allergen induced asthma,
obesity, ocular allergy, organ transplant, osterarthritis, otitis media, paget's disease,
pancreatitis, Parkinson's disease, pericarditis, periodic fever, periodonitis, pertussis,
pharyngitis and adenitis (PFAPA syndrome), plant irritant-induced inflammation,
Pneumosystis infection, poison ivy/ urushiol oil-induced inflammation, polyarteritis nodosa,
polycystic kidney disease, polymyositis, pontine glioma, psoriasis, psychosocial stress
diseases, pulmonary disease, pulmonary fibrosis, pulmonary hypertension, pyoderma
gangrenosum, pyogenic sterile arthritis, renal disease, retardation, retinal disease, rheumatic
disease, sarcoidosis, sebborrhea, sepsis, sickle cell, silica-induced diseases, Sjogren's
syndrome, skin diseases, sleep apnea, solid tumors including brain tumors, spinal cord injury,
statin induced myopathy, stroke, subarachnoid hemorrhage, sunburn, thrombocytopenia,
tissue transplant, TNF receptor associated periodic syndrome (TRAPS), toxoplasmosis,
traumatic brain injury, tuberculosis, type 1 diabetes, type 2 diabetes, ulcerative colitis, uveitis,
and wound repair.
[0071] A "therapeutically effective amount" means an amount effective to treat or to
prevent development of, or to alleviate the existing symptoms of, the subject being treated.
Determination of the effective amounts is well within the capability of those skilled in the art,
especially in light of the detailed disclosure provided herein. Generally, a "therapeutically
effective dose" refers to that amount of the compound that results in achieving the desired
effect. For example, in one preferred embodiment, a therapeutically effective amount of a
compound disclosed herein decreases SPR activity by at least 5%, compared to control, at
least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at
least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at
least 80%, at least 85%, or at least 90%.
[0072] The amount of compound administered can be dependent on the subject being
treated, on the subject's age, health, sex, and weight, the kind of concurrent treatment (if any),
severity of the affliction, the nature of the effect desired, the manner and frequency of
treatment, and the judgment of the prescribing physician. The frequency of dosing also can
be dependent on pharmacodynamic effects on arterial oxygen pressures. However, the most
preferred dosage can be tailored to the individual subject, as is understood and determinable
by one of skill in the art, without undue experimentation. This typically involves adjustment
of a standard dose (e.g., reduction of the dose if the patient has a low body weight).
[0073] While individual needs vary, determination of optimal ranges of effective amounts
of the compound is within the skill of the art. For administration to a human in the curative
or prophylactic treatment of the conditions and disorders identified herein, for example,
typical dosages of the compounds of the present invention can be about 0.05 mg/kg/day to
about 50 mg/kg/day, for example at least 0.05 mg/kg, at least 0.08 mg/kg, at least 0 .1 mg/kg,
at least 0.2 mg/kg, at least 0.3 mg/kg, at least 0.4 mg/kg, or at least 0.5 mg/kg, and preferably
50 mg/kg or less, 40 mg/kg or less, 30 mg/kg or less, 20 mg/kg or less, or 10 mg/kg or less,
which can be about 2.5 mg/day (0.5 mg/kg x 5kg) to about 5000 mg/day (50mg/kg x 100kg),
for example. For example, dosages of the compounds can be about 0.1 mg/kg/day to about
50 mg/kg/day, about 0.05 mg/kg/day to about 10 mg/kg/day, about 0.05 mg/kg/day to about 5
mg/kg/day, about 0.05 mg/kg/day to about 3 mg/kg/day, about 0.07 mg/kg/day to about 3
mg/kg/day, about 0.09 mg/kg/day to about 3 mg/kg/day, about 0.05 mg/kg/day to about 0 .1
mg/kg/day, about 0.1 mg/kg/day to about 1 mg/kg/day, about 1 mg/kg/day to about 10
mg/kg/day, about 1 mg/kg/day to about 5 mg/kg/day, about 1 mg/kg/day to about 3
mg/kg/day, about 3 mg/day to about 500 mg/day, about 5 mg/day to about 250 mg/day, about
10 mg/day to about 100 mg/day, about 3 mg/day to about 10 mg/day, or about 100 mg/day to
about 250 mg/day. Such doses may be administered in a single dose or it may be divided into
multiple doses.
[0074] An SPR inhibitor is contemplated to be useful in the treatment of any condition
wherein the lowering of BH4 levels will provide benefits. The SPR inhibitor is useful alone,
or in combination with other compounds, which may act to promote the reduction of BH4
levels. The present section provides a description of how the SPR inhibitors of the invention
may be therapeutically administered to a subject in need thereof.
[0075] One of the therapeutic embodiments of the invention is the provision, to a subject in
need thereof, compositions comprising one or more SPR inhibitors. In one aspect, the SPR
inhibitor formulation for therapy in a subject is selected based on the route of administration
and in certain aspects includes liposome and micelle formulations as well as classic
pharmaceutical preparations.
[0076] In various aspects, administration of the compositions is systemic or local, and in
still other aspects comprises a single site injection of a therapeutically-effective amount of the
SPR inhibitor composition. Any route known to those of skill in the art for the administration
of a therapeutic composition of the invention is contemplated including, for example,
intravenous, intramuscular, subcutaneous, oral, or a catheter for long-term administration.
[0077] Combination Therapy: In addition to therapies based solely on the delivery of the
SPR inhibitor composition, combination therapy is specifically contemplated. In the context
of the invention, it is contemplated that the SPR inhibitor composition therapy is used
similarly in conjunction with other agents commonly used for the treatment of elevated levels
of BH4 and/or SPR.
[0078] The combination therapy compositions are provided in a combined amount
effective to produce the desired therapeutic outcome in the treatment of reduced levels of
BH4 and/or make a detectable change in an indication as described herein. This process
involves administering the SPR inhibitor and the second agent(s) or factor(s) at the same
time. Methods thus include administering a single composition or pharmacological
formulation that includes both agents, or administering two distinct compositions or
formulations, at the same time, wherein one composition includes the SPR inhibitor
therapeutic composition and the other includes the second therapeutic agent.
[0079] Alternatively, the SPR inhibitor treatment precedes or follows the second
therapeutic agent treatment by intervals ranging from minutes to weeks. In embodiments
where the second therapeutic agent and the SPR inhibitor are administered separately, one
generally ensures that a significant period of time did not transpire between the times of each
delivery, such that the second therapeutic agent and the SPR inhibitor are able to exert an
advantageously combined effect. In such instances, it is contemplated that one administers
both modalities within about 12-24 hours of each other, or alternately, within about 6-12
hours of each other, or alternately, with a delay time of only about 12 hours. However, in
some situations, it is desirable to extend the time period for treatment significantly, where
several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the
respective administrations.
[0080] Systemic delivery of SPR inhibitors to patients is a very efficient method for
delivering a therapeutically effective amount of the compound to counteract the immediate
clinical manifestations of a disease or disorder. Alternatively, local delivery of the SPR
inhibitor and/or the second therapeutic agent is appropriate in certain circumstances. In a
certain embodiment, it is contemplated that the SPR inhibitor is delivered to a patient for an
extended period of time. It is further contemplated that the SPR inhibitor is taken throughout
a patient's lifetime to lower SPR activity levels.
Dosing and Pharmaceutical Formulations
[0081] Also provided herein are pharmaceutical compositions that includes a compound as
disclosed herein, together with a pharmaceutically acceptable excipient such as a diluent or
carrier. Compounds and pharmaceutical compositions suitable for use in the present invention
include those wherein the compound can be administered in an effective amount to achieve
its intended purpose. Administration of the compound described in more detail below.
[0082] Suitable pharmaceutical formulations can be determined by the skilled artisan
depending on the route of administration and the desired dosage. See, e.g., Remington's
Pharmaceutical Sciences, 1435-712 (18th ed., Mack Publishing Co, Easton, Pennsylvania,
1990). Formulations may influence the physical state, stability, rate of in vivo release and
rate of in vivo clearance of the administered agents. Depending on the route of
administration, a suitable dose may be calculated according to body weight, body surface
areas or organ size. Further refinement of the calculations necessary to determine the
appropriate treatment dose is routinely made by those of ordinary skill in the art without
undue experimentation, especially in light of the dosage information and assays disclosed
herein as well as the pharmacokinetic data obtainable through animal or human clinical trials.
[0083] The phrases "pharmaceutically acceptable" or "pharmacologically acceptable" refer
to molecular entities and compositions that do not produce adverse, allergic, or other
untoward reactions when administered to an animal or a human. As used herein,
"pharmaceutically acceptable carrier" includes any and all solvents, dispersion media,
coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the
like. The use of such excipients for pharmaceutically active substances is well known in the
art. Except insofar as any conventional media or agent is incompatible with the therapeutic
compositions, its use in therapeutic compositions is contemplated. Supplementary active
ingredients also can be incorporated into the compositions. In exemplary embodiments, the
formulation may comprise corn syrup solids, high-oleic safflower oil, coconut oil, soy oil, L-
leucine, calcium phosphate tribasic, L-tyrosine, L-proline, L-lysine acetate, DATEM (an
emulsifier), L-glutamine, L-valine, potassium phosphate dibasic, L-isoleucine, L-arginine, L-
alanine, glycine, L-asparagine monohydrate, L-serine, potassium citrate, L-threonine, sodium
citrate, magnesium chloride, L-histidine, L-methionine, ascorbic acid, calcium carbonate, L-
glutamic acid, L-cystine dihydrochloride, L-tryptophan, L-aspartic acid, choline chloride,
taurine, m-inositol, ferrous sulfate, ascorbyl palmitate, zinc sulfate, L-carnitine, alpha-
tocopheryl acetate, sodium chloride, niacinamide, mixed tocopherols, calcium pantothenate,
cupric sulfate, thiamine chloride hydrochloride, vitamin A palmitate, manganese sulfate,
riboflavin, pyridoxine hydrochloride, folic acid, beta-carotene, potassium iodide,
phylloquinone, biotin, sodium selenate, chromium chloride, sodium molybdate, vitamin D3
and cyanocobalamin.
[0084] As used herein, "pharmaceutically acceptable salts" include, for example base
addition salts and acid addition salts.
[0085] Pharmaceutically acceptable base addition salts may be formed with metals or
amines, such as alkali and alkaline earth metals or organic amines. Pharmaceutically
acceptable salts of compounds may also be prepared with a pharmaceutically acceptable
cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the
art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations.
Carbonates or hydrogen carbonates are also possible. Examples of metals used as cations are
sodium, potassium, magnesium, ammonium, calcium, or ferric, and the like. Examples of
suitable amines include isopropylamine, trimethylamine, histidine, Ν ,Ν '-
dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine,
ethylenediamine, N-methylglucamine, and procaine.
[0086] Pharmaceutically acceptable acid addition salts include inorganic or organic acid
salts. Examples of suitable acid salts include the hydrochlorides, formates, acetates, citrates,
salicylates, nitrates, phosphates. Other suitable pharmaceutically acceptable salts are well
known to those skilled in the art and include, for example, formic, acetic, citric, oxalic,
tartaric, or mandelic acids, hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric
acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic
acids, for example acetic acid, trifluoroacetic acid (TFA), propionic acid, glycolic acid,
succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid,
tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid,
benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-
phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic
acid; and with amino acids, such as the 20 alpha amino acids involved in the synthesis of
proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic
acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane 1,2-
disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene 2-sulfonic
acid, naphthalene 1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose 6-phosphate, N-
cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic
compounds, such as ascorbic acid.
[0087] Pharmaceutical compositions containing the compounds disclosed herein can be
manufactured in a conventional manner, e.g., by conventional mixing, dissolving,
granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or
lyophilizing processes. Proper formulation is dependent upon the route of administration
chosen.
[0088] For oral administration, suitable compositions can be formulated readily by
combining a compound disclosed herein with pharmaceutically acceptable excipients such as
carriers well known in the art. Such excipients and carriers enable the present compounds to
be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions
and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral
use can be obtained by adding a compound as disclosed herein with a solid excipient,
optionally grinding a resulting mixture, and processing the mixture of granules, after adding
suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include,
for example, fillers and cellulose preparations. If desired, disintegrating agents can be added.
Pharmaceutically acceptable ingredients are well known for the various types of formulation
and may be for example binders (e.g., natural or synthetic polymers), lubricants, surfactants,
sweetening and flavoring agents, coating materials, preservatives, dyes, thickeners, adjuvants,
antimicrobial agents, antioxidants and carriers for the various formulation types.
[0089] When a therapeutically effective amount of a compound disclosed herein is
administered orally, the composition typically is in the form of a solid (e.g., tablet, capsule,
pill, powder, or troche) or a liquid formulation (e.g., aqueous suspension, solution, elixir, or
syrup).
[0090] When administered in tablet form, the composition can additionally contain a
functional solid and/or solid carrier, such as a gelatin or an adjuvant. The tablet, capsule, and
powder can contain about 1 to about 95% compound, and preferably from about 15 to about
90% compound.
[0091] When administered in liquid or suspension form, a functional liquid and/or a liquid
carrier such as water, petroleum, or oils of animal or plant origin can be added. The liquid
form of the composition can further contain physiological saline solution, sugar alcohol
solutions, dextrose or other saccharide solutions, or glycols. When administered in liquid or
suspension form, the composition can contain about 0.5 to about 90% by weight of a
compound disclosed herein, and preferably about 1 to about 50% of a compound disclosed
herein. In one embodiment contemplated, the liquid carrier is non-aqueous or substantially
non-aqueous. For administration in liquid form, the composition may be supplied as a
rapidly-dissolving solid formulation for dissolution or suspension immediately prior to
administration.
[0092] When a therapeutically effective amount of a compound disclosed herein is
administered by intravenous, cutaneous, or subcutaneous injection, the composition is in the
form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such
parenterally acceptable solutions, having due regard to pH, isotonicity, stability, and the like,
is within the skill in the art. A preferred composition for intravenous, cutaneous, or
subcutaneous injection typically contains, in addition to a compound disclosed herein, an
isotonic vehicle. Such compositions may be prepared for administration as solutions of free
base or pharmacologically acceptable salts in water suitably mixed with a surfactant, such as
hydroxypropylcellulose. Dispersions also can be prepared in glycerol, liquid polyethylene
glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these
preparations can optionally contain a preservative to prevent the growth of microorganisms.
[0093] Injectable compositions can include sterile aqueous solutions, suspensions, or
dispersions and sterile powders for the extemporaneous preparation of sterile injectable
solutions, suspensions, or dispersions. In all cases the form must be sterile and must be fluid
to the extent that easy syringability exists. It must be stable under the conditions of
manufacture and storage and must resist the contaminating action of microorganisms, such as
bacteria and fungi, by optional inclusion of a preservative. The carrier can be a solvent or
dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene
glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable
oils. In one embodiment contemplated, the carrier is non-aqueous or substantially non
aqueous. The proper fluidity can be maintained, for example, by the use of a coating, such as
lecithin, by the maintenance of the required particle size of the compound in the case of
dispersion and by the use of surfactants. The prevention of the action of microorganisms can
be brought about by various antibacterial and antifungal agents, for example, parabens,
chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be
preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged
absorption of the injectable compositions can be brought about by the use in the compositions
of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0094] Sterile injectable solutions are prepared by incorporating the active compounds in
the required amount in the appropriate solvent with various of the other ingredients
enumerated above, as required, followed by filtered sterilization. Generally, dispersions are
prepared by incorporating the various sterilized active ingredients into a sterile vehicle which
contains the basic dispersion medium and the required other ingredients from those
enumerated above. In the case of sterile powders for the preparation of sterile injectable
solutions, the preferred methods of preparation are vacuum-drying and freeze-drying
techniques which yield a powder of the active ingredient plus any additional desired
ingredient from a previously sterile-filtered solution thereof.
[0095] Slow release or sustained release formulations may also be prepared in order to
achieve a controlled release of the active compound in contact with the body fluids in the GI
tract, and to provide a substantially constant and effective level of the active compound in the
blood plasma. For example, release can be controlled by one or more of dissolution,
diffusion, and ion-exchange. In addition, the slow release approach may enhance absorption
via saturable or limiting pathways within the GI tract. For example, the compound may be
embedded for this purpose in a polymer matrix of a biological degradable polymer, a water-
soluble polymer or a mixture of both, and optionally suitable surfactants. Embedding can
mean in this context the incorporation of micro-particles in a matrix of polymers. Controlled
release formulations are also obtained through encapsulation of dispersed micro-particles or
emulsified micro-droplets via known dispersion or emulsion coating technologies.
[0096] For administration by inhalation, compounds of the present invention are
conveniently delivered in the form of an aerosol spray presentation from pressurized packs or
a nebulizer, with the use of a suitable propellant. In the case of a pressurized aerosol, the
dosage unit can be determined by providing a valve to deliver a metered amount. Capsules
and cartridges of, e.g., gelatin, for use in an inhaler or insufflator can be formulated
containing a powder mix of the compound and a suitable powder base such as lactose or
starch.
[0097] The compounds disclosed herein can be formulated for parenteral administration by
injection (e.g., by bolus injection or continuous infusion). Formulations for injection can be
presented in unit dosage form (e.g., in ampules or in multidose containers), with an added
preservative. The compositions can take such forms as suspensions, solutions, or emulsions
in oily or aqueous vehicles, and can contain formulatory agents such as suspending,
stabilizing, and/or dispersing agents.
[0098] Pharmaceutical formulations for parenteral administration include aqueous
solutions of the compounds in water-soluble form. Additionally, suspensions of the
compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic
solvents or vehicles include fatty oils or synthetic fatty acid esters. Aqueous injection
suspensions can contain substances which increase the viscosity of the suspension.
Optionally, the suspension also can contain suitable stabilizers or agents that increase the
solubility of the compounds and allow for the preparation of highly concentrated solutions.
Alternatively, a present composition can be in powder form for constitution with a suitable
vehicle (e.g., sterile pyrogen-free water) before use.
[0099] Compounds disclosed herein also can be formulated in rectal compositions, such as
suppositories or retention enemas (e.g., containing conventional suppository bases). In
addition to the formulations described previously, the compounds also can be formulated as a
depot preparation. Such long-acting formulations can be administered by implantation (e.g.,
subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the
compounds can be formulated with suitable polymeric or hydrophobic materials (for
example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble
derivatives, for example, as a sparingly soluble salt.
[00100] In particular, a compound disclosed herein can be administered orally, buccally, or
sublingually in the form of tablets containing excipients, such as starch or lactose, or in
capsules or ovules, either alone or in admixture with excipients, or in the form of elixirs or
suspensions containing flavoring or coloring agents. Such liquid preparations can be
prepared with pharmaceutically acceptable additives, such as suspending agents. A
compound also can be injected parenterally, for example, intravenously, intramuscularly,
subcutaneously, or intracoronarily. For parenteral administration, the compound is best used
in the form of a sterile aqueous solution which can contain other substances, for example,
salts, or sugar alcohols, such as mannitol, or glucose, to make the solution isotonic with
blood.
[00101] For veterinary use, a compound disclosed herein is administered as a suitably
acceptable formulation in accordance with normal veterinary practice. The veterinarian can
readily determine the dosing regimen and route of administration that is most appropriate for
a particular animal.
[00102] In some cases, all the necessary components for the treatment of an SPR-related
disorder using a compound as disclosed herein either alone or in combination with another
agent or intervention traditionally used for the treatment of such disease may be packaged
into a kit. Specifically, the present invention provides a kit for use in the therapeutic
intervention of the disease comprising a packaged set of medicaments that include the
compound disclosed herein as well as buffers and other components for preparing deliverable
forms of said medicaments, and/or devices for delivering such medicaments, and/or any
agents that are used in combination therapy with the compound disclosed herein, and/or
instructions for the treatment of the disease packaged with the medicaments. The instructions
may be fixed in any tangible medium, such as printed paper, or a computer readable magnetic
or optical medium, or instructions to reference a remote computer data source such as a world
wide web page accessible via the internet.
Synthesis of Compounds Disclosed Herein
[00103] The compounds disclosed herein can be prepared following the methods outlined
in detail in the Examples, using suitable modifications to the starting reagents. One of skill in
the art, in view of the teachings of the Examples and using typical organic chemistry
techniques, can synthesize a compound as disclosed herein.
[00104] In some cases, compounds of formula I can be prepared by converting an
appropriate thiouracil to a hydrazine intermediate, coupling the hydrazine intermediate with
an appropriate enamine reagent to form a compound of formula I or an intermediate having a
pyrazolyl moiety, and further reacting the intermediate having a pyrazolyl moiety so as to
couple with an appropriate amine (for example, using reagents such as HATU or
HATU/HOAt) to provide a compound of formula I as shown in the Scheme 1 and Scheme 2 .
Scheme 1
n erme a e Route 1
Intermediate 2
Scheme 2
[00105] In some cases, compounds of formula I can be prepared by converting an
appropriate dichloropyrimidine to a hydrazine intermediate, coupling the hydrazine
intermediate with an appropriate enamine reagent to form an intermediate having a pyrazolyl
moiety, and further reacting the intermediate having a pyrazolyl moiety so as to couple with
an appropriate amine (for example, using reagents such as HATU or HATU/HOAt) to
provide a compound of formula I as shown in Schemes 3 and 4 .
Scheme 3
Scheme 4
[00106] In some cases, compounds of formula I can be prepared by converting an
appropriate cyclopentanone to a hydrazine intermediate, coupling the hydrazine intermediate
with an appropriate enamine reagent to form an intermediate having a pyrazolyl moiety, and
further reacting the intermediate having a pyrazolyl moiety so as to couple with an
appropriate amine (for example, using reagents such as HATU or HATU/HOAt) to provide a
compound of formula I as shown in Scheme 5 .
Scheme 5
[00107] In some cases, compounds of formula I can be prepared by coupling an
appropriate hydrazine intermediate with an appropriate enamine, enol ether, aldehyde, or
ketone reagent to form an intermediate having a pyrazolyl moiety, and further reacting the
intermediate having a pyrazolyl moiety so as to couple with an appropriate amine (for
example, using reagents such as HATU or HATU/HOAt) to provide a compound of formula I
as shown in Scheme 6 .
Scheme 6
Intermediate 1
[00108] In some cases, compounds of formula I can be prepared by coupling an
appropriate hydrazine intermediate with an appropriate dialdehyde reagent to form an
intermediate having a pyrazolyl moiety, and further reacting the intermediate having a
pyrazolyl moiety so as to couple with an appropriate amine (for example, using reagents such
as HATU or HATU/HOAt) to provide a compound of formula I as shown in Scheme 7 .
Scheme 7
[00109] In some cases, compounds of formula I can be prepared by coupling an
appropriate chloropyrimidine or sulfonyl pyrimidine with an appropriate pyrazolyl moiety to
form a compound of formula I or an intermediate having a pyrazolyl moiety, and further
reacting the intermediate having a pyrazolyl moiety so as to couple with an appropriate amine
(for example, using reagents such as HATU or HATU/HOAt) to provide a compound of
formula I as shown in Schemes 8, 9, 10 and 11.
Scheme 8
Scheme 10
Scheme 11
[00110] In some cases, compounds of formula I can be prepared by coupling an
appropriate bromo-cyclopropylideneacetate with an appropriate pyrazolyl moiety to form an
intermediate having a pyrazolyl moiety, and further reacting the intermediate having a
pyrazolyl moiety so as to couple with an appropriate amine (for example, using reagents such
as HATU or HATU/HOAt) to provide a compound of formula I as shown in Scheme 12.
Scheme 12
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[00111] In some cases, compounds of formula I can be prepared by coupling an
appropriate azide with an appropriate β-keto ester to form an intermediate having a triazolyl
moiety, and further reacting the intermediate having a triazolyl moiety so as to couple with an
appropriate amine (for example, using reagents such as HATU or HATU/HOAt) to provide a
compound of formula I as shown in Scheme 13.
Scheme 13
[00112] Amines that are not commercially available can be prepared by standard
procedures. In some cases, amines that are not commercially available can be prepared by
coupling an appropriate aryl bromide with a mono-protected cyclic diamine, followed by
deprotection of the amine protecting group to obtain the amine, for example, as shown in
Scheme 14.
Scheme 14
[00113] In some cases, amines that are not commercially available can be prepared by
reducing an appropriate protected aminoketone to obtain the corresponding alcohol,
protecting the alcohol with an appropriate protecting group, further reacting with an
appropriate reagent so as to convert the protected alcohol to a desired functional group (e.g., a
cyano group), followed by deprotection of the amine protecting group to obtain the amine, for
example, as shown in Scheme 15.
Scheme 15
Assessment of SPR Inhibitory Activity
[00114] The compounds disclosed herein can be assessed for SPR inhibitory activity.
Typically, a compound is assayed by an enzymatic assay (e.g., a TR-FRET assay) and/or a
cellular assay (e.g., SKN-N-BE(2) cells or human PBMC (Peripheral Blood Mononuclear
Cells)) as described below.
[00115] TR-FRET Assay: A TR-FRET (homogeneous, time-resolved, fluorescence
resonance energy transfer) assay was used to assess activity of compounds following standard
assay conditions. Terbium labeled SNAP-hSPR and SSZ (sulfasalazine) labeled SNAP-
EGFP were used as the protein pair in this assay according to the procedure described in
Haruki et al., Science, 430:987 (2013). Compounds were screened at different concentrations
and IC50 values calculated.
[00116] SKN-N-BE(2) Cellular Assay: SK-N-BE (2) cells were seeded in sterile, 96-well
plates and incubated for 12-24 hours at 37°C with 5% C0 2 supply. Media was removed and
fresh DMEM/F-12 media (containing Glutamine & Pen/Strep but no FBS) was added.
Compounds (at different concentrations) were added to different wells. The plates were then
incubated for 6-48 hours at 37°C with 5% C0 2 supply. Plates were then centrifuged and the
supernatant was removed. The plates were then optionally washed once with PBS. They
were then sealed and stored at -80°C or immediately used. The cells were lysed and the level
of BH4 was assessed by LC-MS.
[00117] hPBMC Assay: PBMCs were either purchased or isolated from fresh human
blood and used either as a fresh preparation or frozen for later use. The assay system was
prepared by pre-treating the assay plates overnight with a solution containing anti-human
CD3 antibody. Human PBMCs were suspended in assay medium and plated into the assay
plates at a density of l-4xl0 5 cells per well. The desired concentration of the test compound
was added to each well. A solution of human anti-CD28 antibody was also added to each
well. Plates were incubated for 12-48 hours at 37° C and 5% C0 2. Assay plates were
centrifuged for 5-15 minutes at 1-3000 RMP and supematants were removed. The cells were
lysed, sealed and used directly or frozen at -80° C. LC-MS was used to quantify the amount
of inhibition of BH4 production.
Assessment of Pain Behavior
[00118] The compounds disclosed herein can be assessed for effect on pain behavior.
Typically, a compound is assayed by a behavioral pharmacology model as described below.
[00119] Behavioral Pharmacology Model: Compounds were administered by oral gavage
to rats that had undergone one of two nerve injury surgeries: spared nerve injury to injure two
of the three peripheral branches of the sciatic nerve or chronic constriction injury of the
sciatic nerve. Paw withdrawal thresholds to mechanical stimulation using calibrated von Frey
filaments were used as measurement of neuropathic pain-like behaviors.
EXAMPLES
[00120] In the examples and throughout the specification, the following abbreviations are
used.
h hour
r.t. room temperature
RT retention time
br broad
M mass
HPLC High Performance Liquid Chromatography
LC-MS Liquid Chromatography Mass Spectrometry
ES+ Electrospray Positive Ionisation
ES- Electrospray Negative Ionisation
brine aqueous sodium chloride solution
EDC 1-(3-dimethylaminopropyl)-3 -
ethylcarbodiimide hydrochloride
HATU 0-(7-azabenzotriazol-l-yl)-N,N,N',N'-
tetramethyluronium hexafluoropho sphate
Pd(PPh 3)4 tetrakis(triphenylphosphine)palladium(0)
HOAt l-Hydroxy-7-azabenzotriazole
PE Petroleum ether
SGC Silica gel chromatography
TLC Thin layer chromatography
GC-MS Gas chromatography mass spectrometry
PdCl2(dppf) [ , -
bis(diphenylphosphino)ferrocene]dichlorop
alladium(II)
T3P Propylphosphonic anhydride
COMU (1-Cyano-2-ethoxy-2-
oxoethylidenaminooxy)dimethylamino-
morpholino-carbenium
hexafluorophosphate
SCX propylsulfonic acid bonded sorbent
purification cartridge
General Procedures
[00121] The following analytical LC-MS methods were used.
Method A : (2 min IPC)
MET/CR/1673
Column: Supelco Ascentis Express C I 8, 30 mm x 2.1 mm, 2.7 µιη
Flow rate: 1.0 ml/min
Mobile Phase: A, Formic acid (aqueous) 0.1% and B, Formic acid
(MeCN) 0.1%
Injection Vol: 3 µΐ
Temp.: 40 °C
Detection: 215 nm (nominal)
Gradient Time (minutes) - % B
0.00 - 5
1.50 - 100
1.60 - 100
1.61 - 5
Method B : (1.7 min IPC)
MET/CR/1410
Column: Kinetex Core-Shell C18, 50 mm x 2.1 mm, 5.0 µιη
Flow rate: 1.2 ml/min
Mobile Phase: A, Formic acid (aqueous) 0.1% and B, Formic acid
(MeCN) 0.1%
Injection Vol: 3 µΐ
Temp.: 40 °C
Detection: 215 nm (nominal)
Gradient Time (minutes) - % B
0.00 - 5
1.20 - 100
1.30 - 100
1.31 - 5
Method C : (7 min IPC)
MET/u-HPLC (low pH 7 min method)
Column: Phenomenex Kinetex-XB C I 8, 2.1 mm x 100 mm, 1.7 µιη
Flow rate: 0.6 ml/min
Mobile Phase: A, Formic acid (aqueous) 0.1% and B, Formic acid
(MeCN) 0.1%
Injection Vol: 3 µΐ
Temp.: 40 °C
Detection: 215 nm (nominal)
Gradient Time (minutes) - % B
0.00 - 5
5.30 - 100
5.80 - 100
5.82 - 5
he following preparative HPLC and SFC methods were used.
Method D :
SFC: 10% Methanol: 90% CQ2 on a 25cm QJ-H Column, at 15ml/min.
Method E :
Generic high pH prep method (Gilson 3 and Gilson 5)
Column: Waters Xbridge C18 (30 x 100mm, lOum)
Flow rate: 40 ml/min
Mobile Phase: A, Water + 0.2% Ammonium hydroxide, B, Acetonitrile +
0.2% Ammonium hydroxide
Injection Vol.: 1500 µΐ
Temperature: r.t.
Detection: 215 nm
Gradient Time (minutes) - % B
0.0 - 5
2.5 - 5
16.05 - 95
18.2 - 95
19.1 - 5
20 - 5
Method F :
Generic neutral pH prep method (Waters 1)
Column: Waters Sunfire C18 (30 x 100mm, lOum), Part no. 186003971
Flow rate: 40ml/min
Mobile Phase: A, Water, B, Acetonitrile
Injection Vol: 1500 µΐ
Temperature: r.t.
Detection: 215 nm
Gradient Time (minutes) - % B
0 - 10
2 - 10
2.5 - 15
14.5 - 100
15.5 - 100
16 - 10
17 - 10
Method G :
Generic low pH prep method (Waters 2)
Column: Waters Sunfire C18 (30 x 100mm, lOum), Part no. 186003971
Flow rate: 40 ml/min
Mobile Phase: A, Water + 0.1% Formic acid, B, Acetonitrile + 0.1%
Formic acid
Injection Vol.: 1500 µΐ
Temperature: r.t.
Detection: 215 nm
Gradient Time (minutes) - % B
0 - 5
2 - 5
2.5 - 10
14.5 - 10
15.5 - 100
16 - 5
he following preparative chiral separation and analysis methods were used.
Method H :
Separation
Column: SFC ChiralPak AS (250mm x 20mm, 5um)
Flow rate: 50 mL/min
Eluent: MeOH/C0 2 50% (TFA was added as a modifier)
Injection Vol: 0.7 mL (7 mg)
Detection: 218 nm
Method I :
Analysis
Column: SFC ChiralPak AS (250mm x 4.6mm, 5um)
Flow rate: 4 mL/min
Eluent: MeOH/CQ2 45% (TFA was added as a modifier)
Method J :
Separation
Column: HPLC Lux C I (20mm x 250mm, 5um)
Flow rate: 2 1 mL/min
Eluent: HEPT/EtOH (50:50) (TFA was added as a modifier)
Injection Vol: 0.5 mL (10 mg)
Detection: 210nm
Method K :
Analysis
Column: HPLC Lux C I (4.6mm x 250mm, 5um)
Eluent: HEPT/EtOH (40:60) (TFA was added as a modifier)
Flow rate: 4 mL/min.
Method L :
Separation
Column: ChiralPak AD (20mm x 250mm, 20um)
Eluent: EtOH (TFA was added as a modifier)
Flow rate was 2 1 mL/min
Method M :
Analysis
Column: HPLC using a YMC AMY-C (4.6mm x 250mm, 5um)
Eluent EtOH (TFA was added as a modifier)
Flow rate: 1 mL/min
Method N :
Separation
Column: HPLC Chiralcel OD-H 25cm
Eluent: ethanol + 0.1% formic acid
Flow rate: 5ml/min
Method O :
Separation
Column: Lux A2 (20mm x 250mm, 5um)
Eluent: EtOH (TFA was added as a modifier)
Flow rate: 2 1 mL/min
Detection: 210 nm
he following LC-MS methods were used.
Method A':
Column: SunFire C18 (4.6x 50 mm, 3.5 um)
Mobile phase: H20 (0.05%TFA) (A) / ACN (0.05%TFA) (B)
Elution program: Gradient from 5 to 100% of B in 1.3 min at 2mL/min
Temperature: 50 °C
Detection: UV (214, 254 nm) and MS (ESI, Pos mode, 110 to 1000 amu)
Method B':
Column: Chromolith Fast Gradien RP-18e, 50-3mm
Mobile Phase: A : Water (0.01%TFA) B: ACN (0.01%TFA)
Gradient: 5%B increase to 100%B within 0.8min, 100%B for l.lmin.
Flow Rate: 1.5mL/min
Column Temperature: 40 °C
Mass Range: 103-1100
Method :
Column: Sunfire C18 4.6X50mm, 3.5um
Mobile phase: H20 (0.01%TFA) (A) / ACN (0.01% TFA) (B)
Elution program: Gradient from 5 to 95% of B inl.4min at 2.0ml/min
Temperature: 45 °C
Detection: UV (214, 254 nm) and MS (ESI, POS mode, 113 to 1200 amu)
Method D':
Column: Sunfire C18 2.5um3*30mm
Mobile Phase: A : water (0.01%TFA) B: ACN (0.01%TFA)
Gradient: 5%-95% B in 1.5min
Flow Rate: 1.5mL/min
Mass Range: 110-1000 UV: 214nm; 254nm
Oven Temperature: 50 °C
Method E':
Column: SunFire CI 8, 4.6*50mm, 3.5um
Mobile Phase: A : Water (0.01%TFA) B: ACN (0.01%TFA)
Gradient: 5 B increase to 95 B within 1.2min, 95 B for 1.3min, back
to 5 B within O.Olmin.
Flow Rate: 2.0 mL/min
Column Temperature: 50 °C
Method F':
Column :Xbridge C18 (4.6x 50 mm, 3.5um)
Mobile phase: H20 (10 mmol NH4HC0 3) (A) / ACN(B)
Elution program: Gradient from 5 to 95% of B in 1.3min at 1.8ml/min
Temperature: 50 °C
Detection: UV (214, 254 nm) and MS (ESI, POS mode, 110 to 1000 amu)
Method G':
Column: Xbridge, 3.5um, 50*4.6mm
Mobile Phase: A : 10m mol/L NH4HC0 3 in water B: ACN
Gradient: 5%B increase to 95%B withinl.5min, 95%B for 1.0min,back to
5%B within O.Olmin.
Flow Rate: 2 mL/min
Oven Temperature: 50 °C
Method H':
Column: Xbridge C18 4.6*50mm 3.5um
Mobile Phase: A : lOmM NH4HC0 3 in water B: ACN
Gradient: 5%B increase to 95%B within 1.2min, 95%B for 1.3min, back
to 5%B within O.Olmin.
Flow Rate: 2.0 mL/min
Oven Temperature: 50 °C
Method P :
Column: Gemini-NX 3u C18 (4.6x 50 mm, 3um)
Mobile phase: H20 (10 mmol NH4HC0 3) (A) / ACN (B)
Elution program: Gradient from 10 to 95% of B inl.5min at 1.8mL/min
Temperature: 50 °C
Detection: UV (214, 254 nm) and MS (ESI, Pos mode, 70 to 900 amu)
Method J':
Column: Xbridge CI8(2) (4.6x 50 mm, 3.5um)
Mobile phase: H20 (10 mmol NH4HC03) (A) / ACN (B)
Elution program: Gradient from 10 to 95% of B in 1.5min at 1.8mL/min
Temperature: 50 °C
Detection: UV (214, 254 nm) and MS (ESI, Pos mode, 110 to 1100 amu)
Method K':
Column: YMC C18 Plus, 4.6*50mm, 3um, 12nm
Mobile Phase: A : water (lOmM Ammonium hydrogen carbonate) B:
ACN
Gradient: 5%-95% B in 1.6min
Flow Rate: 1.6mL/min
Oven Temperature: 50 °C
MS Range: 110-1100
Preparative Example 1 - Method 1; Formation of intermediates from corresponding
thiouracils
[00125] Intermediate 1: Preparation of 2-hydrazinyl-6-methyl-3,4-dihydropyrimidin-4-one
[00126] Step 1: Synthesis of 6-methyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one
[00127] (EV-AO5743-001)
[00128] To water (500 mL) was added NaOH (97%, 15.7 g, 381 mmol) and the suspension
stirred at r.t. for 10 mins. 6-methyl-2-sulfanylidene-l,2,3,4-tetrahydropyrimidin-4-one (98%,
53.5 g, 369mmol) was added and the mixture stirred until fully dissolved for 10 mins.
lodomethane (28.99 mL, 461 mmol) was added dropwise and the mixture stirred at r.t. for 4
h . The colorless solid was filtered, washed with ice cold water (2 x 100 mL) and dried under
vacuum at 60 °C to afford the title compound (57 g, 98%) as a colorless solid.
[00129] Method A : LC-MS m/z = 156.9 [M + H]+; RT = 0.61 min.
[00130] Step 2: Synthesis of 2-hydrazinyl-6-methyl-3,4-dihydropyrimidin-4-one
(Intermediate 1)
[00131] (EV-AN7477-001) (Intermediate 1)
[00132] To a stirred solution of 6-methyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one
(11.9 g, 76.18 mmol) in EtOH (30 mL) was added hydrazine hydrate (15.75 mL, 0.32 mol)
and stirred at 80 °C for 5.5 h . The reaction mixture was allowed to cool to r.t. and the
resulting precipitate was collected and dried by vacuum filtration, washing with water (3
mL) to afford the title compound (9.20 g, 85%) as an off white powder.
[00133] Method A : LC-MS m/z = 140.90 [M + H]+; RT = 0.18 min.
[00134] Intermediate 2 : Preparation of 5-methyl-l-(4-methyl-6-oxo-l,6-dihydropyrimidin-
2-yl)-lH-pyrazole-4-carboxylic acid
[00135] Step 1: Synthesis of methyl-5-methyl-l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-
yl)-lH- pyrazole-4-carboxylate
[00136] Q-310 (EV-AO7527-001)
[00137] To a stirred suspension of hydrazinyl-6-methyl-3,4-dihydropyrimidin-4-one
(Intermediate 1, 6.82 g, 48.66 mmol) in EtOH (70 mL) was added methyl (2Z)-2-
[(dimethylamino)methylidene]-3-oxobutanoate (8.33 g, 48.66 mmol) (Intermediate 3)
followed by addition of AcOH (9.75 mL) and stirred at 80 °C for 1 h . The reaction mixture
was cooled to r.t., at which point the product precipitated out of solution, and was filtered
under vacuum, washing sparingly with EtOH, to afford the title compound (6.02 g, 50%) as a
fluffy pale peach powder.
[00138] Method A : LC-MS m/z = 248.95 [M + H]+; RT = 1.01 min.
[00139] Step 2 : Synthesis of 5-methyl-l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-lH-
pyrazole-4-carboxylic acid (Intermediate 2)
[00140] (EV-AO7528-001) (Intermediate 2)
[00141] To a stirred suspension of methyl-5-methyl-l-(4-methyl-6-oxo-l,6-
dihydropyrimidin-2-yl)-lH- pyrazole-4-carboxylate (6.02 g, 24.25 mmol) in THF (40 mL)
was added 3M aq NaOH solution (40.42 mL), followed by water (20 mL) to aid dissolution
and stirred at r.t. for 1 h . The reaction mixture was concentrated in vacuo to remove the THF
and then acidified to pH 6 using 1M aq HC1 solution. The resultant white solid was filtered
under vacuum, washing with Et20 , and dried to afford the title compound (5.45 g, 96%) as an
off white powder.
[00142] Method A : LC-MS m/z = 234.9 [M + H]+; RT = 0.84 min.
[00143] Intermediate 3 : Preparation of methyl-2-[(dimethylamino)methylidene]-3-
oxobutanoate
CH,[00144] (EV-AL6988-001) (Intermediate 3)
[00145] Methyl 3-oxobutanoate (40 g, 0.34 mol) and l,l-dimethoxy-N,N-
dimethylmethanamine (54.92 mL, 0.41 mol) were combined and stirred at 80 °C for 2 hours.
The reaction mixture was concentrated in vacuo and the resulting oil was dried for 24 hours
under vacuum to afford 56.53 g (86.3%) of the title compound as a dark red solid: 1H NMR
(500 MHz, DMSO-J6) δ 7.62 (s, 1H), 3.63 (s, 3H), 3.24 - 2.96 (m, 3H), 2.90 - 2.58 (m, 3H),
2.13 (s, 3H).
[00146] Intermediate 4 : Preparation of 2-ethyl-2,3-dihydro-lH-indole
[00147] (EV-AB8093-001) (Intermediate 4)
[00148] The intermediate was formed using the procedure from US Patent Publication
2011/0021500.
[00149] A solution of 2-ethyl-lH-indole ( 1 g, 6.89 mmol) in acetic acid (15 ml) at r.t. was
treated portion wise with sodium cyanoborohydride (2.03 g, 32.37 mmol); addition caused
effervescence and a slight exotherm. The resultant suspension was stirred at r.t. for 20 h . The
reaction mixture was concentrated in vacuo and the residue treated with 4M aq HC1 solution
(30mL) with scrubbing. The mixture was stirred at r.t. for 1 h, then cooled to 0 °C and
treated with 4M aq NaOH solution (40 mL). Once the addition was complete the mixture was
extracted with EtOAc (x2). The extracts were washed with brine, dried over MgS0 4 and
concentrated in vacuo to afford the title compound (l.lg, 97%) as a pale yellow mobile oil.
[00150] Method A : LC-MS m/z = 147.9 [M + H]+; RT = 0.96 min.
Example 1 - Synthesis of 6-methyl-2-[5-methyl-4-(l,2 <3.4-tetrahvdroisoquinoline-2-
carbonyl)-lH-pyrazol-l-yl1-3,4-dihvdropyrimidin-4-one
[00151] Q-279 (EV-AO7529-002).
[00152] To a stirred solution of 5-methyl-l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-
lH-pyrazole-4-carboxylic acid (Intermediate 2, 6.60 g, 28.18 mmol) in DMF (80 mL) was
added COMU (13.28 g, 31.00 mmol), DIPEA (12.06 mL, 70.45 mmol) and 1,2,3,4-
tetrahydroisoquinoline (3.93 mL, 31.00 mmol) and stirred at r.t. for 1 h . The reaction mixture
was quenched by addition of saturated NaHC0 3 solution (20 mL) and water (20 mL) and
extracted with DCM (4 x 100 mL). The combined organic extracts were dried over sodium
sulphate, concentrated in vacuo and triturated using MeCN to afford the title compound (4.71
g, 48%) as an off white powder.
[00153] Method C: LC-MS m z = 350. 1 [M + H]+; RT = 2.54 min.
Examples 2-39 - Synthesis of dihydropyrimidinones
[00154] Examples 2-39 were prepared according to the procedure described in Example 1
by reacting Intermediate 2 (5-methyl-l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-lH-
pyrazole-4-carboxylic acid) with the appropriate amine and the coupling agent specified in
Table 1. All amines used in Table 1 were commercially available except for example 38
which was synthesized using Intermediate 4 (2-ethyl-2,3-dihydro-lH-indole).
Table 1
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Examples 40-43 - Chiral Separation
[00155] Examples 40-43 in Table 2 were prepared by chiral separation of racemic
compounds in Table 1. The stereochemistry was arbitrarily assigned.
Table 2
Example 44 - Synthesis of 5-chloro-6-methyl-2-[5-methyl-4-(l <2<3<4-
tetrahvdroisoquinoline-2-carbonyl)-lH-pyrazol-l-yl1-3,4-dihvdropyrimidin-4-one
[00156] Q-456 (EV-A0757 1-002).
[00157] To a solution of 6-methyl-2-[5-methyl-4-( 1,2,3,4-tetrahydroisoquinoline-2-
carbonyl)-lH-pyrazol-l-yl]-3,4-dihydropyrimidin-4-one (Example 1, Q-279 (EV-A07529-
002), 100 mg, 0.286 mmol) in AcOH (2 mL) was added NCS (40 mg, 0.301 mmol) and
stirred at 90 °C for 1 h . The reaction mixture was concentrated in vacuo and triturated using
MeCN to afford the title compound (60 mg, 54%) as a white powder.
[00158] Method C: LC-MS m/z = 384.2 [M + H]+; RT = 2.99 min.
Example 45 - Synthesis of 5-chloro-6-methyl-2-[5-methyl-4-(l <2<3<4-
tetrahvdroisoquinoline-2-carbonyl)-lH-pyrazol-l-yl1-3,4-dihydropyrimidin-4-one
[00159] Q-421 (EV-AQ0223-002).
[00160] Chlorination of 6-methyl-2-[5-methyl-4-( 1,2,3,4-tetrahydroisoquinoline-2-
carbonyl)-lH-pyrazol-l-yl]-3,4-dihydropyrimidin-4-one (Example 7, Q-359 (EV-AP2325-
001) using the procedure described in Example 44 afforded the title compound (54 mg, 42%)
as a white powder.
[00161] Method C: LC-MS m/z = 404.2 [M + H]+; RT = 2.88 min.
Example 46 - Synthesis of 6-methyl-2-[5-methyl-4-(l <2<3.4-tetrahvdroisoquinolin-2-
ylmethyl)-lH-pyrazol-l-yl1-3,4-dihvdropyrimidin-4-one
[00162] Q-311 (EV-AO7520-002).
[00163] To a stirred solution of 6-methyl-2-[5-methyl-4-(l,2,3,4-tetrahydroisoquinoline-2-
carbonyl)-lH-pyrazol-l-yl]-3,4-dihydropyrimidin-4-one (Example 1, Q-279 (EV-A07529-
002), 165 mg, 0.472 mmol) in THF (3 mL) at 0 °C was added LiAlH4 (216 µΐ , 0.519
mmol) and stirred at r.t. for 1 h . The reaction mixture was quenched by the addition of water
(4 mL), NaOH (4 mL) and then further water (4 mL). The reaction mixture was acidified to
pH 5 using acetic acid and then neutralized to pH 7 using saturated sodium bicarbonate
solution. The reaction mixture was extracted with DCM (3 x 40 mL) and the combined
organic extracts dried over Na2S0 4, concentrated in vacuo and triturated using MeCN (3 mL)
to afford the title compound (57 mg, 35%) as a white powder.
[00164] Method C: LC-MS m/z = 336. 1 [M + H]+; RT = 1.29 min.
Preparative Example 2 - Preparation of intermediate thiouracils and thio ethers
[00165] Intermediate 5 : Preparation of 2-sulfanylidene-lH,2H,3H,4H-pyrazolo[l,5-
a][1,3 ,5] triazin-4-one
[00166] Step 1: Synthesis of ethyl N-[(lH-pyrazol-5-yl)carbamothioyl]carbamate
[00167] (EV-AQ38 14-001).
[00168] To a solution of lH-pyrazol-5-amine (3 g, 36.1 mmol) in acetone (50 ml) was
added over 5 mins (slight exotherm) ethyl N-carbothioylcarbamate (3.96 ml, 0.03 mol) and
stirred at r.t. for 2 h . The yellow solution was treated with ice cold water (50 ml) which
caused a transient precipitation. The flask was cooled in ice and a precipitate formed. The
solid was collected by filtration, washed with water and dried under vacuum to afford the title
compound (5.0g, 46%) as a yellow solid.
[00169] Method A : LC-MS m/z = 214.90 [M + H]+; RT = 0.94.
[00170] Step 2: Synthesis of 2-sulfanylidene-lH,2H,3H,4H-pyrazolo[l,5-a][l,3,5]triazin-
4-one
[00171] (EV-AQ027 1-002) (Intermediate 5)
[00172] To ethyl N-[(lH-pyrazol-5-yl)carbamothioyl]carbamate (2.5 g, 11.67 mmol) was
added 2M aq NaOH solution (23.3 ml) and stirred at r.t. for 2 h . The solution was acidified
with concentrated H2SO4 and the resultant precipitate filtered under vacuum to afford a pale
yellow powder. Purification by recrystallisation using water afforded the title compound
(1.54 g, 94%) as a pale yellow powder.
[00173] Method A : LC-MS m/z = 168.95 [M + H]+; RT = 0 .19.
[00174] Intermediate 6 : Preparation of 2-sulfanylidene-l,2,3,4,5, 6,7,8-
octahydroquinazolin-4-one
[00175] (EV-AQ0232-001).
[00176] To a solution of ethyl 2-oxocyclohexane-l-carboxylate (9.40 ml, 58.75 mmol) in
MeCN (40ml) was added thiourea (5.37 g, 70.5 mmol) and DBU (13.15 ml, 88.13 mmol) and
stirred at 80 °C overnight.
[00177] The reaction mixture was concentrated in vacuo and the residue redis solved in
water. The reaction mixture was acidified to pH 3/4 using 5M aq HCl solution, the precipitate
filtered, washing with H20 and Et20 , and dried under vacuum to afford the title compound
(10.70 g, 98%) as an off white powder.
[00178] Method A : LC-MS : m z = 183 .0 (M+H)+; RT = 0.7 1.
[00179] Intermediate 7 : Synthesis of 6-methyl-4-sulfanylidene-l,2,3,4-
tetrahydropyrimidin-2-one
/
[00180] (EV-AQ0296-002) (Intermediate 7)
[00181] To a solution of 6-methyl-l,2,3,4-tetrahydropyrimidine-2,4-dione (2.0 g, 15.86
mmol) in dioxane (30 ml) was added 2,4-bis(4-methoxyphenyl)-l,3,2,4-dithiadiphosphetane
2,4-disulfide (6.41 g, 15.86 mmol) and stirred at 100 °C for 2 h . The reaction mixture was
cooled to r.t. and the white precipitate filtered under vacuum, washing with dioxane (20 ml),
to afford the title compound (1.85 g, 82%) as an off white powder.
[00182] Method B: LC-MS: m z = 142.85 (M+H)+; RT = 0.36.
[00183] Intermediate 8: Synthesis of 3,6-dimethyl-2-(methylsulfanyl)-3,4-
dihydropyrimidin-4-one
[00184] (EV-AO7509-001) (Intermediate 8)
[00185] 3,6-dimethyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one was prepared from
(3E)-l,l,l-trichloro-4-methoxypent-3-en-2-one using the procedure found in: Zanatta, Nilo;
Madruga, Claudia C ; Marisco, Patricia C ; Da Rosa, Luciana S.; Da Silva, Fabio M.;
Bonacorso, Helio G.; Martins, Marcos A. P.; Journal of Heterocyclic Chemistry; vol. 47; nb.
5; (2010); p . 1234 - 1239, affording the title compound (4.68 g, 78%) as a brown powder.
[00186] Method A : LC-MS: m z = 170.95 (M+H)+; RT = 0.97 min.
Examples 47-54
[00187] Examples 47-54 in Table 3 were prepared in an analogous fashion to Example 1
starting with the corresponding commercial thiouracil, methyl thioether or the specified
intermediate, and coupling the intermediate acid with the appropriate amine using the
specified coupling conditions.
Table 3

Examples 55-56 - Chiral Separation
[00188] Examples 55-56 in Table 4 were prepared by chiral separation of racemic
compounds in Table 3 . The stereochemistry was arbitrarily assigned.
Table 4
Preparative Example 3 - Formation of intermediates from the corresponding
dichloropyrimidines
[00189] Intermediate 9 : Preparation of 2-chloro-3H,4H-thieno[3,2-d]pyrimidin-4-one
[00190] (EV-AP2383-001) (Intermediate 9)
[00191] To a stirred solution of 2,4-dichlorothieno[3,2-d]pyrimidine (20 g, 97.5 mmol) in
THF (80 mL) was added 5M aq NaOH solution (98 mL, 488 mmol) and stirred at 50 °C for 6
h . The reaction mixture was acidified to pH 5 using acetic acid. The solution was then
extracted with EtOAc (2 x 50 mL) and the combined organics were dried over Na2S0 4,
filtered and concentrated in vacuo to yield the title compound (11.3 g, 60.5 mmol, 62%) as a
yellow powder.
[00192] Method A : LC-MS m/z = 186.9 [M + H]+; RT = 0.77 min.
[00193] Intermediate 10: Preparation of 2-hydrazinyl-3H,4H-thieno[3,2-d]pyrimidin-4-
one H (EV-AP23 84-001) (Intermediate 10)
[00194] To a stirred solution of 2-chloro-3H,4H-thieno[3,2-d]pyrimidin-4-one ( 11.34 g,
60.8 mmol) in EtOH (90 mL) was added hydrazine hydrate (5.91 mL, 121.5 mmol) and
stirred at 80 °C overnight. The reaction mixture was cooled to r.t. and the resultant precipitate
was collected via filtration, and washed with water (15 mL) to yield the title compound (7.4
g, 40.6 mmol, 67%) as a pale yellow powder.
[00195] Method A : LC-MS m/z = 182.9 [M + H]+; RT = 0.18 min.
[00196] Intermediate 11: 5-methyl-l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-
pyrazole-4-carboxylic acid
[00197] Step 1: Synthesis of methyl-5-methyl-l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-
yl}- lH-pyrazole-4-carboxylate
[00198] (EV-AP2385-001).
[00199] To a stirred solution of 2-hydrazinyl-3H,4H-thieno[3,2-d]pyrimidin-4-one (7 g,
38.4 mmol) in EtOH (75 mL) and AcOH (7.70 mL, 134.5 mmol) was added (2Z)-2-
[(dimethylamino)methylidene]-3-oxobutanoate (7.89 g, 46.1 mmol) and stirred at 50 °C for 3
h . The reaction mixture was cooled to r.t. and the resulting precipitate was isolated via
filtration to yield the title compound ( 11.2 g, 22.5 mmol, 59%) as a pale yellow powder.
[00200] Method A : LC-MS m/z = 291.0 [M + H]+; RT = 1.15 min.
[00201] Step 2 : Synthesis of 5-Methyl-l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-
pyrazole-4-carboxylic acid
[00202] (EV-AP23 86-001) (Intermediate 11).
[00203] To a solution of methyl-5-methyl-l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-
lH-pyrazole-4-carboxylate (6.53 g, 22.5 mmol) in 2:1 THF/methanol (37 mL) was added
2.5M aq NaOH solution (54 mL, 135 mmol) and stirred at r.t. for 2 h . The organics were
removed in vacuo, the residue acidified to pH 5 with 2M aq HC1 solution and the resulting
precipitate was collected via filtration to yield the title compound (6.22 g, 19.9 mmol, 89%)
as a beige powder.
[00204] Method A : LC-MS m/z = 277.0 [M + H]+; RT = 0.97 min.
[00205] Intermediate 12: Preparation of 2-methyl-4-(trifluoromethyl)piperidine (4:1
mixture of diastereoisomers)
[00206] (EV-AB8098-002) (Intermediate 12).
[00207] A solution of 2-methyl-4-(trifluoromethyl)pyridine (800 mg, 4.97 mmol) in 25%
acetic acid in MeOH (100 ml) [0.05M] was reacted on the H-Cube [10% Pt on C cartridge,
90 bar and 80 °C, lml/min. Upon completion, the reaction mixture was treated with a solution
of 4M HC1 in dioxane (2 ml, 8 mmol) and then concentrated in vacuo to yield a white
solid. The solid was dissolved in MeOH, treated with ammonia (7M in MeOH) and
concentrated in vacuo to afford the title compound (270 mg, 32%) as a white solid.
[00208] Method A : LC-MS m/z = 168.00 [M + H]+; RT = 0 .17 min.
[00209] Intermediate 13: Preparation of 4-(l-cyano-l-methylethyl)piperidin-l-ium
chloride
[00210] Step 1: Synthesis of tert-butyl 4-(l-cyano-l-methylethyl)piperidine-l-carboxylate
[00211] (EV-AQ8828-001)
[00212] To a stirred solution of tert-butyl 4-(cyanomethyl)piperidine-l-carboxylate (0.2 g,
8.13 mmol) in dry THF (2 niL) at 0 °C was added slowly KHMDS ( 1 M in toluene, 2.68 niL,
2.68 mmol). The reaction mixture was allowed to stir for 10 minutes, after which a solution
of iodomethane (0.11 mL, 1.78 mmol) in dry THF (2 mL) was added slowly. The reaction
was warmed to room temperature and stirred overnight. The reaction mixture was quenched
with aqueous ammonium chloride and extracted with ethyl acetate. The extracts were dried
(Na2S0 4) and concentrated in vacuo to afford the title compound (246 mg, 98%) as a yellow
powder: 1H NMR (250 MHz, Chloroform-d) δ 4.20 (s, 2H), 2.63 (m, 2H), 1.80 (m, 2H), 1.47
(s, 3H), 1.46 (s, 9H), 1.33 (s, 6H).
[00213] Step 2 : Synthesis of 4-(l-cyano-l-methylethyl)piperidin-l-ium chloride
[00214] (EV-AQ8830-001) (Intermediate 13).
[00215] Tert-butyl 4-(l-cyano-l-methylethyl)piperidine-l-carboxylate (EV-AQ8828-001,
243 mg, 0.963 mmol) was suspended in HC1 (4 M in dioxane, 7 mL) and the reaction was
stirred at room temperature for 3 hours. The resultant precipitate was filtered and washed
with ether to afford the title compound (95 mg, 51%) as a yellow powder: 1H NMR (500
MHz, DMSO-d6) δ 8.96 (s, 1H), 8.51 (s, 1H), 2.87 - 2.78 (m, 2H), 1.95 - 1.87 (m, 2H), 1.72
- 1.63 (m, 1H), 1.54 - 1.45 (m, 2H), 1.29 (s, 6H).
Examples 57-74 - Synthesis of thienopyrimidines
[00216] Examples 57-74 in Table 5 were prepared using the method described in Example
1 reacting intermediate 11 (5-methyl-l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-
pyrazole-4-carboxylic acid) with the appropriate amine using the specified coupling reagent.
Table 5


Example 75 - Preparation of 2-|4-[(2R <6S)-2<6-dimethylpiperidine-l-carbonyl1-5-
methyl-lH-pyrazol-l-yl|-3H <4H-thieno[3,2-d1pyrimidin-4-one.
[00217] Q-417 (EV-AP2568-002)
[00218] To a solution of 5-methyl-l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-
pyrazole-4-carboxylic acid (Intermediate 11, (EV-AP2386-001), 75 mg, 0.27 mmol) in DCM
(5 ml) was added thionyl chloride (0.2 ml, 2.71 mmol) followed by DMF (cat, 1 drop) and
stirred at 50 °C for 2 h . The reaction mixture was concentrated in vacuo and DCM added and
the concentration repeated (x2). The crude acid chloride (assume 0.271 mmol) was
suspended in more DCM (5 ml) at 0 °C and (cis)-2,6-dimethylpiperidine (0.04 ml, 0.41
mmol) and triethylamine (0.09 ml, 0.68 mmol) were added dropwise. The reaction mixture
was stirred at r.t. for 2 h . The reaction mixture was washed with water (5 mL) and brine
solution (5 mL) and the organic fraction was concentrated in vacuo. The crude residue was
dissolved in THF: 1M NaOH (1:1, 2 mL) and stirred at r.t. Methanol (0.5 ml) was added. The
organics from the reaction mixture were removed in vacuo and the reaction mixture acidified
to pH 5 using 1M aq HC1 solution. The aqueous was extracted using DCM (2 x 5 mL) and
the combined organic extracts were dried over Na2S04, filtered and concentrated in vacuo.
The crude residue was purified by prep HPLC (Method G) to afford the title compound (14.2
mg, 14%) as an off-white powder.
[00219] Method A : LC-MS m/z = 372.2 [M + H]+; RT = 3.05 min.
Examples 76-77
[00220] Examples in Table 6 were prepared by chiral separation of racemic compounds in
Table 5 . The stereochemistry was arbitrarily assigned.
Table 6
LC-MS MS Column
Example Separation
Ref. No. LBN Structure (RT) (M+H) + Retention*
No method
Method C Method C (min)
6.43
76 Q-414 EV-AQ0229-001
X I ,
3.29 392.2 L
Method M
8.41
77 Q-415 EV-AQ0229-002
.
3.29 392.2 L
Method M
Preparative Example 4 - Formation of intermediates from the corresponding
dichloropyrimidines
[00221] Intermediate 14: Preparation of 2-chloro-4-methoxy-6-methylpyrimidine
H[00222] (EV-AL6985-002)
[00223] To a solution of 2,4-dichloro-6-methylpyrimidine ( 1 g, 6.14 mmol) in THF (10
ml) was added 0.5M NaOMe in MeOH (18.4 ml, 9.20 mmol) at 0 °C and stirred at r.t.
overnight. A further 0.5 equivalents of 0.5 M NaOMe in MeOH (6.14 ml, 3.07 mmol) were
added at 0 °C and the reaction stirred at r.t. for 1 h . The reaction mixture was diluted with
water (30 ml) and extracted with EtOAc (2 x 50 ml). The combined organic extracts were
washed with brine (20 ml), dried and concentrated in vacuo and the residue purified via
column chromatography (100:0 - 75:25 Heptane-EtOAc) to afford the title compound (275
mg, 28%) as a colourless crystalline solid.
[00224] Method A : LC-MS m/z = 158.9 [M + H]+; RT = 1.05 min.
[00225] Intermediate 15: Preparation of 5-chloro-6H,7H-[l,3]thiazolo[5,4-d]pyrimidin-7-
one (EV-AQ0263-001)
[00227] Step 1: Synthesis of 7-(benzyloxy)-5-chloro-[l,3]thiazolo[5,4-d]pyrimidine
[00228] (EV-AQ0259-002)
[00229] To a solution of 5,7-dichloro-[l,3]thiazolo[5,4-d]pyrimidine (980 mg, 4.76 mmol)
in THF (20 mL) at 0 °C was added benzyl alcohol (495 ul, 4.76 mmol) and sodium hydride
(114 mg, 4.76 mmol, 60% in mineral oil) and stirred at r.t. for 22 h . To the reaction mixture
was added water (20ml) and extracted with EtOAc (2 x 50 ml). The combined organic
extracts were washed with brine, dried over sodium sulfate and concentrated in vacuo.
Purification by chromatography on Si0 2 (gradient 100:0 - 90:10, Heptane-EtOAc) afforded
the title compound (708 mg, 47%) as a white powder.
[00230] Method A : LC-MS m/z = 277.85 [M + H]+; RT = 1.39 min.
[00231] Step 2 : Synthesis of 5-chloro-6H,7H-[l,3]thiazolo[5,4-d]pyrimidin-7-one
[00233] 7-(benzyloxy)-5-chloro-[l,3]thiazolo[5,4-d]pyrimidine (EV-AQ0259-002, 708
mg, 2.24 mmol) was dissolved in a 1:1 mixture of 37% aq HC1-THF (10 mL) and stirred at
room temperature for 18 h . The reaction mixture was filtered under vacuum, washing with
THF and Et20, to afford 5-chloro-6H,7H-[l,3]thiazolo[5,4-d]pyrimidin-7-one (246 mg,
58%) as a pale yellow powder.
[00234] Method A : LC-MS m/z = 187.80 [M + H]+; RT = 0.49 min.
[00235] Intermediate 16: Synthesis of 2,4-dichloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine
[00236] (EV-AP2589-001)
[00237] To a solution of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (1.5 g, 7.98 mmol) in
THF (30 ml) at 0 °C was added sodium hydride (60% oil suspension, 383 mg, 9.57 mmol)
and stirred at 0 °C to r.t. for 20 mins. lodomethane (0.6 ml, 9.57 mmol) was added and stirred
at r.t. for 3 h .
[00238] The mixture was quenched by addition of saturated ammonium chloride solution
(20 mL). EtOAc was then added resulting in formation of a precipitate. The precipitate was
filtered and the filtrate extracted with EtOAc (x2). The combined organic fractions were
washed with water, dried over Na2S04, filtered and concentrated in vacuo to afford the title
compound (1.65 g, 97.2%) as a yellow powder.
[00239] Method A : LC-MS m/z = 201.90, 203.90 [M + H]+; RT = 1.21 min.
Examples 78-88
[00240] Examples 78-88 in Table 7 were synthesized following the procedure described
for Example 57 starting from the corresponding dichloropyrimidine or specified intermediate
and coupling the intermediate acid with the appropriate amine using the specified coupling
conditions.
Table 7
80 Q-323 EV-AN7481-001 3.26 386.2 COMU
81 Q-320 EV-AO8806-002 340.1 2.17 COMU
82 Q-321 EV-AO8807-002 338.2 2.96 COMU
83 Q-429 EV-AQ0246-002 406.2 3.16 T3P
84 Q-378 EV-AP2343-001 375.2 2.62 TBTU
Commercial
85 Q-436 EV-AQ7 107-002 2.23 370.2 T3P chloro-
pyrimidone
[00241] Intermediate 17: Preparation of 2-hydrazinyl-3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-4-one (EV-AQ7 134-001)
[00243] Step 1: Synthesis of 2-sulfanylidene- 1H,2H,3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-4-one
[00244] (EV-AQ7 13 1-001)
[00245] To a solution of methyl 2-oxocyclopentanecarboxylate (17.83 mL, 143.65 mmol)
in acetonitrile (150 mL) was added thiourea (16.4 g, 215.47 mmol) followed by DBU (25.73
mL, 172.38 mmol) and stirred at 80 °C for 24 h . The reaction mixture was concentrated in
vacuo and dissolved in water. The solution was acidified to pH3/4 using 5M aq HCl solution
and the resulting precipitate was collected and dried under vacuum after washing with water
and diethyl ether. The solid was dried further at 40 °C under vacuum overnight to afford the
title compound (17.81 g, 73.7%) as a beige powder.
[00246] Method A : LC-MS: m/z = 168.9 (M+H)+, RT = 0.2 - 0.45 min.
[00247] Step 2 : Synthesis of 2-(methylsulfanyl)-3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-4-one
[00249] To a suspension of 2-sulfanylidene- 1H,2H,3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-4-one (EV-AS7 13 1-001, 17.81 g, 105.88 mmol) in water (100 mL)
was added NaOH (4.66 g, 116.46 mmol) followed by the drop wise addition of iodomethane
(7.25 mL, 116.46 mmol). The reaction mixture was stirred at room temperature for 1.5 h,
then cooled to 5 °C and the resultant precipitate was collected by vacuum filtration. The solid
was washed with ice cold water (50 mL) water and diethyl ether (50 mL) and dried further
under vacuum at 40 °C to afford the title compound (17.78 g, 89.4%) as an off white powder.
[00250] Method A : LC-MS: m/z = 182.9 (M+H)+; RT = 0.89 min.
[00251] Step 3 : Synthesis of 2-hydrazinyl-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-
one
[00252] (EV-AQ7 134-001)
[00253] To a solution of 2-(methylsulfanyl)-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-
one (EV-AQ7 133-001, 17.78 g, 97.56 mmol) in EtOH (30 mL) was added hydrazine hydrate
(23.73 mL, 487.81 mmol). The reaction mixture was stirred at 90 °C for 24 h and then at 85
°C for a further 7 h . The cooled reaction mixture was filtered and washed with EtOH (15 mL)
and water (10 mL) to afford the title compound (13.1 g, 80.8%) as a white powder.
[00254] Method B: LC-MS: m/z = 166.9 (M+H)+, RT = 0.19 min.
[00255] Intermediate 18: Preparation of 5-methyl-l-{4-oxo-3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-2-yl}-lH-pyrazole-4-carboxylic acid (Q-481, EV-AQ7 139-001)
[00257] Step 1: Synthesis of 2-{5-methyl-4-[4-(trifluoromethyl)piperidine-l-carbonyl]-
lH-pyrazol-l-yl} -3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one
[00258] (EV-AQ7 137-001)
[00259] To a solution of 2-hydrazinyl-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one
(EV-AQ7 134-001, 19 g, 114.33 mmol) in ethanol (120 mL) was added methyl 2-
[(dimethylamino)methylidene]-3-oxobutanoate (EV-AL6988-001, 21.53 g, 125.77 mmol)
followed by acetic acid (22.91 mL, 400.17 mmol). The reaction mixture was stirred at 50 °C
for 3.5 h . After 15 mins additional ethanol (170 mL) was added to maintain stirring. The
reaction mixture was cooled and the solvent volume reduced to approximately half. The
resultant precipitate was collected and dried by vacuum filtration to afford the title compound
(21.84 g, 69.6%) as a beige powder.
[00260] Method B: LC-MS: m/z = 275.0 (M+H)+, RT = 0.98 min.
[00261] Step 2 : Synthesis of 5-methyl-l-{4-oxo-3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-2-yl}-lH-pyrazole-4-carboxylic acid (Q-481, EV-AQ7 139-001)
[00262] (EV-AQ7 139-001)
[00263] Methyl 5-methyl-l-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}-lH-
pyrazole-4-carboxylate (EV-AQ7 137-001, 21.84 g, 79.63 mmol) was suspended in 3:2:1
water/THF/ methanol (300 mL) and 2.5M aq NaOH solution (191 mL) was added. The
reaction mixture was stirred at r.t. for 3 h . The organics from the reaction mixture were
removed in vacuo. The residue was acidified with 5M aq HCl solution and the resulting
precipitate was collected and dried under vacuum filtration at 45 °C for 5 days to afford the
title compound (21.6 g, 100%) as a beige powder.
[00264] Method C: LC-MS: m/z = 261.1 (M+H)+, RT = 1.81 min.
[00265] Intermediate 19: Preparation of +(syn)-2-methyl-4-(trifluoromethyl)piperidine
hydrochloride
[00266] (EV-AQ3807-001)
[00267] A solution of 2-methyl-4-(trifluoromethyl)pyridine (3 g, 18.62 mmol) in MeOH
(100ml) was treated with a solution of 4M HCl in dioxane (5.6 ml, 22.3 mmol) followed by
platinum (iv) oxide (253 mg, 1.12 mmol) and the resultant suspension was hydrogenated in a
pressure vessel at 50 psi and r.t. for 4 h . The catalyst was cautiously removed by filtration
over Celite and the filtrate concentrated in vacuo to afford the title compound (3.7g, 99%) as
a white solid.
[00268] Method A : LC-MS m/z = 168.0 [M + H]+; RT = 0.21 min.
[00269] Intermediate 20: Synthesis of 2-methyl-4-phenylpiperidin-4-ol hydrochloride EV-
AQ7 159-002 used in (EV-AQ7163-003)
[00270] Step 1: Synthesis of tert-butyl 4-hydroxy-2-methyl-4-phenylpiperidine-l-
carboxylate formation using phenyllithium
[00271] (EV-AQ7 159-002)
[00272] To a solution of phenyllithium (1.8M in Bu20, 7.16 ml, 12.89 mmol) in THF (15
mL) at -78oC was added dropwise l-boc-2-methyl-4-piperidinone (2.5 g, 11.72 mmol) in
more THF (5 mL). The reaction mixture was warmed to room temperature and stirred for 3
hours. The reaction was quenched by pouring onto ice water. EtOAc (2x 25 mL) was added
and the product extracted. The combined organics were dried (Na2S0 4), filtered and
concentrated in vacuo. The crude residue was purified by chromatography on Si0 2 Eluting
with 0-100% EtOAc in heptane to afford the title compound ( 2.97 g, 73.9%) as a yellow oil
[00273] Method B: LC-MS: m/z = 192.0 (M-Boc)+, RT = 1.19 min.
[00274] Step 2: Synthesis of 2-methyl-4-phenylpiperidin-4-ol hydrochloride
[00275] (EV-AQ7 16 1-001)
[00276] To a solution of tert-butyl 4-hydroxy-2-methyl-4-phenylpiperidine-l-carboxylate
(EV-AQ7 159-002, 1.5 g, 5.15 mmol) in dioxane (3 mL) was added HCl in dioxane (4M, 6.43
mL, 25.74) and the reaction mixture stirred at room temperature for 1 hour. The reaction
mixture was concentrated in vacuo re-dissolved in DCM and concentrated again to afford
1.22 g (83.3%) of the title compound as an orange gum.
[00277] Method B: LC-MS: m/z = 192.0 (M+H)+, RT = 0.21 min.
[00278] Intermediate 2 1: Synthesis of 2-(4-{ 3-hydroxy-3-phenyl-8-
azabicyclo[3.2.1]octane-8-carbonyl}-5-methyl-lH-pyrazol-l-yl)-3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-4-one.
[00279] (EV-AQ7 182-001)
[00280] 2-(4-{3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]octane-8-carbonyl}-5-methyl-lH-
pyrazol-l-yl)-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one was prepared by the
procedure described for Intermediate 2 1 (EV-AQ7 16 1-001) substituting l-boc-2-methyl-4-
piperidinone with tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate, affording the
title compound (505 mg, 35%) as a an off white powder.
[00281] Method B: LC-MS: m z = 203.9 (M+H)+, RT = 0.27 mins.
[00282] Intermediate 22: Synthesis of 3-phenyl-8-azabicyclo[3.2.1]octane hydrochloride
EV-AQ7 185-002
[00283] Step 1: Synthesis of tert-butyl 3-phenyl-8-azabicyclo[3.2.1]oct-2-ene-8-
carboxylate
[00284] (EV-AQ7 180-002)
[00285] To a solution of phenyllithium (2.0M in Bu20, 3.66 ml, 7.32 mmol) in THF (15
mL) at -78 °C was added dropwise tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate
(1.5 g, 6.66 mmol) in THF (5 mL). The reaction was warmed to r.t. over 1 h and stirred for
another 1 h . 1/3 of the reaction mixture was removed for an analogous chemistry and the
remaining 2/3 of the reaction mixture was cooled to -78 °C and treated with methanesulfonyl
chloride (1.03 mL, 13.32 mmol) followed by triethylamine (3.06 mL, 21.97 mmol). The
reaction mixture was then warmed to r.t. and stirred overnight. The reaction mixture was
cooled to -78 °C again and more methanesulfonyl chloride (2.06 mL, 26.64 mmol) and
triethylamine (6.12 mL, 43.94 mmol) were added. The reaction mixture was then warmed to
r.t. and stirred for 3.5 h . The reaction was diluted with water and extracted with EtOAc (3 x
20 mL). The combined organics were washed with water (10 mL) and brine (10 mL), dried
over Na2S0 4 and concentrated in vacuo. The crude residue was purified by chromatography
on Si0 2 eluenting with Heptane/EtOAc (0-100%) to afford the title compound (480 mg,
36.8%) as an off-white solid.
[00286] Method B: LC-MS: m/z = 229.95 (M- Bu)+, RT = 1.37 min.
[00287] Step 2 : Synthesis of 3-phenyl-8-azabicyclo[3.2.1]oct-2-ene hydrochloride
[00288] (EV-AQ7183-001)
[00289] To a solution of tert-butyl 3-phenyl-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate
(EV-AQ7 180-002, 97%, 480 mg, 1.63 mmol) in dioxane (3 mL) was added HC1 in dioxane
(4M, 2.04 mL, 8.16 mmol) and the mixture was stirred at r.t. for 4 h . The reaction mixture
was concentrated in vacuo re-dissolved in DCM and concentrated again to afford the title
compound (355 mg, 93.2%) as an off white powder.
[00290] Method B: LC-MS: m/z = 186.0 (M+H)+, RT = 0.79 min.
[00291] Step 3 : Synthesis of 3-phenyl-8-azabicyclo[3.2.1]octane hydrochloride
[00292] (EV-AQ7 185-002)
[00293] 3-phenyl-8-azabicyclo[3.2.1]oct-2-ene hydrochloride (EV-AQ7183-001, 355 mg,
1.92 mmol) was dissolved in MeOH: EtOAc (1:1, 45 mL) and subjected to H-cube
hydrogenation ( 1 mL/min, 20 bar, 60 °C, controlled H2 mode) over an Pd/C (10%) cat cart.
The procedure was repeated at 40 bar, 60 °C and again at 60 bar, 60 °C. The reaction mixture
was concentrated in vacuo to afford the title compound (305 mg, 76%) as an off white
powder.
[00294] Method B: LC-MS: m/z = 188.0 (M+H)+, RT = 0.74 mins.
[00295] Intermediate 23: Synthesis of 4-methoxy-4-phenylpiperidin-l-ium chloride EV-
AQ8865-001
[00296] Step 1: Synthesis of tert-butyl-4-hydroxy-4-phenylpiperidine-l-carboxylate
[00297]
[00298] A solution l-Boc-4-piperidinone ( 1 g, 5.02 mmol) in THF (5 mL) was added
dropwise to a solution of phenyllithium (1.8M in Bu20 , 3.07 mL, 5.52 mmol) in THF (5 mL)
at -78 °C. The reaction was warmed to r.t. and stirred for 4 h . The reaction was quenched by
pouring onto ice water and extracted with EtOAc (2 x 25 mL). The combined organic
extracts were dried over MgS04 and concentrated in vacuo. The crude residue was purified
by chromatography on Si0 2, eluenting with Heptane/EtOAc (gradient 100:0 - 20:80) to
afford the title compound (1.095 g, 79%) as a yellow powder.
[00299] Method B: LC-MS: m/z = 177.9 (M-Boc)+, RT = 1.15 min.
[00300] Step 2 : Synthesis of tert-butyl 4-methoxy-4-phenylpiperidine-l-carboxylate
[00301] (EV-AQ8859-001)
[00302] To a stirred solution of 4-hydroxy-4-phenyl-piperidine-l-carboxylic acid tert-butyl
ester (1.08 g, 3.91 mmol) in dry THF (25 mL) was added NaH (60% in oil, 0.17 g, 4.30
mmol) and stirred for 1 h before methyl iodide (0.37 mL, 5.86 mmol) was added and stirred
overnight. The mixture was retreated with NaH (60%, 0.17 g, 4.30 mmol), followed by
methyl iodide (0.37 mL, 5.86 mmol) and stirred overnight. The mixture was retreated for a
third time with NaH (60%, 0.17 g, 4.30 mmol), followed by methyl iodide (0.37 mL, 5.86
mmol) and stirred for 4 h . Brine (40 mL) was added and the product extracted with EtOAc (2
x 50 mL). The combined organic extracts were dried over MgS0 4, concentrated in vacuo and
purified by chromatography, eluting with Heptane/EtOAc (gradient 100:0 - 85:15) to afford
the title compound (610 mg, 54%) as an off-white powder.
[00303] Method B: LC-MS: m/z = 192.02 (M-Boc)+, RT = 1.30 mins.
[00304] Step 3 : Synthesis of 4-methoxy-4-phenylpiperidin-l-ium chloride
[00305] (EV-AQ8862-001)
[00306] 4-methoxy-4-phenylpiperidine-l-carboxylate (603 mg, 2.07 mmol) was dissolved
in HC1 in dioxane (4M, 6 mL, 24.0 mmol) and stirred at r.t. overnight. The reaction mixture
was concentrated in vacuo and triturated with ether to afford the title compound (391 mg,
83%) as a colourless powder.
[00307] Method B: LC-MS: m/z = 191.9 (M+H)+, RT = 0.64 mins.
[00308] Intermediate 24: Synthesis of 4-(2,2,2-trifluoroethoxy) piperidine
[00309] Step 1: Synthesis of 4-(2,2,2-trifluoroethoxy)pyridine
[00310] (EV-AQ7 197-001)
[00311] To a solution of 2,2,2-trifluoroethanol (0.96 mL, 13.33 mmol) and NaH (60% in
oil, 533.26 mg, 13.33 mmol) was added 4-chloropyridine hydrochloride ( 1 g, 6.67 mmol) in
anhydrous DMSO (20 mL). The reaction mixture was stirred at 0 °C to r.t. overnight. Water
(10 mL) was added and the product extracted with DCM (2 x 50 mL). The combined organic
extracts were washed with water (10 mL) and brine (10 mL), dried over Na2S0 4, filtered and
concentrated in vacuo to afford the title compound (510 mg, 38.9%) as a tan gum.
[00312] Method B: LC-MS: m z = 178.0 (M+H)+, RT = 0.31 min.
[00313] Step 2 : Synthesis of 4-(2,2,2-trifluoroethoxy) piperidine
[00314] (EV-AS3700-001)
[00315] 4-(2,2,2-trifluoroethoxy)pyridine (EV-AQ7 197-001, 510 mg, 2.88 mmol) was
dissolved in EtOH: acetic acid (3:1, 60 mL) and subjected to H-cube hydrogenation
(lml/min, 90 bar, 80 °C) over a 5% Rh/C cat cart. The reaction mixture was concentrated in
vacuo to afford the title compound (104 mg, 11.9%) as a tan gum.
[00316] Method B: LC-MS: m/z = 184.0 (M+H)+, RT = 0.21-0.33 min.
[00317] Intermediate 25: Synthesis of +(syn)-4-methyl-2-(trifluoromethyl)piperidine
hydrochloride
[00318] (EV-AQ8830-001)
[00319] A solution of 4-methyl-2-(trifluoromethyl)pyridine ( 1 g, 6.21 mmol) in MeOH (20
ml) was treated with HCl (4M in dioxane, 1.9 mL), followed by platinum (iv) oxide (85 mg,
0.37 mmol) and the resultant suspension was hydrogenated in a pressure vessel at 50 psi and
r.t. for 20 h . More platinum (iv) oxide (85 mg, 0.37 mmol) was added along with AcOH (10
ml) and the hydrogenation was continued for 20 h .
[00320] The catalyst was removed by filtration over Celite and the filtrate evaporated
under vacuum, the residue was triturated with ether to provide the title compound (460 mg,
36%) as a white solid.
[00321] Method B: LC-MS m/z = 167.95 [M + H]+; RT = 0.18 min.
Examples 89-141
[00322] Examples in Table 8 were prepared using Method 1 reacting Intermediate 18 (5-
methyl-l-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-yl}-lH-pyrazole-4-carboxylic
acid) with the appropriate amine using the specified coupling reagent.
Table 8
93 Q-461 EV-AQ7 145-002 2.1 358.3 T3P
94 Q-462 EV-AQ7 146-002 3.13 420.2 T3P
95 Q-505 EV-AQ7 172-001 1.67 405.2 T3P
96 Q-496 EV-AQ7 172-002 3.03 448.1 T3P
97 Q-418 EV-AQ8866-003 2.72 396.2 T3P
98 Q-497 EV-AQ7 172-003 2.63 417.2 T3P
99 Q-498 EV-AQ7 172-004 3.06 443.2 T3P
100 Q-499 EV-AQ7173-001 3.04 461.1 T3P
101 Q-500 EV-AQ7173-002 3.45 450.2 T3P
102 Q-501 EV-AQ7173-003 3.18 434.2 T3P
103 Q-502 EV-AQ7 176-001 3.14 476.1 T3P
104 Q-464 EV-AQ8829-001 2.02 353.1 T3P
105 Q-470 EV-AQ8832-001 1.9 330.1 T3P
106 Q-477 EV-AQ8837-001
0
2.86 406.2 T3P
107 Q-478 EV-AQ8838-001 1.92 344.2 T3P
108 Q-504 EV-AQ8853-001 2.5 468.1 T3P
109 Q-424 EV-AQ0237-002 2.47 364.2 COMU
110 Q-428 EV-AQ0241-002 3.22 404.2 T3P
111 Q-473 EV-AR5330-002 2.98 429.2 T3P
112 Q-479 EV-AR5333-002 2.83 376.2 T3P
113 Q-490 EV-AR5335-002 3.00 378.2 T3P
114 Q-491 EV-AR5343-002 3.46 418.2 T3P

120 Q-486 EV-AR5352-002 2.9 466.1 T3P
121 Q-506 EV-AR5357-002 1.68 415.1 T3P
122 Q-507 EV-AR5363-002 2.97 477.2 T3P
123 Q-468 EV-AQ3 828-001 3.07 420.2 T3P
124 Q-476 EV-AQ3831-001 2.93 410.2 T3P



Examples 142-145
[00323] Examples in Table 9 were prepared by chiral separation of racemic compounds in
Table 8. The stereochemistry was arbitrarily assigned.
Table 9
Preparative Example 6 - Direct cyclisation of hydrazines
[00324] Intermediate 26: Preparation of methyl-2-[(dimethylamino)methylidene]-3-
oxobutanoate
[00326] Methyl 3-oxobutanoate (40 g, 0.34 mol) and l,l-dimethoxy-N,N-
dimethylmethanamine (54.92 mL, 0.41 mol) were combined and stirred at 80 °C for 2 h . The
reaction mixture was concentrated in vacuo and the resulting oil was dried for 24 h under
vacuum to afford the title compound (56.53 g, 86.3%) as a dark red solid.
[00327] 1H NMR (500 MHz, DMSO-J6) δ 7.62 (s, 1H), 3.63 (s, 3H), 3.24 - 2.96 (m, 3H),
2.90 - 2.58 (m, 3H), 2.13 (s, 3H).
[00328] Intermediate 27 : Preparation of 2-[(dimethylamino)methylidene] -1-(1,2,3 ,4-
tetrahydroisoquinolin-2-yl)butane- 1,3-dione (EV-AP2538-001)
[00330] Step 1: Synthesis of l-(l,2,3,4-tetrahydroisoquinolin-2-yl)butane-l,3-dione
[00331] (EV-AP2535-001)
[00332] To a solution of 1,2,3,4-tetrahydroisoquinoline (10.0 mL, 78.83 mmol) in toluene
(80 mL) was added methyl 3-oxobutanoate (12.76 mL, 118.25 mmol) and triethylamine
(13.19 mL, 94.6 mmol) and stirred at 105 °C for 15.5 hours. Water (15 mL) was added to the
cooled reaction mixture and the organic phase was extracted. The organics were dried over
Na2S0 4, filtered and concentrated in vacuo. The crude residue was purified by
chromatography on Si0 2, eluting with 0-100% EtOAc in heptane to afford the title compound
(12.8 g, 70.2%) as viscous yellow oil.
[00333] Method A : LC-MS: m/z = 218.0 (M+H)+; RT = 1.03 min.
[00334] Step 2 : Synthesis of 2-[(dimethylamino)methylidene]-l-(l,2,3,4-
tetrahydroisoquinolin-2-yl)butane- 1,3-dione
[00335] (EV-AP253 8-001)
[00336] l-(l,2,3,4-tetrahydroisoquinolin-2-yl)butane-l,3-dione (EV-AP2535-001, 2 g,
9.21 mmol) and l,l-dimethoxy-N,N-dimethylmethanamine (1.47 mL, 11.1 mmol) were
combined and stirred at 80 °C for 15 h . The reaction mixture was concentrated in vacuo to
afford the title compound (2.51 g, 96.1%) as a beige powder.
[00337] Method A : LC-MS: m/z = 273.0 (M+H)+; RT = 0.99 min.
[00338] Intermediate 28: Preparation of (2E)-2-[(dimethylamino)methylidene]-l-[4-
(trifluoromethyl)piperidin-l-yl]butane-l,3-dione (EV-AP2553-001)
[00340] The title compound was prepared in an analogous manner to intermediate EV-
AP2535-001 starting with 4-trifluoromethylpiperidine hydrochloride (10.5g, 55.4 mm) to
afford the title compound (13.4 g, 87%) as a dark orange powder.
[00341] Method A : LC-MS: m z = 293.0 (M+H); RT = 0.97 min.
[00342] Intermediate 29: Preparation of l-(lH-pyrazole-4-carbonyl)-4-
(trifluoromethyl)piperidine (EV-AQ8818-00 1)
[00343] (EV-AQ8818-001)
[00344] To a stirred solution of lH-pyrazole-4-carboxylic acid (1.0 g, 8.92 mmol) and
DIPEA (5.4 mL, 31.2 mmol) in THF (15 mL) was added T3P (50% in EtOAc, 10.5 mL, 17.8
mmol) and stirred at r.t. for 5 mins. 4-(trifluoromethyl)piperidine hydrochloride (2.03 g, 10.7
mmol) was then added and the solution was stirred at r.t. overnight. The reaction mixture was
cooled, partitioned between DCM (30 mL) and saturated NaHC0 3 solution (40 mL) and the
aqueous fraction extracted with DCM (2 x 30 mL). The combined organic fractions were
dried over MgS0 4 and the solvent removed in vacuo. The resulting oil was purified via
chromatography on Si0 2 MeOH/DCM (gradient 100:0 - 90:10) to afford the title compound
(673 mg, 61%) as a yellow powder.
[00345] Method A : LC-MS m z = 248.0 [M + H]+; RT = 0.98 min.
[00346] Intermediate 30: Preparation of Synthesis of 6-chloro-2-hydrazinyl-3H,4H-
thieno[3,2-d]pyrimidin-4-one
[00347] Step 1: Synthesis of methyl lH,2H,3H,4H-thieno[3,2-d]pyrimidine-2,4-dione
[00348] (EV-AP2346-001)
[00349] A mixture of methyl 3-aminothiophene-2-carboxylate (3.5 g, 22.3 mmol) and urea
(8.75 mL, 144.7 mmol) was heated at 180 °C for 5 h . The mixture was cooled to -90 °C and
water (40 mL) was added. The mixture was stirred at r.t. overnight and the resulting
precipitate isolated via filtration to afford the title compound (3.66 mg, 98%) as an off-white
powder.
[00350] Method A : LC-MS m/z = 214.0 [M + H]+; RT = 0.79 min.
[00351] Step 2 : Synthesis of 6-nitro-lH,2H,3H,4H-thieno[3,2-d]pyrimidine-2,4-dione
[00352] H (EV-AP2349-001)
[00353] lH,2H,3H,4H-thieno[3,2-d]pyrimidine-2,4-dione (EV-AP2346-001, 3.65 g, 21.7
mmol) was added portion wise to a stirred solution of fuming HNO3 (12 mL) and H2SO4
(95%, 12 mL) at 0 °C. The reaction was warmed to r.t. and stirred for 1 h . The precipitated
solid was collected via filtration to afford the title compound (1.28 g, 28%) as an orange
powder.
[00354] Method A : LC-MS m/z = 214.0 [M + H]+; RT = 0.79 min.
[00355] Step 3 : Synthesis of 2,4,6-trichlorothieno[3,2-d]pyrimidine
[00357] A stirred suspension of 6-nitro-lH,2H,3H,4H-thieno[3,2-d]pyrimidine-2,4-dione
(EV-AP2349-001, 1.2 g, 21.7 mmol) in phenylphosphonic dichloride (5 mL, 35.3 mmol) was
stirred at 180 °C for 4 h . The mixture was cooled to -100 °C and transferred slowly onto
vigorously stirred ice/water (40 mL). The resulting suspension was stirred at r.t. for 30 mins
and was then extracted with DCM (2 x 40 niL). The combined organic fractions were dried
over Na2S04, concentrated in vacuo, and purified via chromatography on Si0 2 (0:100-10:90
MeOH-DCM) followed by further chromatography on Si0 2 (0:100-50:50 EtOAc-heptane) to
yield the title compound (752 mg, 55%) as a colourless powder.
[00358] Method A : LC-MS m/z = 240.7 [M + H]+; RT = 1.43 min.
[00359] Step 4 : Synthesis of 2,6-dichloro-3H,4H-thieno[3,2-d]pyrimidin-4-one
[00361] To a stirred solution of 2,4,6-trichlorothieno[3,2-d]pyrimidine (EV-AP2352-
001,749 mg, 3.13 mmol) in THF (12 mL) was added 1M aq NaOH solution (16 mL, 16
mmol) and stirred at r.t. overnight. The solution was acidified to pH ~5 with 5M aq HC1
solution and the resulting precipitate isolated via filtration to afford the title compound (400
mg, 58%) as a colourless powder.
[00362] Method A : LC-MS m/z = 220.8 [M + H]+; RT = 1.02 min.
[00363] Step 5 : Synthesis of 6-chloro-2-hydrazinyl-3H,4H-thieno[3,2-d]pyrimidin-4-one
[00364] H (EV-AP2359-001)
[00365] To a stirred solution of 2,6-dichloro-3H,4H-thieno[3,2-d]pyrimidin-4-one (EV-
AP2354-001, 361 mg, 1.63 mmol) in ethanol (5 mL) was added hydrazine hydrate (199 ,
4.08 mmol) and stirred at 80 °C overnight. The reaction mixture was cooled, the precipitate
was collected via filtration and the solid washed with water to afford the title compound (247
mg, 70%) as a yellow powder.
[00366] Method A : LC-MS m/z = 216.9 [M + H]+; RT = 0.74 min.
[00367] Intermediate 31: Preparation of 5-chloro-2-hydrazinyl-3,4-dihydropyrimidin-4-
one
[00368] Step 1: Synthesis of 5-chloro-2-hydrazinyl-3,4-dihydropyrimidin-4-one
[00369] (EV-AP2350-001)
[00370] To a solution of 2,4,5-trichloropyrimidine (5.00 g, 27.3 mmol) in THF (12 mL)
was added 1M aq NaOH (35.4 mL, 35.4 mmol) and stirred at r.t. for 3 days. The solution was
acidified to pH ~5 with 5M aq HCl and extracted with DCM (2 x 40 mL). The combined
organic fractions were dried over Na2S04, concentrated in vacuo and triturated with 1:4
DCM-heptane to afford the title compound (2.33 g, 52%) as an orange powder.
[00371] Method A : LC-MS m/z = 164.8 [M + H]+; RT = 0.38 min.
[00372] Step 2 : Synthesis of 5-chloro-2-hydrazinyl-3,4-dihydropyrimidin-4-one
[00373] (EV-AP2357-001)
[00374] To a solution of 2,5-dichloro-3,4-dihydropyrimidin-4-one (EV-AP23 50-001, 200
mg, 1.21 mmol) in ethanol (3 mL) was added hydrazine hydrate (148 , 3.03 mmol) and
stirred at 50 °C overnight. The reaction mixture was cooled to r.t. and the resulting precipitate
isolated via filtration to afford the title compound (88 mg, 45%) as an off-white powder.
[00375] Method A : LC-MS m/z = 160.9 [M + H]+; RT = 0 .17 min.
[00376] Intermediate 32: Preparation of 5-tert-butyl-2-hydrazinyl-3,4-dihydropyrimidin-4-
one
[00377] Step 1: Synthesis of ethyl 2-formyl-3,3-dimethylbutanoate.
[00378] (EV-AO7549-002)
[00379] To a solution of ethyl 3,3-dimethylbutanoate (5.814 ml, 34.67 mmol) and ethyl
formate (8.366 ml, 104.01 mmol) in DCM (60 ml) at 0 °C under nitrogen was added TiCl4
(52.01 ml, 52.01 mmol) and Et3N (11.61 mL, 83.21 mmol) and stirred at 0 °C - r.t. overnight.
To the reaction mixture was added water, which was then extracted with DCM (2 x 50 ml).
The combined organic extracts were washed with brine, dried over Na2S0 4, concentrated in
vacuo and purified via column chromatography (100:0 - 0:100 Heptane-EtOAc) to afford the
title compound (2.72 mg, 42%) as a free flowing orange oil.
[00380] 1H NMR (500 MHz, DMSO-d6) δ 9.74 (d, J = 3.6 Hz, 1H), 4.21 - 4.10 (m, 2H),
3.07 (d, J = 3.6 Hz, 1H), 1.21 (t, J = 7.1 Hz, 3H), 1.07 (s, 9H).
[00381] Step 2 : Synthesis of 5-tert-butyl-2-(methylsulfanyl)-3,4,5,6-tetrahydropyrimidin-
4-one
[00382] (EV-AO7576-001)
[00383] To a solution of ethyl 2-formyl-3,3-dimethylbutanoate (EV-AO7549-002, 92%,
100 mg, 0.534 mmol) in water (2 ml) was added 1M aq NaOH solution (534 µΐ , 0.534 mmol)
and thiourea (122 mg, 1.603 mmol) and stirred at 100 °C for 1 h . The reaction mixture was
allowed to cool to r.t. and acidified to pH 2-3 using 1M aq HC1 solution to afford a white
precipitate. The reaction mixture was filtered, washing with MeCN, to afford the title
compound (72 mg, 73%) as a pearly white solid.
[00384] Method A : LC-MS m/z = 184.9 [M + H]+; RT = 0.93 min.
[00385] Step 3 : Synthesis of 3,6-dimethyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one
[00386] (EV-AO7579-001)
[00387] To water (20 ml) was added NaOH (97%, 286 mg, 6.925 mmol). After the sodium
hydroxide had dissolved 5-tert-butyl-2-sulfanylidene-l,2,3,4-tetrahydropyrimidin-4-one (EV-
AO7576-001, 1.16 g, 6.295 mmol) was added and the mixture stirred until dissolved.
Iodomethane (435 ul, 6.925 mmol) was added dropwise and the mixture stirred at r.t.
overnight. The solid was filtered and washed with ice cold water (2 x 10 ml) to afford the
title compound (686 mg, 54%) as an off white solid.
[00388] Method A : LC-MS m/z = 198.9 [M + H]+; RT = 1.09 min.
[00389] Step 4 : Synthesis of 5-tert-butyl-2-hydrazinyl-3,4-dihydropyrimidin-4-one
[00390] (EV-A0758 1-001)
[00391] To a solution of 5-tert-butyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one (EV-
AO7579-001, 600 mg, 3.026 mmol) in pyridine (5 ml) was added hydrazine hydrate (1.47 ml,
30.26 mmol) and stirred at 100 °C overnight. The reaction mixture was concentrated in vacuo
and triturated using Et20 to afford the title compound (331 mg, 60%) as an off white powder.
[00392] Method A : LC-MS m/z = 183.0 [M + H]+; RT = 0.40 min.
[00393] Intermediate 33: Preparation of 2-hydrazinyl-6-(trifluoromethyl)-3,4-
dihydropyrimidin-4-one (EV-AO7596-001)
[00394]
[00395] 2-hydrazinyl-6-(trifluoromethyl)-3,4-dihydropyrimidin-4-one was prepared by an
analogous route to Intermediate 32 substituting with 2-sulfanylidene-6-(trifluoromethyl)-
l,2,3,4-tetrahydropyrimidin-4-one, which afforded the title compound (212 mg, 31%) as an
off white powder.
[00396] Method A : LC-MS m/z = 194.9 [M + H]+; RT = 0.52 min.
[00397] Intermediate 34: Preparation of 6-hydrazinyl-lH,4H,5H-pyrazolo[3,4-
d]pyrimidin-4-one (EV-AQ7 120-00 1)
[00398] Step 1: Synthesis of 4-(benzyloxy)-6-chloro-lH-pyrazolo[3,4-d]pyrimidine
[00399] (EV-AQ7 113-003)
[00400] To a solution of benzyl alcohol (0. 19 mL, 1.85 mmol) in dioxane (3 mL) at 0 °C
was added potassium t-butoxide (436.38 mg, 3.89 mmol) followed by 4,6-dichloro-lH-
pyrazolo[3,4-d]pyrimidine (350 mg, 1.85 mmol). The reaction mixture was warmed to r.t.
over 15 mins and then stirred for 2 1 h . The reaction mixture was quenched by the addition of
sat aq NH4C 1 solution (2 mL) and extracted with EtOAc (2 x 5 mL). The combined organic
fractions were dried over Na2S0 4, filtered and concentrated in vacuo. The crude material was
purified by chromatography on Si0 2, eluting with 0-50% EtOAc in heptane to afford the title
compound (325 mg, 41.1%) as a white solid.
[00401] Method A : LC-MS: m/z = +261.0, 262.9 (M+H)+; RT = 1.28 min.
[00402] Step 2 : Synthesis of 6-chloro-lH,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one
[00404] To a solution of 4-(benzyloxy)-6-chloro-lH-pyrazolo[3,4-d]pyrimidine (EV-
AQ71 13-003, 61%, 325 mg, 0.76 mmol) in THF (2.5 mL) was added 4M HCl in dioxane (1.9
mL) and stirred at r.t. for 1.5 h . Cone. HCl (2.5 mL) was then added and the reaction stirred
for a further 2 h . The resulting precipitate was collected and dried under vacuum filtration to
afford the title compound (128 mg, 98.7%) as a white powder.
[00405] Method A : LC-MS: m/z = +170.9, 172.8 (M+H)+; RT = 0.20
[00406] Step 3 : Synthesis of 6-hydrazinyl-lH,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one
[00407] H (EV-AQ7 120-001)
[00408] To a solution of 6-chloro-lH,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one (EV-
AQ7 115-001, 128 mg, 0.75 mmol) in ethanol (2 mL) was added hydrazine hydrate (0.18 mL,
3.75 mmol). The reaction vessel was sealed and the reaction mixture irradiated in the
microwave at 100 °C for 30 mins. The reaction mixture was cooled and the resulting
precipitate was collected and dried under vacuum to afford the title compound (90 mg,
72.2%) as a white powder.
[00409] Method A : LC-MS: m/z = +166.9 (M+H)+; RT = 0.17 min.
[00410] Intermediate 35: Preparation of 2-hydrazinyl-5,6-dimethyl-3,4-dihydropyrimidin-
4-one (EV-AP2534-001)
[00411] Step 1: Synthesis of 5,6-dimethyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one
[00412] (EV-AB 8059-001)
[00413] To a suspension of 5,6-dimethyl-2-sulfanylidene-l,2,3,4-tetrahydropyrimidin-4-
one (2 g, 12.8 mmol) in water (15 mL) was added sodium hydroxide (527.47 mg, 13.19
mmol) followed by iodomethane ( 1 mL, 16 mmol) and stirred at r.t. overnight. The reaction
mixture was cooled to 5 °C and the resulting precipitate was collected by vacuum filtration.
The solid was washed with water and dried under vacuum at 40 °C to afford the title
compound (1.67g, 76%) as a white powder.
[00414] Method A : LC-MS m/z = 170.9 [M + H]+; RT = 0.83 min.
[00415] Step 2 : Synthesis of 2-hydrazinyl-5,6-dimethyl-3,4-dihydropyrimidin-4-one
[00416] (EV-AP2534-001)
[00417] To 5,6-dimethyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one (EV-AB8059-
001, 1 g, 5.87 mmol) was added hydrazine hydrate (1.43 mL, 29.37 mmol) and stirred at 100
°C for 1.5 h . The reaction was then allowed to stand at r.t. over the weekend. A further
portion of hydrazine hydrate (1.43 mL, 29.37 mmol) was added and stirred at 100 °C for 1 h .
The reaction mixture was cooled to r.t. and ice cold methanol (3 mL) was added. The
resultant precipitate was collected by vacuum filtration and washed with more ice cold
methanol (5 mL). The solid was dried further under vacuum to afford the title compound (618
mg, 68.2%) as a white powder.
[00418] Method A : LC-MS m/z = 154.9 [M + H]+; RT = 0 .17 min.
[00419] Intermediate 36: Preparation of 5-chloro-6H,7H-[l,3]thiazolo[4,5-d]pyrimidin-7-
one (EV-AQ0249-001)
[00421] EV-AQ0249-001 was synthesized in an analogous method to the synthesis of EV-
AQ0263-001, affording the title compound (190mg, 56%) as a yellow powder.
[00422] Method A : LC-MS m/z = 187.85 [M + H]+; RT = 0.37 min.
[00423] Intermediate 37a: Synthesis of 2-hydrazinyl-3H,4H-pyrrolo[2,l-f][l,2,4]triazin-4-
one
[00424] Step 1: Synthesis of 2-chloro-3H,4H-pyrrolo[2,l-f][l,2,4]triazin-
[00426] To a solution of 2,4-dichloropyrrolo[2,l-f][l,2,4]triazine (2 g, 10.6 mmol) in THF
(100 ml) was added sodium hydroxide (5M, 10.64 ml, 53.2 mmol) and the reaction mixture
was stirred at room temperature for 16 hours and at 50 °C for 4 hours.
[00427] The yellow solution was cooled to room temperature and concentrated in vacuo
and acidified (pH 3-4, 2M HCl). The resultant precipitate was collected by filtration, washed
with water followed by ether, to afford the title compound (1.79 g, 99%) as a pale yellow
powder after drying under vacuum.
[00428] Method B: LC-MS m/z = 160.0 [M + H]+; RT = 0.79 min.
[00429] Step 2 : Synthesis of 2-hydrazinyl-3H,4H-pyrrolo[2,l-f][l,2,4]triazin-4-one
[00430] EV-AQ3863-001
[00431] Hydrazine hydrate (43.04 µΐ , 0.88 mmol) was added to a stirred solution of 2-
chloro-3H,4H-pyrrolo[2,l-f][l,2,4]triazin-4-one (100 mg, 0.59 mmol) in EtOH (2 ml) and the
reaction was stirred at room temperature for 18 hours before the suspension was heated at 80
°C for 40 hours.
[00432] More hydrazine hydrate (43.04 µΐ , 0.88 mmol) was added and the reaction mixture
was heated at 80 °C for 16 hours
[00433] The yellow suspension was cooled to 4 °C, the solid was collected by filtration,
washed with cold water (-0.5 ml) and dried under vacuum to provide the title compound (64
mg, 65%) as a yellow solid.
[00434] Method B: LC-MS m/z = 166.9 [M + H]+; RT = 0.20 min.
[00435] Preparation of 2-[5-methyl-4-(l,2,3,4-tetrahydroisoquinoline-2-carbonyl)-lH-
pyrazol-l-yl]-3H,4H-thieno[2,3-d]pyrimidin-4-one
[00436] Q-382 (EV-AP2544-001)
[00437] To a solution of 2-hydrazinyl-3H,4H-thieno[2,3-d]pyrimidin-4-one (formed in an
analogous manner to Intermediate 4) (EV-AP2372-001, 120 mg, 0.66 mmol) in ethanol (3
mL) was added 2-[(dimethylamino)methylidene]-l-(l,2,3,4-tetrahydroisoquinolin-2-
yl)butane -1,3-dione (Intermediate 27, 90%, 199.3 mg, 0.66 mmol) followed by acetic acid
(0.13 mL, 2.31 mmol). The vessel was sealed and the reaction mixture stirred at r.t. for 5
mins and then heated at 80 °C for 5 h . The reaction mixture was concentrated in vacuo. The
crude residue was purified by chromatography on Si0 2 eluting with 0-10% methanol in
DCM. The material was purified further by PREP-HPLC (Method G) to afford the title
compound (20.9 mg, 8.1%) as an off white powder.
[00438] Method C: LC-MS m/z = 392. 1 [M + H]+; RT = 3 .12 min.
Examples 146-156 and 157a
[00439] The examples in Table 10 were synthesized by cyclizing the corresponding
hydrazine intermediate with either intermediate 27 or intermediate 28 using the procedure
described in example 1.
Table 10
LC-MS MS
Example
Ref. No. LBN Structure (RT) (M+H)+ Comments
No
Method C Method C
Intermediate
146 Q-438 EV-AQ7 122-002 2.19 396.2
34
147 Q-407 EV-AQ0209-002 3.25 406.2
148 Q-409 EV-AQ02 18-002 3.14 426.2
149 Q-448 EV-AQ0295-002 2.02 396.2

[00440] Intermediate 37b: Synthesis of ethyl 2-formyl-3-oxopropanoate EV-AQ88 17-001
[00441] (EV-AQ88 17-001)
[00442] To a stirred suspension of sodium hydride (60%, 1.68 g, 42.1 mmol) in THF (20
mL) was added ethyl formate (8.5 mL, 105.7 mmol). The solution was cooled to 0 °C and a
solution of ethyl 3,3-diethoxypropanoate (4 g, 21.0 mmol) in THF (10 mL) was added
dropwise over 30 mins and the reaction mixture stirred at r.t. overnight. 2M aq HCl (30 mL)
was added under whilst cooling with ice and the reaction stirred at r.t. for 30 mins. The
reaction mixture was extracted with diethyl ether (2 x 50 mL) and the combined organic
extracts were dried over MgS0 4 and concentrated in vacuo to afford the title compound (3.02
g, 99.7%) as an amber liquid.
[00443] 1H NMR (250 MHz, Chloroform-d) δ 9.13 (s, 2H), 4.29 (q, J = 7.1 Hz, 2H), 1.37 -
1.28 (m, 3H).
Example 158a - Preparation of 6-methyl-2-[5-methyl-3-(l,2 <3.4-tetrahvdroisoquinoline-
2- 3 οην1)-1Η -ρνΓ3ζο1-1-ν1]-3,4-(1ί ν Γθρνη ί 1ί -4-ο 0-432 (EV-AO0253-002)
[00444] Step 1: Synthesis of methyl 3-[2-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-
yl)hydrazin- 1-ylidene]butanoate
[00445] (EV-AQ3 804-001)
[00446] A solution of 2-hydrazinyl-6-methyl-3,4-dihydropyrimidin-4-one (Intermediate 1,
EV-AO5744-001, 826 mg, 5.89 mmol) and methyl 3-oxobutanoate (763 µΐ , 7.07 mmol) in
EtOH (20 ml) was heated at reflux for 3 h . The reaction mixture was cooled to r . ,
concentrated in vacuo and triturated with EtOH, washing with EtOH followed by Et20 , to
afford the title compound (886 mg, 63%) as a pink solid.
[00447] Method A : LC-MS m/z = 239.00 [M + H]+; RT = 0.71 min.
[00448] Step 2 : Synthesis of methyl 3-methyl-l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-
yl)-lH-pyrazole-4-carboxylate
[00449] (EV-AQ3 806-002)
[00450] A solution of methyl 3-[2-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)hydrazin-
l-ylidene]butanoate (EV-AQ3 804-001, 300 mg, 1.26 mmol) in anhydrous DMF (4 ml) at 0
°C was treated dropwise with phosphoric trichloride (352 µΐ , 3.78 mmol) and stirred at 0 °C
for 2 h . The reaction mixture was quenched by the addition of water ( 1 ml), poured onto
crushed ice and left to stand for 30 mins. The solution was neutralised with 1M aq NaOH
solution and then concentrated in vacuo. The residue was dissolved in water (20 ml) and
extracted with EtOAc (3 x 50 ml). The organic extracts were washed with brine, dried over
magnesium sulfate, concentrated in vacuo and triturated using Et20 to afford methyl 3-
methyl-l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-lH-pyrazole-4-carboxylate ( 119 mg,
38%) as a pink solid.
[00451] Method A : LC-MS m/z = 249.00 [M + H]+; RT = 1.01 min.
[00452] Step 3 : Synthesis of 3-methyl- l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-lH-
pyrazole-4-carboxylic acid
[00453] (EV-AQ025 1-001)
[00454] To a solution of methyl 3-methyl- l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-
lH-pyrazole-4-carboxylate (EV-AQ3806-002, 120 mg, 0.44 mmol) in THF (3 mL) was
added 3M aq NaOH solution (0.97 ml) and stirred at r.t. for 2 h . The reaction mixture was
concentrated in vacuo to remove the organic solvent and the aqueous solution acidified to pH
3 using 5M aq HC1 solution. A beige precipitate formed which was filtered washing with
H2O and Et20 to afford 3-methyl-l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-lH-
pyrazole-4-carboxylic acid (110 mg, 95%) as a beige powder.
[00455] Method A : LC-MS m/z = 235.0 [M + H]+; RT = 0.83 min.
[00456] Step 4 : Synthesis of 6-methyl-2-{ 3-methyl-4-[4-(trifluoromethyl)piperidine- 1-
carbonyl] -1H-pyrazol- 1-yl }-3 ,4-dihydropyrimidin-4-one
[00457] Q-432 (EV-AQ0253-002)
[00458] To a suspension of 3-methyl-l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-lH-
pyrazole-4-carboxylic acid (EV-AQ025 1-001, 35 mg, 0.15 mmol) in THF (2 ml) was
added DIPEA (91 µΐ , 0.52 mmol), T3P (50% in EtOAc) (176 µΐ , 0.30 mmol) and 4-
(trifluoromethyl)piperidine hydrochloride (34 mg, 0.18 mmol) and stirred at r.t. for 3 h . The
reaction mixture was concentrated in vacuo, redissolved in water (10 ml) and extracted with
EtOAc (3 x 20 ml). The combined organic extracts were dried over sodium sulfate,
concentrated in vacuo and purified via chromatography on Si0 2 (gradient 100:0 - 80:20,
DCM-MeOH) to afford 6-methyl-2-{3-methyl-4-[4-(trifluoromethyl)piperidine-l-carbonyl]-
lH-pyrazol-l-yl}-3,4-dihydropyrimidin-4-one (16 mg, 29%) as an off white powder.
[00459] Method C: LC-MS m/z = 370.2 [M + H]+; RT = 2.40 min.
Preparative Example 7 - Formation of products via cyclization to form substituted
pyrazoles
Intermediate 1
SYNTHESIS OF INTERMEDIATES
[00460] Intermediate 38: Synthesis of 2,4-dichloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine
[00461] (EV-AP2589-001)
[00462] To a solution of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (1.5 g, 7.98 mmol) in
THF (30 ml) at 0 °C was added sodium hydride (60% oil suspension, 383 mg, 9.57 mmol)
and stirred at 0 °C - r.t. for 20 mins. Iodomethane (0.6 ml, 9.57 mmol) was added and stirred
at r.t. for 3 h . The mixture was quenched by addition of saturated ammonium chloride
solution (20 mL). EtOAc was then added resulting in formation of a precipitate. The
precipitate was filtered and the filtrate extracted with EtOAc (x2). The combined organic
fractions were washed with water, dried over Na2S04, filtered and concentrated in vacuo to
afford the title compound (1.65 g, 97.2%) as a yellow powder.
[00463] Method A : LC-MS m/z = 201.90, 203.90 [M + H]+; RT = 1.21
[00464] Intermediate 39: Synthesis of 5-chloro-6H,7H-[l,3]thiazolo[5,4-d]pyrimidin-7-
one
[00465] Step 1: Synthesis of 7-(benzyloxy)-5-chloro-[l,3]thiazolo[5,4-d]pyrimidine
[00466] (EV-AQ0259-002)
[00467] To a solution of 5,7-dichloro-[l,3]thiazolo[5,4-d]pyrimidine (980 mg, 4.76 mmol)
in THF (20 mL) at 0 °C was added benzyl alcohol (495 ul, 4.76 mmol) and sodium hydride
(114 mg, 4.76 mmol, 60% in mineral oil) and stirred at r.t. for 22 h . To the reaction mixture
was added water (20ml) and extracted with EtOAc (2 x 50 ml). The combined organic
extracts were washed with brine, dried over sodium sulfate and concentrated in vacuo.
Purification by chromatography on Si0 2 (gradient 100:0 - 90:10, Heptane-EtOAc) afforded
the title compound (708 mg, 47%) as a white powder.
[00468] Method A : LC-MS m/z = 277.85 [M + H]+; RT = 1.39 min.
[00469] Step 2 : Synthesis of 5-chloro-6H,7H-[l,3]thiazolo[5,4-d]pyrimidin-7-one
[00471] 7-(benzyloxy)-5-chloro-[l,3]thiazolo[5,4-d]pyrimidine (EV-AQ0259-002, 708
mg, 2.24 mmol) was dissolved in a 1:1 mixture of 37% aq HC1-THF (10 mL) and stirred at
r.t. for 18 h . The reaction mixture was filtered under vacuum, washing with THF and Et20,
to afford the title compound (246 mg, 58%) as a pale yellow powder.
[00472] Method A : LC-MS m/z = 187.80 [M + H]+; RT = 0.49 min.
[00473] Intermediate 40: Methyl-2-[(dimethylamino)methylidene]-4-methyl-3-
oxopentanoate
[00474] (EV-A0753 1-001)
[00475] To methyl 4-methyl-3-oxopentanoate (1.98 ml, 13.87 mmol) was added 1,1-
dimethoxy-N,N-dimethylmethanamine (2.21 ml, 16.65 mmol) and the solution was stirred at
80 °C for 1 h . The reaction mixture was concentrated in vacuo to afford methyl-2-
[(dimethylamino)methylidene]-4-methyl-3-oxopentanoate (2.76 g, 95%) as an orange oil.
[00476] Method A : LC-MS m/z = 200.0 [M + H]+; RT = 1.00
[00477] Intermediate 41: Methyl-2-[(dimethylamino)methylidene]-4-methyl-3-
oxopentanoate
[00478] (EV-AQ0297-001)
[00479] To methyl 4-methyl-3-oxopentanoate (1.98 ml, 13.87 mmol) was added 1,1-
dimethoxy-N,N-dimethylmethanamine (2.21 ml, 16.65 mmol) and the solution was stirred at
80 °C for 1 h . The reaction mixture was concentrated in vacuo to afford methyl-2-
[(dimethylamino)methylidene]-4-methyl-3-oxopentanoate (2.76 g, 95%) as an orange oil.
[00480] Method A : LC-MS m/z = 200.0 [M + H]+; RT = 1.00
Examples 157b, 158b, and 159-180
[00481] The compounds in Table 11 were prepared by cyclization of the intermediate
hydrazine with the appropriate enamine followed by coupling using the specified reagent.
Table 11


ı 99
200
Preparative Example 8 - Formation of intermediates via SNAr
Example 181 - Preparation of l-(l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl|-lH-
Pyrazole-4-carbonyl)-4-phenylpiperidine-4-carbonitrile EV-AR5394-002)
[00483] Step 1: Synthesis of ethyl l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-
pyrazole-4-carboxylate
[00484] (EV-AR53 86-001)
[00485] To a solution of 2-chloro-3H,4H-thieno[3,2-d]pyrimidin-4-one (Intermediate 9,
647 mg, 3.47 mmol) in DMF (2 ml) was added ethyl lH-pyrazole-4-carboxylate
(Intermediate Y, 437 mg, 3.12 mmol), caesium carbonate (1.69 g, 5.20 mmol), L-proline (160
mg, 1.39 mmol) and copper (I) iodide (132 mg, 0.69 mmol). The reaction mixture was then
de-gassed and stirred at 120 °C overnight. The reaction mixture was concentrated in vacuo
and a 0.2M aq EDTA solution (20 ml) and DCM (30 ml) were added and the mixture was
stirred at r.t. overnight. The organic phase was separated and the aqueous phase was extracted
with DCM (10ml). The combined organic phases were washed with water, dried over sodium
sulfate and concentrated in vacuo to afford the title compound (559, 44%) as a beige powder.
[00486] Method B: LC-MS m/z = 290.95 [M + H]+; RT = 1.02 min.
[00487] Step 2 : Synthesis of l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-pyrazole-
4-carboxylic acid. Intermediate 42
[00488] (EV-AR5392-002)
[00489] To a solution of methyl ethyl l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-
pyrazole-4-carboxylate (EV-AR53 86-001, 80%, 559 mg, 1.54 mmol) in THF (5 mL) and
water (5 ml) was added 6M aqueous NaOH solution (2.57 ml) and the reaction mixture
stirred at r.t. for 4 h . The reaction mixture was concentrated in vacuo to remove the organic
solvent and the aqueous mixture acidified to pH 4 using 5M aq HC1 solution. The reaction
mixture was extracted with EtOAc (2 x 50 ml) and the combined organic extracts dried over
sodium sulfate and concentrated in vacuo to afford the title compound (307 mg, 72%) as a
pale grey powder.
[00490] Method B: LC-MS m/z = 262.95 [M + H]+; RT = 0.82 min.
[00491] Step 3 : Synthesis of l-(l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-
pyrazole-4-carbonyl)-4-phenylpiperidine-4-carbonitrile
[00492] Q-523 (EV-AR53 87-002)
[00493] To a suspension ofl-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-pyrazole-4-
carboxylic acid (EV-AR5392-001, 80%, 52 mg, 0.159 mmol) in THF (2 ml) was
added DIPEA (69 µΐ , 0.40 mmol), T3P (50% in EtOAc) (234 µΐ , 0.40 mmol) and 4-
phenylpiperidine-4-carbonitrile (33 mg, 0.17 mmol) and the reaction mixture stirred at r.t. for
2 h . The reaction mixture was concentrated in vacuo and to the crude sample added DCM (2
ml) and saturated NaHC03 solution ( 1 ml). The solution was then passed through a phase
separator cartridge and concentrated in vacuo. Purification using an SCX cartridge followed
by trituration with MeOH afforded the title compound (31 mg, 45%) as an off white powder.
[00494] Method C: LC-MS m/z = 43 1.0 [M + H]+; RT = 2.83 min.
Examples 182-184
[00495] The compounds in Table 12 were prepared in an analogous manner to Example
181 by coupling the appropriate amine with intermediate 42
Table 12
[00496] Intermediate 43: Synthesis of l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-
pyrazole-3-carboxylic acid
[00498] Step 1: Synthesis of 2-chloro-4-[(2-methoxyethoxy)methoxy]thieno[3,2-
d]pyrimidine
[00499] (EV-AP2543-001)
[00500] To a solution of 2-chloro-3H,4H-thieno[3,2-d]pyrimidin-4-one (EV-AP253 1-001,
750 mg, 4.02 mmol) and DIPEA (1.03 mL, 6.03 mmol) in THF (15 mL) was added dropwise
l-(chloromethoxy)-2-methoxyethane (0.5 ml, 4.42 mmol) and stirred at r.t. overnight. To the
reaction mixture was added EtOAc (50 mL) washed with water (2 x 15 mL) and brine
solution (15 mL). The organic fraction was dried over Na2S0 4 and concentrated in vacuo to
afford the title compound (1.09, 87.9%) (as a mixture of N and O alkylation products) as a
tan oil.
[00501] Method A : LC-MS: m z = 274.9, 276.9 (M+H)+; RT = 1.03, 1.19 min, A = 52 and
37% respectively.
[00502] Step 2 : Synthesis of ethyl l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-
pyrazole-3-carboxylate
[00503] (EV-AP2547-001)
[00504] To a solution of 2-chloro-4-[(2-methoxyethoxy)methoxy]thieno[3,2-d]pyrimidine
(EV-AP2543-001, 902 mg, 3.28 mmol) in DMF (20 mL) was added caesium carbonate (1.71
g, 5.25 mmol) and ethyl lH-pyrazole-5-carboxylate (506.13 mg, 3.61 mmol) and stirred at
120 °C for 30 mins. The reaction mixture was cooled to 0 °C, diluted with 1M aqueous HCl
solution (45 mL) and stirred at 0 °C to r.t. for 30 mins. The resulting precipitate was filtered
under vacuum and dried to afford the title compound (275 mg, 28%) as a pale brown powder.
[00505] Method A : LC-MS: m/z = +291.1 (M+H)+; RT = 1.12 min.
[00506] Step 3 : Synthesis of l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-pyrazole-
3-carboxylic acid Intermediate 43
[00507] (EV-AP2548-001)
[00508] Ethyl l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-pyrazole-3-carboxylate
(EV-AP2547-001, 310 mg, 1.07 mmol) was suspended in 2:2:1 THF/water/methanol (10 mL)
and 2.5M aq NaOH solution (2.6 mL) was added. The reaction mixture was stirred at r.t. for
1.5 h . The reaction mixture was concentrated in vacuo and the aqueous solution acidified to
pH 4 with 2M aq HCl solution. The resulting precipitate was filtered and dried under vacuum
filtration to afford the title compound (260 mg, 91 ) as a pale brown powder.
[00509] Method A : LC-MS: m/z = +262.9 (M+H)+; RT = 0.92 min.
Example 185 - 2-[3-(1,2,3,4- θ ί ο ί ο1ί -2- ο 1 -1Η
- ζ ο 1-1 - 1 -
3H,4H-thieno[3,2-d1pyrimidin-4-one
[00510] Q-388 (EV-AP2549-002)
[00511] To a solution of l-{4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl}-lH-pyrazole-3-
carboxylic acid (Intermediate 43) (EV-AP2548-001, 80 mg, 0.31 mmol) in DMF (1.0 mL)
was added COMU (143.71 mg, 0.34 mmol), DIPEA (0.13 mL, 0.76 mmol) and 1,2,3,4-
tetrahydroisoquinoline (0.04 mL, 0.34 mmol) and stirred at r.t. for 2 h . The reaction mixture
was concentrated in vacuo and the crude material was purified by PREP-HPLC (Method G)
to afford the title compound (28.7 mg, 24.9%) as a fluffy pale yellow solid.
[00512] Method C: LC-MS: m z = +378.1 (M+H)+; RT = 2.98 min.
Examples 186-187
[00513] The examples in Table 13 were prepared analogously to example 181 coupling
intermediate 43
Table 13
Example 188 - Preparation of 2-methyl-6-|3-[4-(trifluoromethyl)piperidine-l-
3 οην11-1Η -ρνΓ3ζο1-1-ν1|-3,4-(1 ί ν Γθρνη ί 1ί -4-οη (0-437, EV-AQ7121-003)
[00514]
[00515] Step 1: Synthesis of ethyl l-(2-methyl-6-oxo-l,6-dihydropyrimidin-4-yl)-lH-
pyrazole-3-carboxylate
[00516] 3 (EV-AQ7 119-001)
[00517] To a microwave vessel was added 6-chloro-2-methyl-3,4-dihydropyrimidin-4-one
(450 mg, 3.11 mmol), ethyl lH-pyrazole-5-carboxylate (610.74 mg, 4.36 mmol), caesium
carbonate (1.72 g, 5.29 mmol), L-proline (143.36 mg, 1.25 mmol) and copper (I) iodide
(118.57 mg, 0.62 mmol) in DMF (10 mL). The reaction mixture was de-gassed by bubbling
through nitrogen gas for 5 mins and then irradiated in the microwave at 140 °C for 4 h .
Additional 6-chloro-2-methyl-3,4-dihydropyrimidin-4-one (150 mg, 1.04 mmol) was added
and the reaction irradiated at 140 °C for a further 1.5 h . EtOAc was added to the cooled
reaction mixture and the organic layer washed with brine (x2). The organics were dried over
Na2S0 4, concentrated in vacuo and purified by chromatography on Si0 2, eluting with 0-
100% EtOAc in heptane followed by a flush with 50% methanol in EtOAc to afford the title
compound (294 mg, 11.4%) as a beige powder.
[00518] Method A : LC-MS: m/z = +249.0 (M+H)+; RT = 1.00 min.
[00519] Step 2 : Synthesis of l-(2-methyl-6-oxo-l,6-dihydropyrimidin-4-yl)-lH-pyrazole-
3-carboxylic acid
[00520] (EV-AQ7 123-001)
[00521] Ethyl l-(2-methyl-6-oxo-l,6-dihydropyrimidin-4-yl)-lH-pyrazole-3-carboxylate
(EV-AQ7 119-001, 30%, 240 mg, 0.29 mmol) was suspended in 2:2:1 THF/water/methanol
(10 mL) and 2.5M aq NaOH (1.7 mL) was added. The reaction mixture was stirred at r.t. for
25 mins. The organics from the reaction mixture were removed in vacuo. The residue was
acidified with 2M aq HCl solution and the resulting precipitate was collected and dried under
vacuum filtration to afford the title compound (55 mg, 86.1%) as a beige powder:
[00522] Method A : LC-MS: m/z = +221.0 (M+H)+; RT = 0.78.
[00523] Step 3 : Synthesis of 2-methyl-6-{3-[4-(trifluoromethyl)piperidine-l-carbonyl]-
1H-pyrazol- 1-yl}-3 ,4-dihydropyrimidin-4-one
[00524] Q-437, EV-AQ7 121-003
[00525] To a solution of l-(2-methyl-6-oxo-l,6-dihydropyrimidin-4-yl)-lH-pyrazole-3-
carboxylic acid (EV-AQ7123-001 75 mg, 0.34 mmol) in THF (2 mL) was added DIPEA
(0.20 mL, 1.19 mmol) and T3P 50% in EtOAc (0.40 mL, 0.68 mmol). The reaction mixture
was stirred at r.t. for 10 mins and 4-(trifluoromethyl)piperidin-l-ium.HCl (77.5 mg, 0.41
mmol) was added before stirring for a further 14 h . The reaction mixture concentrated in
vacuo and the crude residue partitioned between water ( 1 mL) and DCM (5 mL). The organic
phase was extracted, washed with saturated NaHC0 3 solution ( 1 ml), water ( 1 mL) and brine
solution (5 mL) and dried over Na2S0 4 and concentrated in vacuo. The crude residue was
purified by Prep HPLC (method G) to afford the title compound (43.2 mg, 35.7%) as an off
white powder.
[00526] Method C: LC-MS: m/z = +356.2 (M+H)+; RT = 2.32 min.
[00527] Intermediate 44 Synthesis of l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yL)-lH-
pyrazole-3-carboxylic acid
[00529] Step 1: Synthesis of 2-chloro-4-[(4-methoxyphenyL)methoxy]-6-
methylpyrimidine
[00530] (EV-AP23 17-001)
[00531] To a stirred solution of (4-methoxyphenyL)methanol (3.39 g, 3.05 mL, 24.5
mmol) in THF (40 mL) at 0 °C was added NaH (60% in oil, 1.47 g, 36.8 mmol). After 1 h, a
solution of 2,4-dichloro-6-methylpyrimidine (4.0 g, 24.5 mmol) in THF (15 mL) was added
dropwise and stirred at 0 °C to r.t. overnight. The reaction mixture was quenched by the
addition of saturated aq NH4CI solution (40 mL) and extracted with EtOAc (3 x 75 mL). The
combined organic fractions were washed with brine solution (40 mL), dried over Na2S04
and concentrated in vacuo. The resulting residue was purified via chromatography on Si0 2,
eluent Heptane/EtOAc (gradient 100:0 - 75:25), to afford the title compound (2.37 g, 36 %)
as a colourless crystalline solid.
[00532] Method A : LC-MS m/z = 256.0 [M + H]+; RT = 1.39 min.
[00533] Step 2 : Synthesis of ethyl-l-{4-[(4-methoxyphenyL)methoxy]-6-methylpyrimidin-
2-yl }-1H-pyrazole-3 -carboxylate
[00534] (EV-AP233 1-001)
[00535] To a stirred solution of ethyl- lH-pyrazole-5 -carboxylate (0.945 g, 6.74 mmol) in
THF (65 mL) at 0 °C was added NaH (60%, 290 mg, 7.25 mmol) and stirred at 0 °C for 30
mins. 2-chloro-4-[(4-methoxyphenyL)methoxy]-6-methylpyrimidine (1.70 g, 6.42 mmol) was
then added and the reaction mixture stirred at reflux for 4 days. The cooled reaction mixture
was quenched with saturated NH4CI aqueous solution (40 mL) and extracted with EtOAc (2
x 40 mL). The combined organic fractions were dried (Na2S04), concentrated in vacuo and
purified via chromatography on S1O2, eluting with Heptane/EtOAc (gradient 100:0 - 70:30)
to afford the title compound (1.23 g, 52%) as a colourless powder.
[00536] Method A : LC-MS m/z = 369.1 [M + H]+; RT = 1.43 min.
[00537] Step 3 : Synthesis of ethyl-l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yL)-lH-
pyrazole-3 -carboxylate
[00538] (EV-AP2334-001)
[00539] To a stirred solution of ethyl-l-{4-[(4-methoxyphenyL)methoxy]-6-
methylpyrimidin-2-yl}-lH-pyrazole-3-carboxylate (1.06 g, 2.73 mmol) in EtOAc (25 mL)
was added Pd on carbon (10%, lOOmg) and the solution exposed to an atmosphere of ¾ (g)
overnight. The solution was filtered through celite, washing with EtOAc, the filtrate
concentrated in vacuo and the residue purified via chromatography, eluting with
Heptane/EtOAc (gradient 100:0 - 20:80) to afford the title compound (400 mg, 59%) as a
colourless powder.
[00540] Method A : LC-MS m/z = 249.0 [M + H]+; RT = 1.01 min.
[00541] Step 4 : Synthesis of l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yL)-lH-pyrazole-
3-carboxylic acid
[00542] (EV-AP2335-001)
[00543] To a stirred solution of ethyl- l-(4-methyl-6-oxo- l,6-dihydropyrimidin-2-yL)- 1H-
pyrazole-3-carboxylate (386 mg, 1.56 mmol) in 2:1 THF/methanol (8 mL) was added 3M
aqueous NaOH solution (3.1 mL) and the reaction mixture was stirred at r.t. for 2 h . The
organics were removed in vacuo, the residue acidified to pH 4/5 with 2M aqueous HC1
solution and extracted with EtOAc (3 x 20 mL). The combined organics were dried over
Na2S04 and concentrated in vacuo to afford the title compound (337 mg, 98%) as a
colourless powder.
[00544] Method A : LC-MS m/z = 220.9 [M + H]+; RT = 0.79 min.
Examples 189-190
[00545] The examples in Table 14 were prepared by coupling intermediate 44 with the
appropriate amine using COMU as the coupling agent.
Table 14
Example 191 - 7-{4-[4-(trifluoromethyl)piperidine-l-carbonyl1-lH-pyrazol-l-yl|-5H <6H-
imidazori,2-clpyrimicliii-5-oiie
[00547] Step 1: Synthesis of 7-chloro-5-(methylsulfanyL)imidazo[l,2-c]pyrimidine
hydrochloride
[00548] (EV-AQ8808-001)
[00549] To a stirred solution of 6-chloro-2-(methylsulfanyL)pyrimidin-4-amine (1.5 g,
8.54 mmol) in dioxane (4 mL) was added chloroacetaldehyde (50%, 1.63 mL, 12.8
mmol) and stirred at 95 °C overnight. The reaction mixture was cooled in an ice bath and the
resulting precipitate filtered and washed with dioxane to afford the title compound (1.41 g,
70%) as a colourless powder.
[00550] Method A : LC-MS m/z = 199.8 [M + H]+; RT = 0.93 min
[00551] Step 2 : Synthesis of 7-chloro-5H,6H-imidazo[l,2-c]pyrimidin-5-one
[00552] (EV-AQ8809-001)
[00553] To a stirred solution of methyl 7-chloro-5-(methylsulfanyL)imidazo[l,2-
c]pyrimidine hydrochloride (EV-AQ8808-001,1.32 g, 5.59 mmol) in methanol (4 mL) was
added 2M aqueous KOH solution (10 mL, 20 mmol) and stirred at reflux overnight. The
solution was cooled to r.t. and acidified to pH 5/6 using 5M aq HC1 solution. The resulting
precipitate was isolated via vacuum filtration to afford the title compound (704 mg, 74%) as a
tan powder.
[00554] Method A : LC-MS m z = 169.9 [M + H]+; RT = 0.23 min
[00555] Step 3: 7-{4-[4-(trifluoromethyl)piperidine- 1-carbonyl] -lH-pyrazol- 1-yl }-5H,6H-
imidazo[ 1,2-c]pyrimidin-5-one
[00556] Q-452 (EV-AQ8822-001)
[00557] To a stirred solution of 7-chloro-5H,6H-imidazo[l,2-c]pyrimidin-5-one (EV-
AQ8809-001,100 mg, 0.59 mmol) and cesium carbonate (288 mg, 0.89 mmol) in DMF (3
mL) was added l-(lH-pyrazole-4-carbonyL)-4-(trifluoromethyL)piperidine (intermediate29,
EV-AQ8818-001,175 mg, 0.71 mmol) and the reaction was stirred at 70 °C for 2 h and 100
°C for 3 h . Copper iodide (22 mg, 0.12 mmol) and L-proline (27 mg, 0.24 mmol) were added
the reaction heated at 100 °C overnight. The reaction was transferred to the microwave at
heated at 150 °C for 6 hours. The reaction was cooled to r.t., concentrated in vacuo and
purified via PREP-HPLC (Method G) to yield the title compound (70 mg, 31%) as a
colourless powder.
[00558] Method C: LC-MS m/z = 379.2 [M + H]+; RT = 2.00 min.
Example 192 - Preparation of 2-chloro-7-fluoro-3H,4H-pyrrolo[2J-f][l,2,41triazin-4-
one
[00559] Q-525 (EV-AS3703-002)
[00561] Step 1: Synthesis of 2-chloro-7-fluoro-3H,4H-pyrrolo[2,l-f][l,2,4]triazin-4-one
[00562] (EV-AS3703-002)
[00563] To a solution of 2,4-dichloro-7-fluoropyrrolo[2,l-f][l,2,4]triazine
(WO201 1/88045 Al, 2011) (446 mg, 2.16 mmol) in THF (20 ml) was added 5M aq NaOH
solution (2.16 ml, 10.82 mmol) and stirred at r.t. for 22 h . The reaction mixture was
concentrated in vacuo and the residue acidified to pH 5 using 2M aq HCl solution. The
resulting precipitate was collected under vacuum filtration, washing with diethyl ether, to
afford the title compound (283 mg, 35%) as an off-white powder.
[00564] Method B: LC-MS m/z = 187.9 [M + H]+; RT = 0.86 min.
[00565] Step 2 : Synthesis of 7-fluoro-2-{4-[4-(trifluoromethyl)piperidine-l-carbonyl]-lH-
pyrazol- 1-yl}-3H,4H-pyrrolo [2, 1-f] [1,2,4] triazin-4-one
[00566] Q-525 (EV-AS3703-002)
[00567] The title compound was prepared in an analogous manner to Example 191 using
2-chloro-7-fluoro-3H,4H-pyrrolo[2,l-f][l,2,4]triazin-4-one (140 mg, 0.75 mmol) and
purifying by preparative HPLC [method G] to give 7-fluoro-2-{4-[4-
(trifluoromethyl)piperidine- 1-carbonyl] -1H-pyrazol- 1-yl}-3H,4H-pyrrolo [2, 1-f] [1,2,4] triazin-
4-one one (42 mg, 14%) as an off white powder.
[00568] Method C: LC-MS m/z = 398.0 [M + H]+; RT = 2.82 min.
Example 193 - Preparation of 2-{4-[4-(trifluoromethyl)piperidine-l-carbonyl1-lH-
pyrazol-l-yl|-3H <4H<5H<6HJH-cvclopenta[d]pyrimidin-4-one (0-526, EV-AR5391-002)
[00569] Step 1: Synthesis of 2-chloro-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one
[00571] To a solution of 2,4-dichloro-5H,6H,7H-cyclopenta[d]pyrimidine (3 g, 15.87
mmol) in THF (15 mL) was added 6M aq NaOH solution (10 eq, 26.45 ml) and the reaction
stirred at 50 °C for 48 h . The reaction mixture was concentrated in vacuo to remove the
organic solvent. The resulting aqueous solution was acidified to pH 4 with 5M aq HC1
solution and extracted with EtOAc (2 x 50 ml), dried over sodium sulfate and concentrated in
vacuo to afford the title compound (2.09 g, 75%) as a pale orange powder.
[00572] Method B: LC-MS m/z = 170.9 [M + H]+; RT = 0.68 min.
[00573] Step 2 : Synthesis of 2-{4-[4-(trifluoromethyl)piperidine-l-carbonyl]-lH-pyrazol-
1-yl}-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one
[00574] (EV-AR5391-002)
[00575] To a solution of 2-chloro-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (EV-
AR5385-002, 200 mg, 1.17 mmol) in DMF (2 ml) was added l-(lH-pyrazole-4-carbonyl)-4-
(trifluoromethyl)piperidine (EV-AQ8818-001, 319 mg, 1.29 mmol), caesium carbonate (573
mg, 1.76 mmol), L-proline (54 mg, 0.47 mmol) and copper (I) iodide (45 mg, 0.23 mmol).
The reaction mixture was then de-gassed and stirred at 120 °C for 20 h . The reaction mixture
was concentrated in vacuo and then a 0.2M aq solution of EDTA (20ml) and DCM (30ml)
were added and the mixture stirred at r.t. for 4 h . The organic phase was separated and the
aqueous phase extracted with DCM (20ml). The combined organic extracts were washed with
water (10 ml), dried over sodium sulfate and concentrated in vacuo. Purification by PREP-
HPLC (Method G) afforded the title compound (140 mg, 31%) as a beige powder.
[00576] Method C: LC-MS m/z = 382.1 [M + H]+; RT = 2.51 min
Example 194
[00577] The example in Table 15 was prepared by the procedure described in Example
192, starting instead with 2,4-dichlorothieno[3,2-d]pyrimidine.
Table 15
Example 195 - Preparation of 2-{4-[4-(trifluoromethyL)piperidine-l-carbonyl1-lH-
pyrazol-l-yl|-3H <4H<5HJH-furor3,4-dlpyrimidin-4-one (0-453, EV-AO8825-001)
[00578] Step 1: Synthesis of 2-chloro-3H,4H,5H,7H-furo[3,4-d]pyrimidin-4-one
[00579] (EV-AQ8821-001)
[00580] To a stirred solution of 2,4-dichloro-5H,7H-furo[3,4-d]pyrimidine (EV-AQ8821-
001,1 g, 5.24 mmol) in THF (10 mL) was added 1M aq NaOH solution (10.5 mL, 10.5
mmol) and stirred at r.t. overnight. The solution was acidified to pH 4/5 with acetic acid and
extracted with DCM (3 x 30 mL). The combined organic extracts were dried over MgS04
and concentrated in vacuo to afford the title compound (890 mg, 99%) as an orange powder.
[00581] 1H NMR (500 MHz, DMSO-d6) δ 4.88 (t, J = 3.3 Hz, 2H), 4.81 (t, J = 3.3 Hz,
2H).
[00582] Step 2 : Synthesis of 2-{4-[4-(trifluoromethyL)piperidine-l-carbonyl]-lH-pyrazol-
1-yl}-3H,4H,5H,7H-furo [3 ,4-d]pyrimidin-4-one
[00583] Q-453 (EV-AQ8825-001)
[00584] To a stirred solution of 7-chloro-5H,6H-imidazo[l,2-c]pyrimidin-5-one (EV-
AQ8821-001,100 mg, 0.58 mmol) and caesium carbonate (283 mg, 0.87 mmol) in DMF (3
mL) was added l-(lH-pyrazole-4-carbonyL)-4-(trifluoromethyL)piperidine (Intermediate V,
EV-AQ8818-001,143 mg, 0.58 mmol) and stirred under microwave conditions at 120 °C for
5 h . The reaction was cooled to r.t., concentrated in vacuo and purified via PREP-HPLC
(Method G) to afford (59 mg, 27%) as a colourless powder.
[00585] Method C: LC-MS m z = 382.2 [M - H]+; RT = 2.28 min
Example 196 - Preparation of e-methyl- - -d^^^-tetrahydroisoquinoline- -
3 οην1)-1Η -ρνΓ3ζο1-1-ν11-3,4-(1ί ν Γθρνη ί 1ί -4 -οη O -308 EV-AN7470-001)
[00586] Step 1: Synthesis of 4-[(4-methoxyphenyl)methoxy]-6-methyl-2-
(methylsulfanyl)pyrimidine
[00587] (EV-AN0086-002)
[00588] To solution of 6-methyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one
Intermediate 1 Step 1 (EV-AO5743-001, 7 g, 44.8 mmol) in water (50ml) and dioxane
(100ml) was added NaOH (2.15 g, 53.8 mmol) followed by l-(chloromethyl)-4-
methoxybenzene (8.42 g, 53.8 mmol) and stirred at 50 °C for 1 h . The reaction mixture was
cooled to r.t. and the resultant precipitate filtered under vacuum and purified by
chromatography on Si0 2, eluting with Heptane/EtOAc (gradient 100:0 - 0:100) to afford the
title compound (1.54 g, 11.4%) as an oil.
[00589] Method A : LC-MS: m z = +277.0 (M+H)+; RT = 1.40 min.
[00590] Step 2 : Synthesis of 2-methanesulfonyl-4-[(4-methoxyphenyl)methoxy]-6-
methylpyrimidine
[00591] (EV-A057 10-002)
[00592] To a solution of 4-[(4-methoxyphenyl)methoxy]-6-methyl-2-
(methylsulfanyl)pyrimidine (EV-AN0086-002, 1.5 g, 5.43 mmol) in DCM (15 mL) under
nitrogen at 0 °C was added mCPBA (75%, 2.50 g, 10.86 mmol) and stirred at r.t. for 1 h . The
reaction was diluted with chloroform (50 mL) and more mCPBA (200mg, 0.87 mmol) was
added and the reaction stirred at r.t. for a further 1 h . The reaction was quenched by addition
of 0.5M aq sodium thiosulfate solution (20 mL). The organic layer was extracted and washed
with saturated NaHC0 3 solution (3 x 20 mL), dried over Na2S0 4 and concentrated in vacuo
to afford the title compound (1.64g , 104%) as a pale yellow oil.
[00593] Method A : LC-MS: m/z = +331.1 (M+Na)+, RT = 1.23 min.
[00594] Step 3 : Synthesis of ethyl l-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-
2-yl }-1H-pyrazole-3 -carboxylate
[00595] (EV-AN7465-001)
[00596] To a solution of ethyl lH-pyrazole-5-carboxylate (95.44 mg, 0.68 mmol) in DMF
(5 mL) at 0 °C was added NaH (60% in oil, 31.13 mg, 0.78 mmol) and stirred at 0 °C - r.t.
for 30 mins. 2-methanesulfonyl-4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidine (EV-
A057 10-002, 200 mg, 0.65 mmol) in DMF (5 mL) was added and the reaction mixture
stirred at r.t. for 1.5 h . The reaction mixture was quenched by the addition of water (10 mL)
and extracted with EtOAc (3 15 mL). The combined organic fractions were washed with
water (3 x 10 mL), brine solution (10 mL), dried over Na2S0 4, and concentrated in vacuo.
Purification by chromatography on Si0 2 eluting with Heptane/EtOAc (gradient 100:0 -
0:100) to afford the title compound (154 mg, 62.5%) as a clear oil.
[00597] Method A : LC-MS: m/z = 391.1 (M+Na)+; RT = 1.43.
[00598] Step 4 : Intermediate 46 Synthesis of l-{4-[(4-methoxyphenyl)methoxy]-6-
methylpyrimidin-2-yl }-1H-pyrazole-3-carboxylic acid
[00599] (EV-AN7466-001)
[00600] Ethyl 1-{4-[(4-methoxyphenyl)methoxy] -6-methylpyrimidin-2-yl }-1H-pyrazole-
3-carboxylate (EV-AN7466-001, 125 mg, 0.34 mmol) was suspended in 2:2:1
THF/water/methanol (7.5 mL) and 2.5M aq NaOH solution (0.81 mL) was added. The
reaction mixture was stirred at r.t. for 30 mins. The organics were removed in vacuo and the
aqueous solution acidified with 2M aq HCl solution. The resultant precipitate was collected
and dried under vacuum filtration. The filtrate was then extracted with EtOAc (2 x 10 mL)
and the combined extracts dried over Na2S0 4, concentrated in vacuo and combined with the
precipitate to afford the title compound ( 115 mg, 93.6%) as an off white powder.
[00601] Method A : LC-MS: m/z = 363.1 (M+Na)+; RT = 1.24 min.
[00602] Step 5 : Synthesis of 2-(l-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-
yl}-1H-pyrazole-3 -carbonyl)- 1,2,3 ,4-tetrahydroisoquinoline
[00603] (EV-AN7468-001)
[00604] To a solution of l-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-lH-
pyrazole-3-carboxylic acid (EV-AN7466-001, 115 mg, 0.34 mmol) in DMF (1.5 mL) was
added COMU (159.18 mg, 0.37 mmol), DIPEA (0.14 mL, 0.84 mmol) and 1,2,3,4-
tetrahydroisoquinoline (0.05 mL, 0.37 mmol) and stirred at r.t. overnight. To the reaction
mixture was added ice water and extracted with EtOAc (2 x 5 mL). The combined organic
extracts were washed with saturated NaHC0 3 solution (5 mL), brine solution (5 mL), dried
over Na2S0 4 and concentrated in vacuo. Purification by chromatography on Si0 2, eluting
with Heptane/EtOAc (gradient 100:0 - 0:100), afforded the title compound (119 mg, 70.4%)
as an opaque gum.
[00605] Method A : LC-MS: m/z = +456.0 (M+H)+; RT = 1.52 min.
[00606] Step 6 : Synthesis of 6-methyl-2-[3-(l,2,3,4-tetrahydroisoquinoline-2-carbonyl)-
1H-pyrazol- 1-yl] -3 ,4-dihydropyrimidin-4-one
[00607] Q-308, EV-AN7470-001
[00608] To a solution of 2-(l-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-
lH-pyrazole-3-carbonyl)-l,2,3,4-tetrahydroisoquinoline (EV-AN7468-001, 89 mg, 0.2
mmol) in DCM (2 mL) was added TFA (0.16 mL) and stirred at r.t. for 2 h . The reaction
mixture was concentrated in vacuo, re-dissolved in DCM, washed with saturated NaHC0 3
solution, dried over Na2S0 4 and concentrated in vacuo. Purification by PREP-HPLC (Method
G) method) followed by a free base with saturated NaHC0 3 solution afforded the title
compound (35.7 mg, 54.5%) as an off white solid.
[00609] Method A : LC-MS: m z = +336.1 (M+H)+; RT = 2.50.
Examples 197-198
[00610] The examples in Table 16 were made in an analogous manner to example 197
coupling Intermediate 46 with the appropriate amine followed by deprotection.
Table 16
Example 199 - 2-|3,5-dimethyl-4-r2-oxo-2-(pyrrolidin-l-yl)ethyll-lH-pyrazol-l-yl|-6-
methyl-3,4-dihvdropyrimidin-4-one EV-AN7461-001
[00612] The title compound (20.1 mg, 25.6%) was prepared in an analogous manner to
Example 196, reacting ethyl 2-(3,5-dimethyl-lH-pyrazol-4-yl)acetate with Example 196 step
2 using HATU for the coupling with pyrrolidine.
[00613] Method C: LC-MS: m/z = 316.2 (M+H)+; RT = 2.05 min.
Example 200 - Preparation of 6-methyl-2-[5-methyl-3-(l,2,3. 4-tetrahvdroisoquinoline-2-
3 ο -1Η -ρ 3ζο1-1- 11-3,4-άί ι ά θρ ίάί -4-ο (0-365, EV-AO7568-002)
[00615] Step 1: Synthesis of ethyl-l-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-
2-yl }-5-methyl- 1H-pyrazole-3 -carboxylate
[00616] (EV-AO7559-002)
[00617] To a solution of 2-methanesulfonyl-4-[(4-methoxyphenyl)methoxy]-6-
methylpyrimidine (Example 196 Step 2, 500 mg, 1.622 mmol) in DMF (10 mL) at 0 °C was
added NaH (60% in oil) (60%, 78 mg, 1.946 mmol) and then ethyl 5-methyl-lH-pyrazole-3-
carboxylate (275 mg, 1.784 mmol) and the reaction mixture stirred at r.t. for 2 h . The reaction
mixture was quenched by the addition of water (10 mL) and extracted with EtOAc (3 x 20
mL). The combined organic extracts were washed with water (2 x 10 mL), brine solution (10
mL), dried over Na2S0 4, concentrated in vacuo and purified via chromatography on Si0 2
(gradient 100:0 - 0:100, Heptane-EtOAc), to afford the title compound (406 mg, 65%) as a
colourless oil.
[00618] Method A : LC-MS m/z = 383.1 [M + H]+; RT = 1.45 min.
[00619] Step 2 : Synthesis of l-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-
5-methyl-lH-pyrazole-3-carboxylic acid
[00620] (EV-A0756 1-001)
[00621] To a solution of ethyl l-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-
yl}-5-methyl-lH-pyrazole-3-carboxylate (EV-AO7559-002, 406 mg, 1.062 mmol) in 2:2:1
THF/water/methanol (25 mL) was added 2.5M aqueous NaOH (2.55 ml) and the reaction
mixture stirred at r.t. overnight. The reaction mixture was concentrated in vacuo and the
residue acidified with 2M aq HC1 solution to pH 6 to afford a white precipitate which was
filtered and dried under vacuum to give the title compound (340 mg, 90%) as a white
powder.
[00622] Method A : LC-MS m/z = 377.0 [M + H]+; RT = 1.26 min.
[00623] Step 3 : Synthesis of 2-(l-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-
yl}-5-methyl-lH-pyrazole-3-carbonyl)-l,2,3,4-tetrahydroisoquinoline
[00624] (EV-AO7563-002)
[00625] To a stirred solution of 5-methyl-l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-
lH-pyrazole-4-carboxylic acid (EV-A0756 1-001, 150 mg, 0.423 mmol) in DMF (2 ml) were
added COMU (199 mg, 0.466 mmol), DIPEA (181 µΐ , 1.058 mmol) and 1,2,3,4-
tetrahydroisoquinoline (59 µΐ , 0.466 mmol). The resulting mixture was stirred at r.t. for 2 h .
The reaction mixture was concentrated in vacuo to remove the DMF and the crude residue
redis solved in water (50 ml). The reaction mixture was quenched by addition of saturated
sodium bicarbonate solution (20 ml) extracted with DCM (3 x 100 ml). The combined
organic extracts were dried over sodium sulphate, concentrated in vacuo and purified via
chromatography on Si0 2 (gradient 100:0 -0:100, Heptane-EtOAc) to afford the title
compound (152 mg, 61%) as a yellow viscous oil.
[00626] Method A : LC-MS m/z = 470.2 [M + H]+; RT = 1.51 min.
[00627] Step 4 : Synthesis of 6-methyl-2-[5-methyl-3-(l,2,3,4-tetrahydroisoquinoline-2-
carbonyl)- 1H-pyrazol- 1-yl] -3 ,4-dihydropyrimidin-4-one
[00628] Q-365 (EV-AO7568-002)
[00629] 2-( 1-{4-[(4-methoxyphenyl)methoxy] -6-methylpyrimidin-2-yl }-5-methyl- 1H-
pyrazole-3-carbonyl)-l,2,3,4-tetrahydroisoquinoline (EV-AO7563-002, 80%, 152 mg, 0.259
mmol) was dissolved in MeOH (10 mL) and subjected to H-cube conditions (lml/min, 1 bar,
50 °C, Full H2 mode) over a Pd/C (10%) cat cartridge. The solvent was then removed in
vacuo and the residue purified by trituration using MeCN to afford the title compound (61
mg, 67%) as a white powder.
[00630] Method C: LC-MS m/z = 350.2 [M + H]+; RT = 2.8 1 min
Example 201 - Synthesis of e-methyl- -rS-methyl-S-d^^^-tetrahvdroisoquinoline- -
carbonyl)-lH-pyrazol-l-yl1-3,4-dihvdropyrimidin-4-one
[00631] Q-366 (EV-AO7569-002)
[00632] The title compound was prepared analogously to Example 200 using ethyl 4-
methyl-lH-pyrazole-3-carboxylate in place of ethyl 5-methyl-lH-pyrazole-3-carboxylate.
[00633] Method C: LC-MS m/z = 350.2 [M + H]+; RT = 2.8 1 min.
Example 203 - Preparation of 2-{4-[4-(trifluoromethyl)piperidine-l-carbonyl1-lH-
pyrazol-l-yl|-3H <4H-pyrrolo[2J-f1[l,2 <41triazin-4-one (0-467, EV-AO3851-002)
[00634] Step 1: Synthesis of 2-methanesulfonyl-3H,4H-pyrrolo[2,l-f][l,2,4]triazin-4-one
[00635] (EV-AQ3847-001)
[00636] To 2-(methylsulfanyl)-3H,4H-pyrrolo[2,l-f][l,2,4] triazin-4-one (900 mg, 4.97
mmol) in AcOH (18 ml) was added hydrogen peroxide (35%, 8.7 ml, 0.1 mol) and the
resultant suspension was stirred r.t. for 39 h, during which time the suspension dissolved and
a precipitate formed. The precipitate was collected by vacuum filtration, washed with water
followed by ether to afford the title compound (950 mg, 88%) as a white solid.
[00637] Method B: LC-MS m/z = 213.9 [M + H]+; RT = 0.73 min.
[00638] Step 2 : Synthesis of 2-{4-[4-(trifluoromethyl)piperidine-l-carbonyl]-lH-pyrazol-
1-yl }-3H,4H-pyrrolo[2, 1-f] [1,2,4] triazin-4-one
[00639] (EV-AQ3 85 1-002)
[00640] 1-( 1H-pyrazole-4-carbonyl)-4-(trifluoromethyl)piperidine (EV-AQ3840-00 1,
243.49 mg, 0.98 mmol) was added to a solution of 2-methanesulfonyl-3H,4H-pyrrolo[2,l-
f][l,2,4]triazin-4-one (200 mg, 0.94 mmol) and caesium carbonate (458.44 mg, 1.41 mmol)
in DMF (4 ml) and stirred under microwave conditions at 175 °C for 9 h . The reaction
mixture was concentrated in vacuo, redissolved in water and extracted with EtOAc (x2). The
combined organic extracts were washed with brine, dried over MgS0 4 and concentrated in
vacuo to afford a clear gum. Purification by PREP-HPLC afforded the title compound (37
mg, 10%) as a white solid. Meanwhile a solid had precipitated from the aqueous, the solid
was collected under vacuum filtration, washed with water followed by ether and dried under
vacuum overnight to afford a further batch of the title compound (113 mg, 32%) as a white
solid.
[00641] Method C: LC-MS m/z = 380.0 [M + H]+; RT = 2.66 min.
Example 204 - Preparation of 6-methyl-2-|l-[3-oxo-3-(l,2 <3.4-tetrahvdroisoquinolin-2-
ν1 ρΓθρν 11-1Η-ρνΓ3ζο1-4-ν1|-3,4- ί ν Γθρνηηιί ίη-4-οη (0-291, EV-AN7447-001) and
Example 205 - 4-methyl-6-|l-[3-oxo-3-(l,2 <3.4-tetrahvdroisoquinolin-2-yl)propyl1-lH-
pyrazol-4-yl|-l,2-dihvdropyrimidin-2-one (0-292, EV-AN7447-002).
[00642] Step 1: Synthesis of ethyl 3-[3,5-dimethyl-4-(tetramethyl-l,3,2-dioxaborolan-2-
yl)-lH-pyrazol-l-yl]propanoate
[00643] (EV-AN7436-002)
[00644] To a solution of pyrazole-4-boronic acid pinacol ester (500 mg, 2.58 mmol) in
acetonitrile (10 mL) was added ethyl acrylate (0.42 mL, 3.87 mmol), followed by DBU (0.39
mL, 2.58 mmol) and stirred at r.t. for 15.5 h . The reaction mixture was concentrated in vacuo
and purified by chromatography on Si0 2, eluting with Heptane/EtOAc (gradient 100:0 -
0:100) to afford the title compound (310 mg, 38%) as a clear oil.
[00645] Method A : LC-MS: m/z = +295.0 (M+H)+; RT = 1.25 min.
[00646] Step 2 : Synthesis of 2-chloro-4-methyl-6-[2-(trimethylsilyl)ethoxy]pyrimidine and
4-chloro-6-methyl-2-[2-(trimethylsilyl)ethoxy]pyrimidine
004)
[00648] To a stirred solution of 2-(trimethylsilyl)ethanol (3.5 mL) in THF (7 mL) at 0 °C
was added NaH (60% in oil, 490.74 mg, 12.27 mmol). The reaction mixture was warmed to
r.t. over 15 mins and then cooled again to 0 °C. To the reaction mixture was added 2,4-
dichloro-6-methylpyrimidine (2 g, 12.27 mmol) in THF (8 mL) and stirred at 0 °C for 1.5 h .
The reaction mixture was quenched by the addition of saturated NH4C 1 aqueous solution (10
mL) and extracted with EtOAc (3 x 25 mL). The combined organic extracts were washed
with brine solution (10 mL), dried over Na2S0 4 and concentrated in vacuo. Purification by
chromatography on Si0 2, eluting with Heptane/EtOAc (gradient 100:0 - 50:50) to afford the
title compound (2.21g, 72.2%, 2.7:1 mixture of regioisomers) as a white solid.
[00649] Method A : LC-MS: m/z = 216.9, 218.9 (M+H)+; RT = 1.62 min.
[00650] Step 3 : Synthesis of ethyl 3-(4-{4-methyl-6-[2-(trimethylsilyl)ethoxy]pyrimidin-2-
yl}- lH-pyrazol-l-yl)propanoate and ethyl 3-(4-{6-methyl-2-[2-
(trimethylsilyl)ethoxy]pyrimidin-4-yl }-lH-pyrazol- 1-yl)propanoate
(EV-AN7442-001)
[00652] To a solution of 2-chloro-4-methyl-6-[2-(trimethylsilyl)ethoxy]pyrimidine (EV-
AN7439-004,185 mg as a mixture of regioisomers, 0.76 mmol), ethyl 3-[4-(tetramethyl-
l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l-yl]propanoate (EV-AN743 6-002, 93%, 358.56 mg,
1.13 mmol) and CsF (172.2 mg, 1.13 mmol) in DME, ethanol (2:1, 7.5 mL) was added
Pd(PPh 3)4 (87.33 mg, 0.08 mmol) and stirred under microwave conditions at 120 °C for 15
mins. The reaction mixture was cooled to r.t. and water (10 mL) and EtOAc (15 mL) were
added. The organic fraction was extracted and the aqueous phase re-extracted with more
EtOAc (2 x 5 mL). The combined organics were washed with brine solution (5 mL), dried
over Na2S0 4 and concentrated in vacuo. Purification by chromatography on Si0 2 eluting with
Heptane/EtOAc (gradient 100:0 - 0:100) to afford the title compound (285 mg, 81.1%, 2:1
mixture of regioisomers) as a clear oil.
[00653] Method A : LC-MS: m/z = +377.2 (M+H)+; RT = 1.45 min.
[00654] Step 4 : Synthesis 3-(4-{4-methyl-6-[2-(trimethylsilyl)ethoxy]pyrimidin-2-yl}-lH-
pyrazol-l-yl)propanoic acid and 3-(4-{6-methyl-2-[2-(trimethylsilyl)ethoxy]pyrimidin-4-yl}-
lH-pyrazol-l-yl)propanoic acid
(EV-AN7445-001)
[00656] Ethyl 3-(4-{4-methyl-642-(trimethylsilyl)ethoxy]pyrimidin-2-yl}-lH-pyrazol-l-
yl)propanoate (EV-AN7442-001, 285 mg (as a mixture of regioisomers), 0.76 mmol) was
suspended in 2:2:1 THF/water/methanol (12.5 mL) and sodium hydroxide (147.13 mg, 3.68
mmol) was added. The reaction mixture was stirred at r.t. for 1 h . The organics were removed
in vacuo and the aqueous solution acidified with 2M aq HC1 solution and extracted with
EtOAc (2 x lOmL). The combined organics were dried over Na2S0 4 and concentrated in
vacuo to afford the title compound (239 mg, 94%, 2:1 mixture of regioisomers) as a
colourless oil.
[00657] Method A : LC-MS: m/z = +349.2 (M+H)+; RT = 1.27 min.
[00658] Step 5 : Synthesis of 3-(4-{4-methyl-6-[2-(trimethylsilyl)ethoxy]pyrimidin-2-yl}-
lH-pyrazol-l-yl)-l -(l,2,3,4-tetrahydroisoquinolin-2-yl)propan-l-one and 3-(4-{6-methyl-2-
[2-(trimethylsilyl)ethoxy]pyrimidin-4-yl }-IH-pyrazol- 1-yl)- 1-(1 ,2,3 ,4-tetrahydroisoquinolin-
2-yl)propan- 1-one
[00660] To a solution of 3-(4-{4-methyl-642-(trimethylsilyl)ethoxy]pyrimidin-2-yl}-lH-
pyrazol-l-yl)propanoic acid (EV-AN7445-001, 120 mg (as a mixture of regioisomers), 0.29
mmol) in DMF (4 ml) was added TBTU (278.63 mg, 0.87 mmol), DIPEA (0.12 mL, 0.72
mmol) and 1,2,3,4-tetrahydroisoquinoline (0.06 mL, 0.43 mmol) and stirred at r.t. for 15 h .
To the reaction mixture was added ice water and extracted with EtOAc (2 x 5 mL). The
combined organic extracts were washed with brine (5 mL), dried over Na2S0 4 and
concentrated in vacuo to afford the title compound (162 mg, 87%, as a mixture of
regioisomers) as a colourless oil.
[00661] Method: LC-MS: m/z = +464.2 (M+H)+; RT = 1.47 min.
[00662] Step 6 : Synthesis of 6-methyl-2-{ l-[3-oxo-3-(l,2,3,4-tetrahydroisoquinolin-2-
yl)propyl]-lH-pyrazol-4-yl}-3,4-dihydropyrimidin-4-one (Q-291, EV-AN7447-001) and 4-
methyl-6-{ l-[3-oxo-3-(l,2,3,4-tetrahydroisoquinolin-2-yl)propyl]-lH-pyrazol-4-yl}-l,2-
dihydropyrimidin-2-one
[00663]
[00664] 3-(4-{4-methyl-642-(trimethylsilyl)ethoxy]pyrimidin-2-yl}-lH-pyrazol-l-yl)-l-
(l,2,3,4-tetrahydroisoquinolin-2-yl)propan-l-one (EV-AN7446-001, 162 mg (as a mixture of
regioisomers), 0.25 mmol) was dissolved in DCM (4 mL) and TFA ( 1 mL) was added. The
reaction mixture was stirred for 1.5 h and then concentrated in vacuo. The crude residue was
re-dissolved in DCM and washed with saturated NaHC0 3 solution, dried over Na2S0 4 and
concentrated in vacuo afforded the title compounds as a mixture of regioisomers.
[00665] Purification by PREP-HPLC (Method G) afforded the first eluting isomer 6-
methyl-2- {1-[3-oxo-3 -( 1,2,3 ,4-tetrahydroisoquinolin-2-yl)propyl] -1H-pyrazol-4-yl }-3 ,4-
dihydropyrimidin-4-one, Example 204 (Q-291, EV-AN7447-001) (20.2 mg, 22.1%) as an off
white powder.
[00666] Method C: LC-MS: m/z = 364.2 (M+H)+; RT = 2.02
[00667] The second eluting isomer 4-methyl-6-{ l-[3-oxo-3-(l,2,3,4-tetrahydroisoquinolin-
2-yl)propyl]-lH-pyrazol-4-yl}-l,2-dihydropyrimidin-2-one Example 205 (Q-292, EV-
AN7447-002) (12.2 mg, 12.5%) was isolated as a beige powder.
Example 206 - 6-methyl-2-|l-[3-oxo-3-(pyrrolidin-l-yl)propyl1-lH-pyrazol-4-yl|-3,4-
dihvdropyrimidin-4-one (0-283, EV-AN7448-001)
[00668] The title compound was prepared in an analogous manner to Example 204 provide
the title compound (12.02 mg, 16.6%). The regioisomer could not be obtained in sufficient
purity for testing.
[00669] Method C: LC-MS: m/z = 302.1 (M+H)+; RT = 1.40
Example 207 - 2-|3,5-dimethyl-l-[3-oxo-3-(l,2 <3,4-tetrahvdroisoquinolin-2-yl)propyl1-
lH-pyrazol-4-yl|-6-methyl-3,4-dihvdropyrimidin-4-one
[00671] The title compound was prepared in an analogous fashion to Example 204 using
3,5-dimethyl-4-(tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole in step 1 to provide the
title compound (21.9 mg, 38.5).
[00672] Method C: LC-MS: m/z = 392.2 (M+H)+; RT = 2.15
Example 208 - 4-|3,5-dimethyl-l-[3-oxo-3-(l,2 <3,4-tetrahvdroisoquinolin-2-yl)propyl1-
lH-pyrazol-4-yl| -6-methyl-1.2-dihvdropyrimidin-2-one (0-285, EV-AN7453-002)
[00673] The title compound was prepared in an analogous fashion to Example 204 using
3,5-dimethyl-4-(tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole in step 1 to provide the
title compound (17.5 mg, 31.1).
[00674] Method C: LC-MS: m/z = 392.2 (M+H)+; RT = 1.82 min.
Example 209 - 2-|3,5-dimethyl-l-[3-oxo-3-(pyrrolidin-l-yl)propyl1-lH-pyrazol-4-yl|-6-
methyl-3,4-dihvdropyrimidin-4-one
[00675] Q-306 (EV-AN7457-001)
[00676] The title compound (20.1 mg, 25.6%) was prepared in an analogous manner to
Example 208 coupling with pyrrolidine.
[00677] Method C: LC-MS: m/z = 330.2 (M+H)+; RT = 1.57 min.
Example 210 - Preparation of 4-methyl-6-|5-methyl-4-[4-(trifluoromethyl)piperidine-l-
3 οην11-1Η -ρνΓ3ζο1-1-ν1|-1,2- άί1ινάΓθρνηάί -2-οη (0-439, EV-AO8815-001) and
Example 211 - 4-methyl-6-|3-methyl-4-[4-(trifluoromethyL)piperidine-l-carbonyl1-lH-
pyrazol-l-yl|-l,2-dihvdropyridin-2-one (O-440, EV-AO8815-002)
[00678] Step 1: Synthesis of 6-chloro-2-hydrazinylidene-4-methyl-l,2-dihydropyridine
[00679] (EV-AQ8803-001)
[00680] 2,6-dichloro-4-methylpyridine (102 mg, 0.63 mmol) was heated to ~ 110 °C in
hydrazine hydrate ( 1 mL) for 3 hours. The solution was cooled to 0 °C and water (3 mL) was
added. The resulting precipitate was isolated via filtration and washed with ice-cold water to
yield 6-chloro-2-hydrazinylidene-4-methyl-l,2-dihydropyridine (32 mg, 32%) as a pale
yellow powder.
[00681] LC-MS m/z = 157.9 [M + H]+; RT = 0.42 min.
[00682] Step 2 : Synthesis of 2-chloro-4-methyl-6-{ 5-methyl-4-[4-
(trifluoromethyL)piperidine-l-carbonyl]-lH-pyrazol-l-yl}pyridine and 2-chloro-4-methyl-6-
{3-methyl-4-[4-(trifluoromethyl)piperidine- 1-carbonyl] -IH-pyrazol- 1-yl jpyridine
(EV-AQ88 10-001)
[00683] To a stirred solution of (2E)-2-[(dimethylamino)methylidene]-l-[4-
(trifluoromethyL)piperidin-l-yl]butane-l,3-dione (EV-AP2353-001, 927 mg, 3.17 mmol) in
EtOH (7 mL) and AcOH (635 µΐ 11.1 mmol) was added 2-chloro-6-hydrazinyl-4-
methylpyridine (500 mg, 3.17 mmol) and the reaction mixture was stirred at 80 °C overnight.
The reaction was cooled ant the solvent removed in vacuo, the resulting residue was
partitioned between DCM (50 mL) and sat. NaHC03 (60 mL), the aqueous fraction was
extracted with DCM (2 x 50 mL) and the combined organic fractions were dried (MgS04)
and concentrated in vacuo to yield 2-chloro-4-methyl-6-{5-methyl-4-[4-
(trifluoromethyL)piperidine-l-carbonyl]-lH-pyrazol-l-yl}pyridine (1.08 g, 88%, mixture of
regioisomers) as a yellow powder.
[00684] LC-MS m/z = 387.1 [M + H]+; RT = 1.41-1.43 min.
[00685] Step 3 : Synthesis of 2-(benzyloxy)-4-methyl-6-{ 5-methyl-4-[4-
(trifluoromethyL)piperidine- 1-carbonyl] -IH-pyrazol- 1-yl jpyridine and 2-(benzyloxy)-4-
methyl-6- {3-methyl-4- [4-(trifluoromethyl)piperidine- 1-carbonyl] -IH-pyrazol- 1-yl jpyridine
(EV-AQ88 13-001)
[00686] To a stirred solution of 2-chloro-4-methyl-6-{5-methyl-4-[4-
(trifluoromethyL)piperidine-l-carbonyl]-lH-pyrazol-l-yl}pyridine (1.08 g, 2.79 mmol)
(Crude mixture from containing regioisomers) in dioxane (15 mL) was added
phenylmethanol (0.32 mL, 3.07 mmol), followed by t-BuOK (345 mg, 3.07 mmol) and the
solution was heated to reflux overnight. A further 1.1 equivalents of t-BuOK (345 mg, 3.07
mmol) and phenylmethanol (0.32 mL, 3.07 mmol) were added and the reaction was refluxed
for a further 3 hours. Saturated NH4CI (50 mL) was added to the cooled solution and the
mixture was extracted with EtOAc (2 x 80 mL), the combined organic fractions were dried
over MgS04, the solvent removed in vacuo and the resulting residue purified via
chromatography on Si0 2 eluting with 0:100-100:0 EtOAc-heptane) to afford the title
compounds (593 mg, 82%, mixture of isomers) as an off-white powder.
[00687] LC-MS m/z = 459.2 [M + H]+; RT = 1.56-1.60 min.
[00688] Step 4 : Synthesis of 4-methyl-6-{5-methyl-4-[4-(trifluoromethyL)piperidine-l-
carbonyl]-lH-pyrazol-l-yl}-l,2-dihydropyridin-2-one and 4-methyl-6-{3-methyl-4-[4-
(trifluoromethyl)piperidine- 1-carbonyl] -lH-pyrazol- 1-yl }-1,2-dihydropyridin-2-one
Q-439 (EV-AQ88 15-001)
[00689] To a stirred solution of 2-(benzyloxy)-4-methyl-6-{5-methyl-4-[4-
(trifluoromethyL)piperidine-l-carbonyl]-lH-pyrazol-l-yl}pyridine (530 mg, 1.16 mmol, as a
mixture of regioisomers) in EtOAc (25 mL) was added Pd on carbon (10%, lOOmg) and the
solution exposed to an atmosphere of ¾ (g) overnight. The solution was filtered through
celite washing with EtOAc, the filtrate concentrated in vacuo and the residue purified via
PREP-HPLC (Method G) to yield 4-methyl-6-{5-methyl-4-[4-(trifluoromethyL)piperidine-l-
carbonyl]-lH-pyrazol-l-yl}-l,2-dihydropyridin-2-one (42 mg, 10%) as a yellow powder and
4-methyl-6- {3-methyl-4- [4-(trifluoromethyL)piperidine- 1-carbonyl] - lH-pyrazol- 1-yl }-1,2-
dihydropyridin-2-one (118 mg, 28%) as a yellow powder.
[00690] LC-MS m/z = 369.1 [M + H]+; RT = 3.46 min.
[00691] Q-440 (EV-AQ88 15-002)
[00692] LC-MS m z = 369. 1 [M + H]+; RT = 3.67 min
Example 212 - Preparation of 4-methyl-6-|4-[4-(trifluoromethyl)piperidine-l-
3 ο 1 - 1Η-ρ 3ζο1-1- 1|-1,2- ί θρ ί -2-ο , O-460. EV-AQ7135-001
[00693] (EV-AQ7 135-001)
[00694] Step 1: Synthesis of 2-chloro-4-methyl-6-{4-[4-(trifluoromethyl)piperidine-l-
carbonyl] -1H-pyrazol- 1-yl jpyridine
[00695] (EV-AQ7 130-001)
[00696] To a solution of l-(lH-pyrazole-4-carbonyl)-4-(trifluoromethyl)piperidine (EV-
AQ8818-001, 91.55 mg, 0.37 mmol) and caesium carbonate (150.83 mg, 0.46 mmol) in DMF
(2 mL) was added 2,6-dichloro-4-methylpyridine (50 mg, 0.31 mmol). The reaction mixture
was stirred at 100 °C for 6 h . The reaction mixture was concentrated under vacuum. The
residue was diluted with water and extracted with EtOAc. The organics were washed with
brine (x2), dried over Na2S0 4 and concentrated under vacuum. The crude residue was
purified by chromatography on Si0 2 eluting with 0-100% EtOAc in heptane to afford the title
compound (45 mg, 39.1%) as an off-white powder.
[00697] Method A : LC-MS : m/z = 373 .1 (M+H)+; RT = 1.43 min.
[00698] Step 2 : Synthesis of 2-(benzyloxy)-4-methyl-6-{4-[4-(trifluoromethyl)piperidine-
1-carbonyl] -1H-pyrazol- 1-yl jpyridine
[00699] (EV-AQ7 129-002)
[00700] To a solution of 2-chloro-4-methyl-6-{4-[4-(trifluoromethyl)piperidine-l-
carbonyl]-lH-pyrazol-l-yl}pyridine (EV-AQ7 130-001, 45 mg, 0.12 mmol) in dioxane (2
mL) was added benzyl alcohol (0.01 mL, 0.13 mmol) and potassium tert-butoxide (14.9 mg,
0.13 mmol) and the solution was heated at 90 °C for 4 h . The reaction mixture was
concentrated under vacuum and purified by chromatography on Si0 2 eluting with 0-100%
EtOAc in heptane to afford the title compound (72 mg, 33.5%).
[00701] Method A : LC-MS: m/z = 445.1 (M+H)+; RT = 1.60 min.
[00702] Step 3 : Synthesis of 4-methyl-6- {4- [4-(trifluoromethyl)piperidine-l -carbonyl] -
lH-pyrazol-l-yl}-l,2-dihydropyridin-2-one, Q-460, EV-AQ7135-001
[00703] Pd on carbon (10%, 17 mg) was added to a stirred solution of 2-(benzyloxy)-4-
methyl-6- {4-[4-(trifluoromethyl)piperidine- 1-carbonyl] - lH-pyrazol- 1-yl jpyridine (EV-
AQ7129-002, 72 mg, 0.16 mmol) in ethanol (5.0 mL) and the solution was stirred under an
atmosphere of ¾ overnight. More Pd on carbon (10%, 17 mg) was added to the reaction and
the stir under an atmosphere of ¾ was continued for a further 5 h . The solution was filtered
through Celite, washing with EtOAc. The filtrate was concentrated under vacuum and the
residue purified by Prep-HPLC (Method G) to afford the title compound (8.2 mg, 14.3%) as
an off- white powder
[00704] Method C: LC-MS: m/z = 355.2 (M+H)+; RT = 2.84 min.
Example 213 - Preparation of 6-|5-methyl-4-[4-(trifluoromethyl)piperidine-l-
carbonyl1-lH-pyrazol-l-yl|-4-(trifluoromethyl)- l,2-dihvdropyridin-2-one.
[00705] (EV-AQ7 15 1-002)
[00706] Step 1: Synthesis of 2-chloro-6-hydrazinyl-4-(trifluoromethyl)pyridine
[00707] (EV-AQ7141-001)
[00708] Hydrazine hydrate (0.05 mL, 0.93 mmol) was added to a suspension of 2,6-
dichloro-4-(trifluoromethyl)pyridine (100 mg, 0.46 mmol) in ethanol (2 mL) and the reaction
vessel was sealed and heated at 40 °C for 1.5 h and then at 70 °C for another 5.5 h .
[00709] The solution was concentrated and the resulting solid was triturated with water to
afford the title compound (70 mg, 51.5%) as a pale brown solid.
[00710] Method B: LC-MS: m/z = 211.9 (M+H)+; RT = 0.91 min.
[00711] Step 2 : Synthesis of methyl l-[6-chloro-4-(trifluoromethyl)pyridin-2-yl]-5-
methyl-lH-pyrazole-4-carboxylate
[00712] (EV-AQ7 144-001)
[00713] To a solution of 2-chloro-6-hydrazinyl-4-(trifluoromethyl)pyridine (EV-AQ7141-
001, 770 mg, 3.64 mmol) and methyl 2-[(dimethylamino)methylidene]-3-oxobutanoate (90%,
934.57 mg, 4.91 mmol) in ethanol (22 mL) was added acetic acid (0.729 mL, 12.74 mmol)
and the reaction mixture was stirred at r.t. for 5 mins and then heated at 50 °C for 1 h . The
mixture was concentrated under vacuum and purified by chromatography on Si02 Eluting
with 0-100% EtOAc in heptane to afford the title compound (1.04 g, 88.5%) as a white
powder.
[00714] Method B: LC-MS: m/z = 320.0 (M+H)+; RT = 1.35 min.
[00715] Step 3 : Synthesis of methyl l-[6-(benzyloxy)-4-(trifluoromethyl)pyridin-2-yl]-5-
methyl-lH-pyrazole-4-carboxylate
[00716] (EV-AQ7 147-001)
[00717] To a solution of methyl l-[6-chloro-4-(trifluoromethyl)pyridin-2-yl]-5-methyl-lH-
pyrazole-4-carboxylate (EV-AQ7 144-001, 600 mg, 1.88 mmol) in dioxane (10 mL) was
added benzyl alcohol (0.21 mL, 2.06 mmol) and potassium tert-butoxide (231.68 mg, 2.06
mmol). The reaction mixture was stirred at 60 °C for 0.5 h . The reaction mixture was
concentrated under vacuum, diluted with water (10 mL), and extracted with EtOAc (25 mL).
The organics were washed with brine, dried (Na2S0 4) and concentrated under vacuum. The
crude material was purified by chromatography on Si0 2 eluting with 0-50% EtOAc
in heptane to afford the title compound (629 mg,48%) (mixture with the benzyl ester) of as a
clear oil.
[00718] Method B: LC-MS: m/z = 392.1 (M+H)+; RT = 1.39 min.
[00719] Step 3 : Synthesis of 5-methyl-l-[6-oxo-4-(trifluoromethyl)-l,6-dihydropyridin-2-
yl]-lH-pyrazole-4-carboxylic acid
[00720] (EV-AQ7 149-003)
[00721] Pd on carbon (10%, 86 mg) was added to a stirred solution of methyl l-[6-
(benzyloxy)-4-(trifluoromethyl)pyridin-2-yl]-5-methyl-lH-pyrazole-4-carboxylate (EV-
AQ7147-001, (mixture with the benzyl ester) (629 mg, 1.61 mmol)) in ethyl acetate (15.0
mL) and the solution was stirred under an atmosphere of H2 overnight. The reaction mixture
was filtered through Celite, washing with EtOAc. The filtrate was concentrated in vacuo and
purified by chromatography on Si0 2 Eluting with 0- 100% EtOAc in heptane to afford the
title compound (107 mg, 21.6%) as an off white powder.
[00722] Method B: LC-MS: m/z = 287.9 (M+H)+; RT = 1.01
[00723] Step 4 : Synthesis of 6-{5-methyl-4-[4-(trifluoromethyl)piperidine-l-carbonyl]-
lH-pyrazol-l-yl}-4-(trifluoromethyl)- l,2-dihydropyridin-2-one, Q-466, EV-AQ7151-002
[00724] To a solution of 5-methyl-l-[6-oxo-4-(trifluoromethyl)-l,6-dihydropyridin-2-yl]-
lH-pyrazole-4-carboxylic acid (200 mg, 0.70 mmol) in THF (6.0 mL) was added DIPEA
(0.417 mL, 2.44 mmol) and T3P 50% in EtOAc (0.821 ml, 1.39 mmol). The reaction mixture
was stirred at r.t. for 10 mins and 4-(trifluoromethyl)piperidin-l-ium.HCl (158.45 mg, 0.84
mmol) was added before stirring for a further 1 h . The reaction mixture concentrated in vacuo
and the crude residue was then suspended in water (5 mL) and DCM (10 mL). The organics
were extracted and the aqueous phase was then acidified to pH3-4 and extracted with more
DCM (5 mL). The combined organics were dried (Na2S0 4), filtered and concentrated in
vacuo. The crude material was purified by PREP-HPLC (Method G) method) to afford the
title compound (19.1 mg, 6.4%) of as an off-white powder.
[00725] Method C: LC-MS: m/z = 423.1 (M+H)+; RT = 3.41
Example 214 - Preparation of 5-{4-[4-(trifluoromethyl)piperidine-l-carbonyl1-lH-
pyrazol-l-yl|-6HJH-thieno[2,3-c1pyridin-7-one (0-511, EV-AR5370-002)
[00726] Step 1: Synthesis of 5-chloro-7-[(4-methoxyphenyl)methoxy]-6H,7H-thieno[2,3-
c]pyridine
[00727] (EV-AR5366-003)
[00728] To a solution of 5-chloro-7-[(4-methoxyphenyl)methoxy]thieno[2,3-c]pyridine
(EV-AR5360-001, 200 mg, 0.65 mmol) in DMF (3 ml) was added caesium carbonate (341
mg, 1.05 mmol) and l-(lH-pyrazole-4-carbonyl)-4-(trifluoromethyl)piperidine (Intermediate
29, EV-AQ8818-001, 178 mg, 0.719 mmol) and stirred at 140 °C for 5 h . The reaction
mixture was concentrated in vacuo and purified by PREP-HPLC (Method G) to afford the
title compound (56 mg, 44%) as an off white powder.
[00729] Method B: LC-MS m/z = 185.8 [M + H]+; RT = 0.86 min.
[00730] Step 2 : Synthesis of 5-{4-[4-(trifluoromethyl)piperidine-l-carbonyl]-lH-pyrazol-
1-yl}-6H,7H-thieno [2,3 -c]pyridin-7-one
[00731] (EV-AR5370-002)
[00732] To a solution of 5-chloro-7-[(4-methoxyphenyl)methoxy]-6H,7H-thieno[2,3-
c]pyridine (EV-AR5366-003, 56 mg, 0.302 mmol) in DMF ( 1 ml) was added 1-(1H-
pyrazole-4-carbonyl)-4-(trifluoromethyl)piperidine (Intermediate 29, 89 mg, 0.362 mmol),
caesium carbonate (147 mg, 0.453 mmol), L-proline (14 mg, 0.121 mmol) and copper (I)
iodide (11 mg, 0.06 mmol). The reaction mixture was then de-gassed and stirred at 140 °C for
16 h . The reaction mixture was cooled to r . , diluted with EtOAc (20 ml) and washed with
brine (2 x 10 ml). The organic extracts were dried over sodium sulfate, concentrated in vacuo
and purified by PREP-HPLC (Method G) followed by trituration using MeCN, to afford the
title compound (32 mg, 27%) as an off white powder.
[00733] Method C: LC-MS m/z = 397. 1 [M + H]+; RT = 2.67 min.
Example 216 - Preparation of 2-|5-[4-(trifluoromethyl)piperidine-l-carbonyl1-l,3-
thiazol-2-yl|-3H,4H-thieno[3,2-d1pyrimidin-4-one
[00734] Step 1: Synthesis of 2-(ethoxycarbonyl)-l,3-thiazole-5-carboxylic acid
[00735] (EV-AS5405-001)
[00736] To a solution of bromopyruvic acid (2.0 g, 11.98 mmol) in anhydrous 1, 4-dioxane
(20 ml) was added ethyl amino(thioxo)acetate (1.60 g, 11.98 mmol) and stirred at 100 °C
overnight. The reaction mixture was cooled to room temperature, basified with saturated
NaHC03 solution and extracted with EtOAc (2 x 20 ml). The organic extracts were
discarded. The aqueous extracts were then acidified to pH 3/4 using 5M aq HCl solution and
extracted with EtOAc (2 x 50 ml). The organic extracts were dried over sodium sulfate and
concentrated in vacuo to afford the title compound (1.34 g, 54%) as an orange powder.
[00737] Method B: LC-MS m z = 201.85 [M + H]+; RT = 0.80 min.
[00738] Step 2 : Synthesis of ethyl 5-[4-(trifluoromethyl)piperidine-l-carbonyl]-l,3-
thiazole-2-carboxylate
[00739] (EV-AS5406-001)
[00740] To a suspension of 2-(ethoxycarbonyl)-l,3-thiazole-5-carboxylic acid (EV-
AS5405-001, 1.34 g, 6.66 mmol) in THF (15 ml) was added DIPEA (2.9 ml, 16.7 mmol),
T3P (50% in EtOAc) (9.8 ml, 16.7 mmol) and 4-(trifluoromethyl)piperidine hydrochloride
(1.39 g, 7.33 mmol) and stirred at r.t. for 2 h . The reaction mixture was concentrated in vacuo
and to the crude residue added DCM (40 ml) and saturated NaHC03 solution (20 ml). The
organic layer was extracted, washed with water (10 ml), dried over sodium sulfate and
concentrated in vacuo to afford the title compound (2.13 g, 75%) as a brown powder.
[00741] Method B: LC-MS m z = 337.0 [M + H]+; RT = 1.09 min.
[00742] Step 3 : Synthesis of 5-[4-(trifluoromethyl)piperidine-l-carbonyl]-l,3-thiazole-2-
carboxylic acid
[00743] (EV-AS5407-001)
[00744] To a solution of ethyl 5-[4-(trifluoromethyl)piperidine-l-carbonyl]-l,3-thiazole-2-
carboxylate (EV-AS5406-001, 79%, 2.10 g, 4.93 mmol) in THF (10 mL) and water (5 ml)
was added 3M aqueous NaOH solution (8.22 ml) and stirred at r.t. for 2 h . The reaction
mixture was concentrated in vacuo to remove the organic solvent and the aqueous mixture
acidified to pH 2/3 using 5M aq HC1 solution. The reaction mixture was extracted with
EtOAc (2 x 50 ml) and the combined organic extracts dried over sodium sulfate and
concentrated in vacuo to afford the title compound (874 mg, 40%) as a brown solid.
[00745] Method B: LC-MS m z = 308.85 [M + H]+; RT = 0.87 min.
[00746] Step 4 : Synthesis of N-(2-carbamoylthiophen-3-yl)-5-[4-
(trifluoromethyl)piperidine- 1-carbonyl] -1,3-thiazole-2-carboxamide
[00747] (EV-AS5408-002)
[00748] To a solution of 5-[4-(trifluoromethyl)piperidine-l-carbonyl]-l,3-thiazole-2-
carboxylic acid (EV-AS5407-001, 70%, 872 mg, 1.98 mmol) in THF (10 ml) was added
HATU (904 mg, 2.38 mmol), DIPEA (848 µΐ , 4.95 mmol) and 3-aminothiophene-2-
carboxamide (310 mg, 2.18 mmol) and stirred at r.t. for 2 h . The reaction mixture was
concentrated in vacuo and redis solved in DCM (2 ml) and water ( 1 ml). The reaction mixture
was filtered through a phase separator cartridge, concentrated in vacuo and purified by
chromatography, eluting with DCM/MeOH (gradient 100:0 - 95:5) to afford the title
compound (1.03 g, 88%) as an orange oil.
[00749] Method B: LC-MS m z = 432.90 [M + H]+; RT = 1.09 min.
[00750] Step 5 : Synthesis of 2-{5-[4-(trifluoromethyl)piperidine-l-carbonyl]-l,3-thiazol-2-
yl}-3H,4H-thieno[3 ,2-d]pyrimidin-4-one
[00751] Q-530 (EV-AS5409-002)
[00752] To a solution of N-(2-carbamoylthiophen-3-yl)-5-[4-(trifluoromethyl)piperidine-l-
carbonyl]-l,3-thiazole-2-carboxamide (EV-AS5408-002, 73%, 45 mg, 0.076 mmol) in
MeOH (3 ml) was added 1M aq NaOH solution (380 µΐ , 0.38 mmol) and stirred at 70 °C for
2 h . The reaction mixture was filtered to remove the precipitate, the filtrate extracted with
EtOAc (2 x 10 ml) and the organic extracts discarded. The aqueous extracts were then
acidified to pH 4/5 using 2M aq HCl solution. A white precipitate formed which was filtered,
washing with water and purified by PREP-HPLC (Method G) to afford the title compound
(12 mg, 38%) as a white powder.
[00753] Method C: LC-MS m z = 415.0 [M + H]+; RT = 2.84 min.
Example 218 - Preparation of 2-(5-methyl-4-{2 <2<2-trifluoro-l-[4-
(trifluoromethvDpiperidin-l-yllethyll-lH-pyrazol-l-vD-aH^H^H^HJH-
cvclopentardlpyrimidin-4-one O-503 EV-AQ7177-001)
[00754] (EV-AQ7 167-001)
[00755] Step 1: Synthesis of 2-[5-methyl-4-(trifluoroacetyl)-lH-pyrazol-l-yl]-
3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one
[00756] (EV-AQ7 169-001)
[00757] To a solution of 2-hydrazinyl-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one
(EV-AQ7 134-001, 150 mg, 0.9 mmol, Intermediate 17) in THF (15 mL) at -10 °C was added
dropwise 3-(ethoxymethylidene)-l,l,l-trifluoropentane-2,4-dione (prepared using the
procedure described in journal of Fluorine Chemistiy, 136, 38-42; 2012) (EV-AQ7 167-001,
199.17 mg, 0.95 mmol) in THF (5 mL) over 20 mins and stirred at -10 °C for 30 mins and at
r.t. for a further 1 h . The reaction mixture was concentrated in vacuo and dissolved in DCM.
The organics were washed with brine, dried over Na2S0 4 and concentrated in vacuo to afford
the title compound (310 mg, 92.4%) as an orange powder, which ionised in the LC-MS as a
mixture of ketone and dehydrate.
[00758] Method B: LC-MS m/z = 331.0 [M + H]+; RT = 0.98 min; 313.0 [M + H]+; RT =
1.14 min
[00759] Step 2 : Synthesis of 2-[5-methyl-4-(2,2,2-trifluoro-l-hydroxyethyl)-lH-pyrazol-
l-yl]-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one
[00760] (EV-AQ7 174-001)
[00761] To a solution of NaBH4 (49.68 mg, 1.3 1 mmol) in MeOH ( 1 mL) was added 1M
aqueous NaOH solution (0.1 mL) followed by 2-[5-methyl-4-(trifluoroacetyl)-lH-pyrazol-l-
yl]-3H,4H,5H,6H,7H- cyclopenta[d]pyrimidin-4-one (EV-AQ7 169-001, 100 mg, 0.32 mmol)
in MeOH (2 mL) and stirred at r.t. for 1 h . The reaction mixture was quenched with water (~2
mL) and concentrated in vacuo. The residue was dissolved in EtOAc, washed with water (3
mL) and brine (3 mL), dried over Na2S0 4 and concentrated in vacuo to afford the title
compound (95 mg, 94.4%) as an orange powder.
[00762] Method B: LC-MS m/z = 315.0 [M + H]+; RT = 0.99 min
[00763] Step 3 : Synthesis of 2-(5-methyl-4-{2,2,2-trifluoro-l-[4-
(trifluoromethyl)piperidin-l-yl]ethyl}-lH-pyrazol-l-yl)-3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-4-one.
[00764] Q-503, EV-AQ7 177-001
[00765] To a solution of 2-[5-methyl-4-(2,2,2-trifluoro-l-hydroxyethyl)-lH-pyrazol-l-yl]-
3H,4H,5H,6H,7H- cyclopenta[d]pyrimidin-4-one (EV-AQ7174-001, 90 mg, 0.29 mmol) in
DCM (3.5 mL) at -10 °C was added Et3N (0.12 mL, 0.86 mmol) followed by triflic anhydride
(0.08 mL, 0.50 mmol) and stirred at -10 °C for 1 h . The reaction mixture was washed with
cold saturated NaHC0 3 solution (3 mL) and water (3 mL). The organic extracts were then
dried over Na2S0 4 and concentrated in vacuo. The residue was dissolved in THF (3 mL),
cooled to 0 °C, added to a stirred solution of 4-(trifluoromethyl)piperidin-l-ium HCl (108.6
mg, 0.57 mmol) and potassium carbonate (118.74 mg, 0.86 mmol) and stirred at 0 °C - r.t. for
15 h . The reaction mixture was concentrated in vacuo and partitioned between DCM (2 mL)
and water (ImL). The organics were isolated using a phase separator cartridge, concentrated
in vacuo and purified by PREP-HPLC (Method G) to afford the title compound (21 mg,
16.3%) as brown powder.
[00766] Method C: LC-MS m/z = 450. 1 [M + H]+; RT = 2.98 min
Example 219 - Preparation of 3-methyl-5-{5-methyl-4-[4-(trifluoromethyL)piperidine-
l-carbonyll-lH-pyrazol-l-yl|phenol (0-494, EV-AR5355-002)
[00767] Stepl: Synthesis of 2-[4-(hydroxymethyL)-5-methyl-lH-pyrazol-l-yl]-
3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one
[00768] (EV-AQ7 157-001)
[00769] To a solution of methyl 5-methyl-l-{4-oxo-3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-2-yl}-lH-pyrazole-4-carboxylate (Intermediate 18 step 1, EV-
AQ7 137-001, 1 g, 3.65 mmol) in THF (20 mL) at 0 °C was added dropwise lithium
aluminium hydride (2.4 M solution in THF, 1.82 mL, 4.35 mmol) and stirred at r.t. for 15 h .
The reaction mixture was quenched by the addition of water (15 mL) and filtered through
Celite, washing with methanol (15 mL). The filtrate was concentrated in vacuo to afford the
title compound (650 mg, 62%) as a pale yellow powder:
[00770] Method B: LC-MS m/z = 245 [M + H]+; RT = 0.89 min
[00771] Step2: Synthesis of 5-methyl-l-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-
2-yl }-1H-pyrazole-4-carbaldehyde
[00772] (EV-AQ7 158-002)
[00773] To a solution of 2-[4-(hydroxymethyL)-5-methyl-lH-pyrazol-l-yl]-
3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (EV-AQ7 157-001, 650 mg, 2.64 mmol) in
DCM (20 niL) and MeOH (10 niL) was added manganese (IV) oxide (1.84 g, 21.12 mmol)
and stirred at r.t. for 15 h . A further portion of manganese (IV) oxide (1.84 g, 21.12 mmol)
was added and stirred at r.t. for 6 h . A further portion of manganese (IV) oxide (0.92 g, 10.56
mmol) was added and stirred at r.t. for 4 days. The reaction mixture was filtered through
Celite, washing with DCM and MeOH, and the filtrate concentrated in vacuo to afford the
title compound (558 mg, 68%) as a beige powder.
[00774] Method B: LC-MS m/z = 245 [M + H]+; RT = 0.89 min
[00775] Step3: Synthesis of l-[(5-methyl-l-{4-oxo-3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-2-yl}-lH-pyrazol-4-yL)methyl]piperidin-2-one.
[00776] Q-494 (EV-AR5355-002)
[00777] To a solution of 5-methyl-l-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-
yl}-lH-pyrazole-4-carbaldehyde (EV-AQ7158-001, 80%, 90 mg, 0.295 mmol) in anhydrous
MeOH (3 mL) was added ethyl 5-aminopentanoate hydrochloride (59 mg, 0.324 mmol) and
Et3N (164 µΐ , 1.179 mmol) and stirred at r.t. for 1 h . To the reaction mixture was added
NaBH4 (13 mg, 0.354 mmol) and stirred at 45 °C for 16 h . The reaction mixture was stirred at
50 °C for a further 3 h . The reaction mixture was cooled to r.t. and diluted with water (10
mL). The aqueous mixture was then acidified to pH 4 using 5 M aq HC1 solution and
extracted with EtOAc (2 x 30 mL). The combined extracts were dried over sodium sulfate,
concentrated in vacuo and purified via PREP-HPLC (Method G) to afford the title compound
(5 mg, 5%) as an off white powder.
[00778] Method C: LC-MS m/z = 328.1 [M + H]+; RT = 2.19 min.
Example 220:
[00779] Step 1: Synthesis of ethyl l-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-
2-yl }-1H-pyrazole-4-carboxylate
[00780] (EV-AN0096-002)
[00781] To a solution of ethyl lH-pyrazole-4-carboxylate (143m g, 1.022mol) in DMF (5
mL) at 0 oC was added NaH (60% in oil) (60%, 45 mg, 1.12 mmol). The reaction mixture
was warmed to r.t. over 30 minutes before 2-methanesulfonyl-4-[(4-
methoxyphenyl)methoxy]-6-methylpyrimidine (Example 196 step 2, EV-A057 10-002, 300
mg, 0.97 mmol) was added in more DMF ( 1 mL). The reaction mixture was stirred at r.t. for
3h. The reaction mixture was quenched by the addition of water (20 mL) and extracted with
EtOAc (3x 30 mL). The combined organic fractions were washed with brine (20 mL), dried
(Na2S0 4) and concentrated under vacuum to an opaque gum which was purified by
chromatography on Si0 2 eluting with 12-100% EtOAc in heptane to afford the title
compound (266mg, 66% yield) as a white powder.
[00782] Method A : LC-MS: m/z = + 391.10 (M+Na) +1.41 min
[00783] Step 2 : Synthesis of l-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-yl}-
lH-pyrazole-4-carboxylic acid
[00784] (EV-AN0098-002)
[00785] To a solution of ethyl l-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-
yl}- lH-pyrazole-4-carboxylate (EV-AN0096-002 (266 mg, 0.64 mmol) in THF (10 ml) was
added NaOH (3M, 1ml) and the reaction was stirred at room temperature for 18h. More
NaOH (2.5M, 1.5ml) was added along with MeOH (1ml) and the reaction stirred for a further
7h. The Organic solvent was evaporated in vacuo and the aqueous phase acidified to pHl
with HC1 (1M). The mixture was extracted with EtOAc (3x30ml), washed with brine (2 x
20ml), dried (Na2S0 4) and evaporated to afford the title compound (199mg, , 64% ) as a
colourless gum.
[00786] Method A : LC-MS: m/z = + 363.0 (M+Na) +1.20 min
[00787] Step 3 : Synthesis of 2-(l-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-
yl}-lH-pyrazole-4-carbonyl)- 1,2,3,4- tetrahydroisoquinoline
3
[00788] (EV-AO8800-002)
[00789] To a stirred solution of l-{4-[(4-methoxyphenyl)methoxy]-6-methylpyrimidin-2-
yl}-lH-pyrazole-4-carboxylic acid (EV-AN0090-001, 199 mg, 0.58 mmol) in DMF (1ml)
was added DIPEA (255 µΐ , 1.46 mmol) followed by TBTU (225 mg, 0.7 mmol). The reaction
was stirred for 3 min after which time 1,2,3,4-tetrahydroisoquinoline (lOlmg, 0.76 mmol)
was added and then the reaction was placed under N2. The reaction was stirred for 16 hours
and then quenched with water (20ml) and extracted with DCM (3x30 ml). The organics were
washed with brine (2x50ml), dried (Na2S0 4) and evaporated under vacuum, followed by
azeotrope with heptane (2x50 mL) to remove residual DMF. The crude product was purified
by chromatography on Si0 2 eluting with 25 - 100% EtOAc in heptane gradient to afford the
title compound (220 mg, 72%) as a colourless gum.
[00790] Method C: LC-MS: m/z = 456.2 (M+H)+ 1.40 min
[00791] Step 4 : Synthesis of 6-methyl-2-[4-(l,2,3,4-tetrahydroisoquinoline-2-carbonyl)-
1H-pyrazol- 1-yl] -3 ,4-dihydropyrimidin-4-one
[00792] Q-314 (EV-AO8801-002)
[00793] 2-( 1-{4-[(4-methoxyphenyl)methoxy] -6-methylpyrimidin-2-yl }-1H-pyrazole-4-
carbonyl)-l,2,3,4-tetrahydroisoquinoline (EV-AO8800-002, 220 mg, 0.42 mmol) was
dissolved in DCM (3 mL) and TFA (0.35mL) was added. The reaction mixture was stirred
for 1 hour and 30 minutes and then concentrated under vacuum. The crude residue was then
re-dissolved in DCM (30ml) and washed with sodium bicarbonate solution (sat, 2 x 10ml),
dried (Na2S0 4) and concentrated under vacuum. The crude material was purified by
preparative HPLC (Method G) to afford the title compound (46 mg, 33%) as an off white
solid
[00794] Method C: LC-MS: m/z = 336.1 (M+H)+ 2.38 min
Example 221 - Preparation of 6-methyl-2-[4-(l,2,3. 4-tetrahvdroisoquinoline-2-
carbonyl)-lH-l <2<3-triazol-l-yl1-3 <4-dihvdropyrimidin-4-one (0-312, EV-A05730-002)
[00795] Step 1: Synthesis of 5-methyl-3H,7H-[l,2,3,4]tetrazolo[l,5-a]pyrimidin-7-one
[00796] C (EV-AO5708-001)
[00797] To a solution of hydrazinyl-6-methyl-3,4-dihydropyrimidin-4-one (Intermediate
1, EV-AN7477-001, 0.5 g, 3.6 mmol) in ice cold acetic acid (3 mL) was added dropwise a
solution of sodium nitrite (0.37 g, 5.4 mmol) in water (0.4 mL). The reaction mixture was
stirred at 5 °C for 1 hour and then concentrated in vacuo. The residue was triturated from
water, filtered and dried in vacuo to afford the title compound (335mg, 59%) as a colourless
solid.
[00798] Method A : LC-MS m/z = 152.1 [M + H]+; RT = 0.24 min
[00799] Step 2 : Synthesis of methyl l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-lH-
1,2,3-triazole-4-carboxylate
[00800] (EV-AO5726-001)
[00801] A solution of -butanol-water 1:1 (4 mL) was degassed with a stream of
nitrogen for 5 minutes and methyl-3H,7H-[l,2,3,4]tetrazolo[l,5-a]pyrimidin-7-one (EV-
AO5708-001, 200 mg, 1.32 mmol), copper (I) chloride (26 mg, 0.26 mmol) and methyl
propionate (98%, 227 mg, 2.65 mmol) were added. The reaction mixture was stirred at 70 °C
for 6 hours. The reaction mixture was diluted with CHC13-10% IPA (5 mL) and washed with
water (5 mL) and brine (5 mL). The aqueous phase was re-extracted with CHC13-10% IPA (3
x 5 mL) and the combined organics were dried (Na2S0 4) and concentrated in vacuo.
Purification by chromatography on Si02, eluting with DCM/Ammonia (7M in methanol) 0-
100%) afforded the title compound (183mg, 53%) as a pale solid.
[00802] Method A : LC-MS m/z = 235.9 [M + H]+; RT = 0.90 min
[00803] Step 3 : Synthesis of l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-lH-l,2,3-
triazole-4-carboxylic acid
[00804] (EV-AO5728-001)
[00805] To a solution of methyl l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-lH- 1,2,3-
triazole-4-carboxylate (EV-AO5726-001, 190 mg, 0.71 mmol) in methanol (3 mL) was added
1M KOH (1.25 mL, 1.25 mmol) and the mixture was stirred at r.t. for 4 hours. The reaction
mixture was concentrated in vacuo and acidified with HC1 (3M , 0.4 mL). The resulting
precipitate was collected by filtration, washed with water (2 x 1 mL) and dried under vacuum
to afford the title compound (137mg, 83%) as a light brown solid.
[00806] Method A : LC-MS m/z = 221.9 [M + H]+; RT = 0.70 min.
[00807] Step 4 : Synthesis of 6-methyl-2-[4-(l,2,3,4-tetrahydroisoquinoline-2-carbonyl)-
lH-l,2,3-triazol-l-yl]-3,4-dihydropyrimidin-4-one, Q-312, EV-A05730-002
[00808] (EV-A05730-002)
[00809] To a solution of l-(4-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-lH-l,2,3-triazole-
4-carboxylic acid (EV-A05728-001 (130 mg, 0.56 mmol) in DMF (2 mL) was added DIPEA
(233.05 µΐ , 1.4 mmol and COMU (98%, 268.42 mg, 0.61 mmol). The reaction mixture was
stirred at r.t. for 2 minutes and 1,2,3,4-tetrahydroisoquinoline (98%, 83.48 mg, 0.61 mmol)
was added and the reaction stirred at r.t. for a further 24 hours. Further COMU (98%, 268.42
mg, 0.61 mmol) and 1,2,3,4-tetrahydroisoquinoline (98%, 83.48 mg, 0.61 mmol) were added
and the mixture stirred at r.t. for 2hr.
[00810] The reaction mixture was concentrated in vacuo and diluted with DCM (10 ml).
The mixture was washed with HC1 ( 1 M 2 x 5 mL), water (5 mL) and brine (5 mL), dried
(Na2S0 4) and concentrated in vacuo. Purification by chromatography on Si02 eluting with
DCM/methanol (0 - 2%) followed by preparative HPLC (Method G) afforded the title
compound (36mg, 19%) as a colourless solid.
[00811] Method C: LC-MS: m/z = 337.1 (M+H)+; RT = 2.56 min
Example 222 - Preparation of 2-{5-[4-(trifluoromethyl)piperidine-l-carbonyl]pyridin-2-
yl|-3H <4H<5H<6HJH-cvclopenta[d]pyrimidin-4-one 0-472 (EV-AR5325-002)
[00812] Step 1: Preparation of 2-(5-bromopyridin-2-yl)-lH,2H,3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-4-one
[00813] Q-465 (EV-AR53 17-001)
[00814] To a solution of 5-bromopyridine-2-carboximidamide (917 mg, 4.584 mmol) in
dry MeOH (10 ml) was added methyl-2-oxocyclopentane-l-carboxylate (1.1 eq, 569 ul,
4.584 mmol), followed by NaOMe (5.4 M in MeOH) (1.1 eq, 934 ul, 5.043 mmol) and stirred
at 60 °C for 20 h . A further portion of methyl- 2-oxocyclopentane-l-carboxylate (0.1 eq, 57
ul, 0.458 mmol) and NaOMe (5.4 M in MeOH) (0.1 eq, 85 ul, 0.458 mmol) was added and
stirred at 60 °C for 1 h . The reaction mixture was concentrated in vacuo, the residue
redissolved in water and the solution acidified to pH 3 using 2 M aqueous HC1 solution. The
precipitate was filtered under vacuum filtration, washed with water and Et20 , and dried to
afford the title compound (832 mg, 62%) as a cream powder.
[00815] Method C: LC-MS m/z = 295.0 [M + H]+; RT = 2.53 min.
[00816] Step 2 : Preparation of methyl-6-{4-oxo-3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-2-yl}pyridine-3-carboxylate
[00817] Q-471 (EV-AR532 1-002)
[00818] To a suspension of 2-(5-bromopyridin-2-yl)-3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-4-one (EV-AR53 17-001, 690 mg, 2.36 mmol) in THF (3 ml) was
added MeOH (3 ml), Mo(CO)6 (249 mg, 0.945 mmol), Pd(OAc)2 (53 mg, 0.236 mmol),
T3u3P (96 mg, 0.472 mmol) and DBU (705 ul, 4.724 mmol) and stirred at 120 °C overnight.
The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3 x 20 mL).
The combined organic extracts were washed with saturated brine solution (10 mL), dried over
Na2S0 4, concentrated in vacuo and purified via chromatography on Si0 2 eluting with
(100:0 - 95:5, DCM-MeOH) followed by trituration using THF to afford the title compound
(109 mg, 17%) as an off white powder.
[00819] Method C: LC-MS m/z = 272. 1 [M + H]+; RT = 2.27 min.
[00820] Step 3 : Preparation of 5-cyclopropyl-l-{4-oxo-3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-2-yl }-1H-pyrazole-4-carboxylic acid.
[00821] (EV-AR5324-001)
[00822] To a solution of methyl 6-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-
yl}pyridine-3-carboxylate (EV-AR532 1-002, 100 mg, 0.369 mmol) in THF (5 mL) was
added 3M aqueous NaOH solution (737 µΐ , 2.21 mmol) and stirred at r.t. for 1 h . The reaction
mixture was concentrated in vacuo to remove the organic solvent and the aqueous mixture
acidified to pH 4 using 5M aq HCl solution; a white precipitate formed. The reaction mixture
was filtered under vacuum to afford the title compound (65 mg, 53%) as an off white powder.
[00823] Method B: LC-MS m/z = 258.0 [M + H]+; RT = 0.84 min.
[00824] Step 4 : Preparation of 2-{5-[4-(trifluoromethyl)piperidine-l-carbonyl]pyridin-2-
yl}-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one.
[00825] Q-472 (EV-AR5325-002)
[00826] To a suspension of 6-{4-oxo-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-2-
yl}pyridine-3-carboxylic acid (EV-AR5324-001, 64 mg, 0.249 mmol) in THF (3 ml) was
added DIPEA (130 µΐ , 0.746 mmol), T3P (50% in EtOAc) (440 µΐ , 0.746 mmol) and 4-
(trifluoromethyl)piperidine hydrochloride (52 mg, 0.274 mmol) and stirred at r.t. for 2 h . The
reaction mixture was concentrated in vacuo and redis solved in EtOAc (20 ml). The reaction
mixture was then washed with water (10 ml), the organic extracts dried over sodium sulfate,
concentrated in vacuo and purified via PREP-HPLC (Method G) to afford the title compound
(45 mg, 46%) as a white powder.
[00827] Method C: LC-MS m/z = 393.2 [M + H]+; RT = 2.65 min.
Example 223 - Synthesis of 2-{4-[4-(trifluoromethyl)piperidine-l-carbonyl1pyridin-2-
yl|-3H <4H<5H<6H<7H-cvclopenta[d1pyrimidin-4-one
Step 1: Preparation of 4-bromopyridine-2-carboxamidine hydrochloride.
[00829] (EV-AR7003-001)
[00830] To a solution of 4-bromopyridine-2-carbonitrile ( 1 g, 5.46 mmol) in anhydrous
MeOH (4mL) was added sodium methoxide in MeOH (0.5 M, 2.19 mL, 1.1 mmol) and
stirred at r.t. for 4h. To the reaction mixture was added ammonium chloride (0.32 g, 6
mmol) and stirred at r.t. overnight. The reaction was diluted with ether (10 mL) and stirred at
r.t. for 30 mins. A precipitate formed that was collected by filtration, washed with ether (2 x
4mL) and dried under vacuum to afford the title compound (967mg, 74.8%) as a white
powder.
[00831] Method B: LC-MS m/z = 199.8, 201.9 [M + H]+; RT = 0.2 min.
[00832] Step 2 : Preparation of 2-(4-bromopyridin-2-yl)-3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-4-one
[00833] (EV-AR7005-001)
[00834] Methyl 2-oxocyclopentane-l-carboxylate (609.16 µΐ , 4.91 mmol) and 4-
bromopyridine-2-carboxamidine hydrochloride (0.97 g, 4.09 mmol) were dissolved in
NaOMe in MeOH (0.5 M, 9.8mL, 4.9 mmol) at r.t. under an atmosphere of nitrogen, and
stirred at 60°C overnight. The reaction mixture was concentrated in vacuo, the residue re-
dissolved in water and the solution acidified to pH 3 using 2 M aq HC1 solution. The
precipitate was collected by filtration, washed with water and diethyl ether, and dried to
afford the title compound (783mg, 65.6%) as a brown powder.
[00835] Method B: LC-MS m/z = 293.85/295 [M + H]+; RT = 1.04 min.
[00836] Step 3 : Synthesis of 2-{4-[4-(trifluoromethyl)piperidine-l-carbonyl]pyridin-2-yl}-
3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one.
[00837] EV-AR7013-003
[00838] To a solution of 2-(4-bromopyridin-2-yl)-3H,4H,5H,6H,7H-
cyclopenta[d]pyrimidin-4-one (50 mg, 0.17 mmol) in anhydrous 1,4-dioxane (2 mL) under
nitrogen was added 4-(trifluoromethyl)piperidin-l-ium chloride (97.36 mg, 0.51 mmol),
palladium acetate (2.88 mg, 0.01 mmol), (9,9-dimethyl-9H-xanthene-4,5-
diyl)bis(diphenylphosphane) (14.86 mg, 0.03 mmol), tripotassium phosphate (0.09 ml, 1.03
mmol), hexakis(oxomethylidene)molybdenum (18.07 mg, 0.07 mmol) and N,N-
dimethylpyridin-4-amine (41.82 mg, 0.34 mmol). The reaction vessel was de-gassed and
back filled with nitrogen (x3), sealed and heated at 140 °C for 45 mins. The reaction mixture
was diluted with EtOAc, concentrated on to silica and purified by chromatography on Si0 2
eluting with 0-5% MeOH/DCM then 5-15% rapid flush to yield a brown gum. The crude
material was dissolved in IPA (0.3mL) and treated with (2E)-but-2-enedioic acid (0.01 ml,
0.09 mmol) solution in IPA and stirred at r.t. for 4 mins before diethyl ether ( 1 mL) was
added . A precipitate slowly formed over 3 h and was left standing overnight. The precipitate
was collected by filtration, washed with ether (2 x ImL) and dried under vacuum to provide
the title compound (9.7mg, 14.2%) as a pale beige solid.
[00839] Method C: LC-MS m z = 393. 1 [M + H]+; RT = 2.59 min.
Example 224 - Synthesis of 2-{4-[4-(trifluoromethyl)piperidine-l-carbonyl]pyridin-2-
yl|-3H,4H-thieno[3,2-d]pyrimidin-4-one
[00840] Step 1: Preparation of phenyl 2-cyanopyridine-4-carboxylate
[00841] (EV-AR7020-001)
[00842] 4-bromopyridine-2-carbonitrile (150 mg, 0.82 mmol), phenyl formate (0.12 ml,
1.07 mmol), palladium(II) acetate (5.52 mg, 0.02 mmol), tri-tert-butylphosphonium
tetrafluoroborate (28.54 mg, 0.1 mmol) and N,N-diethylethanamine (0.15 ml, 1.07
mmol) were added to a microwave vessel under an atmosphere of nitrogen. The reaction
vessel was de-gassed and back filled with nitrogen (x3), sealed and heated at 140 °C for 20
mins under microwave irradiation. A further portion of palladium(II) acetate (5.52 mg, 0.02
mmol) and tri-tert-butylphosphonium tetrafluoroborate (28.54 mg, 0.1 mmol) was added and
the reaction vessel de-gassed and back filled with nitrogen (x3), sealed and heated at 140 °C
for 45 mins under microwave irradiation. The resultant mixture was diluted with water (4
mL) and DCM (3 mL), stirred vigorously and the phases separated using a phase separator
cartridge. The aqueous was re-extracted with DCM (x2) and the organic extracts separated
using a phase separator. The combined organic extracts were concentrated in vacuo and
purified by chromatography on Si0 2, eluting with Heptane/EtOAc (gradient 100:0 - 55:45) to
afford the title compound (94 mg, 51 ) as a pale yellow gum that solidified on standing.
[00843] Method B: LC-MS m/z = 224.9 [M + H]+; RT = 1.1 1 min.
[00844] Step 2 : Preparation of 4-[4-(trifluoromethyl)piperidine-l-carbonyl]pyridine-2-
carbonitrile
[00845] (EV-AR7023-002)
[00846] To a solution of phenyl 2-cyanopyridine-4-carboxylate (101 mg, 0.45 mmol) in
anhydrous THF ( 1 mL), under an atmosphere of nitrogen, was added 4-
(trifluoromethyl)piperidin-l-ium chloride (128.12 mg, 0.68 mmol), N,N-diethylethanamine
(0.13 ml, 0.9 mmol) and N,N-dimethylpyridin-4-amine (2.75 mg, 0.02 mmol) and the
suspension stirred at 45°C for 4 - 5 h . The reaction mixture was diluted with DCM,
concentrated on to silica (1.5g) and purified by chromatography on Si0 2 eluting with
Heptane/EtOAc (gradient 100:0 - 70:30), followed by DCM/MeOH (gradient 100:0 - 45:55),
to afford the title compound (102mg, 80%) as a colourless glass.
[00847] Method B: LC-MS m/z = 284.0 [M + H]+; RT = 1.02 min
[00848] Step 3 : Synthesis of 2-{4-[4-(trifluoromethyl)piperidine-l-carbonyl]pyridin-2-yl}-
3H,4H-thieno[3,2-d]pyrimidin-4-one
[00849] EV-AR7027-002
[00850] To a solution of 4-[4-(trifluoromethyl)piperidine-l-carbonyl]pyridine-2-
carbonitrile (0.1 g, 0.36 mmol) and methyl 3-aminothiophene-2-carboxylate (0.06 g, 0.4
mmol) in THF (2.5 mL) at 0 °C under an atmosphere of nitrogen was added potassium tert-
butoxide (0.04 g, 0.4 mmol) and stirred at 0 °C - r.t. for 3 h . The reaction mixture was
concentrated in vacuo, diluted with saturated ammonium chloride (5 mL) and water and
stirred at r.t. The mixture was extracted with DCM (x2), followed by EtOAc, and the
combined organic extracts dried over Na2S0 4 and concentrated in vacuo. The crude residue
was stirred in diethyl ether (9 mL) for 30 mins at r.t. and the resultant solid was filtered,
washing with diethyl ether (x2) and dried under vacuum to yield the title compound (58 mg,
38.6%) as a white solid.
[00851] Method C: LC-MS m/z = 409. 1 [M + H]+; RT = 2.75 min
Example 225 - Synthesis of 2-(4-{[4-(trifluoromethyl)piperidin-l-yl1sulfonyl|pyridin-2-
yl)-3H<4H<5H<6H<7H-cvclopenta[d]pyrimidin-4-one
[00852] Q-522 (EV-AR7028-002)
[00853] In a pressure tube palladium(II) acetate (0.01 g, 0.03 mmol), Ν ,Ν ,Ν-tributylbutan-
1-aminium bromide (182mg, 0.56 mmol), triphenylphosphine (20mg, 0.08 mmol), sodium
formate (77mg, 1.13 mmol), 1,10-phenanthroline hydrate (1:1) (0.02 g, 0.08 mmol) and
dipotassium oxidosulfanesulfonate oxide (0.23 g, 1.03 mmol) were stirred vigorously in
anhydrous DMSO (3mL), under an atmosphere of nitrogen before 2-(4-bromopyridin-2-yl)-
3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one (Example 223 step 2)(0.15 g, 0.51 mmol)
was added and the vessel sealed and heated at 70 °C for 3 h . The reaction mixture was cooled
to r.t., diluted with MeOH (5 mL) and stirred for 5-10 mins. The mixture was filtered through
a small pad of Celite ®, washing with MeOH (3 x 2mL), concentrated in vacuo and triturated
with diethyl ether (2 x 4 mL). The resulting solid was azeotroped with toluene, cooled to 0°C
and treated with 4-(trifluoromethyl)piperidin-l-ium chloride (0.11 g, 0.56 mmol), DIPEA
(223.59 µΐ , 1.28 mmol) and l-chloropyrrolidine-2,5-dione (41.55 µΐ , 0.51 mmol) in DMF ( 1
mL) and stirred at r.t. for 72 h . The reaction mixture was diluted with water (10 mL),
extracted with EtOAc (3 x 25mL) and the combined extracts washed with water (x 4) and
brine. The organics were dried over Na2S0 4, concentrated in vacuo and triturated with ether.
The solid was suspended in MeOH (~4-5mL) and heated to dissolution. The solution was
concentrated in vacuo and triturated with ether to afford the title compound (96 mg, 44%) as
a pale yellow solid.
[00854] Method C: LC-MS m/z = 429.1 [M + H]+; RT = 3.15 min
Example 226 - Synthesis of 2-r4-(cvclopentyloxy)-lH-pyrazol-l-yll-3H,4H <5H<6H H-
cvclopenta[d1pyrimidin-4-one
[00855] Q-529 (EV-AQ888 1-001)
[00856] To a solution of 2-chloro-3H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-4-one
(Example 193 step 1, 74 mg, 0.43 mmol) and 4-(cyclopentyloxy)-lH-pyrazole (85 mg, 0.46
mmol) in DMF (3 mL) was added cesium carbonate (434 mg, 1.33 mmol). The mixture was
irradiated at 170 °C in the microwave for an hour. After a further 1 hour under these
conditions the cooled reaction mixture was diluted with HC1 (1M 20 mL) and extracted with
EtOAc (20 mL), the organic fraction was dried (MgS04), concentrated under vacuum and
purified by PERP-HPLC (method G) to yield the title compound (32 mg, 26%) as a as a
colourless powder.
[00857] Method C: LC-MS m/z = 287.1 [M + H]+; RT = 3.10 min
Example 227 - Synthesis of 2-(piperidin-4-yl)butanenitrile hydrochloride
[00858] Step 1: Synthesis of tert-butyl 4-(l-cyanopropyl)piperidine-l-carboxylate
[00860] 2.5 M n-BuLi in THF (0.28 mL, 0.7 mmol) was added to a solution of
diisopropylamine (54 mg, 0.536 mmol) in THF (2 mL) at -78 °C. The solution was stirred for
30 min and then a solution of tert-butyl 4-(cyanomethyl)piperidine-l-carboxylate (100 mg,
0.446 mmol) was added dropwise at -78 °C . The resulting solution was stirred for 1 h and
iodoethane (83.6 mg, 0.536 mmol) was added. The reaction mixture was stirred overnight.
The reaction was quenched with sat. NH4C 1 (5 mL), extracted with EtOAc (30 mLX2), the
combined organics were dried over Na2S0 4, concentrated to yield the product (110 mg, 98%
yield) which was used in the next step without purification.
[00861] LC-MS: m/z = 197 (M-55)+, RT = 1.70 min.
[00862] Step 2 : Synthesis of 2-(piperidin-4-yl)butanenitrile hydrochloride
[00863]
[00864] 4.0 M HC1 in dioxane (2 mL) was added to a solution of tert-butyl 4-(l-
cyanopropyl) piperidine-l-carboxylate (110 mg, 0.436 mmol) in DCM (2 mL). The solution
was stirred at r.t for 4 h . Then the reaction was removed the solvent to yield the product (85
mg, 99%) as white solid.
[00865] LC-MS: m/z = 153 (M+H)+
Example 228 - Synthesis of 4-ethylpiperidine-4-carbonitrile hydrochloride
[00866] Step 1: Synthesis of tert-butyl 4-cyano-4-ethylpiperidine-l-carboxylate
[00868] 2.5 M n-BuLi in THF (7.2 mL, 18 mmol) was added to a solution of
diisopropylamine (1.818 g, 18 mmol) in THF (20 mL) at -78 °C. The solution was stirred for
30 min and then the solution was added to the solution of tert-butyl 4-cyanopiperidine-l-
carboxylate (3.15 g, 15 mmol) in THF (40 mL) dropwise at -78 °C. The resulting solution
was stirred for 1 h and iodoethane (83.6 mg, 0.536 mmol) was added. The reaction mixture
was stirred overnight. The reaction was quenched with sat. NH4C 1 (10 mL) and water (20
mL), extracted with EtOAc (50mL X2), the combined organics were dried over
Na2S0 4,concentrated to yield the product (3.4 g, 95.2% yield) which used in the next step
without purification.
[00869] LC-MS: m/z = 183 (M-55)+, RT = 1.879 min.
[00870] Step 2 : Synthesis of 4-ethylpiperidine-4-carbonitrile hydrochloride
[00872] 4.0 M HC1 in dioxane (10 mL) was added to the solution of tert-butyl 4-cyano-4-
ethylpiperidine-l-carboxylate (3.4 g, 14.3 mmol) in DCM (10 mL). The solution was stirred
at r.t. overnight. Then the reaction was removed the solvent to yield the product (2.48 g,
99%) as pale white solid.
[00873] LC-MS: m/z = 139 (M+H)+, RT=1.076 min.
Example 229 - Synthesis of 2-(5-(4-(trifluoromethyl)piperidine-l-carbonyl)thiophen-2-
yl)-6J-dihvdro-3H-cvclopentardlpyrimidin-4(5H)-one O-609
, DME
[00874] Step 1: Synthesis of 2-chloro-4-(4-methoxybenzyloxy)-6,7-dihydi
cyclopenta[d]pyrimidine.
[00876] To a 100 mL of RBF was added (4-methoxyphenyl) methanol (460 mg,
3.33mmol), 15 mL of THF and NaH (60%) (160 mg, 4.0 mmol). The mixture was stirred at
r.t. for 30 min. Then 2,4-dichloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine (600 mg, 3.19
mmol) was added and the mixture was stirred at r.t. for 3 h . The reaction mixture was treated
with water (20 ml) and extracted with EtOAc (100 ml). The organic layer was concentrated
and purified by combiflash (isco, silica gel, UV 254, 40 g, EA/PE=1/10) to give product. LC-
MS: m/z = 291 (M+H)+, RT = 2.012 min.
[00877] Step 2 : Synthesis of 2-chloro-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one.
[00879] To a 100 mL of RBF was added 2-chloro-4-(4-methoxybenzyloxy)-6,7-dihydro-
5H-cyclopenta[d]pyrimidine (350 mg, 1.2 mmol), 8 mL of DCM and 2 ml of CF3COOH.
The mixture was stirred at r.t. for 3 h . The reaction mixture was treated with TEA until pH=8
and then purified by combiflash (isco, silica gel, UV 254, 40 g, EA/PE=1/1) to give product.
LC-MS: m/z = 171 (M+H)+, RT = 1.246 min.
[00880] Step 3 : Synthesis of 5-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-
yl)thiophene-2-carboxylic acid.
[00882] To a 100 mL of RBF was added 2-chloro-6,7-dihydro-3H-
cyclopenta[d]pyrimidin-4(5H)-one (100 mg, 0.58 mmol), 5-boronothiophene-2-carboxylic
acid (350 mg, 2.03 mmol), 3 mL of DME, 1.5 mL of EtOH, 0.5 mL of Na2C0 3 (2 N) and
Pd(PPh 3)4 (100 mg, 0.086 mmol). The mixture was stirred at 110 °C for 1 h . Then the
reaction mixture was purified by combi flash (isco, silica gel, UV 254, 20 g,
MeOH/DCM=l/20) to give product LC-MS: m/z = 263 (M+H)+, RT = 1.358 min.
[00883] Step 4 : Synthesis of 2-(5-(4-(trifluoromethyl)piperidine-l-carbonyl)thiophen-2-
yl)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one.
[00885] To a 100 mL of RBF was added 5-(4-oxo-4, 5,6,7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)thiophene-2-carboxylic acid (80 mg, 0.30 mmol), 4-
(trifluoromethyl)piperidine hydrochloride (60 mg, 0.31 mmol), HOAT (40 mg, 0.30 mmol),
HATU (80 mg, 0.34 mmol), 5 ml of THF and 0.05 ml of TEA. The mixture was stirred at r.t.
for 16 h . Then the reaction mixture was purified by combi flash (isco, silica gel, UV 254, 20
g, MeOH/DCM=l/20) to give product. LC-MS (method ): m/z = 398 (M+H)+, RT = 1.703
min.
Example 230 - Synthesis of 2-(3-(4-(trifluoromethyl) piperidine-l-carbonyl) phenyl)-6,7-
dihvdro-3H-cvclopenta[d1pyrimidin-4(5H)-one (Q-593)
[00886] Step 1: Synthesis of 3-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-
yl)benzoic acid.
[00888] To a 100 mL of RBF was added 2-chloro-6,7-dihydro-3H-
cyclopenta[d]pyrimidin-4(5H)-one (90 mg, 0.53 mmol), 3-boronobenzoic acid (200 mg, 1.20
mmol), K2CO3 (120 mg, 0.87 mmol), 5 mL of dioxane, 1 mL of water and Pd(PPh 3)4 (40 mg,
0.034 mmol). The mixture was stirred at 100 °C for 40 h . Then the reaction mixture was
purified by combiflash (isco, silica gel, UV 254, 20 g, MeOH/DCM=l/10) to give product.
LC-MS: m/z = 257 (M+H)+, RT = 0.994 min.
[00889] Step 2 : Synthesis of 2-(3-(4-(trifluoromethyl)piperidine-l-carbonyl)phenyl)-6,7-
dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one.
[00891] To a 100 mL of RBF was added 3-(4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)benzoic acid (60 mg, 0.23 mmol), 4-(trifluoromethyl)piperidine
hydrochloride (50 mg, 0.26 mmol), HOAT (40 mg, 0.30 mmol), HATU (60 mg, 0.25 mmol),
3 ml of THF and 0.05 ml of TEA. The mixture was stirred at r.t. for 16 h . Then the reaction
mixture was purified by combiflash (isco, silica gel, UV 254, 20 g, MeOH/DCM=l/20) to
give product. LC-MS (method G'): m/z = 392 (M+H)+, RT = 1.608 min.
Example 231 - Synthesis of 2-(4-(3-(3,3-difluoropyrrolidin-l-yl)azetidine-l-carbonyl)-5-
methyl-lH-pyrazol-l-yl)-6,6-dimethyl-6,7-dihvdro-3H-cvclopenta[d1pyrimidin-4(5H)-
one (0-1564)
ste 1 step 2
step 4 step 5
[00892] Step 1: Synthesis of 3,3-dimethylhexanedioic acid.
[00894] 4,4-dimethylcyclohexanone (9 g, 71.3 mmol) and KMn0 4 (22.5 g, 142.6mmol)
were taken up in 450 mL of H20 . To this, an aqueous solution of NaOH ( 1 g, 25 mmol) in 10
mL of H20 was added at r.t. This mixture was stirred at r.t. for 48 hrs. Aqueous sodium
bisulfate was then added until the purple color disappeared. A brown solid was filtered off,
and the filtrate was brought to pH = 2 with cone. HC1. The solution was extracted with
EtOAc (150 mL x 2). The combined organics were dried and concentrated to yield the
product. LC-MS: m/z = 175.1 (M+H)+, RT = 0.35 min.
[00895] Step 2 : Synthesis of dimethyl 3,3-dimethylhexanedioate.
[00897] To a solution of 3,3-dimethylhexanedioic acid (7.8 g, 44.8 mmol) in MeOH (100
mL) was added cone. H2S0 4 ( 1 g, 10 mmol). The mixture was stirred at 80 °C for 2 hrs and
concentrated. NaHC0 3 solution was added to the residue to pH = 7 . The mixture was
extracted with EtOAc (50 mL x 2). The combined organic layers were dried over Na2S0 4
and concentrated under vacuum to yield the product. LC-MS: m/z = 203.1 (M+H)+, RT =
1.89 min.
[00898] Step 3 : Synthesis of methyl 4,4-dimethyl-2-oxocyclopentanecarboxylate.
[00900] The mixture of Na (230 mg, 10 mmol) in MeOH (8 mL) was stirred at r.t. for 5
minutes. Dimethyl 3,3-dimethylhexanedioate ( 1 g, 5 mmol) was added. The mixture was
stirred at r.t. for 30 minutes and concentrated under vacuum to remove MeOH. THF (8 mL)
was added to the residue, and the mixture was stirred at r.t. for 12 hrs. The mixture was
poured into H20 (20 mL). HC1 (2N) was added to pH = 7 . The mixture was extracted with
EtOAc (50 mL x 2). The organic layers were concentrated and purified by column (silica
gel, PE/EtOAc = 1/1) to yield the product. LC-MS: m z = 171.1 (M+H)+, RT = 1.77 min.
[00901] Step 4 : Synthesis of 6,6-dimethyl-2-(methylthio)-6,7-dihydro-3H-
cyclopenta[d]pyrimidin-4(5H)-one.
[00903] To a solution of methyl 4,4-dimethyl-2-oxocyclopentanecarboxylate (750 mg, 4.4
mmol) in H20 (20 mL) was added methyl carbamimidothioate (594 mg, 6.6 mmol) and
Na2C0 3 (1.87 g, 17.6 mmol). The mixture was stirred at r.t. for 12 hrs. The mixture was
extracted with EtOAc (20 mL x 2). The organic layers were concentrated and purified by
column (silica gel, PE/EtOAc = 2/1) to yield the product. LC-MS: m/z = 211.1 (M+H)+, RT
= 1.61 min.
[00904] Step 5 : Synthesis of 2-hydrazinyl-6,6-dimethyl-6,7-dihydi
cyclopenta[d]pyrimidin-4(5H)-one.
[00906] To a solution of 6,6-dimethyl-2-(methylthio)-6,7-dihydro-3H-
cyclopenta[d]pyrimidin-4(5H)-one (250 mg, 1.2 mmol) in EtOH (5 mL) was added
NH2NH2.H2O ( 1 mL). The mixture was stirred at 90 °C for 12 hrs and concentrated under
vacuum to yield the product which was used in next step directly without purification. LC-
MS: m/z = 195.2 (M+H)+, RT = 1.23 min.
[00907] Step 6 : Synthesis of methyl l-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)-5-methyl-lH-pyrazole-4-carboxylate.
[00909] To a solution of 2-hydrazinyl-6,6-dimethyl-6,7-dihydro-3H-
cyclopenta[d]pyrimidin-4(5H)-one (230 mg, 1.2 mmol) in EtOH (5 mL) was added (Z)-
methyl 2-((dimethylamino)methylene)-3-oxobutanoate (246 mg, 1.4 mmol) and AcOH (0.5
mL). The mixture was stirred at 50 °C for 2 hrs and concentrated under vacuum. The crude
residue was purified by column (silica gel, PE/EtOAc = 1/3) to yield the product. LC-MS:
m z = 303.1 (M+H)+, RT = 1.99 min.
[00910] Step 7 : Synthesis of l-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)-5-methyl-lH-pyrazole-4-carboxylic acid.
[00912] To a solution of methyl l-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d] pyrimidin-2-yl)-5-methyl-lH-pyrazole-4-carboxylate (140 mg, 0.5 mmol) in
THF (5 mL) was added a solution of NaOH (60 mg, 1.5 mmol) in H20 (3 mL). The mixture
was stirred at 35 °C for 3 hrs and concentrated under vacuum to remove THF. EtOAc (10
mL) was added to extract the impurity. The aqueous phase was adjusted to pH = 4 with HC1
(2N). The solid was filtered to yield the product. LC-MS: m/z = 289.1 (M+H)+, RT = 1.11
min.
[00913] Step 8: Synthesis of 2-(4-(3-(3,3-difluoropyrrolidin-l-yl)azetidine-l-carbonyl)-5-
methyl-lH-pyrazol-l-yl)-6,6-dimethyl-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one.
[00915] To a solution of l-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)-5-methyl-lH-pyrazole-4-carboxylic acid (49 mg, 0.17 mmol) in
THF (6 mL) was added NMM (68 mg, 0.68 mmol), HATU (76 mg, 0.2 mmol), HOAt (26
mg, 0.2 mmol) and l-(azetidin-3-yl)-3,3-difluoropyrrolidine (46 mg, 0.2 mmol). The mixture
was stirred at r.t. for 2 hrs and concentrated under vacuum. The residue was purified by
Prep-HPLC (NH4HC0 3) to yield the product. LC-MS (method J'): m/z = 433.2 (M+H)+, RT
= 1.46 min.
Example 232 - Synthesis of 2-(2-methyl-3-(4-(trifluoromethyl) piperidine-l-carbonyl)-
lH-pyrrol-l-yl)-6,7-dihvdro-3H-cvclopenta[d]pyrimidin-4(5H)-one) (Q-622)
step 3
[00916] Step 1: Synthesis of 2-methyl-lH-pyrrole-3-carboxylic acid.
[00918] To the solution of ethyl 2-methyl-lH-pyrrole-3-carboxylate (785 mg, 5.12 mmol)
in dioxane (8 mL) was added a solution of lithium hydroxide (1.08 g, 25.62 mmol) in H20 (8
mL). After addition, the reaction mixture was stirred under refluxed for 4h. The mixture was
partitioned with EtOAc and HCl (1M, a.q.). The organic phase was washed with brine, dried
over Na2S0 4 and concentrated to get the title compound. LC-MS: m/z = 126.2 (M+H)+, RT =
0.32 min.
[00919] Step 2 : Synthesis of (2-methyl-lH-pyrrol-3-yl)(4-(trifluoromethyl)piperidin-l-
yl)methanone.
[00921] To the solution of 2-methyl-lH-pyrrole-3-carboxylic acid (100 mg, 0.8 mmol) and
4-(trifluoromethyl)piperidine (147 mg, 0.96 mmol) in DMF (2 mL) were added HATU (456
mg, 1.2 mmol) and DIPEA (206 mg, 1.6 mmol). The reaction mixture was stirred at r.t. for
15h. The mixture was concentrated and purified by SGC (eluting with PE/EtOAc=l/2, silica
gel) to give the title compound. LC-MS: m/z = 261.1 (M+H)+, RT = 1.62 min.
[00922] Step 3 : Synthesis of 2-(2-methyl-3-(4-(trifluoromethyl)piperidine-l-carbonyl)-lH-
pyrrol-l-yl)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one.
[00924] To the solution of 2-chloro-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one
(90 mg, 0.53 mmol) and (2-methyl-lH-pyrrol-3-yl)(4-(trifluoromethyl)piperidin-l-
yl)methanone (164 mg, 0.63 mmol) in DMF (2 mL) were added Cs2C0 3 (344 mg, 1.06
mmol), L-proline (30 mg, 0.26 mmol) and Cul (50 mg, 0.26 mmol). The reaction mixture
was stirred at 140 °C for 15h. The mixture was purified by pre-HPLC (high pH) to give the
title compound. LC-MS (method G'): m/z = 395.0 (M+H)+, RT = 1.42 min.
Example 233 - Synthesis of 5-methyl-l-(4-oxo-4, 5, 6, 7-tetrahydro-3H-
cyclopenta[d1pyrimidin-2-yl)-4-(4-(trifluoromethyl) piperidine-l-carbonyl)-lH-
pyrazole-3-carboxamide (Q-1884)
Step 3
[00925] Step 1: Synthesis of benzyl cyanoformate.
[00927] Benzyl chloroformate (5 g, 0.029 mol) and 1, 4-diazabicyclo [2.2.2] octane (22
mg; 0.20 mmol) were added to a dry reaction vessel under a dry nitrogen atmosphere.
Trimethylsilyl nitrile (2.9 g, 0.029 mol) was added dropwise over about 1 hr. The mixture
was maintained at between 20°C-30°C until the reaction reached completion in about 3 hr.
After distilling off the trimethylsilyl chloride, 4.3 g of crude product was obtained, which was
used directly in the next step. GC-MS: m/z = 161 M+, RT = 9.249 min.
[00928] Step 2 : Synthesis of 4-benzyl 1-tert-butyl 2-acetyl-3-aminofumarate.
[00929]
[00930] To a solution of tert-butyl 3-oxobutanoate (982 mg, 6.22 mmol and benzyl
cyanoformate ( 1 g, 6.21 mmol) in DCM (3mL) was added zinc(II) acetyl acetonate (82 mg,
0.3 1 mmol) and the reaction mixture was stirred at r.t. for 2 h . The reaction mixture was
evaporated, and the residue was taken up in Et20 (20 mL) and the suspension was filtered
over celite. The cake was washed with Et20 (15 mL) and the filtrate evaporated. The residue
was purified by silica gel chromatography (PE/EA=12/1) to afford the title compound. LC-
MS: m/z = 342 (M+Na)+, RT = 1.596 min.
[00931] Step 3 : Synthesis of 3-benzyl 4-tert-butyl 5-methyl-l-(4-oxo-4, 5, 6, 7-tetrahydro-
3H-cyclo-penta [d]pyrimidin-2-yl)-lH-pyrazole-3, 4-dicarboxylate.
[00933] To a solution of 4-benzyl 1-tert-butyl 2-acetyl-3-aminofumarate (575 mg, 1.80
mmol) in 5 mL of EtOH was added 2-hydrazinyl-6,7-dihydro-3H-cyclopenta[d]pyrimidin-
4(5H)-one (300 mg, 1.81 mmol). The suspension was heated to reflux for 15 h . After being
cooled to r.t., the suspension was filtered and the filtrate was concentrated. The residue was
purified by silica gel chromatography using (PE/EA=12/1) to afford the title compound. LC-
MS: m/z = 395 (M-55)+, RT = 2.188 min.
[00934] Step 4 : Synthesis of tert-butyl 3-carbamoyl-5-methyl-l-(4-oxo-4, 5, 6, 7-
tetrahydro-3H-cyclo-penta [d]pyrimidin-2-yl)-lH-pyrazole-4-carboxylate.
[00936] A solution of 3-benzyl 4-tert-butyl 5-methyl- l-(4-oxo-4, 5, 6, 7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)-lH-pyrazole-3,4-dicarboxylate (440 mg, 0.98 mmol) in 8 mL
of 7 M NH3 solution in MeOH was put into a sealed tube and heated at 50°C for 15 h . After
being cooled to r.t., the solution was concentrated to give title compound. LC-MS: m/z = 304
(M-55)+, RT = 1.504 min.
[00937] Step 5 : Synthesis of 3-carbamoyl-5-methyl-l-(4-oxo-4, 5, 6, 7-tetrahydro-3H-
cyclopenta[d]-pyrimidin-2-yl)- lH-pyrazole-4-carboxylic acid.
[00939] To a solution of tert-butyl 3-carbamoyl-5-methyl-l-(4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta-[d]pyrimidin-2-yl)-lH-pyrazole-4-carboxylate (30 mg, 0.084 mmol) in 2 mL of
DCM was added 1 mL of TFA and the mixture was stirred at r.t. for 3h. Then the reaction
mixture was diluted with toluene and concentrated to give the desired product. LC-MS: m/z =
304 (M+H) +, RT = 0.407 min.
[00940] Step 6 : Synthesis of 5-methyl-l-(4-oxo-4, 5, 6, 7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)-4-(4-(trifluoromethyl) piperidine- 1-carbonyl)- lH-pyrazole-3-
carboxamide.
[00942] To a mixture of 3-carbamoyl-5-methyl-l-(4-oxo-4, 5, 6, 7-tetrahydro-3H-
cyclopenta[d]pyram idin-2-yl)-lH-pyrazole-4-carboxylic acid (26 mg, 0.084 mmol) and 4-
(trifluoromethyl) piperidine hydrochloride (16 mg, 0.084 mmol) in 2 mL of DMF was added
NMM (0.05 mL, 0.45 mmol), HOAt (14 mg, 0.10 mmol) and HATU (38 mg, 0.10 mmol).
The reaction mixture was stirred at r.t. for 2 h and filtered. The filtrate was purified by
prepared HPLC (NH4HC0 3) to give the desired product. LC-MS (method F'): m z = 439
(M+H) +, RT = 1.356 min.
Example 234 - Synthesis of 6-fluoro-2-(4-(4-(trifluoromethyl)piperidine-l-carbonyl)-
lH-pyrazol-l-yl)pyrrolori,2-firi,2,41triazin-4(3H)-one (0-616)
[00943] Step 1: (lH-pyrazol-4-yl)(4-(trifluoromethyl)piperidin-l-yl)methanone.
[00945] To a 100 mL of RBF was added lH-pyrazole-4-carboxylic acid (500 mg, 4.46
mmol), 4-(trifluoromethyl)piperidine hydrochloride (1.0 g, 5.29 mmol), HATU (1.2 g, 5.10
mmol), HOAT (700 mg, 5.14 mmol), 40 mL of THF and 2 mL of TEA. The mixture was
stirred at RT for 16 h . The reaction mixture was concentrated and purified by combiflash
(isco, silica gel, UV 254, 40 g, MeOH/DCM=l/10) to give product LC-MS: m/z = 248
(M+H)+, RT = 1.434 min.
[00946] Step 2 : Synthesis of (R)-l-tert-butyl 2-methyl 4,4-difluoropyrrolidine-l,2-
dicarboxylate.
[00948] To a 500 mL of RBF was added (R)-l-tert-butyl 2-methyl 4-oxopyrrolidine-l,2-
dicarboxylate (4.0 g, 16.4 mmol) and 200 mL of DCM. The mixture was cooled to 0 °C and
DAST (24.0 g, 150.0 mmol) in 100 ml of DCM was added drop wise over 1 h . Then the
mixture was stirred at r.t. for 16 h . The reaction mixture was treated with NaHC0 3 (aq) and
extracted with DCM (300 ml), the organic layer was concentrated to give product. LC-MS:
m/z = 166 (M-100)+, RT = 0.344 min.
[00949] Step 3 : Synthesis of (R)-methyl 4,4-difluoropyrrolidine-2-carboxylate.
[00950]
[00951] To a 100 mL of RBF was added (R)-l-tert-butyl 2-methyl 4,4-difluoropyrrolidine-
1,2-dicarboxylate (4.0 g, 15.1 mmol) and 40 mL of HC1 (4 M in dioxane). The mixture was
stirred at RT for 16 h . Then the reaction mixture was concentrated to give product. LC-MS:
m/z = 166 (M+H)+, RT = 0.347 min.
[00952] Step 4 : Synthesis of methyl l-amino-4-fluoro-lH-pyrrole-2-carboxylate.
[00954] To a 250 mL of RBF was added (R)-methyl 4,4-difluoropyrrolidine-2-carboxylate
(2.4 g, 14.5 mmol) in 80 ml of THF was added 24 g of Mn0 2. The mixture was stirred at 70
°C for 16 h . The reaction mixture was filtered and the filtrate was concentrated and purified
by combiflash (isco, silica gel, UV 254, 40 g, EA/PE=l/3) to give product. LC-MS: m/z =
144 (M+H)+, RT = 1.528 min.
[00955] Step 5 : Synthesis of methyl l-amino-4-fluoro-lH-pyrrole-2-carboxylate.
[00957] To a 500 mL of RBF was added NH4C 1 (6.0 g, 112 mmol) in 200 ml of Et20 . The
mixture was cooled to - 5 °C and 9.4 ml of NH4OH was added drop wise with vigorous
stirring. Then 145 ml of NaClO was added drop wise over 2 h . The mixture was stirred for 15
min and the layer was separated. The organic layer was washed with brine and dried with
CaCl2 and used in the next step without further purification. Then to a 100 ml of RBF was
added methyl 4-fluoro-lH-pyrrole-2-carboxylate (1.7 g, 11.8 mmol) and 30 ml of DMF. The
mixture was cooled to 0 °C and NaH (60%) (600 mg, 15.0 mmol) was added. After 45 min,
the previously prepared NH2C 1 (100 ml) was added dropwise. The mixture was stirred at r.t.
for 2 h . The reaction mixture was extracted with EtOAc (200 ml), the organic layer was
concentrated and purified by combiflash (isco, silica gel, UV 254, 40 g, EA/PE=l/5) to give
product. LC-MS: m/z = 159 (M+H)+, RT = 1.49 min.
[00958] Step 6 : Synthesis of methyl l-(3-benzoylthioureido)-4-fluoro-lH-pyrrole-2-
carboxylate.
[00960] To a 250 mL of RBF was added methyl l-amino-4-fluoro- lH-pyrrole-2-
carboxylate (1.7 g, 10.76 mmol), 80 ml of THF and benzoyl isothiocyanate (1.8 g, 11.04
mmol). The mixture was stirred at RT under N2 for 16 h . The reaction mixture was
concentrated and purified by combi flash (isco, silica gel, UV 254, 40 g, EA/PE=l/4) to give
product. LC-MS: m/z = 322 (M+H)+, RT = 1.823 min.
[00961] Step 7 : Synthesis of 6-fluoro-2-mercaptopyrrolo [l,2-f][l,2,4]triazin-4(3H)-one.
[00963] To a 100 niL of RBF was added methyl l-(3-benzoylthioureido)-4-fluoro-lH-
pyrrole-2-carboxylate (1.5 g, 4.67 mmol) and 10 ml of NaOH (2 N). The mixture was stirred
at 85 °C under N2 for 1.5 h . The reaction mixture was cooled to 0 °C and EtOH (5 ml), HOAc
(2 ml) was added and stirred at r.t. for 30 min. The reaction mixture was filtered and washed
with Et20 (20 ml) to give product. LC-MS: m/z = 186 (M+H)+, RT = 0.67 min.
[00964] Step 8: Synthesis of 6-fluoro-2-(methylthio)pyrrolo[l,2-f][l,2,4]triazin-4(3H)-one.
[00966] To a 100 mL of RBF was added 6-fluoro-2-mercaptopyrrolo[ 1,2-f] [1,2,4]triazin-
4(3H)-one (700 mg, 3.78 mmol) and 20 ml of THF was added Mel (700 mg, 4.92 mmol). The
mixture was stirred at 45 °C under N2 for 1 h . The reaction mixture was treated with NaHC0 3
(aq) and filtered to give product. LC-MS: m/z = 200 (M+H)+, RT = 1.551 min.
[00967] Step 9 : Synthesis of 6-fluoro-2-(methylsulfonyl)pyrrolo[l,2-f][l,2,4]triazin-
4(3H)-one.
[00969] To a 50 mL of RBF was added 6-fluoro-2-(methylthio)pyrrolo[ 1,2-f] [1,2,4]triazin-
4(3H)-one (100 mg, 0.50 mmol) and 4 ml of HOAc was added 2 ml of H20 2. The mixture
was stirred at 170 °C in a microwave for 15 h . The reaction mixture was filtered to give
product. LC-MS: m/z = 232 (M+H)+, RT = 1.368 min.
[00970] Step 10: Synthesis of 6-fluoro-2-(4-(4-(trifluoromethyl) piperidine-l-carbonyl)-
lH-pyrazol- 1-yl)pyrrolo[ 1,2-f] [1,2,4]triazin-4(3H)-one.
[00972] To a microwave tube was added 6-fluoro-2-(methylsulfonyl)pyrrolo[l,2-
f][l,2,4]triazin-4(3H)-one (100 mg, 0.43 mmol), (lH-pyrazol-4-yl)(4-
(trifluoromethyl)piperidin-l-yl)methanone (110 mg, 0.44 mmol), C S2CO3 (160 mg, 0.49
mmol) and 2 ml of NMP. The mixture was stirred at r.t. for 2 days. The reaction mixture was
concentrated and purified by combi flash (isco, silica gel, UV 254, 20 g, MeOH/DCM=l/10)
to give product. LC-MS (method G'): m/z = 399 (M+H)+, RT = 1.399 min.
Examples 235-236
[00973] Examples 235-236 in Table 17 were prepared in an analogous fashion to Example
234 starting with the corresponding starting materials.
Example 237 - Synthesis of 7-fluoro-2-(4-(4-(trifluoromethyl)piperidine-l-carbonyl)-
lH-pyrazol-l-yl)pyrrolo[l,2-f1[l <2<41triazin-4(3H)-one (Q-525)
[00974] Step 1: Synthesis of 2,4-dichloro -7-fluoropyrrolo[l,2-f][l,2,4]triazine.
[00976] A mixture of 2,4-dichloropyrrolo[l,2-f] [1,2,4] triazine (6.0 g, 31.9 mmol) and 1-
(chloromethyl)-4-fluoro-l,4-diazonia-bicyclo[2.2.2]octane tetrafluoroborate (22.6 g, 63.8
mmol) in acetonitrile (250 mL) was stirred at 45 °C for 16 h under N2 atmosphere. The
mixture was concentrated, the residue was diluted with DCM (400 mL), washed with H20
(50 mL x 3), and dried over Na2S0 4. The filtrate was concentrated to give the crude product.
LC-MS: m/z = 206.0 (M+H)+, RT = 1.873 min.
[00977] Step 2 : Synthesis of 2-chloro-7-fluoropyrrolo[l,2-f][l,2,4]triazin-4(3H)-one
[00979] To a mixture of 2,4-dichloro-7-fluoropyrrolo[l,2-f][l,2,4]triazine (6.33 g, 30.7
mmol) in THF/H 20 (30 ml/30 mL) was added sodium hydroxide (6.16 g, 154 mmol). The
mixture was stirred at 50 °C for 4 h, and cooled to r.t. The mixture was adjusted to pH = 3-4
with 4 N HCl and extracted with EtOAc (100 mL x 4). The combined organics were dried
over Na2S0 4 and concentrated to give 5.2 g of the crude product. 2 g of the crude product
was purified by prep-HPLC (TFA/CH 3CN/H20 ) to give the product. LC-MS: m z = 188.0
(M+H)+, RT = 1.486 min.
[00980] Step 3 : Synthesis of 7-fluoro-2-(4-(4-(trifluoromethyl)piperidine-l-carbonyl)-lH-
pyrazol- 1-yl)pyrrolo[ 1,2-f] [1,2,4] triazin-4(3H)-one.
[00982] To a mixture of 2-chloro-7-fluoropyrrolo[l,2-f][l,2,4]triazin-4(3H)-one (302 mg,
1.61 mmol), (lH-pyrazol-4-yl)(4-(trifluoromethyl)piperidin-l-yl)methanone (398 mg, 1.61
mmol) and Cs2C0 (1049 mg, 3.22 mmol) in dry DMF (20 mL) were added L-proline (93
mg, 0.8 mmol) and Cul (152 mg, 0.8 mmol) under N2 atmosphere. The mixture was stirred at
140 °C for 20 h . The mixture was cooled to r.t., diluted with H20 (100 mL), pH adjusted to 3-
4 with 1 N HCl, and extracted with EtOAc (100 mL x 5). The combined organics were dried
over Na2S0 4 and concentrated. The residue was purified by prep-HPLC (TFA/CH 3CN/H20 )
to give the crude product which was further purified by prep-HPLC
(NH4HC0 3/CH3CN/H20 ) to give the product. LC-MS (method D'): m/z = 399.2 (M+H)+,
RT = 1.002 min.
Examples 238-239
[00983] Examples 238-239 in Table 18 were prepared in an analogous fashion to Example
237 starting with the corresponding starting materials.
Table 18
Example 240 - Synthesis of 2-(5-methyl-4-(4-(4-
(trifluoromethoxy)phenylsulfonyl)piperazine-l-carbonyl)-lH-pyrazol-l-yl)pyrrolo[l <2-
firi,2,41triazin-4(3H)-one (0-1798)
[00984] Step 1: Synthesis of tert-butyl-4-(5-methyl-l-(4-oxo-3,4-dihydropyrrolo[l,2-
f][1,2,4] triazin-2-yl)- lH-pyrazole-4-carbonyl)piperazine- 1-carboxylate.
[00986] To the solution of 5-methyl-l-(4-oxo-3,4-dihydropyrrolo[l,2-f][l,2,4]triazin-2-
yl)-lH-pyrazole-4-carboxylic acid (2 g, 7.715 mmol) and tert-butyl-piperazine- 1-carboxylate
(1.6 g, 8.487 mmol) in THF (40 mL) were added HATU (3.52 g, 9.258 mmol), HOAT (1.05
g, 7.715 mmol) and TEA (2.34 g, 23.146 mmol), the reaction mixture was stirred at r.t. for 15
h . The mixture was concentrated and purified by SGC (eluting with DCM/MeOH=20/l) to
give the title compound. LC-MS: m/z = 428.3 (M+H)+, RT = 1.535 min.
[00987] Step 2 : Synthesis of 2-(5-methyl-4-(piperazine-l-carbonyl)-lH-pyrazol-l-
yl)pyrrolo[ 1,2-f] [1,2,4] triazin-4(3H)-one dihydrochloride.
[00989] To the solution of tert-butyl-4-(5-methyl-l-(4-oxo-3,4-dihydropyrrolo[l,2-
f][l,2,4]triazin-2-yl)-lH-pyrazole-4-carbonyl)piperazine-l-carboxylate (3.88 g, 9.077 mmol)
in DCM (50 mL) was added HC1 (20 mL, 4 M in dioxane). The reaction mixture was stirred
at r.t. for 15 h . The mixture was concentrated to give the title compound. LC-MS: m/z =
328.2 (M+H)+, RT = 1.146 min.
[00990] Step 3: Synthesis of 2-(5-methyl-4-(4-(4-
(trifluoromethoxy)phenylsulfonyl)piperazine-l-carbonyl)-lH-pyrazol-l-yl)pyrrolo[l,2-
f][1,2,4] triazin-4(3H)-one
[00992] To the solution of 2-(5-methyl-4-(piperazine-l-carbonyl)-lH-pyrazol-l-
yl)pyrrolo[l,2-f][l,2,4]triazin-4(3H)-one dihydrochloride (50 mg, 0.125 mmol) and TEA (51
mg, 0.50 mmol) in DCM (3 mL) was added 4-(trifluoromethoxy)benzene-l-sulfonyl chloride
(39 mg, 0.15 mmol). The reaction mixture was stirred at r.t. for 15 h . The mixture was
purified by prep-HPLC (high pH) to give the title compound. LC-MS (method J'): m/z =
552.2 (M+H)+, RT = 1.671 min.
Examples 241-289
[00993] Examples 241-289 in Table 19 were prepared in an analogous fashion to Example
240 starting with the corresponding starting materials.
Ta ble 19
Ex. No. Ref. No. LC-MS MS (M+H)+ LC-MS Method
(Retention Time)
241 Q-1794 1.51 493.2 J '
243 Q-1796 1.62 536.2 J '
243 Q-1797 1.436 434.2 J '
244 Q-1798 1.671 552.2 J '
245 Q-1799 1.524 486.2 J '
246 Q-1800 1.719 524.3 J '
247 Q-1801 1.630 520.2 J '
248 Q-1804 1.84 498.1
249 Q-1805 1.488 503.2 J'
250 Q-1807 1.86 486.1
251 Q-1814 1.695 542.1 J'
252 Q-1815 1.701 561.3 J'
253 Q-1819 1.562 502.2 J'
254 Q-1820 1.691 510.2 J'
255 Q-1821 1.502 474.2 J'
256 Q-1822 1.606 502.2 J'
257 Q-1823 1.553 486.2 J'
258 Q-1824 1.51 493.2 J'
259 Q-1825 1.648 536.1 J'
260 Q-1826 1.646 536.2 J'
261 Q-1827 1.461 546.2 J'
262 Q-1829 1.527 512.2 J'
263 Q-1830 1.681 536.2 J'
264 Q-1831 1.623 518.2 J'
265 Q-1832 1.6 472
266 Q-1833 1.72 525.1
267 Q-1834 1.647 536.2 J'
268 Q-1835 1.757 604.2 J'
269 Q-1836 1.73 536 A '
270 Q-1837 1.62 546.2 J'
271 Q-1838 1.51 493.2 J'
272 Q-1839 1.84 528.1
273 Q-1840 1.82 570 A '
274 Q-1841 1.961 518.1
275 Q-1842 1.955 508.0
276 Q-1845 1.748 512.1
277 Q-1846 1.720 435.1
278 Q-1847 1.498 493.2 J'
279 Q-1848 1.511 487.2 J'
280 Q-1857 1.7 469.1
281 Q-1858 1.680 542.1 J'
282 Q-1859 1.508 519.2 J'
283 Q-1861 1.966 552.1
284 Q-1862 1.850 503.0
285 Q-1864 1.56 519.2 E '
286 Q-1875 1.823 532.1
287 Q-1876 1.93 520
288 Q-1882 1.832 526.5
289 Q-1885 1.940 544.0
Example 290 - Synthesis of 2-(5-methyl-4-(2 <6-diazaspiro[4.51decane-2-carbonyl)-lH-
Pyrazol-l-yl)-6,7-dihvdro-3H-cvclopenta[d1pyrimidin-4(5H)-one (Q-577)
[00994] Step 1: Synthesis of tert-butyl 2-(5-methyl-l-(4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)-lH-pyrazole-4-carbonyl)-2,6-diazaspiro[4.5]decane-6-
carboxylate.
[00996] The mixture of 5-methyl-l-(4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-
2-yl)-lH-pyrazole-4-carboxylic acid (50 mg, 0.19 mmol), tert-butyl 2,6-
diazaspiro[4.5]decane-6-carboxylate (55 mg, 0.19 mmol), HATU (109.6 mg, 0.29 mmol),
HOAt (39 mg, 0.29 mmol) and TEA (0.05 mL, 0.38 mmol) was stirred at r.t. for 2 h . The
reaction was concentrated. The residue was purified by prep-TLC (DCM/MeOH = 15/1,
silica, UV254) to get the title compound. LC-MS: m z = 483 (M+H)+, RT = 1.544 min.
[00997] Step 2 : Synthesis of 2-(5-methyl-4-(2,6-diazaspiro[4.5]decane-2-carbonyl)- 1H-
pyrazol-l-yl)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one.
[00999] To a solution of tert-butyl 2-(5-methyl- l-(4-oxo-4,5,6,7-tetrahydro-3H-cyclo
penta[d]pyrimidin-2-yl)-lH-pyrazole-4-carbonyl)-2,6-diazaspiro[4.5]decane-6-carboxylate
(50 mg, 0.1 mmol) in DCM ( 1 mL) was added HCl (4M in dioxane, 1 mL). The mixture was
stirred at r.t. for 1 h . The reaction was concentrated. The residue was purified by prep-HPLC
(high pH) to get the title compound. LC-MS (method ): m/z = 383 (M+H)+, RT = 1.21
min.
Examples 291-292
[001000] Examples 291-292 in Table 20 were prepared in an analogous fashion to
Example 290 starting with the corresponding starting materials.
Table 20
Example 293 - Synthesis of 3-(4-(5-methyl-l-(4-oxo-4 <5<6,7-tetrahydro-3H-
cvclopenta[d]pyrimidin-2-yl)-lH-pyrazole-4-carbonyl)piperazine-l-
carbonyl)bicvclo[1.1.11pentane-l-carboxylic acid (Q-627)
Example 293 - Synthesis of 3-(4-(5-methyl-l-(4-oxo-4 <5<6,7-tetrahydro-3H-
cvclopenta[d]pyrimidin-2-yl)-lH-pyrazole-4-carbonyl)piperazine-l-
carbonyl)bicyclo[ 1.1.1]pentane-1-carbonitrile (Q-632)
[001001] Step 1: Synthesis of dimethyl bicyclo[l.l. l]pentane-l,3-dicarboxylate.
[001003] To a solution of bicyclo[ 1.1.1 ]pentane-l,3-dicarboxylic acid ( 1 g, 6.4 mmol) in
MeOH (50 mL) was added SOCl2 (6 mL) dropwise. The reaction was stirred at 80 °C for 15
h . The reaction was concentrated. The residue was treated with aq. NaHC0 3 (80 mL) and
extracted with DCM (2x60 mL). The combined organic layers were concentrated to get the
title compound.
[001004] Step 2 : Synthesis of 3-(methoxycarbonyl)bicyclo[l.l.l]pentane-l-carboxylic
acid.
[001006] To a solution of dimethyl bicyclo[l.l.l]pentane-l,3-dicarboxylate (1.1 g, 5.98
mmol) in THF/MeOH (1/1, 10 mL) was added NaOH (2M, 3 mL). The reaction was stirred at
r.t. for 15 h . The reaction was concentrated. The residue was treated with water (50 mL),
adjusted pH = 5 with HCl (2M), and extracted with DCM (2x50 mL). The combined organic
layers were concentrated to get the title compound.
[001007] Step 3 : Synthesis of tert-butyl 4-(3-(methoxycarbonyl)bicyclo[l.l.l]pentane-l-
carbonyl) piperazine-l-carboxylate.
[001009] The mixture of 3-(methoxycarbonyl)bicyclo[l.l.l]pentane-l-carboxylic acid
(600 mg, 3.53 mmol), tert-butyl piperazine-l-carboxylate (656 mg, 3.53 mmol), EDCI (1.01
g, 5.29 mmol), HOBt (715 mg, 5.29 mmol) and TEA ( 1 mL, 7.06 mmol) in THF (30 mL)
was stirred at room temperature for 15 h . The reaction was treated with water (50 mL),
extracted with EtOAc (2x50 mL). The combined organic layers were concentrated to get the
title compound. LC-MS: m z = 283 (M-56+H)+; RT = 1.68 min.
[001010] Step 4 : Synthesis of methyl 3-(piperazine-l-carbonyl)bicyclo[l.l.l]pentane-l-
carboxylate hydrochloride.
[001012] To a solution of tert-butyl 4-(3-(methoxycarbonyl)bicyclo[l.l.l]pentane-l-
carbonyl)piperazine-l-carboxylate (1.05 g, 3.1 mmol) in DCM (10 mL) was added HCl (4M
in dioxane, 10 mL). The mixture was stirred at r.t. for 2 h . The reaction was concentrated to
get the title compound (850 mg, 99%). LC-MS: m/z = 239 (M+H)+, RT = 0.92 min.
[001013] Step 5 : Synthesis of methyl 3-(4-(5-methyl-l-(4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d] pyrimidin-2-yl)-lH-pyrazole-4-carbonyl)piperazine-l-
carbonyl)bicyclo[ 1.1.1]pentane- 1-carboxylate.
[001015] The mixture of 5-methyl- l-(4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)-lH-pyrazole-4-carboxylic acid (585 mg, 2.25 mmol), methyl 3-
(piperazine-l-carbonyl)bicyclo[l.l.l]pentane-l-carboxylate hydrochloride (850 mg, 3.1
mmol), HATU (1.28 g, 3.37 mmol), HOAt (460 mg, 3.37 mmol) and TEA ( 1 mL) in THF (30
mL) was stirred at r.t. for 15 h . The reaction was concentrated. The residue was purified by
combi-flash (40 g, DCM/MeOH = 20/1, silica, UV254) to get the title compound. LC-MS:
m z = 481 (M+H)+, RT = 1.48 min.
[001016] Step 6 : Synthesis of 3-(4-(5-methyl-l-(4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)-lH-pyrazole-4-carbonyl)piperazine-l-
carbonyl)bicyclo[ 1.1.1]pentane- 1-carboxylic acid.
[001018] To a solution of methyl 3-(4-(5-methyl-l-(4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d]pyri midin-2-yl)-lH-pyrazole-4-carbonyl)piperazine-l-
carbonyl)bicyclo[l.l.l]pentane4 -carboxylate (120 mg, 0.25 mmol) in THF/MeOH (1/1, 4
mL) was added LiOH (2 M, 1 mL). The reaction mixture was stirred at r.t. for 1 h . The
reaction was treated with water (20 mL), adjust pH = 5 with HC1 (2M). The mixture was
extracted with EtOAc (2x30 mL). The combined organic layers were concentrated. The
residue was purified by prep-HPLC (low pH) to get the title compound. LC-MS (method C):
m/z = 467 (M+H)+, RT = 1.34 min.
[001019] Step 7 : Synthesis of 3-(4-(5-methyl-l-(4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)-lH-pyrazole-4-carbonyl)piperazine-l-
carbonyl)bicyclo[ 1.1.1]pentane- 1-carboxamide.
[001021] The mixture of 3-(4-(5-methyl-l-(4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)-lH-pyrazole-4-carbonyl)piperazine-l-
carbonyl)bicyclo[l.l.l]pentane-l-carboxylic acid (80 mg, 0.17 mmol), NH4C 1 (13.6 mg, 0.26
mmol), HOBt (49.2 mg, 0.26 mmol), EDCI (34.7 mg, 0.26 mmol) and TEA (0.07 mL) in
THF (5 mL) was stirred at r.t. for 15 h . The reaction was concentrated. The residue was
purified by prep-HPLC (low pH) to get the title compound. LC-MS: m/z = 466 (M+H)+, RT
= 1.28 min.
[001022] Step 8: Synthesis of 3-(4-(5-methyl-l-(4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)-lH-pyrazole-4-carbonyl)piperazine-l-
carbonyl)bicyclo[ 1.1.1]pentane- 1-carbonitrile.
[001024] To a solution of 3-(4-(5-methyl-l-(4-oxo-4,5,6,7-tetrahydro-3H-
cyclopenta[d]pyrimidin-2-yl)-lH-pyrazole-4-carbonyl)piperazine-l-
carbonyl)bicyclo[l.l.l]pentane-l-carboxamide (45 mg, 0.1 mmol) in DCM (3 mL) was
added TEA (0.6 mL) and trifluoroacetic anhydride (0.4 mL). The mixture was stirred at r.t.
for 15 h . The reaction was concentrated. The residue was purified by prep-HPLC (high pH)
to get the title compound. LC-MS (method F'): m/z = 448 (M+H)+, RT = 1.35 min.
Example 295 - Synthesis of 2-(4-(2<2-dimethyl-4-(2<2<2-trifluoroethyl)piperazine-l-
carbonyl)-5-methyl-lH-pyrazol-l-yl)pyrrolori,2-firi,2,41triazin-4(3H)-one (0-949)
Q-949
[001025] Step 1: Preparation of 5-methyl-l-(4-oxo-3,4-dihydropyrrolo[l,2-f][l,2,4]triazin-
2-yl)-lH-pyrazole-4-carbonyl chloride.
[001027] To a solution of 5-methyl-l-(4-oxo-3,4-dihydropyrrolo[l,2-f][l,2,4]triazin-2-yl)-
lH-pyrazole-4-carboxylic acid (50 mg, 0.193 mmol) and oxalyl dichloride (74 mg, 0.579
mmol) in DCM (8 mL) was added DMF (3 drops) at r.t. The mixture was stirred at r.t. for 2 h
until the reaction was completed. The mixture was concentrated to give the crude product (80
mg) which was used to next step directly.
[001028] Step 2 : Preparation of 2-(4-(2,2-dimethyl-4-(2,2,2-trifluoroethyl)piperazine-l-
carbonyl)-5-methyl- 1H-pyrazol- 1-yl)pyrrolo[1,2-f] [1,2,4] triazin-4(3H)-one
[001030] A solution of 5-methyl-l-(4-oxo-3,4-dihydropyrrolo[l,2-f][l,2,4]triazin-2-yl)-
lH-pyrazole-4-carbonyl chloride (80 mg, 0.288mmol), 3,3-dimethyl-l-(2,2,2-
trifluoroethyl)piperazine hydrochloride (74 mg, 0.317mmol) and TEA (87 mg, 0.864mmol)
in DCM (8 mL) was stirred at r.t. overnight. The mixture was concentrated to remove
solvent, and the residue was purified with prep-HPLC (high pH) to the target. LC-MS
(method F): m/z = 438.1 (M+H)+, RT = 1.67min.
Examples 296-299
[001031] Examples 296-299 in Table 2 1 were prepared in an analogous fashion to
Example 295 starting with the corresponding starting materials.
Table 21
Examples 300-946
[001032] Examples 300-946 in Table 22 were prepared according to the methods
described herein starting with appropriate starting materials.
Table 22
324 Q-0565 1.164 461 .3 B " HATU/HOAt
325 Q-0566 1.449 274.02 C
326 Q-0567 1.103 441 .3 B " HATU/HOAt
327 Q-0568 1.104 429.4 B " HATU/HOAt
328 Q-0569 1.21 8 370. 1 H " HATU/HOAt
329 Q-0570 1.540 439. 1 H " HATU/HOAt
330 Q-0571 1.408 443.2 H " HATU/HOAt
331 Q-0572 1.343 395 G' HATU/HOAt
332 Q-0573 1.483 459 G' HATU/HOAt
333 Q-0574 1.469 477 G' HATU/HOAt
334 Q-0575 1.17 1 369.2 C HATU/HOAt
335 Q-0576 1.288 384. 1 H " HATU/HOAt
336 Q-0578 1.29 407.2 H " HATU/HOAt
337 Q-0579 1.489 499 G' HATU/HOAt
338 Q-0580 1.603 384.2 H " HATU/HOAt
339 Q-0582 1.284 445 H " HATU/HOAt
340 Q-0583 0.938 345 G' HATU/HOAt
341 Q-0584 0.969 359 H " HATU/HOAt
342 Q-0585 1.475 442.0 G' HATU/HOAt
343 Q-0586 1.380 380.0 G' HATU/HOAt
344 Q-0587 1.484 479 H " HATU/HOAt
345 Q-0588 1.029 343. 1 G' HATU/HOAt
346 Q-0589 0.934 329.0 G' HATU/HOAt
347 Q-0590 1.489 479.0 H " HATU/HOAt
348 Q-0591 1.42 502.9 G' HATU/HOAt
349 Q-0592 1.51 5 457 G' HATU
350 Q-0594 1.675 470 G' HATU/HOAt
351 Q-0596 1.668 362. 1 HATU/HOAt
352 Q-0597 1.089 520.2 B " HATU
353 Q-0598 1.396 493.9 G' HATU/HOAt
354 Q-0599 1.458 427.9 G' HATU/HOAt
355 Q-0600 1.349 394.0 G' HATU/HOAt
356 Q-0601 1.444 475.0 G' HATU/HOAt
357 Q-0602 1.17 1 386.0 G' HATU/HOAt
358 Q-0603 1.804 495 HATU/HOAt
359 Q-0604 1.494 478.0 G' HATU/HOAt
360 Q-0605 1.584 488 H " HATU/HOAt
361 Q-0606 1.441 4 12.9 G' HATU/HOAt
362 Q-0607 1.502 477.9 G' HATU/HOAt
363 Q-0608 1.477 460.0 G' HATU/HOAt
364 Q-061 0 0.723 369.2 B " HATU/HOAt
365 Q-061 1 0.975 457.2 B " HATU/HOAt
366 Q-061 2 1.481 481 .1 HATU/HOAt
367 Q-061 4 1.046 342. 1 H " HATU/HOAt
368 Q-061 5 0.951 443.3 B " HATU
369 Q-061 7 1.092 358.0 H " HATU/HOAt
370 Q-061 8 1.246 3 18 .1 H "
371 Q-061 9 1.61 2 292. 1 E "
372 Q-0620 1.026 439.3 B " HATU/HOAt
373 Q-0621 1.050 358. 1 H " HATU/HOAt
374 Q-0623 1.277 398. 1 H " HATU/HOAt
375 Q-0624 1.41 0 460. 1 H " HATU/HOAt
376 Q-0626 1.56 423.2 F " HATU/HOAt
377 Q-0630 1.280 466.2 A' EDCI/HOBt
378 Q-0633 1.405 328.2 F " HATU/HOAt
379 Q-0634 1.463 327.2 F " HATU/HOAt
380 Q-0635 1.504 354. 1 F " HATU/HOAt
381 Q-0681 1.557 353. 1 F " HATU/HOAt
382 Q-0690 2 403 F " HATU/HOAt
383 Q-0691 1.559 404. 1 E " HATU/HOAt
384 Q-0693 1.399 368. 1 F " HATU/HOAt
385 Q-0696 1.609 497.2 F " HATU/HOAt
386 Q-0697 1.568 498.2 F " HATU/HOAt
387 Q-0698 1.584 384.2 F " HATU/HOAt
388 Q-0700 1.698 384. 1 E " HATU/HOAt
389 Q-0701 1.51 9 480. 1 F " HATU/HOAt
390 Q-0702 1.56 429.2 F " HATU/HOAt
391 Q-0703 1.341 354.2 F " HATU/HOAt
392 Q-0704 1.547 426. 1 F " HATU/HOAt
393 Q-0705 1.476 340. 1 F " HATU/HOAt
394 Q-0706 1.543 354.2 F " HATU/HOAt
395 Q-0707 1.576 465. 1 F " HATU/HOAt
396 Q-0708 1.505 339. 1 F " HATU/HOAt
397 Q-0709 2 353 F " HATU/HOAt
398 Q-071 0 1.426 381 .2 F " HATU/HOAt
399 Q-071 1 1.541 370. 1 F " HATU/HOAt
400 Q-071 2 1.408 4 12 .1 F " HATU/HOAt
401 Q-071 3 1.555 395. 1 F " HATU/HOAt
402 Q-071 5 1.51 8 440.2 F " HATU/HOAt
403 Q-071 6 1.547 489. 1 F " HATU/HOAt
404 Q-071 8 1.580 465. 1 E " HATU/HOAt
405 Q-071 9 1.429 479.2 F " HATU/HOAt
406 Q-0720 1.337 380.3 F " HATU/HOAt
407 Q-0721 1.473 493.2 F " HATU/HOAt
408 Q-0722 1.156 343.2 F " HATU/HOAt
409 Q-0723 1.4 429.3 F " HATU/HOAt
4 10 Q-0724 1.598 426. 1 F " HATU/HOAt
4 11 Q-0725 1.607 367. 1 A' HATU/HOAt
4 12 Q-0726 1.71 2 4 15 .1 A' HATU/HOAt
4 13 Q-0727 1.625 367.2 F " HATU/HOAt
4 14 Q-0730 1.71 7 372. 1(M-55)+ A' HATU/HOAt
4 15 Q-0731 1.61 7 391 .2 E " HATU/HOAt
4 16 Q-0734 1.566 426. 1 F " HATU.HOAt
4 17 Q-0735 1.397 427. 1 C HATU/HOAt
4 18 Q-0736 1.378 442.3 C HATU/HOAt
4 19 Q-0737 1.664 4 11.1 A' HATU/HOAt
420 Q-0739 1.494 454.3 F " HATU/HOAt
421 Q-0743 1.31 1 355.2 F " HATU/HOAt
422 Q-0744 1.802 396. 1 F " HATU/HOAt
423 Q-0745 1.758 455.2 A' HATU/HOAt
424 Q-0747 1.61 7 427. 1 F " HATU/HOAt
425 Q-0748 1.474 454.3 F " HATU/HOAt
426 Q-0749 1.526 4 12 .1 F " HATU/HOAt
427 Q-0750 1 428 F " HATU/HOAt
428 Q-0751 1.437 369.8 I " HATU/HOAt
429 Q-0752 1.424 4 11.7 I " HATU/HOAt
430 Q-0753 1.525 398 F " HATU/HOAt
431 Q-0754 1.589 445. 1 F " HATU/HOAt
432 Q-0755 1.356 371 .1 F " HATU/HOAt
433 Q-0756 1 342 F " HATU/HOAt
434 Q-0757 1.584 421 .1 F " HATU/HOAt
435 Q-0758 1.768 4 13 .1 A' HATU/HOAt
436 Q-0759 1.575 390. 1 F " HATU/HOAt
437 Q-0760 1.404 4 10.2 F " HATU/HOAt
438 Q-0761 1.539 389. 1 F " HATU/HOAt
439 Q-0762 1.702 398. 1(M-55)+ A' HATU/HOAt
440 Q-0764 1.425 368. 1 F " HATU/HOAt
441 Q-0768 1.593 4 12 .1(M-55)+ F " HATU/HOAt
442 Q-0770 1.53 4 12 .1 F " HATU/HOAt
443 Q-0771 1.584 4 11.1 F " HATU/HOAt
444 Q-0772 1.595 468.2 F " HATU/HOAt
445 Q-0773 1.432 462 (M+Na)+ F " HATU/HOAt
446 Q-0774 1.327 247 A'
447 Q-0775 1.464 367. 1 F " HATU/HOAt
448 Q-0777 1.487 381 .1 F " HATU/HOAt
449 Q-0779 1.398 261 .0 A'
450 Q-0780 1.434 289. 1 F "
451 Q-0781 1.528 382. 1 F " HATU/HOAt
452 Q-0782 1.490 439. 1 F " HATU/HOAt
453 Q-0783 1.51 8 4 11.1 F " HATU/HOAt
454 Q-0784 1.562 425. 1 F " HATU/HOAt
455 Q-0785 1.537 454.2 F " HATU/HOAt
456 Q-0788 1.525 454.2 F " HATU/HOAt
457 Q-0789 1.393 335. 1 F " HATU/HOAt
458 Q-0790 1.53 454.2 F " HATU/HOAt
459 Q-0791 1.378 325. 1 F " HATU/HOAt
460 Q-0792 1.482 437. 1 F " HATU/HOAt
461 Q-0793 1.347 369.2 E " HATU/HOAt
462 Q-0794 1.353 299.2 E " HATU/HOAt
463 Q-0795 1.371 385. 1 F " HATU/HOAt
464 Q-0796 1.475 389. 1 F " HATU/HOAt
465 Q-0797 1.485 445.2 F " HATU/HOAt
466 Q-0798 1.658 468.2 F " HATU/HOAt
467 Q-0799 1.439 375. 1 F " HATU/HOAt
468 Q-0800 1.41 366.2 F " HATU/HOAt
469 Q-0802 1.558 404.2 F " HATU/HOAt
470 Q-0803 1.560 4 11.0 A' HATU/HOAt
471 Q-0804 1.444 375. 1 F " HATU/HOAt
472 Q-0805 1.41 5 423. 1 F " HATU/HOAt
473 Q-0806 1.504 384. 1(M-55)+ F " HATU/HOAt
474 Q-0807 1.420 361 .1 F " HATU/HOAt
475 Q-0808 1.577 367.2 F " HATU/HOAt
476 Q-0809 1.537 398. 1(M-55)+ F " HATU/HOAt
477 Q-081 2 1.41 1 404.2 F " HATU/HOAt
478 Q-081 3 1.533 353. 1 F " HATU/HOAt
479 Q-081 4 1.340 355. 1 F " HATU/HOAt
480 Q-081 5 1.401 383. 1 F " HATU/HOAt
481 Q-081 6 1.467 375. 1 F " HATU/HOAt
482 Q-081 7 1.459 392.2 F " HATU/HOAt
483 Q-081 8 1.460 4 18 .1 F " HATU/HOAt
484 Q-081 9 1.534 353. 1 F " HATU/HOAt
485 Q-0820 1.664 468.2 F " HATU/HOAt
486 Q-0821 1.301 382. 1 A' HATU/HOAt
487 Q-0822 1.585 357 A' HATU/HOAt
488 Q-0823 1.597 422.2 E " HATU/HOAt
489 Q-0824 1.3 367. 1 F " HATU/HOAt
490 Q-0825 1.365 366. 1 F " HATU/HOAt
491 Q-0826 1.503 394. 1 F " HATU/HOAt
492 Q-0827 1.651 438.0 F " HATU/HOAt
493 Q-0828 1.71 5 472. 1 F " HATU/HOAt
494 Q-0829 1.509 429.2 F " HATU/HOAt
495 Q-0830 1.651 438. 1 F " HATU/HOAt
496 Q-0831 1.367 406. 1 F " HATU/HOAt
497 Q-0832 1.535 396. 1 F " HATU/HOAt
498 Q-0833 1.703 472. 1 F " HATU/HOAt
499 Q-0835 1.593 439. 1 F " HATU/HOAt
500 Q-0836 1.647 473. 1 F " HATU/HOAt
501 Q-0837 1.635 437. 1 A' HATU/HOAt
502 Q-0839 1.389 275. 1 F "
503 Q-0840 1.702 472. 1 F " HATU/HOAt
504 Q-0842 1.501 384. 1(M-55)+ F " HATU/HOAt
505 Q-0843 1.305 405. 1 A' HATU/HOAt
506 Q-0844 1.51 0 407. 1 F " HATU/HOAt
507 Q-0845 1.389 430.2 F " HATU/HOAt
508 Q-0846 1.61 1 430.2 F " HATU/HOAt
509 Q-0847 1.088 368.2 E " HATU/HOAt
5 10 Q-0848 1.41 1 396. 1 A' HATU/HOAt
5 11 Q-0849 1.41 3 380.2 F " HATU/HOAt
5 12 Q-0850 1.507 428.2 F " HATU/HOAt
5 13 Q-0851 1.566 442.2 F " HATU/HOAt
5 14 Q-0852 1.600 496.2 F " HATU/HOAt
5 15 Q-0853 1.333 366. 1 A' HATU/HOAt
5 16 Q-0854 1.674 499.2 F" HATU/HOAt
5 17 Q-0855 1.502 406.2 F " HATU/HOAt
5 18 Q-0856 1.348 368. 1 F " HATU/HOAt
5 19 Q-0857 1.499 384. 1(M-55)+ F " HATU/HOAt
520 Q-0858 1.556 408.2 F " HATU/HOAt
521 Q-0859 1.367 434. 1 F " HATU/HOAt
522 Q-0860 1.506 440. 1 F " HATU/HOAt
523 Q-0861 1.534 464. 1(M+Na)+ F " HATU/HOAt
524 Q-0862 1.267 382. 1 F " HATU/HOAt
525 Q-0863 1.386 343. 1 F " HATU/HOAt
526 Q-0865 1.580 4 12 .1(M-55)+ F " HATU/HOAt
527 Q-0866 1.270 365. 1 F " HATU/HOAt
528 Q-0867 1.497 428.2 F " HATU/HOAt
529 Q-0868 1.287 406.2 F " HATU/HOAt
530 Q-0869 1.560 455. 1 F " HATU/HOAt
531 Q-0870 1.738 498. 1 F " HATU/HOAt
532 Q-0871 1.443 433. 1 F " HATU/HOAt
533 Q-0872 1.261 382. 1 F " HATU/HOAt
534 Q-0873 1.245 365. 1 F " HATU/HOAt
535 Q-0874 1.54 378. 1 A' HATU/HOAt
536 Q-0875 1.654 430. 1 F " HATU/HOAt
537 Q-0876 1.65 448.2 F " HATU/HOAt
538 Q-0877 1.51 1 456.2 F " HATU/HOAt
539 Q-0878 1.509 476.2(M+Na)+ F " HATU/HOAt
540 Q-0879 1.264 396. 1 F " HATU/HOAt
541 Q-0880 1.548 448.3 F " HATU/HOAt
542 Q-0881 1.346 382. 1 F " HATU/HOAt
543 Q-0882 1.507 431 .2 F " HATU/HOAt
544 Q-0883 1.365 352. 1 F " HATU/HOAt
545 Q-0884 1.61 6 436. 1 F " HATU/HOAt
546 Q-0885 1.631 442.2 F " HATU/HOAt
547 Q-0886 1.325 396.2 F " HATU/HOAt
548 Q-0887 1.57 442.2 F " HATU/HOAt
549 Q-0888 1.32 384.2 A' HATU/HOAt
550 Q-0890 1.61 8 260. 1 C
551 Q-0891 1.341 422.2 F " HATU/HOAt
552 Q-0892 1.558 442 F " HATU/HOAt
553 Q-0893 2 451 F " HATU/HOAt
554 Q-0894 1.704 464. 1 F " HATU/HOAt
555 Q-0895 1.223 381 .2 F " HATU/HOAt
556 Q-0896 1.474 389. 1 F " HATU/HOAt
557 Q-0897 1.54 476. 1(M+Na)+ F " HATU/HOAt
558 Q-0899 1.569 442. 1 F " HATU/HOAt
559 Q-0900 1.499 375. 1 F " HATU/HOAt
560 Q-0901 1.275 434. 1 F " HATU/HOAt
561 Q-0902 1.557 421 .1 F " HATU/HOAt
562 Q-0905 1.597 5 15.2 F " HATU/HOAt
563 Q-0906 1.688 404. 1 D " HATU/HOAt
564 Q-0907 1.598 4 11.1 D " HATU/HOAt
565 Q-0908 1.538 424. 1 F " HATU/HOAt
566 Q-0909 1.569 431 .1 F " HATU/HOAt
567 Q-091 0 1.81 8 389 D " HATU/HOAt
568 Q-091 1 1.41 9 450.2 F " HATU/HOAt
569 Q-091 2 1.642 482 F " HATU/HOAt
570 Q-091 3 1.51 2 450.2 F " HATU/HOAt
571 -091 4 1.538 476. 1(M+Na)+ F " HATU/HOAt
572 Q-091 5 1.577 442.3 J' HATU/HOAt
573 Q-091 6 2 456 F " HATU/HOAt
574 Q-091 7 1.745 383.2 C HATU/HOAt
575 Q-091 8 1.293 367. 1 F " HATU/HOAt
576 Q-091 9 1.284 394.2 J' HATU/HOAt
577 Q-0920 1.925 395. 1 D " HATU/HOAt
578 Q-0921 1.435 339.2 J' HATU/HOAt
579 Q-0922 1.332 369. 1 F " HATU/HOAt
580 Q-0923 1.388 366. 1 F " HATU/HOAt
581 Q-0924 1.528 469.3 J' HATU/HOAt
582 Q-0925 4.538 438. 1 F " HATU/HOAt
583 Q-0926 1.463 377. 1 F " HATU/HOAt
584 Q-0927 1.525 353. 1 F " HATU/HOAt
585 Q-0928 1.520 469.3 J' HATU/HOAt
586 Q-0929 1.504 454. 1 F " HATU/HOAt
587 Q-0930 1.467 450.2 F " HATU/HOAt
588 Q-0931 1.890 354.2 C HATU/HOAt
589 Q-0932 1.51 5 498.3 F " HATU/HOAt
590 Q-0933 1.402 422.2 C HATU/HOAt
591 Q-0934 1.553 367.2 J' HATU/HOAt
592 Q-0935 1.298 4 10.2 J' HATU/HOAt
593 Q-0936 1.889 461 .1 C HATU/HOAt
594 Q-0937 1.330 405.2 J' HATU/HOAt
595 Q-0938 1.5 397. 1 F " HATU/HOAt
596 Q-0939 1.680 486.2 J' HATU/HOAt
597 Q-0940 1.667 457.2 J' HATU/HOAt
598 Q-0941 1.500 392.2 J' HATU/HOAt
599 Q-0942 1.287 393.2 J' HATU/HOAt
600 Q-0943 1.980 436.2 C HATU/HOAt
601 Q-0944 1.989 435.2 C HATU/HOAt
602 Q-0945 1.322 404. 1 C HATU/HOAt
603 Q-0946 1.502 452 J' HATU/HOAt
604 Q-0947 1.828 381 C HATU/HOAt
605 Q-0948 1.379 393.2 F " HATU/HOAt
606 Q-0950 1.298 398.2 F " HATU/HOAt
607 Q-0951 1.51 8 450.2 F " HATU/HOAt
608 Q-0952 1.453 429. 1 F " HATU/HOAt
609 Q-0953 1.479 435.3 J' HATU/HOAt
6 10 Q-0954 1.328 436.3 J' HATU/HOAt
6 11 Q-0955 1.352 434.3 J' HATU/HOAt
6 12 Q-0956 1.609 424.2 J' HATU/HOAt
6 13 Q-0957 1.391 396.2 J' HATU/HOAt
6 14 Q-0958 1.331 434.2 F " HATU/HOAt
6 15 Q-0959 1.61 409. 1 F " HATU/HOAt
6 16 Q-0960 1.647 435.2 J' HATU/HOAt
6 17 Q-0961 1.406 357.2 J' HATU/HOAt
6 18 Q-0962 1.498 422.2 J' HATU/HOAt
6 19 Q-0963 1.585 461 .2 J' HATU/HOAt
620 Q-0964 1.555 449.2 J' HATU/HOAt
621 Q-0965 1.572 401 .2 J' HATU/HOAt
622 Q-0966 1.501 395.2 J' HATU/HOAt
623 Q-0967 1.605 463.2 J' HATU/HOAt
624 Q-0968 1.61 2 456.3 J' HATU/HOAt
625 Q-0969 1.420 4 10.2 J' HATU/HOAt
626 Q-0970 1.781 486.2 C HATU/HOAt
627 Q-0971 1.253 403.2 J' HATU/HOAt
628 Q-0972 1.993 490. 1(M+Na)+ C HATU/HOAt
629 Q-0973 1.329 371 .2 F " HATU/HOAt
630 Q-0974 2.082 459.3 C HATU/HOAt
631 Q-0975 1.520 480.2 J' HATU/HOAt
632 Q-0976 1.695 357.2 C HATU/HOAt
633 Q-0977 1.282 433.2 F " HATU/HOAt
634 Q-0978 1.853 406.2 C HATU/HOAt
635 Q-0979 1.745 379. 1 C HATU/HOAt
636 Q-0980 1.708 424. 1 C HATU/HOAt
637 Q-0981 1 372 J' HATU/HOAt
638 Q-0982 1.51 9 409.3 J' HATU/HOAt
639 Q-0983 1.425 434.2 C HATU/HOAt
640 Q-0984 1.958 461 .2 C HATU/HOAt
641 Q-0985 1.279 354.2 J' HATU/HOAt
642 Q-0986 1.852 434.2 C HATU/HOAt
643 Q-0987 1.424 397. 1 F " HATU/HOAt
644 Q-0988 1.51 5 420.2 F " HATU/HOAt
645 Q-0989 1.61 9 458.3 J' HATU/HOAt
646 Q-0990 1.746 455. 1 F " HATU/HOAt
647 Q-0991 1.928 4 15 .1 C HATU/HOAt
648 Q-0992 1.871 424.2 C HATU/HOAt
649 Q-0993 1.348 4 18.2 F " HATU/HOAt
650 Q-0994 1.587 4 18.2 D " HATU/HOAt
651 Q-0995 1 446 C HATU/HOAt
652 Q-0996 1.576 425. 1 F " HATU/HOAt
653 Q-0997 1.448 460. 1 F " HATU/HOAt
654 Q-0998 1.539 385. 1 F " HATU/HOAt
655 Q-0999 1.472 406.2 F " HATU/HOAt
656 Q-1 000 1.562 441 .1 F " HATU/HOAt
657 Q-1 001 1.643 364.2 C HATU/HOAt
658 Q-1 002 1.667 364.2 C HATU/HOAt
659 Q-1 003 1.81 2 422. 1 C HATU/HOAt
660 Q-1 004 1.863 430. 1 C HATU/HOAt
661 Q-1 005 1.474 354 F " HATU/HOAt
662 Q-1 006 1.523 425. 1 F " HATU/HOAt
663 Q-1 007 1.448 4 11.1 F " HATU/HOAt
664 Q-1 008 1.552 4 11.1 F " HATU/HOAt
665 Q-1 009 1.280 386.2 A' HATU/HOAt
666 Q-1 0 10 1.321 400.2 D " HATU/HOAt
667 Q-1 0 1 1 1.447 460. 1 F " HATU/HOAt
668 Q-1 0 12 1.429 464.2 F " HATU/HOAt
669 Q-1 0 13 1.42 396 F " HATU/HOAt
670 Q-1 0 14 1.51 3 425. 1 F' HATU/HOAt
671 Q-1 0 15 1.584 478.2 F' HATU/HOAt
672 Q-1 0 16 1.37 4 14.2 F' HATU/HOAt
673 Q-1 0 17 1.81 9 395.2 C HATU/HOAt
674 Q-1 0 18 1.528 478.2 D " HATU/HOAt
675 Q-1 0 19 1.832 464.2 C HATU/HOAt
676 Q-1 020 1.540 4 10.2 F " HATU/HOAt
677 Q-1 021 1.355 400. 1 F " HATU/HOAt
678 Q-1 022 1.33 369.2 F " HATU/HOAt
679 Q-1 023 1.772 376.2 C HATU/HOAt
680 Q-1 024 1.832 376. 1 C HATU/HOAt
681 Q-1 025 1.35 400.2 F " HATU/HOAt
682 Q-1 026 1.367 4 14.2 F " HATU/HOAt
683 Q-1 027 1.331 4 14.2 C HATU/HOAt
684 Q-1 028 2 437 D " HATU/HOAt
685 Q-1 029 1.81 0 464.2 C HATU/HOAt
686 Q-1 030 1.339 400.2 J' HATU/HOAt
687 Q-1 031 1.31 5 386.2 J' HATU/HOAt
688 Q-1 032 1.326 438.2 J' HATU/HOAt
689 Q-1 033 1.483 428. 1(M-H)- F " HATU/HOAt
690 Q-1 034 1.461 390.2 F " HATU/HoAt
691 Q-1 035 1.589 450.2 J' HATU/HOAt
692 Q-1 036 1.566 464.2 J' HATU/HOAt
693 Q-1 037 1.844 481 .1 F " HATU/HOAt
694 Q-1 038 1.934 393.2 C HATU/HOAt
695 Q-1 039 1.427 359. 1 F " HATU/HOAt
696 Q-1 040 1.494 341 .1 F " HATU/HOAt
697 Q-1 041 1.41 6 395.2 J' HATU/HOAt
698 Q-1 042 1.803 440. 1 D " HATU/HOAt
699 Q-1 043 1.474 455.2 J' HATU/HOAt
700 Q-1 044 1.556 425. 1 F " HATU/HOAt
701 Q-1 045 1.545 469.3 J' HATU/HOAt
702 Q-1 046 1.505 492.2 F " HATU/HOAt
703 Q-1 047 1.866 4 12 J' HATU/HOAt
704 Q-1 048 1.891 354.2 C HATU/HOAt
705 Q-1 049 1.786 378.2 C HATU/HOAt
706 Q-1 050 1.747 349. 1 D " HATU/HOAt
707 Q-1 051 1.680 437.2 J' HATU/HOAt
708 Q-1 052 1.949 453.2 J' HATU/HOAt
709 Q-1 053 1.487 406. 1 F " HATU/HOAt
7 10 Q-1 054 1.903 425.2 C HATU/HOAt
7 11 Q-1 055 1 4 10 J' HATU/HOAt
7 12 Q-1 056 2.054 487.2 C HATU/HOAt
7 13 Q-1 057 1.401 464.3 F " HATU/HOAt
7 14 Q-1 058 1.381 465.2 F " HATU/HOAt
7 15 Q-1 059 1.373 356. 1 J' HATU/HOAt
7 16 Q-1 060 1.472 424.2 J' HATU/HOAt
7 17 Q-1 061 1.696 451 .2 C HATU/HOAt
7 18 Q-1 062 1.773 4 12.2 C HATU/HOAt
7 19 Q-1 063 1.745 4 13.2 C HATU/HOAt
720 Q-1 064 2.066 435.2 C HATU/HOAt
721 Q-1 065 2.049 435.2 C HATU/HOAt
722 Q-1 066 1.425 425.2 J' HATU/HOAt
723 Q-1 067 1.390 426.2 J' HATU/HOAt
724 Q-1 070 1.271 466.2 F " HATU/HOAt
725 Q-1 071 1.991 409. 1 C HATU/HOAt
726 Q-1 072 1.802 395.2 C HATU/HOAt
727 Q-1 073 1.431 407.2 J' HATU/HOAt
728 Q-1 074 1.563 463. 1 F " HATU/HOAt
729 Q-1 075 1.51 7 464. 1 F " HATU/HOAt
730 Q-1 076 1.7 4 11.2 C HATU/HOAt
731 Q-1 077 1.284 467.3 F " HATU/HOAt
732 Q-1 078 1.945 450. 1 C HATU/HOAt
733 Q-1 079 1.486 471 .2 I " HATU/HOAt
734 Q-1 080 1.522 470.2 I " HATU/HOAt
735 Q-1 081 1.759 451 .2 A' HATU/HOAt
736 Q-1 082 1.490 422. 1 C HATU/HOAt
737 Q-1 083 1.691 422. 1 A' HATU/HOAt
738 Q-1 084 1.551 488. 1 C HATU/HOAt
739 Q-1 085 1.401 478.2 F " HATU/HOAt
740 Q-1 086 1.533 506.3 F " HATU/HOAt
741 Q-1 087 1.430 407. 1 F " HATU/HOAt
742 Q-1 088 1.373 436.3 F " HATU/HOAt
743 Q-1 089 1.344 437.3 F " HATU/HOAt
744 Q-1 090 1.61 7 453.2 C HATU/HOAt
745 Q-1 091 1.35 454.2 J' HATU/HOAt
746 Q-1 092 1.387 408.3 E " HATU/HOAt
747 Q-1 093 1.446 435. 1 J' HATU/HOAt
748 Q-1 094 1.499 394.2 C HATU/HOAt
749 Q-1 095 1.61 4 421 .2 J' HATU/HOAt
750 Q-1 096 1.572 422.2 J' HATU/HOAt
751 Q-1 097 1.570 487.2 C HATU/HOAt
752 Q-1 098 1.466 373.2 J' HATU/HOAt
753 Q-1 099 1.669 487.2 c HATU/HOAt
754 Q-1 100 1.648 488.2 c HATU/HOAt
755 Q-1 10 1 1.490 487.2 c HATU/HOAt
756 Q-1 102 1.82 4 13.3 c HATU/HOAt
757 Q-1 103 1.799 393.2 c HATU/HOAt
758 Q-1 104 1.41 436.2 J' HATU/HOAt
759 Q-1 105 1.494 422.2 J' HATU/HOAt
760 Q-1 106 1.752 422.2 c HATU/HOAt
761 Q-1 107 1 437 J' HATU/HOAt
762 Q-1 108 2 478.2 J' HATU/HOAt
763 Q-1 109 1.349 451 .2 F " HATU/HOAt
764 Q-1 110 1.986 446.3 C HATU/HOAt
765 Q-1 111 1.851 438.2 C HATU/HOAt
766 Q-1 112 1.792 383.2 C HATU/HOAt
767 Q-1 113 1.753 384.2 C HATU/HOAt
768 Q-1 114 1.422 408.2 C HATU/HOAt
769 Q-1 115 1.584 422.2 A' HATU/HOAt
770 Q-1 116 1.866 438. 1 C HATU/HOAt
771 Q-1 117 1.469 422.2 J' HATU/HOAt
772 Q-1 118 1.755 425. 1 C HATU/HOAt
773 Q-1 119 1.437 377.2 J' HATU/HOAt
774 Q-1 120 1.640 4 18 .1 C HATU/HOAt
775 Q-1 12 1 1.396 394. 1 J' HATU/HOAt
776 Q-1 122 1.923 421 .1 C HATU/HOAt
777 Q-1 123 1.545 435.2 F " HATU/HOAt
778 Q-1 124 1.921 409.2 C HATU/HOAt
779 Q-1 125 1.398 4 10.2 J' HATU/HOAt
780 Q-1 126 1.549 379.2 J' HATU/HOAt
781 Q-1 128 1.781 394. 1 C HATU/HOAt
782 Q-1 129 1.31 2 394. 1 J' HATU/HOAt
783 Q-1 130 1.51 7 421 .1 F " HATU/HOAt
784 Q-1 13 1 1.704 459.2 J' HATU/HOAt
785 Q-1 132 1.657 423.2 F " HATU/HOAt
786 Q-1 134 1.974 479. 1 C HATU/HOAt
787 Q-1 135 1.637 505.2 J' HATU/HOAt
788 Q-1 136 1.35 488.2 F " HATU/HOAt
789 Q-1 137 1.896 463. 1 C HATU/HOAt
790 Q-1 138 2 .162 521 .1 C HATU/HOAt
791 Q-1 139 2 .19 1 555. 1 C HATU/HOAt
792 Q-1 140 1.894 506. 1 C HATU/HOAt
793 Q-1 14 1 1.571 455.2 J' HATU/HOAt
794 Q-1 144 1.731 394. 1 C HATU/HOAt
795 Q-1 145 1.820 464. 1 C HATU/HOAt
796 Q-1 146 2 .125 492. 1 C HATU/HOAt
797 Q-1 147 2.069 492. 1 C HATU/HOAt
798 Q-1 148 2 .135 526. 1 C HATU/HOAt
799 Q-1 149 1.566 489.2 J' HATU/HOAt
800 Q-1 150 1.588 473. 1 C HATU/HOAt
801 Q-1 15 1 1.602 505.2 J' HATU/HOAt
802 Q-1 152 1.753 521 .2 J' HATU/HOAt
803 Q-1 153 2.078 555. 1 C HATU/HOAt
804 Q-1 154 1.91 2 506. 1 C HATU/HOAt
805 Q-1 155 1.748 521 .2 J' HATU/HOAt
806 Q-1 156 1.683 505.2 J' HATU/HOAt
807 Q-1 157 1.91 9 489.2 D " HATU/HOAt
808 Q-1 158 1.842 459. 1 D " HATU/HOAt
809 Q-1 159 2.031 539. 1 C HATU/HOAt
8 10 Q-1 160 2.009 476. 1 C HATU/HOAt
8 11 Q-1 16 1 1.350 472.2 J' HATU/HOAt
8 12 Q-1 162 1.366 472.2 J' HATU/HOAt
8 13 Q-1 163 1.886 522. 1 C HATU/HOAt
8 14 Q-1 164 1.593 488.2 D " HATU/HOAt
8 15 Q-1 165 2.043 505. 1 C HATU/HOAt
8 16 Q-1 166 2 .114 492.0 C HATU/HOAt
8 17 Q-1 167 2 .139 526. 1 C HATU/HOAt
8 18 Q-1 168 1.383 394.2 C HATU/HOAt
8 19 Q-1 170 1.482 440.2 J' HATU/HOAt
820 Q-1 17 1 1.648 539.2 J' HATU/HOAt
821 Q-1 172 1.989 5 12 .1 C HATU/HOAt
822 Q-1 173 2 .183 555. 1 C HATU/HOAt
823 Q-1 174 1.683 447.2 J' HATU/HOAt
824 Q-1 175 1.668 539.2 J' HATU/HOAt
825 Q-1 176 1.63 505.2 J' HATU/HOAt
826 Q-1 177 1.521 349. 1 E " HATU/HOAt
827 Q-1 178 1.838 541 .1 C HATU/HOAt
828 Q-1 179 1.997 522 C HATU/HOAt
829 Q-1 180 1.937 506.2 c HATU/HOAt
830 Q-1 18 1 2.01 0 5 12 .1 c HATU/HOAt
831 Q-1 182 1.477 488. 1 c HATU/HOAt
832 Q-1 183 1.469 438.2 J' HATU/HOAt
833 Q-1 184 1.959 368. 1 c HATU/HOAt
834 Q-1 185 1.689 405. 1 c HATU/HOAt
835 Q-1 186 2.022 449. 1 c HATU/HOAt
836 Q-1 187 1.550 459. 1 c HATU/HOAt
837 Q-1 188 1.856 506. 1 c HATU/HOAt
838 Q-1 189 1.41 396.3 J' HATU/HOAt
839 Q-1 190 1.524 506.2 J' HATU/HOAt
840 Q-1 19 1 1.402 383.2 J' HATU/HOAt
841 Q-1 192 1.78 395.2 c HATU/HOAt
842 Q-1 193 1.863 490. 1 c HATU/HOAt
843 Q-1 194 1.456 436. 1 c HATU/HOAt
844 Q-1 196 1.963 506. 1 c HATU/HOAt
845 Q-1 197 1.865 506. 1 c HATU/HOAt
846 Q-1 198 1.537 453.2 J' HATU/HOAt
847 Q-1 199 2.083 449.2 c HATU/HOAt
848 Q-1 200 2.004 450.2 c HATU/HOAt
849 Q-1 201 1.405 369.2 c HATU/HOAt
850 Q-1 202 1.575 489.2 J' HATU/HOAt
851 Q-1 203 1.525 496.2 J' HATU/HOAt
852 Q-1 205 1.366 382.3 J' HATU/HOAt
853 Q-1 206 1.690 459. 1 c HATU/HOAt
854 Q-1 207 1.857 397.2 c HATU/HOAt
855 Q-1 208 1.786 395. 1 c HATU/HOAt
856 Q-1 209 1.377 381 .2 J' HATU/HOAt
857 Q-1 2 10 2.026 5 12.2 c HATU/HOAt
858 Q-1 2 11 1.928 5 12.2 c HATU/HOAt
859 Q-1 2 12 1.559 496.3 J' HATU/HOAt
860 Q-1 2 13 1.31 8 396.2 J' HATU/HOAt
861 Q-1 2 14 1.61 5 384.2 c HATU/HOAt
862 Q-1 2 15 1.926 445.2 c HATU/HOAt
863 Q-1 2 16 2 458.3 J' HATU/HOAt
864 Q-1 2 17 1.780 394. 1 c HATU/HOAt
865 Q-1 2 18 1.584 438.2 J' HATU/HOAt
866 Q-1 2 19 1.88 4 17 .1 C HATU/HOAt
867 Q-1 220 1.847 409.2 C HATU/HOAt
868 Q-1 221 1.331 355.2 C HATU/HOAt
869 Q-1 222 1.51 6 354.2 J' HATU/HOAt
870 Q-1 223 1.427 397.2 J' HATU/HOAt
871 Q-1 224 1.645 391 .1 C HATU/HOAt
872 Q-1 225 1.759 423. 1 C HATU/HOAt
873 Q-1 226 1.708 409. 1 C HATU/HOAt
874 Q-1 227 1.895 451 .1 C HATU/HOAt
875 Q-1 228 1.767 439. 1 C HATU/HOAt
876 Q-1 229 1.41 8 461 .2 J' HATU/HOAt
877 Q-1 230 1.626 505.2 J' HATU/HOAt
878 Q-1 231 1.874 506. 1 C HATU/HOAt
879 Q-1 232 1.668 427. 1 C HATU/HOAt
880 Q-1 233 1.578 426.2 J' HATU/HOAt
881 Q-1 234 1.792 461 .1 C HATU/HOAt
882 Q-1 235 1.474 488. 1 C HATU/HOAt
883 Q-1 236 1.924 522. 1 C HATU/HOAt
884 Q-1 237 1.762 362. 1 C HATU/HOAt
885 Q-1 238 2.05 460. 1 C HATU/HOAt
886 Q-1 239 1.404 375.2 J' HATU/HOAt
887 Q-1 240 1.542 436.2 J' HATU/HOAt
888 Q-1 241 1.272 382. 1 C HATU/HOAt
889 Q-1 243 1.368 404.2 J' HATU/HOAt
890 Q-1 244 1.254 369. 1 C HATU/HOAt
891 Q-1 246 1.646 390. 1 C HATU/HOAt
892 Q-1 247 1.401 405.2 J' HATU/HOAt
893 Q-1 249 1.388 386.2 J' HATU/HOAt
894 Q-1 250 1.786 4 17 .1 C HATU/HOAt
895 Q-1 251 1.162 328.2 J' HATU/HOAt
896 Q-1 254 1.35 404.2 J' HATU/HOAt
897 Q-1 255 1.537 404. 1 HATU/HOAt
898 Q-1 256 1.477 4 10.2 J' HATU/HOAt
899 Q-1 259 1.677 375. 1 C HATU/HOAt
900 Q-1 260 1.71 9 4 10 .1 C HATU/HOAt
901 Q-1 263 1.409 375.2 J' HATU/HOAt
902 Q-1 266 1.778 424. 1 C HATU/HOAt
903 Q-1 269 1.699 394. 1 C HATU/HOAt
904 Q-1 288 2 524. 1 C HATU/HOAt
905 Q-1 289 2 524.2 J' HATU/HOAt
906 Q-1 291 1.603 422. 1 C HATU/HOAt
907 Q-1 292 4.560 438.2 E " HATU/HOAt
908 Q-1 296 1.345 4 11.2 J' HATU/HOAt
909 Q-1 301 1.400 394.3 D " HATU/HOAt
9 10 Q-1 305 1.461 422.2 F " HATU/HOAt
9 11 Q-1 306 1.485 389.2 E " HATU/HOAt
9 12 Q-1 3 11 1.680 432. 1 C HATU/HOAt
9 13 Q-1 3 13 1.537 403.2 E " HATU/HOAt
9 14 Q-1 320 1.753 394. 1 C HATU/HOAt
9 15 Q-1 322 1.61 2 4 18.2 C HATU/HOAt
9 16 Q-1 341 1.450 450.2 E " HATU/HOAt
9 17 Q-1 343 1.256 407.2 J ' HATU/HOAt
9 18 Q-1 344 1.709 4 13 .1 C HATU/HOAt
9 19 Q-1 346 1.673 378. 1 C HATU/HOAt
920 Q-1 362 1.462 432.2 J ' HATU/HOAt
921 Q-1 365 1.547 436.2 J ' HATU/HOAt
922 Q-1 483 1.633 425. 1 c HATU
923 Q-1 535 1.506 468.2 J ' HOAt/HATU
924 Q-1 539 1.607 406. 1 c HATU/HOAt
925 Q-1 558 1.402 434.2 J ' HATU/HOAt
926 Q-1560 1.493 423.0 c HATU/HOAt
927 Q-1 563 1.524 439.2 J ' HATU/HOAt
928 Q-1 565 1.479 404.2 J ' HATU/HOAt
929 Q-1 581 1.663 420. 1 c HATU/HOAt
930 Q-1 591 1.494 482.2 J ' HOAt/HATU
931 Q-1 597 1.757 289. 1 c
932 Q-1 641 1.424 303.2 J '
933 Q-1 728 1.448 488. 1 F " HATU/HOAt
934 Q-1 8 18 1.561 474.3 J ' HATU/HOAt
935 Q-1 866 1.889 504. 1 C HATU/HOAt
936 Q-1 886 1.573 460. 1 J ' HATU/HOAt
937 Q-1 889 1.925 425. 1 C HATU/HOAt
938 Q-1 925 1.343 364. 1 D " HATU/HOAt
939 Q-1 932 1.381 365.0 J ' HATU/HOAt
940 Q-1 984 1.784 467.0 C HATU/HOAt
941 Q-1 985 1.561 405. 1 C HATU/HOAt
942 Q-2007 1.285 460.3 D " HATU/HOAt
943 Q-2008 1.756 426.0 C HATU/HOAt
944 Q-2009 1.850 444.0 C HATU/HOAt
945 Q-201 6 1.509 4 12 .1 J ' HATU/HOAt
946 Q-201 7 1.556 439.0 J ' HATU/HOAt
Preparative Example 9 - Formation of Amines
Preparation of 4-(azetidin-3-yl)-2-fluoropyridine TFA
[001033] Step 1: (l-(tert-butoxycarbonyl)azetidin-3-yl)zinc(II) iodide.
[001034] oc
[001035] 1,2-Dibromoethane (1.992 g, 10.6 mmmol) was added to the suspension of Zn
(2.86 g, 44.1 mmol) in dry THF (40 mL) under N2 atmosphere. The mixture was refluxed for
15 min and cooled to r.t. TMSC1 (764 mg, 7.08 mmol) was added to the mixture slowly.
After the addition, the mixture was stirred for 45 min at r.t. and then tert-butyl 3-
iodoazetidine-l-carboxylate (5 g, 17.7 mmol) in dry THF (10 mL) was added. The mixture
was stirred for 2 h at 40 °C to give the zinc reagent solution, which was used in next step
directly.
[001036] Step 2 : Synthesis of tert-butyl 3-(2-fluoropyridin-4-yl)azetidine-l-carboxylate.
[001037] Boc
[001038] 4-Bromo-2-fluoropyridine (3 g, 17.142 mmol) in THF (10 ml) was added to the
mixture of Pd(dba) 3 (1.57 g, 1.714 mmol) and Pd(2-furyl) 3 (1.2 g, 5.143 mmol) under N2
atmosphere. Then (l-(tert-butoxycarbonyl)azetidin-3-yl)zinc(II) iodide (7.2 g, 20.571 mmol)
solution in THF (50 mL) was added. The mixture was stirred at 60 °C for 5 h . The reaction
was quenched with H20 (10 mL). The precipitate was filtered. The filtrate was extracted with
EtOAc (30 mL x 2) and washed with water (200 mL). The combined organics were dried
over Na2S0 4. The solvent was then removed and the residue was purified by silica gel
chromatography with CH2Cl2/MeOH: 50/1 to yield the product. LC-MS: m z = 253 (M+H)+,
RT = 1.457 min.
[001039] Step 3 : Synthesis of 4-(azetidin-3-yl)-2-fluoropyridine TFA salt.
[001041] TFA (5 mL) was added to a solution of tert-butyl 3-(2-fluoropyridin-4-
yl)azetidine-l-carboxylate (1.926 g, 7.634 mmol) in DCM (5 mL). The solution was stirred
r.t. for 3 h . The solvent was removed from the reaction to yield the product which was used in
the next step without further purification. LC-MS: m/z = 153 (M+H)+.
Preparation l-(3,3-difluorocyclobutyl)piperazine:
Step 1
[001042] Stepl: Synthesis of l-benzyl-4-(3,3-difluorocyclobutyl)piperazine.
[001044] To a 100 mL of RBF was added N-benzyl-2-chloro-N-(2-chloroethyl)ethanamine
hydrochloride (2.3 g, 8.61 mmol), 3,3-difluorocyclobutanamine hydrochloride (1.0 g, 6.99
mmol), 20 mL of EtOH, and 6 mL of DIPEA. The mixture was stirred at reflux under N2 for
16 h . The reaction mixture was concentrated and purified by combi flash (isco, silica gel, UV
254, 40 g, EA/PE=l/3) to give the product. LC-MS (UV 214) 267.2 (M+H)+, RT = 2.01
min.
[001045] Step 2 : Synthesis of l-(3,3-difluorocyclobutyl)piperazine.
[001046]
[001047] To a 100 mL of RBF was added l-benzyl-4-(3,3-difluorocyclobutyl)piperazine
(1.0 g, 3.76 mmol), 30 mL of EtOAc, 0.05 mL of HOAc, and 400 mg of Pd(OH) 2. The
mixture was stirred at r.t. under H2 (2 atm) for 16 h . The reaction mixture was filtered and the
filtrate was concentrated to give the title product. LC-MS (UV 214) 177.2 (M+H)+, RT =
1.17 min.
Preparation of l-(2,2-difluorocyclobutyl)piperazine hydrochloride:
[001048] Step 1: Synthesis of tert-butyl-4-(2-oxocyclobutyl)piperazine-l-carboxylate.
[001050] To the solution of l,2-bis(trimethylsilyloxy)cyclobut-l-ene (12.5 g, 54.24 mmol)
in MeOH (40 mL) was added dropwise a solution of tert-butyl-piperazine-l-carboxylate (10.1
g, 54.24 mmol) in MeOH (60 mL) over 30 min. After addition, the reaction mixture was
stirred at r.t. for 15 h . The mixture was concentrated and purified by SGC (eluting with
DCM/MeOH=20/l) to get the title compound. LC-MS: m/z = 199.1 (M-56)+, RT = 1.80 min.
[001051] Step 2 : Synthesis of tert-butyl-4-(2,2-difluorocyclobutyl)piperazine-l-
carboxylate.
[001053] To the solution of tert-butyl-4-(2-oxocyclobutyl)piperazine-l-carboxylate (7.2 g,
28.31 mmol) in DCM (50 mL) was added DAST (13.69 g, 84.93 mmol). The reaction
mixture was stirred at r.t. for 15 h . It was then quenched with sat. NaHC0 3 (100 mL),
extracted with DCM (80 mLX3), and the combined organics were dried over Na2S0 4 and
concentrated. The residue was purified by SGC (eluting with PE/EtOAc= 10/ 1-1/1) to give
the title compound. LC-MS: m/z = 277.2 (M+H)+, RT = 2.01 min.
[001054] Step 3 : Synthesis of l-(2,2-difluorocyclobutyl)piperazine hydrochloride.
[001056] To a solution of tert-butyl-4-(2,2-difluorocyclobutyl)piperazine-l-carboxylate
(950 mg, 3.44 mmol) in DCM (10 mL) was added HCl (4 mL, 4 M in dioxane). The reaction
mixture was stirred at r.t. for 15 h, concentrated, and washed with EtOAc (40 mL) to give the
title compound. LC-MS: m/z = 177.2 (M+H)+, RT = 1.15 min.
Preparation of 2-(piperidin-4-yl)oxazole-4-carbonitrile hydrochloride:
[001057] Step 1: Synthesis of methyl 2-(l-(tert-butoxycarbonyl)piperidin-4-yl)-2,5-
dihydrooxazole-4-carboxylate.
[001059] The mixture of methyl 2-amino-3-hydroxypropanoate (80 g, 516.4 mmol) and
DABCO (157.74 g, 1408.45 mmol) in 2 liters of DCM was stirred for 40 min. Then tert-butyl
4-formylpiperidine-l-carboxylate (100 g, 469.48 mmol) was added to the mixture and stirred
for 40 min at r.t. The mixture was cooled to 0 °C and then NBS (68.68 g, 516.4 mmol) in 500
mL of DCM was added dropwise to the mixture. The mixture was warmed to r.t. and stirred
overnight. The reaction was quenched with sat. aq. Na2S205, extracted with DCM (300 Ml
X2), and washed with aq. NaHC0 3. The combined organics were dried over Na2S0 4,
concentrated and purified by SGC (PE/EA=3/2) to get the title compound. LC-MS: m/z = 335
(M+23)+, RT = 1.97 min.
[001060] Step 2 : Synthesis of methyl 2-(l-(tert-butoxycarbonyl)piperidin-4-yl)oxazole-4-
carboxylate.
[001062] A mixture of methyl 2-(l-(tert-butoxycarbonyl)piperidin-4-yl)-2,5-
dihydrooxazole (10 g, 32.25 mmol), NBS (5.74 g, 32.25 mmol), and K2C0 3 (5.34 g,
38.7mmol) in 100 mL of DCE was heated to 80 °C and stirred for 2 h . The mixture was then
cooled to 0 °C and quenched with sat. aq. Na2S20 3, extracted with DCM (100 mL X 3), and
washed with aq. NaHC0 3. The combined organics were dried over Na2S0 4, concentrated
and purified by SGC (PE/EA=3/2) to get the title compound. LC-MS: m/z = 333 (M+23)+,
RT = 1.48 min.
[001063] Step 3 : Synthesis of 2-(l-(tert-butoxycarbonyl)piperidin-4-yl)oxazole-4-
carboxylic acid.
[001064]
[001065] A solution of methyl 2-(l-(tert-butoxycarbonyl)piperidin-4-yl) oxazole-4-
carboxylate (6 g, 19.35 mmol) and LiOH.H 20 (2.438 g, 58.06 mmol) in THF/H 20 (40 mL,
v/v=l/l) was stirred for 16 h at 25°C. The mixture was adjusted to pH=3 with 1 N HC1 and
then extracted with EA (60 mL X3). The combined organics were dried over Na2S0 4. The
solvent was removed under reduced pressure. The residue was used for the next step directly.
LC-MS: m/z = 319 (M+23)+, RT = 1.34 min.
[001066] Step 4 : Synthesis of tert-butyl 4-(4-carbamoyloxazol-2-yl)piperidine-l-
carboxylate.
[001068] The mixture of 2-(l-(tert-butoxycarbonyl)piperidin-4-yl)oxazole-4-carboxylic
acid (4 g, 13.51 mmol), NH4C 1 (1.702 g, 27.02 mmol), HATU(6.16 g, 16.212 mmol), HOAt
(2.204 g, 16.212 mmol) and TEA(4.093 g, 40.53 mmol) in 50 mL of THF was stirred
overnight at r . . The reaction was quenched with water, extracted with EA (60 mLX3), and
washed with aq. NaCl. The combined organics were dried over Na2S0 4, concentrated, and
purified by SGC (PE/EA=l/4) to get the title compound. LC-MS: m/z = 318 (M+23)+, RT =
1.77 min.
[001069] Step 5 : Synthesis of tert-butyl 4-(4-cyanooxazol-2-yl) piperidine-l-carboxylate.
[001070]
[001071] To a solution of tert-butyl 4-(4-carbamoyloxazol-2-yl) piperidine-l-carboxylate
(2.5 g, 8.474 mmol) in TEA (10 mL) and THF (10 mL) was added TFAA (4 mL) dropwise at
0 °C. The reaction mixture was stirred at room temperature overnight. The solvent was
removed under reduced pressure, and the residue was purified by SGC (PE/EA=2/1) to get
the title compound. LC-MS: m z = 300 (M+23)+; RT = 2.01 min.
[001072] Step 6 : 2-(piperidin-4-yl) oxazole-4-carbonitrile hydrochloride.
[001074] To a solution of tert-butyl 4-(4-cyanooxazol-2-yl)piperidine-l-carboxylate (1.3 g,
4.693 mmol) in EA (5 mL) was added 3N HCl/EA (5 mL). The mixture was stirred for 1 h at
r.t. The resulting precipitate was collected and dried under vacuum after washing with diethyl
ether to afford the title compound. LC-MS: m/z = 178 (M+l)+, RT = 0.21 min.
Preparation of 5-(azetidin-2-yl)-2-fluoropyridine hydrochloride:
1) Zn (9 eq)
50°C, 2 h
3) 2 ( 1 .0 eq)
0°C, 6h
step 2
[001075] Step 1: Synthesis of (E)-N-((6-fluoropyridin-3-yl)methylene)-2-methylpropane-
2-sulfinamide.
[001077] A mixture of 6-fluoronicotinaldehyde (4.7 g, 37.6 mmol) and titanium
isopropoxide (1.37 g, 75.2 mmol) in dry THF (90 mL) was stirred at r.t. for 30 mins under
nitrogen. Then a solution of 2-methyl-2-propanesulfinamide (4.56 g, 37.6 mmol) in dry THF
(10 mL) was added. The reaction mixture was stirred at r.t. for 16 h, diluted with EtOAc (200
mL) and MeOH (50 mL), and then brine (100 mL) was added slowly. The mixture was
stirred at r.t. for 30 mins and filtered. The solid was washed with EtOAc (200 mL x 2). The
filtrate was extracted with EtOAc (200 mL x 3). The combined organics were washed with
brine (50 mL x 2), dried over Na2S0 4, and concentrated. The residue was purified by SGC
(PE/EtOAc = 5/1) to give the title compound. LC-MS: m z = 303 (M+H)+, RT = 1.61 min.
[001078] Step 2 : Synthesis of methyl 3-(l,l-dimethylethylsulfinamido)-3-(6-fluoropyridin-
3-yl) propanoate.
[001080] To a suspension of Zn dust (13.13 g, 200.7 mmol) in dry THF (130 mL) was
added 1, 2-Dibromoethane (7.53 g, 40.1 mmol). The mixture was stirred at reflux for 20 mins
and then was cooled to r.t. TMSC1 (2.91 g, 26.8 mmol) was added and stirred for 1 h at r.t.
Then methyl 2-bromoacetate (10.05 g, 66.9 mmol) was added and stirred for 2 h at 50 °C.
The mixture was cooled to r.t. The resulting solution was dropped into a solution of (E)-N-
((6-fluoropyridin-3-yl) methylene)-2-methylpropane-2-sulfinamide (5.09 g, 22.3 mmol) in
dry THF (20 mL) at 0 °C. The mixture was stirred at 0 °C for 6 h, diluted with DCM (100
mL), washed with 0.25 M aq. citric acid (200 mL x 2), sat. aq. NaHC0 3 (50 mL x 2), brine
(50 mL x 2), dried over Na2S0 4, and concentrated to give the title compound. LC-MS: m/z =
303 (M+H)+, RT = 1.61 min.
[001081] Step 3 : Synthesis of N-(l-(6-fluoropyridin-3-yl)-3-hydroxypropyl)-2-
methylpropane-2-sulfinamide.
[001083] To a solution of methyl 3-(l,l-dimethylethylsulfinamido)-3-(6-fluoropyridin-3-
yl)propanoate (3.32 g, 11.0 mmol) in dry THF (50 mL) was added 1 M LiAlH4 THF solution
(22 mL, 22 mol) at 0 °C. The mixture was stirred at 0 °C for 30 mins, diluted with EtOAc
(200 mL), quenched with Na2S0 4 10H2O (22 g) in portions. The mixture was stirred at r.t. for
30 mins and filtered. The solid was washed with MeOH (20 mL). The filtrate was dried over
Na2S0 4 and concentrated to give the crude title compound. LC-MS: m/z = 275 (M+H)+; RT
= 1.60 min.
[001084] Step 4 : Synthesis of 5-(l-(tert-butylsulfinyl) azetidin-2-yl)-2-fluoropyridine.
[001085]
[001086] To a solution of N-(l-(6-fluoropyridin-3-yl)-3-hydroxypropyl)-2-methylpropane-
2-sulfinamide (2.7 g, 9.85 mmol) in dry THF (50 mL) was added potassium hydroxide (1.65
g, 29.55 mmol) and 4-methylbenzene-l-sulfonyl chloride (2.25 g, 11.82 mmol). The mixture
was stirred at reflux for 5 h and cooled to r.t. The mixture was diluted with DCM (200 mL),
washed with brine (20 mL x 2), dried over Na2S0 4 and concentrated. The residue was
purified by SGC (PE/EtOAc = 2/1) to give the title compound. LC-MS: m/z = 257 (M+H)+;
RT = 1.61 min.
[001087] Step 5 : Synthesis of 5-(azetidin-2-yl)-2-fluoropyridine hydrochloride.
[001089] To a solution of 5-(l-(tert-butylsulfinyl)azetidin-2-yl)-2-fluoropyridine (1.14 g,
4.45 mmol) in DCM (20 mL) was added 4 M HCl/Dixoane solution (16.7 mL, 66.8 mmol) at
0 °C. The mixture was stirred at r.t. for 30 mins then concentrated to give the title compound.
LC-MS: m/z = 124 (M-28)+, RT = 0.308 min.
Preparation 6-cyclopropyl-3,6-diaza-bicyclo[3.1.1]heptane dihydrochloride:
step 1
V
[001090] Step 1: Synthesis of tert-butyl 6-cyclopropyl-3,6-diaza-bicyclo[3.1.1]heptane-3-
carboxylate.
[001092] To a solution of tert-butyl 3,6-diaza-bicyclo[3.1.1]heptane-3-carboxylate (1.5g,
7.58mmol) and (l-ethoxycyclopropoxy)trimethylsilane (3.1ml, 15.45mmol) in 10 ml of
MeOH and 10 ml of THF were added sodium cyanoborohydride (715mg, 11.35mmol) and
acetic acid (2.2ml, 38.50mmol). The mixture was stirred at 60 °C under N2 for 12 h . After
cooling to r.t., 1 ml of water was added and the mixture was stirred for 5 min. It was then
treated with 1 N NaOH (2.5ml) and stirred for 15 min. The mixture was concentrated and the
aqueous phase was extracted with DCM (100ml). The organic phase was washed with 1 N
NaOH (50ml). The combined aqueous phase was extracted with DCM (2x100ml). The
combined organics were washed with brine, dried over sodium sulphate and concentrated to
give crude product which was used for the next step without further purification. LC-MS: m/z
= 239 (M+H)+, RT = 2.26 min.
[001093] Step 2 : Synthesis of 6-cyclopropyl-3,6-diaza-bicyclo[3.1.1]heptane
dihydrochloride.
[001095] To a solution of tert-butyl 6-cyclopropyl-3,6-diaza-bicyclo[3.1.1]heptane-3-
carboxylate (1.8g crude, 7.56 mmol) in 40 mL of dichloromethane was added 25 mL of 4 N
HC1 solution in 1,4-dioxane. The mixture was stirred at r.t. for 7 h and then stirred at 4 °C
overnight. The upper clear solution was poured out and the sticky solid on the bottom of the
flask was dried under vaccum to give the product. LC-MS: m/z = 139 (M+H)+, RT = 0.44
min.
Preparative Example 10 - Formation of 4-(2,2,2-trifluoroethyl)piperidine
Preparative Example 11 - Formation of (lR,5S)-3-azabicvclo[3.1.01hexan-l-ol
Preparative Example 12 - Formation of tert-butyl 4-(lH-indol-4-vi)piperidine-l-
carboxylate
Preparative Example 13 - Formation of 1J,l,3.,3,3-hexafluoro-2-(piperidin-4-yl)propan-
2-ol
Preparative Example 14 - Formation of 4-((3,4-difluorophenyl)sulfonyl)piperidine
Preparative Example 15 - Formation of l-(2.2-difluorocvclopentvDpiperazine
Preparative Example 16 - 4-(trifluoromethyl)azepane
Preparative Example 17 - 2-(pyridin-4-yl)-4,5,6,7-tetrahvdrothiazolor5,4-clpyridine
Examples 947-953
[001096] Examples 947-953 in Table 23 were prepared by coupling an appropriate
carboxylic acid with an appropriate amine using the specified reaction conditions.
Table 23
Example 954 - Assays of SPR Inhibitory Activity
[001097] Compounds were assayed for SPR inhibitory activity using a TR-FRET
(homogeneous, time-resolved, fluorescence resonance energy transfer) assay according to the
procedure described in Haruki et al., Science, 430:987 (2013). Terbium labelled SNAP-
hSPR and SSZ (sulfasalazine) labelled SNAP-EGFP were used as the protein pair in this
assay. Compounds were screened at different concentrations, and IC50 and Kd values
calculated. SPR inhibitory activity of the compounds is provided in Table 24.
[001098] Compounds were assayed for SPR inhibitory activity using a SKN-N-BE(2)
cellular assay according to the following procedure. SK-N-BE (2) cells were seeded in
sterile, 96-well plates and incubated for 12-24 hours at 37°C with 5% C0 2 supply. Media
was removed and fresh DMEM/F-12 media (containing Glutamine & Pen/Strep but no FBS)
was added. Compounds (at different concentrations) were added to different wells. The
plates were then incubated for 6-48 hours at 37°C with 5% C0 2 supply. Plates were then
centrifuged and the supernatant was removed. The plates were then optionally washed once
with PBS. They were then sealed and stored at -80°C or immediately used in the next step.
The cells were lysed and the levels of BH4 were assessed by LC-MS. SPR inhibitory activity
of the compounds is provided in Table 24.
[001099] Compounds were assayed for inhibition of BH4 production using human
peripheral blood mononuclear cells (PBMCs) according to the following procedure. PBMCs
were either purchased or isolated from fresh human blood and used either as a fresh
preparation or frozen for later use. The assay system was prepared by pre-treating the assay
plates overnight with a solution containing anti-human CD3 antibody. Human PBMCs were
suspended in assay medium and plated into the assay plates at a density of l-4xl0 5 cells per
well. The desired concentration of the test compound was added to each well. A solution of
human anti-CD28 antibody was also added to each well. Plates are incubated for 12-48 hours
at 37° C and 5% C0 2. Assay plates were centrifuged for 5-15 minutes at 1-3000 RMP and
supernatants were removed. The cells were lysed, sealed and used directly or frozen at -80°
C. LC-MS was used to quantify the amount of inhibition of BH4 production and is provided
in Table 24.
Table 24
Q-001 5 100
Q-001 6 101
Q-001 7 118
Q-001 8 125
Q-001 9 129
Q-0020 129
Q-0021 133
Q-0022 139
Q-0023 141
Q-0024 153
Q-0025 268
Q-0026 295
Q-0027 326
Q-0028 364
Q-0029 406
Q-0030 484
Q-0031 495
Q-0055 7
Q-0214 1123 Q-0351 0.01 4.6
Q-0248 0.6 575 Q-0352 0.02 13
Q-0279 0.007 1.0 2.2 Q-0353 0.05 15
Q-0280 0.06 16 Q-0354 0.002 0.1 0.38
Q-0281 0.06 9.0 Q-0358 0.1 22
Q-0282 0.03 4.4 Q-0359 0.003 1. 1
Q-0283 1.5 Q-0361 0.01 0.6
Q-0284 2.9 Q-0362 0.02 2.9
Q-0285 40 Q-0363 0.03 5.8
Q-0286 0.01 Q-0364 0.07 16
Q-0287 0.02 Q-0365 0.05 12
Q-0290 2.0 Q-0366 0.4 128
Q-0291 2.7 Q-0367 0.07 11
Q-0292 40 Q-0368 0.01 2.9
Q-0298 0.02 1.5 Q-0369 0.2 28
Q-0299 0.005 1.2 Q-0370 0.1 22
Q-0300 0.009 5.0 Q-0371 0.07 14
Q-0301 0.2 Q-0372 0.005 0.3
Q-0302 0.009 1.2 Q-0373 0.02 1.5
Q-0303 0.007 0.9 Q-0374 0.009 1.2
Q-0304 0.04 67 Q-0375 0.02 2.5
Q-0305 0.03 4.6 Q-0376 0.03 8.2
Q-0306 25 Q-0377 0.04 6.3
Q-0307 0.009 4.2 Q-0378 0.03 4.1 0.74
Q-0308 0.02 2.0 Q-0379 0.002 0.084 0.28
Q-0310 0.06 12 Q-0380 0.007 2.7
Q-031 1 0.04 11 Q-0381 0.01 2.1
Q-0312 0.02 10 Q-0382 0.003 0.1
Q-031 3 0.006 1.5 Q-0383 0.3 69
Q-0314 0.02 5.8 Q-0384 14
Q-031 6 0.3 Q-0385 0.03 3.8
Q-031 7 0.06 20 Q-0387 0.01 3.7
Q-031 8 0.006 2.1 Q-0388 0.1 36
Q-031 9 0.01 2.2 Q-0389 0.02 5.6
Q-0320 1.3 Q-0390 0.02 12
Q-0321 0.9 Q-0393 0.006 0.8
Q-0322 0.2 Q-0394 1.5
Q-0323 0.3 35 Q-0395 0.02 0.5
Q-0327 0.007 12 Q-0396 0.002 0.061
Q-0328 0.01 53 Q-0397 0.02 2.3
Q-0329 0.01 3.5 Q-0398 0.01 0.072
Q-0330 0.02 6.1 Q-0399 0.003 0.024
Q-0331 0.08 15 Q-0400 0.004 0.2
Q-0332 0.01 2.5 Q-0401 0.03 0.4
Q-0333 0.02 12 Q-0402 0.01 0.041
Q-0334 0.08 49 Q-0403 0.009 1. 1
Q-0339 0.009 1.5 Q-0404 0.04 4.3
Q-0340 0.007 1. 1 Q-0405 0.01 1.5
Q-0341 0.005 1.8 Q-0406 0.05 2.0
Q-0342 0.01 2.4 Q-0407 1.7
Q-0343 0.1 40 Q-0408 0.01 0.075
Q-0344 0.07 23 Q-0409 0.2 25
Q-0345 0.01 78 Q-0410 0.002 0.2
Q-0346 0.008 5.3 Q-041 1 0.009 2.7
Q-0347 0.01 7.5 Q-0412 0.009 0.5
Q-0348 0.01 6.4 Q-041 3 2.2
Q-0349 0.03 57 Q-041 4 0.006 0.3
Q-0350 0.02 11 Q-041 5 0.03 1.2
Q-0416 0.02 2.8 Q-0475 0.005 0.3
Q-0417 0.004 0.9 Q-0476 0.003 0.056
Q-0418 0.002 0.05 0.032 Q-0477 0.005 0.091
Q-0419 0.005 0.7 Q-0478 0.006 1.4
Q-0420 0.007 Q-0479 0.006 0.1
Q-0421 0.003 0.7 Q-0480 0.009 0.3
Q-0422 0.003 0.2 Q-0481 0.03 95
Q-0423 0.005 0.1 0.41 Q-0482 0.008 1.0
Q-0424 0.004 1. 1 Q-0483 0.004 0.049
Q-0425 0.03 2.1 Q-0485 0.009 0.062
Q-0426 0.1 16 Q-0486 0.006 0.1
Q-0427 0.009 3.1 1. 1 Q-0487 0.003 0.6
Q-0428 0.003 0.019 Q-0488 0.02 1.2
Q-0429 0.1 49 Q-0489 0.008 0.053
Q-0431 0.003 0.5 Q-0490 0.007 0.1
Q-0432 0.04 6.5 Q-0491 0.02 0.037
Q-0433 0.2 58 Q-0492 0.008 0.2
Q-0434 0.005 0.2 Q-0493 0.03 0.029
Q-0435 0.02 1.2 Q-0494 0.006 0.3
Q-0436 4.6 Q-0495 0.005 0.051
Q-0437 5.0 Q-0496 0.007 0.4
Q-0438 0.10 35 Q-0497 0.009 0.4
Q-0439 0.001 0.096 Q-0498 0.02 0.03
Q-0440 0.009 1.4 Q-0499 0.02 0.044
Q-0441 0.1 3 1 Q-0500 0.03 0.097
Q-0442 0.004 0.2 Q-0501 0.009 0.2
Q-0443 0.009 3.9 Q-0502 0.02 0.4
Q-0444 0.01 2.7 Q-0503 4.0
Q-0445 0.01 0.9 Q-0504 0.004 0.058
Q-0446 0.007 0.096 Q-0505 0.004 0.1
Q-0447 0.4 Q-0506 0.003 0.2
Q-0448 1.5 Q-0507 0.01 0.2
Q-0449 0.003 0.078 Q-0508 0.03 2.0
Q-0450 0.005 0.3 Q-0509 0.003 0.068
Q-0451 0.002 0.019 0.013 Q-0510 0.005 0.1
Q-0452 0.8 Q-051 1 0.003 0.3
Q-0453 0.006 1.6 1.3 Q-0513 0.01 0.047
Q-0454 0.3 Q-051 4 0.007 0.057
Q-0455 16 Q-051 5 0.04 5.3
Q-0456 0.008 0.5 Q-0517 0.002 0.1
Q-0457 0.1 Q-051 8 0.003 0.5 0.032
Q-0458 0.006 0.4 Q-051 9 0.003 0.053 0.12
Q-0459 0.002 0.059 Q-0520 0.003 0.2
Q-0460 0.003 0.6 Q-0521 0.008 0.1
Q-0461 0.003 0.4 Q-0522 0.3 10
Q-0462 0.005 0.094 Q-0523 0.02 0.1
Q-0463 0.004 0.3 Q-0524 0.004 1. 1
Q-0464 0.003 0.3 Q-0525 0.001 0.019 0.024
Q-0465 0.3 150 Q-0526 0.003 0.028
Q-0466 0.001 0.059 Q-0527 0.03 0.045
Q-0467 0.002 0.082 0.1 Q-0528 0.07 0.8
Q-0468 0.007 0.2 Q-0529 0.01 0.1
Q-0469 0.004 0.037 Q-0530 0.03 1.8
Q-0470 0.005 1.0 Q-0531 0.004 0.062
Q-0471 0.08 16 Q-0532 0.02 0.044
Q-0472 0.2 17 Q-0533 0.002 0.069
Q-0473 0.006 0.092 Q-0534 0.003 0.1
Q-0474 0.007 0.6 Q-0535 0.004 0.4
Q-0536 0.007 0.059 Q-0598 0.004 0.01
Q-0537 0.04 0.2 Q-0599 0.002 0.012
Q-0540 0.3 Q-0600 0.001 0.057
Q-0541 0.2 Q-0601 0.005 0.1
Q-0542 0.1 Q-0602 0.02 1.2
Q-0543 0.003 0.4 Q-0603 0.006 0.1
Q-0544 0.03 Q-0604 0.007 0.072
Q-0545 0.002 0.041 Q-0605 0.2 10
Q-0546 0.009 0.084 Q-0606 0.002 0.051
Q-0547 2.3 10 Q-0607 0.005 0.087
Q-0548 0.02 2.1 Q-0608 0.002 0.056
Q-0549 0.004 0.4 Q-0609 0.001 0.084
Q-0550 0.002 0.1 Q-0610 0.01 10
Q-0551 0.006 0.5 Q-061 1 0.004 0.029
Q-0552 0.007 0.038 Q-0612 0.01 2.6
Q-0553 0.006 0.2 Q-061 4 0.01 1.6
Q-0555 0.02 0.7 Q-061 5 0.003 0.019
Q-0556 0.007 0.6 Q-061 6 0.002 0.1
Q-0557 0.008 0.6 Q-0617 0.02 3.0
Q-0558 5.0 10 Q-061 8 0.001 0.025
Q-0559 0.007 0.038 Q-061 9 0.003 0.3
Q-0560 0.003 0.012 Q-0620 0.001 0.1
Q-0561 0.004 0.01 1 Q-0621 0.02 5.2
Q-0562 0.004 0.2 Q-0622 0.001 0.058
Q-0563 0.005 0.3 Q-0623 0.001 0.078
Q-0564 0.2 4.0 Q-0624 0.002 0.032
Q-0565 0.006 0.01 1 Q-0626 0.001 0.014
Q-0566 5.0 10 Q-0627 0.009 10
Q-0567 0.003 0.02 Q-0630 0.009 10
Q-0568 0.006 0.2 Q-0632 0.004 7.3
Q-0569 0.01 0.3 Q-0633 0.005 0.4
Q-0570 0.003 0.023 Q-0634 0.003 0.7
Q-0571 0.003 0.073 0.067 Q-0635 0.002 0.1 0.054
Q-0572 0.002 0.036 0.024 Q-0681 0.001 0.2
Q-0573 0.003 0.035 Q-0690 0.002 0.2 0.072
Q-0574 0.006 0.047 Q-0691 0.002 0.091
Q-0575 0.003 0.2 Q-0693 0.003 0.8 0.45
Q-0576 0.006 0.1 Q-0696 0.004 0.4
Q-0577 0.04 2.1 Q-0697 0.004 0.2
Q-0578 0.008 0.7 Q-0698 0.001 0.071
Q-0579 0.005 0.1 Q-0700 0.002 0.1
Q-0580 0.003 0.022 Q-0701 0.002 0.082
Q-0582 0.02 1.0 Q-0702 0.002 0.032
Q-0583 0.1 3.7 Q-0703 0.004 0.6 0.19
Q-0584 0.2 10 Q-0704 0.002 0.2
Q-0585 0.006 0.033 Q-0705 0.002 0.043
Q-0586 0.002 0.2 0.13 Q-0706 0.002 0.03
Q-0587 0.01 0.021 Q-0707 0.005 0.3
Q-0588 0.07 4.7 Q-0708 0.001 0.097
Q-0589 0.06 1.7 Q-0709 0.001 0.028
Q-0590 0.003 0.015 Q-0710 0.002 0.2
Q-0591 0.003 0.1 0.045 Q-071 1 0.002 0.086
Q-0592 0.02 0.076 Q-0712 0.002 0.3
Q-0593 0.2 7.4 Q-071 3 0.001 0.2
Q-0594 0.3 3.6 Q-071 4 0.03 8.1
Q-0595 0.07 4.4 Q-071 5 0.002 0.097
Q-0596 0.004 0.016 Q-071 6 0.002 0.4
Q-0597 0.003 0.053 Q-071 8 0.004 0.2
Q-0719 0.002 0.2 Q-0790 0.007 1.4
Q-0720 0.001 0.3 Q-0791 0.002 0.6
Q-0721 0.001 0.035 0.026 Q-0792 0.006 2.1
Q-0722 0.02 3.3 Q-0793 0.003 1.0
Q-0723 0.003 0.2 Q-0794 0.01 3.5 0.41
Q-0724 0.002 0.2 Q-0795 0.002 0.5
Q-0725 0.001 0.1 Q-0796 0.001 0.2
Q-0726 0.001 0.074 Q-0797 0.001 0.1 0.027
Q-0727 0.001 0.081 Q-0798 0.002 0.3
Q-0730 0.001 0.2 Q-0799 0.001 0.3
Q-0731 0.002 0.053 Q-0800 0.002 0.6 0.047
Q-0732 0.001 0.1 Q-0802 0.001 0.067
Q-0734 0.004 0.3 Q-0803 0.001 0.2
Q-0735 0.003 0.095 Q-0804 0.001 0.3 0.094
Q-0736 0.002 0.2 Q-0805 0.004 2.3
Q-0737 0.005 0.2 0.037 Q-0806 0.003 1.2
Q-0738 0.001 0.1 Q-0807 0.002 0.4
Q-0739 0.002 0.3 Q-0808 0.001 0.2
Q-0741 0.004 0.4 Q-0809 0.006 0.9
Q-0743 0.004 0.4 Q-0812 0.003 1.0 0.15
Q-0744 0.003 0.1 Q-0813 0.001 0.1 0.065
Q-0745 0.004 0.2 Q-0814 0.002 0.4
Q-0746 0.004 0.6 Q-0815 0.001 0.1 0.072
Q-0747 0.008 0.8 Q-0816 0.001 0.6 0.17
Q-0748 0.004 0.9 Q-0817 0.001 0.2 0.044
Q-0749 0.003 0.05 Q-0818 0.002 0.9
Q-0750 0.003 0.5 0.18 Q-0819 0.001 0.2
Q-0751 0.003 0.2 Q-0820 0.001 0.04
Q-0752 0.004 0.5 Q-0821 0.001 0.1 0.051
Q-0753 0.002 0.2 Q-0822 0.002 0.4 0.13
Q-0754 0.009 0.1 Q-0823 0.001 0.066
Q-0755 0.004 0.5 Q-0824 0.005 1.8
Q-0756 0.004 0.8 Q-0825 0.002 0.4 0.15
Q-0757 0.002 0.2 Q-0826 0.001 0.1
Q-0758 0.002 0.09 Q-0827 0.002 0.065
Q-0759 0.001 0.2 Q-0828 0.004 0.05
Q-0760 0.001 0.4 0.075 Q-0829 0.001 0.08
Q-0761 0.002 0.2 0.14 Q-0830 0.001 0.041
Q-0762 0.002 0.2 Q-0831 0.002 0.4
Q-0764 0.002 0.3 0.10 Q-0832 0.001 0.2
Q-0765 0.005 0.3 Q-0833 0.006 0.2
Q-0768 0.002 0.2 0.045 Q-0835 0.002 0.1 0.039
Q-0770 0.002 0.2 Q-0836 0.005 0.3 0.052
Q-0771 0.001 0.2 Q-0837 0.001 0.2 0.063
Q-0772 0.001 0.2 0.072 Q-0839 0.008 1.5
Q-0773 0.006 1.7 Q-0840 0.003 0.2
Q-0774 0.2 10 Q-0842 0.002 0.7
Q-0775 0.002 1.0 Q-0843 0.001 0.2
Q-0777 0.001 0.3 0.055 Q-0844 0.001 0.2
Q-0779 0.02 10 Q-0845 0.003 0.4
Q-0780 0.001 0.2 Q-0846 0.002 0.2
Q-0781 0.001 0.2 Q-0847 0.02 8.8
Q-0782 0.001 0.1 0.038 Q-0848 0.002 10
Q-0783 0.002 0.3 Q-0849 0.001 0.3 0.044
Q-0784 0.001 0.3 0.12 Q-0850 0.001 0.3 0.074
Q-0785 0.001 0.2 Q-0851 0.002 0.5 0.13
Q-0788 0.01 3.6 Q-0852 0.002 0.8
Q-0789 0.008 2.5 0.44 Q-0853 0.03 10
Q-0854 0.003 0.2 Q-091 7 0.003 0.7 0.10
Q-0855 0.001 0.1 Q-091 8 0.002 0.6 0.12
Q-0856 0.004 1. 1 Q-091 9 1.7
Q-0857 0.003 0.8 Q-0920 0.5
Q-0858 0.044 Q-0921 0.002 0.4 0.047
Q-0859 0.02 8.3 Q-0922 1.0
Q-0860 1.0 Q-0923 1.3
Q-0861 0.4 Q-0924 0.002 0.2 0.051
Q-0862 10 Q-0925 0.5
Q-0863 0.6 Q-0926 0.001 0.2 0.045
Q-0865 0.1 Q-0927 0.001 0.2 0.081
Q-0866 6.7 Q-0928 0.2
Q-0867 0.002 0.4 0.07 Q-0929 2.0
Q-0868 10 Q-0930 0.001 0.3 0.058
Q-0869 0.1 Q-0931 0.2
Q-0870 0.3 Q-0932 0.7
Q-0871 4.0 Q-0933 0.2
Q-0872 10 Q-0934 0.3
Q-0873 10 Q-0935 1.6
Q-0874 1. 1 Q-0936 0.2
Q-0875 0.076 Q-0937 0.004 0.8 0.13
Q-0876 0.088 Q-0938 0.1
Q-0877 0.2 Q-0939 0.083
Q-0878 0.8 Q-0940 0.8
Q-0879 10 Q-0941 0.001 0.3 0.013
Q-0880 0.087 Q-0942 9.1
Q-0881 2.3 Q-0943 0.002 0.018 0.038
Q-0882 0.2 Q-0944 0.001 0.028 0.036
Q-0883 1.3 Q-0945 1.0
Q-0884 0.2 Q-0946 1. 1
Q-0885 0.4 Q-0947 1.0
Q-0886 5.4 Q-0948 0.001 0.1 0.053
Q-0887 0.001 0.2 0.057 Q-0949 0.2
Q-0888 0.005 0.4 0.24 Q-0950 6.2
Q-0890 Q-0951 0.002 0.4 0.045
Q-0891 0.004 0.9 0.24 Q-0952 0.001 0.3 0.083
Q-0892 0.002 0.4 0.076 Q-0953 0.001 0.058 0.021
Q-0893 0.3 Q-0954 9.0
Q-0894 0.1 Q-0955 10
Q-0895 1.4 Q-0956 0.001 0.086 0.014
Q-0896 0.001 0.3 0.049 Q-0957 1.0
Q-0897 0.5 Q-0958 10
Q-0899 0.001 0.3 0.048 Q-0959 1.0
Q-0900 2.3 Q-0960 0.2
Q-0901 10 Q-0961 0.7
Q-0902 0.1 Q-0962 0.3
Q-0905 0.6 Q-0963 4.0
Q-0906 0.003 0.8 0.19 Q-0964 8.9
Q-0907 0.4 Q-0965 0.1
Q-0908 0.001 0.3 0.13 Q-0966 1.3
Q-0909 0.1 Q-0967 1.9
Q-0910 0.002 0.5 0.074 Q-0968 0.4
Q-091 1 0.002 0.4 0.1 1 Q-0969 0.001 0.2 0.16
Q-0912 0.9 Q-0970 0.4
Q-091 3 0.002 0.5 0.087 Q-0971 7.2
Q-091 4 0.6 Q-0972 0.001 0.065 0.014
Q-091 5 0.002 0.5 0.092 Q-0973 0.001 0.7 0.08
Q-091 6 0.7 Q-0974 0.1
Q-0975 1.3 Q-1033 0.008 0.4 0.26
Q-0976 1. 1 Q-1034 0.002 0.2 0.16
Q-0977 0.001 0.5 0.086 Q-1035 0.1
Q-0978 0.001 0.081 0.059 Q-1036 0.07
Q-0979 1.4 Q-1037 0.071
Q-0980 1.3 Q-1038 0.002 0.3 0.34
Q-0981 1.4 Q-1039 0.3
Q-0982 10 Q-1040 0.3
Q-0983 10 Q-1041 0.001 0.046 0.028
Q-0984 0.4 Q-1042 1.0
Q-0985 9.2 Q-1043 1.4
Q-0986 0.002 0.7 0.1 1 Q-1044 1.0
Q-0987 1. 1 Q-1045 0.1
Q-0988 0.069 Q-1046 0.001 0.1 0.083
Q-0989 0.9 Q-1047 0.001 0.2 0.066
Q-0990 0.2 Q-1048 0.001 0.2 0.05
Q-0991 0.1 Q-1049 0.002 0.072 0.025
Q-0992 0.003 0.8 0.098 Q-1050 1.4
Q-0993 0.003 1. 1 0.16 Q-1051 0.001 0.053 0.027
Q-0994 3.0 Q-1052 0.001 0.044 0.083
Q-0995 0.002 0.6 0.18 Q-1053 0.001 0.2 0.23
Q-0996 1.9 Q-1054 0.001 0.028 0.06
Q-0997 1.0 Q-1055 0.001 0.7 0.16
Q-0998 0.001 0.3 0.092 Q-1056 0.003 0.016 0.055
Q-0999 0.2 Q-1057 0.001 0.1 0.067
Q-1000 0.9 Q-1058 0.002 0.093 0.15
Q-1001 1.8 Q-1059 0.002 1.3 2.1
Q-1002 3.4 Q-1060 0.002 0.2 0.22
Q-1003 0.001 0.1 0.051 Q-1061 0.003 0.4 0.21
Q-1004 3.1 Q-1062 0.001 0.1 0.097
Q-1005 0.001 0.3 0.1 Q-1063 0.002 0.055 0.12
Q-1006 1.4 Q-1064 0.002 0.2 0.22
Q-1007 0.001 0.5 0.12 Q-1065 0.001 0.058 0.074
Q-1008 0.3 Q-1066 0.001 0.3 0.082
Q-1009 2.0 Q-1067 0.002 0.1 0.16
Q-1010 4.0 Q-1070 0.002 0.20
Q-101 1 0.8 Q-1071 0.006 0.032
Q-1012 1.3 Q-1072 0.002 0.055
Q-1013 1.5 Q-1073 0.003 0.055
Q-1014 1.4 Q-1074 0.001 0.022
Q-1015 0.4 Q-1075 0.002 0.017
Q-1016 2.4 Q-1076 0.001 0.035
Q-1017 0.3 Q-1077 0.005 0.16
Q-1018 0.7 Q-1078 0.005 0.036
Q-1019 0.4 Q-1079 0.003 0.074
Q-1020 0.002 0.3 0.20 Q-1080 0.002 0.025
Q-1021 1.0 Q-1081 0.002 0.13
Q-1022 0.002 0.1 0.041 Q-1082 0.004 0.12
Q-1023 0.7 Q-1083 0.001 0.068
Q-1024 0.001 0.3 0.056 Q-1084 0.002 0.013
Q-1025 1.2 Q-1085 0.001 0.063
Q-1026 1.7 Q-1086 0.001 0.084
Q-1027 3.1 Q-1087 0.002 0.029
Q-1028 1. 1 Q-1088 0.004 0.29
Q-1029 1.0 Q-1089 0.003 0.35
Q-1030 3.1 Q-1090 0.001
Q-1031 2.3 Q-1091 0.002 0.13
Q-1032 10 Q-1092 0.001 0.33
Q-1093 0.001 0.095 Q-1 151 0.008 0.31
Q-1094 0.001 0.099 Q-1 152 0.008 0.38
Q-1095 0.001 0.027 Q-1 153 0.008 0.63
Q-1096 0.001 0.018 Q-1 154 0.005 0.35
Q-1097 0.001 0.024 Q-1 155 0.01 0.27
Q-1098 0.001 0.21 Q-1 156 0.006 0.1 1
Q-1099 0.001 0.06 Q-1 157 0.004 0.49
Q-1 100 0.001 0.031 Q-1 158 0.002 0.13
Q-1 101 0.001 0.041 Q-1 159 0.02 0.60
Q-1 102 0.001 0.058 Q-1 160 0.003 0.1 1
Q-1 103 0.001 0.10 Q-1 161 0.003 0.31
Q-1 104 0.003 0.1 1 Q-1 162 0.001 0.095
Q-1 105 0.001 0.018 Q-1 163 0.002 0.068
Q-1 106 0.001 0.093 Q-1 164 0.001 0.037
Q-1 107 0.001 0.058 Q-1 165 0.006 0.19
Q-1 108 0.001 0.05 Q-1 166 0.005 0.02
Q-1 109 0.001 0.046 Q-1 167 0.01 0.081
Q-1 110 0.002 0.043 Q-1 168 0.003 0.058
Q-1 111 0.001 0.015 Q-1 169 0.001 0.077
Q-1 112 0.001 0.037 Q-1 170 0.001 0.16
Q-1 113 0.001 0.016 Q-1 171 0.01 0.14
Q-1 114 0.001 0.024 Q-1 172 0.003 0.18
Q-1 115 0.001 0.045 Q-1 173 0.02 0.29
Q-1 116 0.001 0.076 Q-1 174 0.001 0.022
Q-1 117 0.001 0.02 Q-1 175 0.02 0.45
Q-1 118 0.001 0.1 1 Q-1 176 0.009 0.28
Q-1 119 0.002 0.37 Q-1 177 0.009 1.3
Q-1 120 0.001 0.097 Q-1 178 0.009 2.6
Q-1 121 0.001 0.07 Q-1 179 0.002 0.1 1
Q-1 122 0.001 0.025 Q-1 180 0.002 0.047
Q-1 123 0.001 0.057 Q-1 181 0.002 0.01 1
Q-1 124 0.001 0.035 Q-1 182 0.001 0.048
Q-1 125 0.006 0.1 Q-1 183 0.004 0.1 1
Q-1 126 0.001 0.048 Q-1 184 0.002 0.037
Q-1 127 0.001 0.015 Q-1 185 0.001 0.1 1
Q-1 128 0.002 0.048 Q-1 186 0.001 0.036
Q-1 129 0.002 0.05 Q-1 187 0.004 0.19
Q-1 130 0.001 0.057 Q-1 188 0.006 0.29
Q-1 131 0.001 0.027 Q-1 189
Q-1 132 0.001 0.04 Q-1 190 0.01 0.059
Q-1 133 0.002 0.022 Q-1 191 0.001 0.02
Q-1 134 0.003 0.025 Q-1 192 0.001 0.04
Q-1 135 0.01 0.045 Q-1 193 0.007 0.16
Q-1 136 0.002 0.014 Q-1 194 0.002 0.06
Q-1 137 0.003 0.16 Q-1 195 0.002 0.047
Q-1 138 0.02 0.36 Q-1 196 0.003 0.052
Q-1 139 0.02 0.42 Q-1 197 0.003 0.026
Q-1 140 0.008 0.23 Q-1 198 0.001 0.017
Q-1 141 0.001 0.019 Q-1 199 0.001 0.029
Q-1 142 0.001 0.075 Q-1200 0.001 0.15
Q-1 143 0.003 0.31 Q-1201 0.001 0.069
Q-1 144 0.001 0.07 Q-1202 0.005 0.26
Q-1 145 0.003 0.19 Q-1203 0.006 0.18
Q-1 146 0.005 0.38 Q-1204 0.001 0.017
Q-1 147 0.007 0.52 Q-1205 0.003 0.035
Q-1 148 0.01 0.54 Q-1206 0.001 0.07
Q-1 149 0.005 0.21 Q-1207 0.001 0.029
Q-1 150 0.001 Q-1208 0.001 0.061
Q-1209 0.001 0.92 Q-1306 0.5
Q-1210 0.002 0.084 Q-131 1 5.0
Q-121 1 0.01 0.16 Q-1313 5.0
Q-1212 0.001 0.013 Q-1320 0.02
Q-1213 0.003 0.89 Q-1322 0.4
Q-1214 0.006 1.0 Q-1341 5.0
Q-1215 0.001 0.017 Q-1343 0.07
Q-1216 0.001 0.046 Q-1344 0.009 0.32
Q-1217 0.003 0.27 Q-1345 1.4
Q-1218 0.003 0.13 Q-1346 0.05
Q-1219 0.001 0.079 Q-1362 0.001 0.043
Q-1220 0.001 0.022 Q-1365 1.0
Q-1221 0.001 0.037 Q-1483 0.03
Q-1222 0.001 0.025 Q-1535 0.001 0.1 1
Q-1223 0.003 0.024 Q-1539 0.004 0.78
Q-1224 0.009 0.37 Q-1558 0.002 0.092
Q-1225 0.001 0.029 Q-1560 0.8
Q-1226 0.007 0.41 Q-1563 5.0
Q-1227 0.001 0.014 Q-1564 5.0
Q-1228 0.001 0.017 Q-1565 5.0
Q-1229 0.002 0.1 Q-1581 0.004 0.17
Q-1230 0.01 0.18 Q-1591 0.003 0.1 1
Q-1231 0.003 0.062 Q-1597 5.0
Q-1232 0.001 0.056 Q-1641 5.0
Q-1233 0.001 0.023 Q-1728 0.001 0.086
Q-1234 0.002 0.027 Q-1794 0.002 0.25
Q-1235 0.005 0.018 Q-1796 0.001 0.26
Q-1236 0.006 0.048 Q-1797 0.001 0.079
Q-1237 0.003 0.70 Q-1798 0.002
Q-1238 0.002 0.079 Q-1799 0.001 0.10
Q-1239 0.002 0.027 Q-1800 0.002
Q-1240 0.001 0.035 Q-1801 0.002
Q-1241 0.002 0.02 Q-1804 0.002
Q-1242 0.005 0.032 Q-1805 0.001 0.13
Q-1243 0.02 0.051 Q-1807 0.001 0.1 1
Q-1244 0.001 0.036 Q-1814 0.002
Q-1245 0.001 0.026 Q-1815 0.002
Q-1246 0.004 0.10 Q-1818 0.001 0.095
Q-1247 0.002 0.15 Q-1819 0.001 0.091
Q-1249 0.002 0.046 Q-1820 0.001 0.094
Q-1250 0.001 0.024 Q-1821 0.001 0.13
Q-1251 0.05 Q-1822 0.001 0.12
Q-1254 0.1 0.87 Q-1823 0.001 0.1 1
Q-1255 0.1 0.58 Q-1824 0.003
Q-1256 0.03 0.33 Q-1825 0.002
Q-1259 0.1 0.36 Q-1826 0.002
Q-1260 0.03 0.081 Q-1827 0.001
Q-1263 0.1 0.37 Q-1829 0.002
Q-1266 0.2 Q-1830 0.002
Q-1269 0.005 0.053 Q-1831 0.003
Q-1288 0.008 0.60 Q-1832 0.003
Q-1289 0.002 0.07 Q-1833 0.001
Q-1291 0.2 2.4 Q-1834 0.001
Q-1292 5.0 Q-1835 0.004
Q-1295 2.4 Q-1836 0.001 0.27
Q-1296 0.6 Q-1837 0.001
Q-1301 0.01 0.82 Q-1838 0.001 0.17
Q-1305 0.1 1.2 Q-1839 0.002
Q-1 840 0.003 Q-1 886 0.002 0 .11
Q-1 841 0.001 0.087 Q-1 889 0.001 0.036
Q-1 842 0.001 0 .15 Q-1 925 0.001 0 .17
Q-1 845 0.002 Q-1 932 0.003 2.7
Q-1 846 0.001 0 .17 Q-1 984 0.001
Q-1 847 0.001 0.064 Q-1 985 0.002
Q-1 848 0.001 0.21 Q-2007 0.001
Q-1 857 0.001 0 .15 Q-2008 0.002 0.30
Q-1 858 0.001 0.26 Q-2009 0.002 0.37
Q-1 859 0.001 0 .16 Q-201 6 0.001 0.045
Q-1 861 0.001 0.098 Q-201 7 0.002 0 .17
Q-1 862 0.002 0.25 Q-2031 0.003
Q-1 864 0.004 Q-2032 0.006
Q-1 866 0.002 0.08 Q-2041 0.003
Q-1 875 0.001 0 .11 Q-2043 0.005
Q-1 876 0.001 0 .11 Q-2048 0.004
Q-1 882 0.002 0.092 Q-2054 0.004
Q-1 884 0.001 0.084 Q-2055 0.007
Q-1 885 0.01
Example 955 - Behavioral Pharmacology Models
[001100] Compounds were tested in standard behavioral pharmacology models for pain in
rats as described in the literature (see, e.g., Latremoliere et al., Neuron, 86:1393-1406 (2015);
Tegeder et al., Nature Medicine, 12:1269-1277 (2006)). Compounds were administered by
oral gavage to rats that had undergone one of two nerve injury surgeries: spared nerve injury
to injure two of the three peripheral branches of the sciatic nerve (SNI, Decosterd et al., Pain,
87:149-158 (2000)) or chronic constriction injury of the sciatic nerve (CCI, Bennett et al.,
Pain, 33:87-107 (1988)). Paw withdrawal thresholds to mechanical stimulation using
calibrated von Frey filaments were used as measurement of neuropathic pain-like behaviors.
Effect on pain behavior in these models is provided in Table 25.
Table 25
mpk=mg per kg
QD 3 days = daily for 3 days
[001101] The present invention is described in connection with preferred embodiments.
However, it should be appreciated that the invention is not limited to the disclosed
embodiments. It is understood that, given the description of the embodiments of the
invention herein, various modifications can be made by a person skilled in the art. Such
modifications are encompassed by the claims below.
WHAT IS CLAIMED IS:
1. A compound of formula I or , or a pharmaceutically acceptable salt thereof:
wherein:
=^= is an optional double bond;
Z is CR1 or NR1, or if the double bond is present, then Z is CR1 or N;
2 2 2Y is NR or CR , or if the double bond is present, then Y is N or CR ;
X is N or CR a;
1 2R and R , taken together with the atoms to which they are attached form a 4-, 5-, 6-,
or 7-membered ring; or
1 2R and R are independently selected from the group consisting of H, Ci-salkyl,
C 3_5cycloalkyl, Ci-shaloalkyl, and halo;
R5 and R a are independently selected from the group consisting of H and Ci_5alkyl;
L is heteroaryl-Co-5alkylene-, aryl-Co-salkylene-, -S-Ci-salkylene-aryl, -S-Ci_
5alkylene-heteroaryl, -Ci-salkylene-S-aryl, or -Ci-salkylene-S-heteroaryl;
R and R4, taken together with nitrogen atom to which they are attached form a 3-, 4-,
5-, 6-, or 7-membered monocyclic ring or 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered
spiro, fused, and/or bridged polycyclic (e.g., bicyclic) ring; or
R is selected from the group consisting of H, Ci-salkyl, C 3_iocycloalkyl, Ci_
shaloalkyl, aryl, heteroaryl, and Ci_5alkylene-G,
R4 is selected from the group consisting of Ci-salkyl, C 3_iocycloalkyl, Ci-shaloalkyl,
aryl, heteroaryl, and Ci-salkylene-G; and
each G is independently selected from the group consisting of CN, aryl, heteroaryl,
cycloalkyl, and heterocycloalkyl
with the proviso that the compound of formula I is not a compound having a structure
as recited in Table D.
2 . The compound of claim 1, wherein
3 . The compound of claim 1, having a formula IA or IA' :
wherein:
Y is 2 2 2N R or C R , or if the double bond is present, then Y is C R ; and
1 2
R and R , taken together with the atoms to which they are attached form a
4-, 5-, 6-, or 7-membered ring.
4 . The compound of claim 3, having a structure selected from the group
consisting of:
5 . The compound of any one of claims 1, 3 or 4, wherein 1 2R and R , taken
together with the atoms to which they are attached form a heteroaryl ring, an aryl ring, a
heterocycloalkyl ring, or a cycloalkyl ring.
6 . The compound of any one of claims 1 or 3 to 5, wherein 1 2R and R , taken
together with the atoms to which they are attached form a pyrrole ring, a cyclopentene ring, a
thiophene ring, a dihydrofuran ring, a cyclohexene ring, a pyrazole ring, a thiazole ring, a
benzene ring, an imidazole ring, or a cyclobutene ring.
7 . The com ound of claim 4, having a structure:
8. The compound of claim 1, having a formula IB or IB' :
wherein R and R are independently selected from the group consisting of H,
alkyl, C 3_scycloalkyl, Ci_shaloalkyl, and halo.
9 . The compound of claim 1, wherein
is selected from the group consisting of:
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The com ound of claim 9, wherein
11. The compound of any one of claims 1 to 10, wherein L is
12. The compound of any one of claims 1 to 10, wherein L is heteroaryl or aryl.
13. The compound of claim 12, wherein L is a 5- or 6-membered heteroaryl ring.
14. The compound of any one of claims 1 to 10, wherein L is selected from the
group consisting of pyrazolyl, triazolyl, thiazolyl, pyridinyl, imidazolyl, phenyl, thiophenyl,
pyrrolyl, and indolyl.
15. The compound of any one of claims 1 to 10, wherein L is
n is 0 or 1;
Q is CH, CR6, or N;
each R6 is selected from the group consisting of Ci_salkyl, C3_5cycloalkyl,
heterocycloalkyl, Ci-shaloalkyl, halo, benzyl, Ci-shaloalkylene-OH, Ci_5alkylene-CN, Ci_
salkoxy, Ci_5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR 11 , -NR C0 2R lla , -S0 2R ,
S0 2NHR , -SOR 11 , -C0 2R , -CONHR 11 , aryl, and heteroaryl; and
R 11 and R lla are each independently selected from the group consisting of H, Ci_
salkyl, Ci-shaloalkyl, -Co-5alkylene-C3_6cycloalkyl, -Co-salkylene-heterocycloalkyl, -Co-
5alkylene-aryl, and -Co-salkylene-heteroaryl.
The com ound of claim 15 wherein
17. The compound of any one of claims 1 to 10, wherein L is
n is 0, 1, or 2;
R is selected from the group consisting of Ci-salkyl, C3_5cycloalkyl, heterocycloalkyl,
Ci_5haloalkyl, halo, benzyl, Ci-shaloalkylene-OH, Ci_5alkylene-CN, Ci_salkoxy, Ci_
shaloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR 1 1, -NR C0 2R lla , -S0 2R , -S0 2NHR ,
-SOR 1 1, -C0 2R , -CONHR 1 1, aryl, and heteroaryl; and
R 11 and R lla are each independently selected from the group consisting of H, Ci_
salkyl, Ci-shaloalkyl, -Co-5alkylene-C3_6cycloalkyl, -Co-salkylene-heterocycloalkyl, -Co-
5alkylene-aryl, and -Co-salkylene-heteroaryl.
The compound of claim 17, wherein L
19. The compound of any one of claims 1 to 10, wherein L is selected from the
consisting of
20. The compound of any one of claims 1 to 10, wherein L is aryl-Ci-salkylene- or
heteroaryl-Ci- 5alkylene-.
21. The compound of any one of claims 1 to 10, wherein L is -S-Ci_5alkylene-aryl,
-S-Ci_5alkylene-heteroaryl, -Ci_5alkylene-S-aryl, or -Ci_5alkylene-S-heteroaryl.
22. The compound of any one of claims 1 to 21, wherein R and R4, taken together
with the nitrogen atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered ring.
23. The compound of claim 22, wherein the 3-, 4-, 5-, 6-, or 7-membered ring is
piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl,
oxaziridinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl,
isothiazolidinyl, azepanyl, diazepanyl, or diazabicycloheptane.
24. The compound of any one of claims 1 to 21, wherein
I _ r~ R 0
O
1 m
m is 0, 1, 2, or 3;
R7' and 9 are each independently selected from the group consisting of halo, Ci_
salkyl, C 3_5cycloalkyl, heterocycloalkyl, Ci-shaloalkyl, Ci-shaloalkylene-OH, Ci-salkylene-
CN, Ci-5alkoxy, Ci_5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR 8, -NR C0 2R a, -
S0 2R8, -C0 2R8, -CONHR 8, aryl, and heteroaryl, or
two R groups, together with the carbon atom(s) to which they are attached, form a 3-,
4-, 5-, 6-, 7-, or 8-membered cycloalkyl, a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocycloalkyl,
aryl, or a 5- or 6-membered heteroaryl ring; and
R8° and R8a are each independently selected from the group consisting of H, Ci_5alkyl,
Ci_5haloalkyl, -Co-salkylene-C3_6cycloalkyl, -Co-salkylene-heterocycloalkyl, -Co-salkylene-
aryl, and -Co-salkylene-heteroaryl; or
one R7 group and R9, together with the atoms to which they are attached, form a 5- or
6-membered heterocyclic or heteroaryl ring.
The compound of any one of claims 1 to 24, wherein
R7' and 9 are each independently selected from the group consisting of halo, Ci_
salkyl, C3_5cycloalkyl, heterocycloalkyl, Ci-shaloalkyl, Ci-shaloalkylene-OH, Ci-salkylene-
CN, Ci-salkoxy, Ci-shaloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR8, -NR C0 2R a, -
S0 2R8, -C0 2R8, -CONHR 8, aryl, and heteroaryl; and
R8° and R8a are each independently selected from the group consisting of H, Ci_5alkyl,
Ci-shaloalkyl, -Co-5alkylene-C 3_6cycloalkyl, -Co-salkylene-heterocycloalkyl, -Co-salkylene-
aryl, and -Co-salkylene-heteroaryl.
26. The compound of any one of claims 1 to 25, wherein R7 or R9 is selected from
the group consisting of C 3_scycloalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, aryl, and
heteroaryl.
27. The compound of any one of claims 1 to 26, wherein R is oxazolyl or
pyridinyl, each of which is optionally substituted with CN or F.
28. The in R is selected from the
group consisting of
29. The compound of any one of claims 1 to 28, wherein R9 is C3_scycloalkyl.
30. The compound of any one of claims 1 to 29, wherein R9 is cyclopropyl or
cyclobutyl, each of which is optionally substituted with 1, 2, 3, or 4 F atoms.
31. The compound of any one of claims 1 to 30, wherein R9 is selected from the
group consisting of - i, and
32. The compound of claim 24, wherein
33. The compound of claim 24 or 32, wherein at least one R7 or R9 is F, CF3, CH3,
CH2CH3, -CH2CF3, cyclopropyl, 1-cyano-cyclopropyl, CN, -C(CH3)2CN, -CH(CN)CH2CH3,
3,3-difluoropyrrolidine, -OH, -OCH3, -OCH2CH3, -OCH2CF3, -C(OH)(CF3)2, -
C(OH)CH3CF3, -C0 2C(CH3)3, -CONHC(CH 3)3, -N(CH3)C0 2C(CH3)3, phenoxy,
phenylsulfonyl, 3,4-difluorobenzenesulfonyl, phenyl, fluorophenyl, difluorophenyl,
cyanophenyl, indolyl, difluoropyrrolidinyl, or benzothiazolyl, or two R groups, together with
the carbon atoms to which they are attached, form a fused benzene ring.
34. The compound of claim 33, wherein at least one R is 3-indolyl, 6-fluoro-3-
indolyl, N-methyl-3 -indolyl, 4-indolyl, 2-benzothiazolyl, or 5-fluoro-2-benzothiazolyl.
35. The compound of claim 24, wherein
¾ NR R i s (R ; and
the two R groups are present on adjacent carbon atoms.
36. The compound of claim 24, wherein
the two R groups are present on the same carbon atom.
37. The compound of claim 24, wherein R9 is -Co-salkylene-aryl.
38. The compound of claim 37, wherein R9 is 2,4-difluorophenyl, 5-fluorophenyl,
phenyl, or 2-chlorophenyl.
39. The compound of any one of claims 1 to 21, wherein R3 and R4, taken together
with the nitrogen atom to which they are attached form a 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or
14-membered spiro, fused, or bridged polycyclic (e.g., bicyclic) ring.
40. The compound of claim 39, wherein the 6- to 14-membered spiro, fused, or
bridged bicyclic ring is 10-azabicyclodecane, 9-azabicyclononane, 8-azabicyclooctane,
azabicycloheptane, 3-azabicyclohexane, diazabicyclononane, diazabicyclooctane,
diazabicycloheptane, diazaspirononane, azaspirononane, diazaspirooctane, azaspirooctane,
spiro [isobenzofuran-piperidine, diazaspiroheptane, azaspiroheptane,
octahydrocyclopenta[£]pyrrole, or octahydrocyclopenta[c]pyrrole.
41. The compound of claim 39 or 40, wherein the 6- to 14-membered spiro, fused,
or bridged polycyclic (e.g., bicyclic) ring is substituted with one or two substituents
independently selected from the group consisting of halo, Ci-salkyl, Ci-shaloalkyl, Ci-salkoxy,
aryloxy, heteroaryloxy, CN, OH, -S0 2R10 , -C0 2R 10 , -CONHR 10 , C3_5cycloalkyl, oxo, aryl,
and heteroaryl; and
R 10 is selected from the group consisting of H, Ci-salkyl, -Co-salkylene-aryl, and -Co-
5alkylene-heteroaryl.
42. The compound of claim 41, wherein at least one substituent is cyclopropyl, F,
-C0 2C(CH3)3, -CH2CF3, CF3, fluorophenyl, cyanophenyl, OH, or phenyl.
43. The compound of any one of claims 1 to 21, wherein
R3 is selected from the group consisting H, CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2,
-CH2CF3, -CH2CH2CN, -CH2CH(OH)CF3, and benzyl; and
R4 is selected from the roup consisting of CH3, -CH2CH3, -CH2CH2CH3,
The compound of claim 43, wherein ¾·
45. A compound of formula II or ΙΓ , or a pharmaceutically acceptable salt thereof:
wherein L is heteroaryl or aryl; and
R is selected from the group consisting of H, Ci-salkyl, C3_iocycloalkyl,
Ci_5haloalkyl, aryl, heteroaryl, and Ci-salkylene-G;
R4 is selected from the group consisting of Ci_salkyl, C3_iocycloalkyl, Ci-shaloalkyl,
aryl, heteroaryl, and Ci_5alkylene-G; or
R and R4, taken together with the nitrogen atom to which they are attached form a 3-,
4-, 5-, 6-, or 7-membered monocyclic ring or a 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-
membered spiro, fused, or bridged bicyclic ring, and
each G is independently selected from the group consisting of CN, aryl, heteroaryl,
cycloalkyl, and heterocycloalkyl.
46. A compound of formula III or ΙΙΓ , or a pharmaceutically acceptable salt
thereof:
wherein:
is an optional double bond;
Z is CR1 or NR1, or if the double bond is present, then Z is CR1 or N;
Y is CR2 or NR2, or if the double bond is present, then Y is CR2 or N;
X is CH or N;
R1 and R2 are independently selected from the group consisting of H, Ci-salkyl,
C 3_5cycloalkyl, Ci-shaloalkyl, and halo; or
R1 and R2, taken together with the atoms to which they are attached form a 5- to 6-
membered ring;
R5 is selected from the group consisting of H and Ci-salkyl;
L is heteroaryl-Co-5alkylene-, aryl-Co-salkylene-, -S-Ci-salkylene-aryl, -S-Ci_
5alkylene-heteroaryl, -Ci_5alkylene-S-aryl, or -Ci_salkylene-S-heteroaryl;
A is selected from the group consisting of
with the proviso that the compound is not
A compound of formula IV or IV, or a pharmaceutically acceptable salt
thereof:
wherein:
is an optional double bond;
Y is NR , or if the double bond is present, then Y is CR ;
R and R2, taken together with the atoms to which they are attached form a 5-
membered ring;
n is 0 or 1;
each R6 is selected from the group consisting of Ci-salkyl, C 3-scycloalkyl,
Ci_5haloalkyl, halo, and benzyl;
Q is CH, CR6, or N;
R and R4, taken together with nitrogen atom to which they are attached form a 3-, 4-
5-, 6-, or 7-membered monocyclic ring or 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered
spiro, fused, or bridged bicyclic ring.
The compound of claim 47, wherein
O
\ i n
m is 0, 1, 2, or 3;
R7' and 9 are each independently selected from the group consisting of halo, Ci_
5alkyl, C3_5cycloalkyl, heterocycloalkyl, Ci-shaloalkyl, Ci-shaloalkylene-OH, Ci-salkylene-
CN, Ci-5alkoxy, Ci_5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR8, -NR C0 2R a, -
S0 2R8, -C0 2R8, -CONHR8, aryl, and heteroaryl, or
two R groups, together with the carbon atom(s) to which they are attached, form a 3-,
4-, 5-, 6-, 7-, or 8-membered cycloalkyl, a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocycloalkyl,
aryl, or a 5- or 6-membered heteroaryl ring; and
R8° and R8a are each independently selected from the group consisting of H, Ci_5alkyl,
Ci-shaloalkyl, -Co-5alkylene-C 3_6cycloalkyl, -Co-salkylene-heterocycloalkyl, -Co-salkylene-
aryl, and -Co-salkylene-heteroaryl; or
one R7 group and R9, together with the atoms to which they are attached, form a 5- or
6-membered heterocycloalkyl or heteroaryl ring.
49. The compound of claim 47 or 48, wherein
and is optionally substituted with one to four substituents selected from the group consisting
ofF, CI, and Ci_3alkyl.
50. The compound of any one of claims 47-49, wherein
51. The compound of any one of claims 47-50, wherein two R groups are present
on adjacent carbon atoms.
52. The compound of claim 51, wherein the two R groups, together with the
carbons to which they are attached, form a 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl or
cycloalkyl group.
53. The compound of any one of claims 47-51, wherein two R groups are present
on the same carbon atom.
54. The compound of claim 53, wherein the two R groups, together with the
carbon to which they are attached, form a 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl or
cycloalkyl group.
55. The compound of claim 52 or 54, wherein the 3-, 4-, 5-, 6-, or 7-membered
heterocycloalkyl or cycloalkyl group is substituted with one or two substituents selected from
the group consisting of fluoro, hydroxy, cyano, methyl, ethyl, trifluoromethyl, trifluoroethyl,
cyanopropyl, methoxy, trifluoromethoxy, trifluoroethoxy, hexafluorohydroxypropyl,
cyclopropyl, 1-cyano-cyclopropyl, 1-trifluoromethylcyclopropyl, 3,3-difluoropyrrolidine,
C(0)-t-butoxy, phenyl, fluorophenyl, difluorophenyl, cyanophenyl, indolyl,
difluoropyrrolindinyl, benzothiazolyl, and N(methyl)C(0)t-butoxy.
56. The compound of claim 47, wherein the 6- to 14-membered spiro, fused, or
bridged bicyclic ring is 10-azabicyclodecane, 9-azabicyclononane, 8-azabicyclooctane,
azabicycloheptane, 3-azabicyclohexane, diazabicyclononane, diazabicyclooctane,
diazabicycloheptane, diazaspirononane, azaspirononane, diazaspirooctane, azaspirooctane,
spiro [isobenzofuran-piperidine, diazaspiroheptane, azaspiroheptane,
octahydrocyclopenta[£]pyrrole, or octahydrocyclopenta[c]pyrrole.
57. The compound of claim 56, wherein the 6- to 14-membered spiro, fused, or
bicyclic ring is substituted with one or two substituents independently selected from the
group consisting of halo, Ci_salkyl, Ci-shaloalkyl, Ci_5alkoxy, aryloxy, heteroaryloxy, CN,
OH, -S0 2R10 , -C0 2R10 , -CONHR 10 , C3-5cycloalkyl, aryl, and heteroaryl; and
R 10 is selected from the group consisting of H, Ci-salkyl, -Co-salkylene-aryl, and -Co-
5alkylene-heteroaryl.
58. A compound as listed in Table C.
59. A compound as listed in Table A.
60. A compound as listed in Table B.
61. A compound of formula V or V , or a pharmaceutically acceptable salt
thereof:
wherein:
=^= is an optional double bond;
1 is N, or if the double bond is present, then Y1 is C;
is a 5-membered ring;
n is 0 or 1;
each R6 is selected from the group consisting of Ci_salkyl, C 3_5cycloalkyl,
Ci_5haloalkyl, halo, and benzyl;
Q is CH, CR6, or N;
R and R4, taken together with nitrogen atom to which they are attached form a 3-, 4-
5-, 6-, or 7-membered monocyclic ring or 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered
spiro, fused, and/or bridged polycyclic ring.
62. The compound of claim 61, wherein - is a pyrrole ring, a cyclopentene
ring, a thiophene ring, a dihydrofuran ring, a pyrazole ring, a thiazole ring, or an imidazole
ring.
The compound of claim 6 1 or 62, wherein
is selected from the group consisting of:
The compound of any one of claims 61-63, wherein
and is optionally substituted with one to four substituents selected from the
group consisting of F, CI, and Ci_3alkyl.
65. The compound of any one of claims 61-64, wherein
The compound any one of claims 61-64, wherein
The compound of any one of claims 61-66, wherein
The compound of any one of claims 61-67, wherein
N and
The compound of any one of claims 61-68, wherein
70. The compound of any one of claims 61-69, wherein R and R4, taken together
with nitrogen atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered ring.
71. The compound of claim 70, wherein the 3-, 4-, 5-, 6-, or 7-membered ring is
piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl,
oxaziridinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl,
isothiazolidinyl, azepanyl, diazepanyl, or diazabicycloheptane.
The com ound of any one of claims 61-71, wherein
O
m
m is 0, 1, 2, or 3;
R7' and 9 are each independently selected from the group consisting of halo, Ci_
5alkyl, C3_5cycloalkyl, heterocycloalkyl, Ci-shaloalkyl, Ci-shaloalkylene-OH, Ci-salkylene-
CN, Ci_5alkoxy, Ci_5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR8, -NR C0 2R a, -
S0 2R8, -C0 2R8, -CONHR8, aryl, and heteroaryl, or
two R groups, together with the carbon atom(s) to which they are attached, form a 3-,
4-, 5-, 6-, 7-, or 8-membered cycloalkyl, a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocycloalkyl,
aryl, or a 5- or 6-membered heteroaryl ring; and
R8° and R8a are each independently selected from the group consisting of H, Ci_5alkyl,
-Co-5alkylene -aryl, and -Co-salkylene-heteroaryl; or
one R7 group and R9, together with the atoms to which they are attached, form a 5- or
6-membered heterocyclic or heteroaryl ring.
The compound of any one of claims 61-72, wherein
R7' and 9 are each independently selected from the group consisting of halo, Ci_
salkyl, C3_5cycloalkyl, heterocycloalkyl, Ci-shaloalkyl, Ci-shaloalkylene-OH, Ci-salkylene-
CN, Ci-salkoxy, Ci_5haloalkoxy, aryloxy, heteroaryloxy, CN, OH, -NHR8, -NR C0 2R a, -
S0 2R8, -C0 2R8, -CONHR8, aryl, and heteroaryl; and
R8° and R8a are each independently selected from the group consisting of H, Ci_5alkyl,
-Co-5alkylene -aryl, and -Co-salkylene-heteroaryl.
74. The compound of claim 72 or 73, wherein R7 or R9 is selected from the group
consisting of C3_5cycloalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, aryl, and heteroaryl.
75. The compound of any one of claims 72-74, wherein R7 is oxazolyl or
pyridinyl, each of which is optionally substituted with CN or F.
The compound of any one of claims 72-75, wherein R7 is selected from the
group consisting of
77. The compound of any one of claims 72-76, wherein R9 is C 3_5cycloalkyl.
78. The compound of any one of claims 72-77, wherein R9 is cyclopropyl or
cyclobutyl, each of which is optionally substituted with 1, 2, 3, or 4 F atoms.
The compound of any one of claims 72-78, wherein R9 is selected from the
group consisting of - - , and
80. The compound of claim 61, wherein the compound is
pharmaceutically acceptable salt thereof.
1. The compound of claim 61, wherein the compound is
pharmaceutically acceptable salt thereof.
82. The compound of claim 61, wherein the compound is
or or a pharmaceutically
acceptable salt thereof.
The com ound of claim 61, wherein the compound
or , or a pharmaceutically
acceptable salt thereof.
84. The compound of claim 61, wherein the compound is
pharmaceutically acceptable salt thereof.
The compound of claim 61, wherein the compound is
pharmaceutically acceptable salt thereof.
86. The compound of claim 61, wherein the compound is
, or a pharmaceutically
acceptable salt thereof.
87. A composition comprising the compound of any one of claims 1 to 86 or a
compound as listed in Table D; and a pharmaceutically acceptable carrier.
88. Use of the compound of any one of claims 1 to 86, a compound listed in Table
D, or the composition of claim 87 as an analgesic, as a treatment for acute or chronic pain, an
anti-inflammatory, or as an immune cell regulator.
89. A method of inhibiting sepiapterin reductase (SPR) comprising contacting
SPR with the compound of any one of claims 1 to 86, a compound listed in Table D, or the
composition of claim 87 in an amount effective to inhibit SPR.
90. A method of treating a subject suffering from pain, comprising administering
to the subject a therapeutically effective amount of the compound of any one of claims 1 to
86, a compound listed in Table D, or the composition of claim 87.
91. The method of claim 90, wherein the pain is acute pain.
92. The method of claim 90, wherein the pain is chronic pain.
93. The method of claim 90, wherein the pain is selected from the group
consisting of AIDS/HIV-related pain, ankylosing spondylitis, arachnoiditis, back pain,
breakthrough pain, burning mouth syndrome, bursitis, cancer pain, carpal tunnel syndrome
pain, cauda equina syndrome, central pain syndrome, Charcot-Marie-Tooth disease, chronic
functional abdominal pain, chronic pancreatitis pain, complex regional pain syndrome,
corneal neuropathic pain, degenerative disc disease, Dercum's disease, dermatomyositis,
diabetic peripheral neuropathy, Ehlers-Danlos syndrome, endometriosis, erythromelalgia,
failed back surgery syndrome, fibromyalgia, intercostal neuraligia, interstitial cystitis,
irritable bowel syndrome, juvenile dermatositis, leg pain, loin pain-haematuria syndrome,
meralgia paresthetica, migraine, multiple sclerosis pain, musculoskeletal pain, myofascial
pain, myositis, neuropathic pain, occipital neuralgia, osteoarthritis pain, Paget's disease,
pelvic pain, peripheral neuropathy, phantom limb pain, pinched nerve, polymyalgia
rhuematica, polymyositis, post-herniorraphy pain syndrome, post-mastectomy pain
syndrome, post-stroke pain, post-thorocotomy pain syndrome, post-traumatic neuropathy,
postherpetic neuralgia, post-polio syndrome, primary lateral sclerosis, psoriatic arthritis,
pudendal neuralgia, Raynaud's disease, restless leg syndrome, rheumatoid arthritis, sacroiliac
joint dysfunction, sarcoidosis, sciatica, postherpetic neuralgia, sickle cell pain, Sjogren's
syndrome, spasmodic torticollis, sphincter of Oddi dysfunction, spinal cord injury, spinal
stenosis, syringomyelia, Tarlov cysts, thoracic outlet syndrome (TOS), temporomandibular
joint disorder, transverse myelitis, trigeminal neuralgia, ulcerative Colitis, vascular pain,
vulvodynia, and whiplash pain.
94. A method of treating a subject suffering from inflammation, comprising
administering to the subject a therapeutically effective amount of the compound of any one of
claims 1 to 86, a compound listed in Table D, or the composition of claim 87.
95. The method of claim 94, wherein the inflammation is chronic inflammation.
96. A method of treating a subject suffering from an immunological disorder,
comprising administering to the subject a therapeutically effective amount of the compound
of any one of claims 1 to 86, a compound listed in Table D, or the composition of claim 87.
97. The method of claim 96, wherein the immunological disorder is selected from
acid-induced lung injury, acne (PAPA), acute respiratory distress syndrome, ageing,
headache, AIDS, alcoholic hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis
(NASH), allergen induced asthma, allergic bronchpulmonay aspergillosis, Alzheimer's
disease, amyotropic lateral sclerosis (ALS), angina pectoris, anhidrotic ecodermal dysplasia-
ID, ankylosiing spondylitis, antiphospholipid syndrome, aphthous stomatitis, appendicitis,
arthritis, asthma, atopic dermatitis, autoimmune diseases, bee sting-induced inflammation,
behcet's disease, Bell's palsey, Blau syndrome, bronchiolitis, burns, cancer, cardiac
hypertrophy, catabolic disorders, cataracts, cerebral aneurysm, Cystic Fibrosis, chemical
irritant-induced inflammation, chronic heart failure, chronic lung disease of prematurity,
chronic obstructive pulmonary disease, colitis, complex regional pain syndrome, congenital
muscular dystrophies, connective tissue diseases, Crohn's disease, cryopyrin-associated
periodic syndromes, cyrptococcosis, cystic fibrosis, deficiency of the interleukin-1-receptor
antagonist (DIRA), dermatitis, dermatomyositis, DIPG (Diffuse Intrinsic Pontine Glioma),
endometriosis, endotoxemia, eosiniphilic esophagitis, familial amyloidotic polyneuropathy,
familial cold urticarial, familial mediterranean fever, fetal growth, FSHD, glaucoma,
glomerular disease, glomerular nephritis, gut diseases, peritoneal endometriosis, head injury,
hearing loss, heart disease, Henoch-Scholein purpura, hepatitis, hereditary periodic fever
syndrome, Herpes zoster and simplex, HrV-1, Huntington's disease, hyaline membrane
disease, hypercholesterolemia, hyperimmunoglobulinemia D with recurrent fever (HIDS),
hypoplastic and tother anemias, incontinentia pigmenti, infectious mononucleosis,
inflammatory bowel disease, inflammatory lung disease, inflammatory neuropathy,
inflammatory pain, insect bite-induced inflammation, irritant-induced inflammation,
ischemia/reperfusion, Kawasaki Disease, kidney disease, kidney injury caused by parasitic
infections [ml], leptospiriosis, leukemia, limb girdle muscular dystrophy 2A, limb girdle
muscular dystrophy 2B, lung injury, lupus, lupus nephritis, lymphoma, meningitis,
mesothelioma, Muckle-Wells syndrome (urticaria deafness amyloidosis), multiple sclerosis,
muscle wasting, muscular dystrophy, myasthenia gravis, mycarditis, mycosis fungoides,
myelodysplastic syndrome, myositis, nasal sinusitis, necrotizing enterocolitis, neonatal onset
multisystem inflammatory disease (NOMID), nephrotic eyndrome, neuritis,
neuropathological diseases, non-allergen induced asthma, obesity, ocular allergy, organ
transplant, osterarthritis, otitis media, paget's disease, pancreatitis, Parkinson's disease,
pericarditis, periodic fever, periodonitis, pertussis, pharyngitis and adenitis (PFAPA
syndrome), plant irritant-induced inflammation, Pneumosystis infection, poison ivy/ urushiol
oil-induced inflammation, polyarteritis nodosa, polycystic kidney disease, polymyositis,
pontine glioma, psoriasis, psychosocial stress diseases, pulmonary disease, pulmonary
fibrosis, pulmonary hypertension, pyoderma gangrenosum, pyogenic sterile arthritis, renal
disease, retardation, retinal disease, rheumatic disease, sarcoidosis, sebborrhea, sepsis, sickle
cell, silica-induced diseases, Sjogren's syndrome, skin diseases, sleep apnea, solid tumors
including brain tumors, spinal cord injury, statin induced myopathy, stroke, subarachnoid
hemorrhage, sunburn, thrombocytopenia, tissue transplant, TNF receptor associated periodic
syndrome (TRAPS), toxoplasmosis, traumatic brain injury, tuberculosis, type 1 diabetes, type
2 diabetes, ulcerative colitis, uveitis, and wound repair.
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